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Abstract 
Microtubules (MTs) are key components of the cytoskeleton in most eukaryotic cells. One 
of the distinctive characteristics of MTs is the “dynamic instability” as their assembly is a 
dynamic process characterized by the continuous transitions between polymerization and 
depolymerization. Because of their dynamicity, MTs play a significant role in a number of 
essential cellular functions, such as maintenance of cell shape, cell motility, intracellular 
transport and cell division. Interfering with the dynamic MT equilibrium prevents proper 
cellular functions and ultimately leads to cell death. This strategy resulted in a productive 
approach that has been widely used in different therapeutic areas for the development of 
efficient drug treatments. 
Chapters 2−4 of this thesis describe the three main projects that underpin my research 
activity in the PhD program: 
(a) Drug design and synthesis of 2-phenylindole derivatives as new tubulin 
polymerization inhibitors and selective colchicine-binding site competitors that showed 
potent antimitotic activity against multi-drug resistant cell lines. These novel compounds 
exhibited potential to treat cancer via both MT-based and MT-independent pathways. 
Moreover, selected examples strongly inhibited the Hedgehog signaling pathway. 
(b) Structure-activity relationship (SAR) studies of multitargeted imidazoles as drug 
candidates for a potential therapeutic approach for Alzheimer’s disease and related 
neurodegenerative diseases. This study led to the identification of several compounds that 
exhibit balanced in vitro multitargeted activity as MT-stabilizing agents and/or 
cyclooxygenase (COX) and 5-lipoxygenase (5-LOX) inhibitors in the low micromolar range. 
In addition, several of these multitargeted agents were found to be brain-penetrant. 
(c) Evaluation of central nervous system (CNS)-active, tubulin polymerization promoters 
as potential candidate therapeutics for the human African trypanosomiasis and possible other 
neuroparasitic infections. These studies led to the identification of a promising drug 
candidate, which combines both in vitro anti-trypanosomal activity and favorable drug-like 
properties, including brain penetration, metabolic stability and oral bioavailability. 
Furthermore, SAR studies conducted on a series of MT-stabilizing triazolopyrimidine and 
phenylpyrimidine analogues led to the identification of several examples that kill 
Trypanosoma brucei in vitro with IC50 values in the single-digit nanomolar range. Finally, 
preliminary screening against another CNS-invasive parasite, Naegleria fowleri, revealed that 
this type of compounds may be of potential use in the context of different parasitic infections. 
 
 
 
 
 
	 vii 
Chapters 5–7 briefly present other research collaborations, in which I have been involved:  
(d) Discovery of 1,1′-biphenyl-4-sulfonamides as potent inhibitors of the human 
carbonic anhydrase ezymes. 
(e) SAR studies of arylboronic acids as dual ligands of fatty acid amide hydrolase 
(FAAH) enzyme and transient receptor potential vanilloid 1 (TRPV1) channel. 
(f) Evaluation of oxetan-3-ol, thietan-3-ol, and derivatives thereof as bioisosteres of the 
carboxylic acid functional group and dual COX/5-LOX inhibitors. 																																						
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Chapter 1: Tubulin and Microtubules 
1.1 Composition and Organization 
Microtubules (MTs) are cytoplasmic filamentous constituents that play essential structural 
and regulatory functions in most eukaryotic cells. They are involved in a wide range of 
processes, such as transport of vesicles and organelles into and out of the cell, cell signaling, 
development and maintenance of cell shape and organization of the endoplasmic reticulum 
and the Golgi apparatus. Furthermore, MTs are the major structural components of the 
axonemes responsible for ciliary and flagellar motility. However, their most crucial function 
is in cell division and mitosis.1,2  
MTs are strictly organized to form hollow tubes that are composed of two polypeptides, 
denoted as α- and β-tubulin, which consist of about 450 amino acid residues with a molecular 
mass of ~55 kDa. The two polypeptodes interact non covalently to form a stable heterodimer 
of dimentions 4 nm × 5 nm × 8 nm and 100,000 daltons in mass, and the association of 
tubulin heterodimers in a head-to-tail fashion create protofilaments, which in turn associate in 
a parallel manner to form sheets of tubulin.3 This arrangement of protofilaments imparts 
polarity to the final structure of the MT. The β-tubulin subunits are exposed at the “plus end” 
of the polymer, which is the more dynamic end of the MT that can actively explore the cell 
and attaches to the kinetochore during mitosis, while the “minus end” is capped by α-tubulin 
subunits and it is generally attached to the centrosome. Thus, the supramolecular structure of 
MT in most eukaryotic cells results in a cylindrical tube of about ~24 nm in diameter and of 
highly variable length ranging 1–100 µm in vivo (Figure 1.1).4 Whereas the arrangement of 13 
protofilaments is the most common organization in vivo,5 it is possible for purified tubulin to 
assemble with a fairly wide range of diameters and to contain 9–18 protofilaments.6 This 
variation reveals that there is some flexibility in the bonds between adjacent protofilaments, at 
least in the direction involved in curvature of the MT wall.  
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Figure 1.1. Schematic representation of the MT organization. Head-to-tail polymerization of 
α- and β-tubulin heterodimers results in protofilaments. Lateral interactions allow 
protofilaments to assemble into sheets of tubulin, which fold on themselves to form polarized 
hollow MT structures of approximately 24 nm in diameter, typically composed of 13 
protofilaments. During the polymerization process, guanosine 5′-triphosphate (GTP)-bound 
α,β-tubulin dimers are added at the plus end of the MT. Concomitantly or soon after 
incorporation into the MT, GTP-bound to β-tubulin is hydrolyzed to the corresponding 
diphosphate (GDP-MT). 
 
The atomic structure of tubulin in one assembled conformation is known from a 3.5 Å 
resolution map obtained by electron crystallography of zinc-induced polymers (Figure 1.2).7,8 
Tubulin structure can be divided into three functional domains: the amino-terminal (N-
terminal) region, an intermediate/central domain, and the carboxyl-terminal (C-terminal) 
region. The N-terminal domain corresponds to amino acid residues 1–205 and includes a 
binding site for guanosine triphosphate (GTP), which is required for mediating MT dynamics 
(see Section 1.3).9 The central domain encompasses residues 206–381 and includes a protease 
sensitive site10,11 and a binding site for the MT-stabilizing agent taxol on β-tubulin isotypes.7 
The C-terminal domain of each tubulin polypeptide forms two long helices (H11 and H12) 
connected by a U-turn and projects outward from the MT surface, making it preferentially 
accessible for several enzymes involved in post-translational modifications (PTMs) of tubulin 
and facilitating the interaction of MTs with MT-binding proteins, such as motor proteins or 
MT-associated proteins (MAPs), which modulate MT function and dynamics (see section 
1.5).12,13 The α- and β-tubulin isotypes, which consist in peptides with different amino acid 
sequences, show 40% homology in the N-terminal domain, whereas the last 50 amino acids of 
the C-terminal domain impart much of the heterogeneity between tubulin isotypes.7,14 The 
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latter region presents a highly acidic C-terminal tail (CTT) of about 20 amino acids, in which 
50% of the amino acids are glutamate or aspartate.15,16 The CTT plays a significant role in 
regulating the interactions between MTs and different binding proteins, and experimental 
evidences confirmed that the cleavage of this acidic tail makes important changes in the MT 
integrity, thus affecting the capacity of MTs to interact with the binding proteins.17  
 
 
Figure 1.2.	 Ribbon diagram of the electron crystallography structure of zinc-induced αβ-
tubulin sheets (α-tubulin in cyan, β-tubulin in purple, GDP in green, GTP in yellow).8,18  
 
1.2 The Tubulin Superfamily  
In addition to the well-known α- and β-tubulins, the tubulin superfamily includes other 
related forms, such as γ, δ, ε, ζ, η, θ, ι, and κ. 
γ-Tubulin was first described in filamentous fungus Aspergillus nidulans19 and shares ~28–
35% amino acid sequence identity with α and β. The fundamental function of γ-tubulin in 
eukaryotes is in the nucleation and polar orientation of MTs. γ-Tubulin is found primarily in 
centrosomes and spindle pole bodies, since these are the areas of most abundant MT 
nucleation. In these organelles, several γ-tubulins and other protein molecules are found in 
complexes known as γ-tubulin ring complexes (γ-TuRCs). One model describes that the γ-
TuRC has γ-tubulins that bind longitudinally to α- and β-tubulins at the minus end of the MT. 
In a second model, γ-TuRC is part of the MT protofilament at the minus end. Either way, the 
	 4 
γ-TuRC acts as a cap at the minus end of the MT thus preventing further addition of tubulin 
subunits there.20  
δ-Tubulin was first discovered in Chlamydomonas and it is primarily located in basal 
bodies and centrosomes,21 where often colocalizes with γ-tubulin.22 The function of δ-tubulin 
is not completely clear. Its location in centrosomes suggests that it may play a structural role 
in organizing these organelles. It is also likely to be involved in the function of basal bodies. 
The fact that in some cells δ-tubulin only becomes concentrated in centrosomes during 
mitosis, suggests that it may have a particular mitotic function, perhaps in centrosome 
separation.  
ε-Tubulin was discovered by searching the human genome23 and, as δ, it is located in both 
basal bodies and centrosomes. During the early stages of the cell cycle, ε-tubulin associates 
predominantly with old centrosomes, while only later in the cell cycle it becomes associated 
with both old and new centrosomes. It appears likely that ε-tubulin is required for the 
formation of basal bodies and centrioles.  
η-Tubulin has not been observed in humans, but in the protists Chlamydomonas and 
Paramecium and the animals Ciona and Xenopus. η-Tubulin is located in basal bodies21 and 
studies in Paramecium have suggested that it is required for basal body duplication. η-Tubulin 
also appears to interact with γ-tubulin24 and with β-tubulin, acting as a minus end capping 
protein.25 
ζ-tubulin has been found in basal bodies of the related protists Trypanosoma and 
Leishmania, as well as in the Xenopus genome. Its role remains unclear. Finally, θ-, ι-, and κ-
tubulins have been identified in the genome of Paramecium. θ-Tubulin occurs in basal bodies, 
while the subcellular localization of ι and κ, as well as their functional roles, remain 
unknown.26 
 
1.3 Microtubule Dynamics: Dynamic Instability and Treadmilling 
MTs are highly dynamic structures with many of them in a state of permanent turnover. 
They show two kinds of non-equilibrium dynamics that are both crucial to mitosis and cell 
division: ‘dynamic instability’ and ‘treamilling’.  
‘Dynamic instability’ is a process in which MT ends switch stochastically between phases 
of slow growing and rapid shortening (Figure 1.3).27,28 In cells, the two ends of a MT are not 
equivalent: the more dynamic plus end grows and shortens more rapidly and more extensively 
than the minus end. MTs can continue to grow as long as the free tubulin concentration is 
above a critical level (Cc, at which α- and β-tubulins polymerize into MTs, whereas at 
concentrations below the Cc, MTs depolymerize). However, even when the tubulin 
concentration is above this level, it is observed that MT ends may suddenly stop growing and 
begin to shrink rapidly. The change from growth to shrinkage has been termed as 
‘catastrophe’. After a while, a shrinking MT end may ‘pause’ and/or begin to grow again; the 
	 5 
latter process is known as ‘rescue’. MTs tend to disassemble when cells are cooled below 
their normal temperature and reassemble when they are rewarmed, but they show dynamic 
instability even under constant warm conditions.6  
 
  
Figure 1.3. Dynamic instability of MTs. Changes in length of a single MT over time.29 		
The second dynamic behaviour is called ‘treadmilling’ that is the net addition of tubulin at 
one MT end and the balanced net loss at the other end. It involves the intrinsic flow of tubulin 
subunits from the plus end of the MT to the minus end and it is created by differences in the 
critical subunit concentrations at the opposite MT ends (Figure 1.4).30–34 The length of the 
MT remains unchanged. This dynamic behaviour occurs in cells as well as in vitro, and it has 
been demonstrated that it is particularly important in mitosis.35 
 
Treadmilling and dynamic instability are compatible behaviours. A specific MT population 
can show primarily treadmilling behaviour, dynamic instability behaviour or some mixture of 
both. The mechanisms that control the degree to which MT population shows one or the other 
behaviour are poorly understood, but probably involve the tubulin isotype composition of the 
MT population, the degree of PTM of tubulin and, especially, the actions of regulatory 
proteins.36  
 
 
  
Figure 1.4. Treadmilling MT. Tubulin heterodimers are added at the plus end of the MT at 
time 0, treadmill through the MT, and are lost from the minus end at time 3.29  
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1.4 GTP Hydrolysis 
During MT assembly, α- and β-tubulin heterodimers polymerize in a head-to-tail fashion 
resulting in a polarized structure with a β-tubulin cap at the plus end and a α-tubulin cap at the 
minus end.37,38 The assembly requires that α- and β-tubulins bind one molecule of GTP each 
monomer. The GTP bound to α-tubulin is trapped between the two monomers thus resulting 
nonexchangeable. It is apparently never hydrolysed and permanently present at the N-site.39,40 
When tubulin subunits associate to create protofilaments, as a consequence of the interaction 
with α-tubulin in the next dimer, the β-tubulin subunit acts as a GTPase and hydrolyzes GTP 
to GDP at the exchangeable E-site. GDP is nonexchangeable, as long as tubulin is present in 
MTs41 and can only be replaced by GTP when tubulin is in the heterodimeric form. The 
hydrolysis rate of GTP by unpolymerized tubulin dimer is very low (0.054 min−1 at most42,43), 
but it dramatically increases during the polymerization process (21 min−1).44 
 The GTP to GDP hydrolysis is not strictly required for MT polymerization; however, this 
conversion plays an important role in determining the MTs dynamic behaviour and instability, 
as GTP-tubulin forms more stable inter-subunit interactions, while GDP-tubulin establishes 
comparatively weaker interactions and is therefore prone to depolymerization. The presence 
of a GTP-bound tubulin at the growing end of the MT (called “GTP cap” or “stabilizing cap”) 
protects the MT from depolymerization, thus stabilizing the MT structure and maintaining the 
association between protofilaments.45 As a consequence, removal of the GTP cap can trigger 
rapid depolymerization events. Upon depolymerization, released tubulin heterodimers can 
exchange GDP with GTP and re-enter the polymerization cycle. These characteristics result in 
the dynamic instability of MTs (Figure 1.5). 
 
  
Figure 1.5. Dynamic instability and the GTP cap. GTP bound to β-tubulin is hydrolyzed to 
GDP and inorganic phosphate (Pi) at the time that tubulin adds to the MT plus ends, or shortly 
thereafter. A MT end containing tubulin-GTP or tubulin-GDP-Pi is stable or “capped,” against 
depolymerization. Hydrolysis of GTP-bound tubulin and the subsequent release of Pi induce 
conformational changes that destabilizes the MT polymer.29 
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Experimental evidences reveal that hydrolysis of GTP to GDP in tubulin is associated with 
a change in tubulin conformation.46–49 Thus, unpolymerized tubulin dimer with GDP bound 
appears to prefer a true curved conformation, which can be readily visualized at MT ends 
where protofilaments are seen to “peel away” from the MT in an outward curving manner 
(Figure 1.6). In contrast, tubulin-GTP is thought to have a straight conformation, or a 
straighter conformation than tubulin-GDP (Figure 1.6).50 However, the tubulin-GDP structure 
that exists throughout most of the MT is held in a straight but strained form by contacts 
between neighbouring subunits in the lattice, which has been proposed to store 
conformational energy and to release it during depolymerization. The hypothesis is that, as 
long as the stabilizing cap is present at the MT end, the tubulin-GDP in the core is held in a 
strained “straight” form, adopting a “curved” conformation only as it dissociates from the MT 
end.50 
 
 
Figure 1.6. Schematic representation of tubulin-GTP conformation versus tubulin-GDP 
conformation.51 
 
1.5 Endogenous Microtubule Modulators 
The non-equilibrium dynamics of MTs are highly regulated in cells as MTs are strictly 
required in many cellular activities, including mitosis, cell division, signaling, adhesion, 
directed migration, polarization, delivery of vesicles and proteins to and retrieval from the 
plasma membrane, and remodelling of cell shape and organization. Thus, a large number of 
MT- or tubulin-interacting proteins play critical roles in regulation of the MT dynamic 
properties. These agents include the MT-associated proteins (MAPs), the MT plus end 
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tracking proteins (+TIPs), the minus end binding proteins and proteins that bind along the 
lengths of MTs, GTPases and guanine nucleotide exchange factors (Figure 1.7). Among these 
agents, MAPs are primarily involved in modulating MT stability and dynamics. They were 
initially identified by their activity to copurify with tubulin through repetitive cycles of 
depolymerization and reassembly. A variety of structural MAPs can interact on the surface of 
MTs and reduce their dynamic behavior by stimulating tubulin polymerization and 
stabilization. The brain is a particularly rich source of MAPs and several structural MAPs 
such as tau, MAP1A, MAP1B, and MAP2 may play a central role in regulation of neuronal 
MT structure and function during development. As an example, MAP1A is abundant in the 
adult brain, whereas MAP1B is a neuritogenesis-associated MAP predominantly expressed 
during the early stages of cell maturation, and tau and MAP2 are expressed in both immature 
and mature neurons.52 Several MAPs also exhibit a pronounced compartment-specific 
distribution such as MAP2A and MAP2B, which preferentially locate in the cell bodies and 
dendrites in mature neurons,53 whereas tau is mostly present in the axons,54 although it can be 
found also in dendrites.55 However, under physiological conditions, the vast majority of tau 
molecules are bound to MT with the primary function to promote MT stabilization.56  
The most abundant and ubiquitous MAP in non-neuronal cells is MAP4 that can localize both 
to interphase and mitotic MTs, which suggests that it may contribute to the role of MTs in 
proliferation and differentiation of cells.57 
In general, the activity of MAPs is regulated by phosphorylation that causes the 
dissociation of MAPs from MTs, promoting depolymerization and increased dynamic 
instability. Furthermore, the stabilizing activity of MAPs is counteracted by proteins that bind 
to tubulin dimers and promote MT depolymerization. This class of proteins included, for 
example, the stathmin (also referred to as oncoprotein 18, OP18; metablastin; p19), which 
was first identified as a highly overexpressed protein in leukemia58,59 and as a protein that 
underwent phosphorylation in response to extracellular stimuli.60 Stathmin is a well-
conserved, ubiquitous, cytosolic phosphoprotein that forms a specific complex with two 
tubulin dimers thereby preventing MT polymerization.61,62 SCG10 belongs to the same gene 
family as stathmin and also promotes MT destabilization. However, while stathmin is 
expressed in a variety of cell types and shows a cytosolic distribution, SCG10 is neuron-
specific and membrane-associated. Both stathmin and SCG10 are regulated by 
phosphorylation and have high expression in the developing nervous system, but persists in 
regions of synaptic plasticity of the adult brain.63−65 
While MAPs such as tau and MAP2 localize to the entire MT surface, proteins like +TIPs, 
such as the cytoplasmic linker protein CLIP-170, the EB1, and others, bind to MT plus ends 
(Figure 1.7). +TIPs are involved in intracellular transport and crosstalk of MTs with the actin 
cytoskeleton.66 Furthermore, they participate in the establishment of neuron polarity, axon 
navigation, and spine growth and maintenance.67 EB1 is a potent inducer of MT 
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polymerization and plays an important role in anchoring the minus end of MTs to the 
centriole. 
Minus end binding proteins include the γ-TuRCs,68 stathmin,69 and possibly ninein.70 The 
GTPase Ran,71 and the chromatin-bound guanine nucleotide exchange factor RCC1 are 
additional recently discovered important MT regulatory proteins. 
Other important families of proteins involved in regulation of MT dynamics and functions 
are the motor proteins, such as kinesins72 and dyneins73 (Figure 1.7). Kinesins and dyneins are 
protein complexes that move along MTs (towards the plus and minus ends, respectively) by 
hydrolysing ATP. They generate forces that are used for various intracellular functions, 
especially for intracellular transport. For example, in neurons, these proteins allow the 
transport of cargoes over long distances from the cell body to the synapses.74 Moreover, 
motor proteins generate forces for ciliary beating75 and self-organization of the mitotic 
spindle, whereas specific kinesins catalyse the depolymerization of MTs,76 thus participating 
in the complex network of interacting proteins that regulate MT dynamics.  
 
  
Figure 1.7. Schematic representation of MT dynamics and their regulation.77 
 
1.6 Post-Translational Modifications of Tubulin 
Tubulin and MTs are subject to a large number of evolutionarily conserved and 
particularly regulated post-translational modifications (PTMs) (Figure 1.8). These 
modifications may be involved in modulating stability and dynamics of MTs and interactions 
with MAPs, but they also may have as yet undiscovered functions. Modifications such as 
phosphorylation, acetylation, palmitoylation, or polyglutamylation occur also on other 
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proteins, while tyrosination and detyrosination, as well as polyglycylation, appear to be 
specific for tubulin. Furthermore, PTMs do not occur in similar manner in α- and β-tubulins; 
thus, acetylation and detyrosination specifically occur in α-tubulin, while phosphorylation, 
polyglutamylation and polyglycylation occur in both tubulin proteins. More than one PTM 
can be found on single MTs resulting in a heterogenous modification that create sort of a 
“tubulin code”. The major PTMs of tubulin are discussed below.  
 
 
Figure 1.8. Schematic representation of the PTMs of α- and β-tubulin dimers.78 
 
Tyrosination/Detyrosination 
Tubulin tyrosination (also called tyrosinylation, tyrosylation, and tyrosinolation) 
corresponds to the attachment of a tyrosine residue to the C-terminal glutamate of α-tubulin 
by the enzyme tubulin tyrosine ligase (TTL). The C-terminal tyrosine is removed by a tubulin 
carboxypeptidase and it can be added back by the enzyme TTL, which requires ATP and 
magnesium ions for the tyrosination reaction. Tubulin monomers that contain a tyrosine as the 
penultimate C-terminal residue are often called “Tyr-tubulin,” while detyrosinated tubulin is 
typically known as ‘‘Glu-tubulin’’ since the penultimate C-terminal residue is a glutamate. 
Tyr-tubulin can be detyrosinated to form Glu-tubulin, which can then be retyrosinated to form 
Tyr-tubulin. 
Glu-tubulin is prevalent in stable MTs with little dynamicity, whereas Tyr-tubulin is found 
mainly in highly dynamic and labile MTs.79,80 MTs containing Tyr-tubulin are present in the 
interphase network and in the metaphase spindle, while Glu-tubulin is absent from the mitotic 
spindle.81 In general, Glu-tubulin has been found in axonemes, basal bodies, centrioles, 
centrosomes as well as in the perinuclear region.82 In neurons, Glu-tubulin is particularly 
enriched in proximal segments of the axon, while Tyr-tubulin is more abundant in the cell 
soma and dendrites. 
Two models describe the molecular mechanism of tyrosinolation/detyrosinolation cycle. In 
the first model, the presence or absence of the C-terminal tyrosine can act as a binary 
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ON/OFF switch for the recruitment of MT dynamics regulators, rather than directly influence 
the intrinsic properties of the protein itself. For example, Glu-tubulin interacts with a complex 
at the growing end of the MT, thereby promoting its stability, but the Glu-tubulin by itself 
does not stabilize the MT.83−85 In the second model, alteration of the C-terminal tyrosine can 
affect the overall conformation of the tubulin molecule and change its intrinsic properties. 
Indeed, the presence of a terminal tyrosine may alter the property of the C-terminus to project 
out from the tubulin molecule rather than lie down along the tubulin surface resulting in 
change of the tubulin conformation.86 One additional possibility is that the TTL can 
incorporate nitrotyrosine, which is generated by the interaction between nitric oxide and a 
tyrosine residue.87 Incorporation of nitrotyrosine into tubulin is irreversible and can cause 
disorganization of the cell, perhaps by altering the relative proportions of stable and unstable 
MTs and/or by affecting the binding of other proteins to the C-terminal region.88 
 
Deglutamylation 
Under physiological conditions, the Glu-tubulin, which resulted from detyrosination of 
Tyr-tubulin, can be further converted to Δ2-tubulin by the removal of the C-terminal 
glutamyl-tyrosine group, potentially by 6-cytoplasmic carboxypeptidases (CCP1-6).89 This 
reaction is irreversible, thus Δ2-Tubulin cannot be tyrosinated or polyglutamylated any 
longer. ∆2-tubulin accumulates in stable MTs and represents about 35% of mammalian brain 
α-tubulin. 
 
Acetylation 
Acetylation of α-tubulin is one of the earliest tubulin PTMs discovered90,91 and consists in 
the addition of an acetyl group to a lysine residue on position 40 (Lys40) of α-tubulin by the 
enzyme acetyltransferase (TAT). Interestingly, acetylation is the only known PTM that occurs 
in the lumenal surface of the MTs, whereas other tubulin PTMs take place on the C-terminal 
domains on the outside of the MT. 
Acetylated α-tubulin (AcTub) is often seen in long-lived and low dynamic MTs, such as in 
the neuronal growth cones, in the leading edges of fibroblasts,92,93 in centrioles, centrosomes, 
primary cilia, and the perinuclear region.94 
AcTub, which can be detected by specific antibodies, can be use as a marker for a stable 
MTs. However, studies conducted by Borisy and coworkers in 1989 revealed that the 
acetylation is most likely a consequence of MT stabilization and not a cause.95 Deacetylation 
of tubulin is mediated by histone deacetylase (HDAC) 5 and 6 and SIRT2 enzyme.96,97 It has 
been demonstrated that HDAC6 is able to deacetylate tubulin in vivo98 and its overexpression 
promotes tubulin deacetylation and induces chemotactic cell movement,96 thus indirectly 
suggesting that acetylation of α-tubulin may play important roles in regulation of cell 
signaling and homeostasis.  
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Polyglutamylation  
Polyglutamylation can occur in both α- and β-tubulins and involves the attachment of 
oligoglutamyl-side chains of variable lengths to the γ-carboxyl group of specific glutamate 
residues in the C-terminal region of tubulin by an isopeptide (α/γ) linkage. To this added 
glutamate are then added several others through α/α linkages, resulting in side chains that can 
vary in length between 1 and 17 glutamyl units.99 Tubulin tyrosine ligase like (TTLL) 
proteins catalyze the polyglutamylation on tubulin dimers. TTLL1 preferentially 
polyglutamylates α-tubulin, while TTLL7 targets β-tubulin.100,101 
Polyglutamylation of tubulin is one of the major PTMs, which occurs in axonal MTs and is 
also enriched in long-lived MTs,102,103 such as those of centrioles, basal bodies, axonemes, 
and axostyles,104,105 whereas less stable MTs are sometimes monoglutamylated.103,106 
However, glutamylation can also occur on less stable MTs, such as in neuronal MTs.107,108 
The mechanism by which this modification occurs is probably quite complex. One TTLL 
enzyme must find an appropriate glutamate residue at the C-terminal end of tubulin to 
catalyze the addition of another glutamate residue through an α/γ linkage (these enzymes are 
called ‘‘initiases’’). After that, TTLL enzymes are also specialized to elongate the amino acid 
chain adding a series of glutamates to the first one through α/α linkages (thus are called 
‘‘elongases’’).109 The fact that polyglutamylation was found in brain Tyr-tubulin and Glu-
tubulin, but not in ∆2-tubulin, suggests that the penultimate glutamate residue may be 
essential for the tubulin polyglutamylase.110 
Polyglutamylation seems to influence binding of MAPs and kinesin to tubulin thus playing 
an important regulatory role in MTs. Indeed, polyglutamylation adds a number of negative 
charges to a region of the molecule that is already strongly negatively charged. Thus, 
polyglutamylated C-terminus will project from the MT surface promoting the interaction of 
tubulin with MAPs and kinesins.111−113  
 
Polyglycylation  
In addition to polyglutamylation, both α- and β-tubulins can undergo polyglycylation that 
consists in the addition of multiple glycine residues to the γ-carboxyl groups of specific 
glutamic acid residues at the C-terminal region.114,115 As in the case of polyglutamylation, in 
polyglycylation the first glycine is connected to the glutamate residue by a α/γ linkage, while 
the remaining glycines are added to the first one through α/α linkages. Unlike 
polyglutamylation, where one chain of glutamates is added to a single specific residue, in 
polyglycylation the glycines are added to more than one glutamate residue in the C-terminal 
region. Thus polyglycylation results as a large-scale modification. For example, in 
Paramecium, up to 34 glycines can be added to a single tubulin molecule.114,116 
Polyglycylation is particularly common in MTs forming stable organelles, such as 
axonemes and basal bodies. Interestingly, it has not been observed in centrioles.105 
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Polyglycylation is also observed in less stable MTs, such as those of the cochlea and 
neurons.117 In these cases, however, polyglycylation appears to be much less, with up to 3 
attached glycines that have been observed as the most extent form of polyglycylation in 
neuronal tubulin.110,118 
The mechanism by which polyglycylation occurs is not completely clear. First, there 
would be the addition of a single glycine to a glutamate through a α/γ linkage. Then, follows 
the addition of more glycines through α/α linkages. The third step would be the removal of 
some or all the glycine residue by a deglycylase that suggests the presence of a 
polyglycylation cycle. 
 
Phosphorylation 
Phosphorylation of mammalian brain β-tubulin was discovered in the early 1970s.119 
Whereas most tubulin PTMs act on α- and β-tubulin subunits already incorporated into 
MTs, phosphorylation can occur on both tubulin dimers and polymers. In addition, although 
several serine as well as tyrosine residues can undergo phosphorylation,120−126 when 
phosphorylation occurs on serine172, it can only take place on β-tubulin.127 
The precise mechanism of phosphorylation of tubulin is not yet clear. Tubulin is 
phosphorylated by a variety of kinases, including the non-receptor tyrosine kinases, such as 
Fes, Jak2, and Syk that specifically targets a tyrosine residue at the C-terminal region of α-
tubulin in vivo and in vitro.122,128 The physiological relevance of tubulin phosphorylation 
remains an active area of research with several studies129−132 suggesting an important role for 
phosphorylation in regulating polymerization, both positively and negatively. Several of the 
MAPs are subject to PTMs and can be phosphorylated at many sites. Some of these events 
may influence the interaction of MAPs with MTs thereby affecting MT dynamicity.10 
Phosphorylation may also induce conformational changes that could, for example, affect MT 
spacing in the axon or dendrites, or influence the availability of the MT surface towards 
several enzymes.133 
 
Palmitoylation  
Tubulin can undergo palmitoylation that constists in the addition of the fatty acid palmitate 
to the sulfhydryl group of a cysteine residue (cys376 of α-tubulin). The presence of a 
covalently linked palmitate could facilitate the connection of a protein to a membrane. 
Mutation of the palmitoylated residue in Saccharomyces cerevisiae showed a striking effect 
during mitosis and changes the position of the nucleus.134 Thus, it is possible that 
palmitoylation may play a role in proper orientation of the mitotic spindle. 
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Changes in tubulin PTMs have been linked to several human disease states ranging from 
cancers and neurodegenerative disorders to stroke.135 For example, low TTL levels have been 
associated with aggressive tumors that are resistant to chemotherapy136−138 and with the 
formation of tentacles rich in detyrosinated tubulin that facilitate penetration into the 
endothelial layer of circulating tumor cells, thus contributing to metastasis.139 Similarly, 
increased levels of TTLL12 and consequently glutamylated tubulin has been associated with 
metastatic progression in prostate cancer.140 In a mouse model of Charcot-Marie-Tooth 
disease, a descrease in acetylated tubulin levels and the axonal transport defects observed in 
these mice were corrected by the administration of HDAC6 inhibitors that also partially 
recovered the acetylated tubulin levels.141 In neurodegenerative disorders, such as 
Huntington’s and Alzheimer’s, were found similar connections between hyperphosphorylated 
stabilizing tau protein and axonal transport deficits.142,143 The cellular mechanisms behind 
these changes in tubulin PTMs are largely unclear. However, a better understanding of these 
mechanisms will likely lead to a better understanding of the disease states as well as aid in the 
identification of novel drug targets.  
 
1.7 The Importance of Microtubule Dynamics in Mitosis 
Highly dynamic MTs in the spindle are required for all stages of mitosis. Mitosis is a 
process of different stages in which duplicated chromosomes of a cell are separated into two 
identical sets before cleavage of the cell into two daughter cells.144 With the development of 
sophisticated methods for observing MT dynamics in living cells, it become possible to 
visualize the dynamics of mitotic-spindle MTs. It is now clear that the prime requirement for 
appropriate cell division is the correct functioning of mitotic spindle throughout mitosis.145−147 
During interphase, the turn over of MTs, in which they exchange tubulin with the soluble 
tubulin pool, is a relatively slow process (half-times range from several minutes to several 
hours)146−148 In interphase, MTs are nucleated at the centrosome or at the MT-organizing 
center (MTOC) located near the cell nucleus,68,149 and they extend toward the cell periphery. 
Following nucleation, the plus ends grow toward the cell periphery, whereas the minus ends 
generally remain at the centrosome. The interphase MT network disassembles at the onset of 
mitosis and is replaced by a new population of spindle MTs that are 4–100 times more 
dynamic than the MTs in the interphase cytoskeleton.147,148,150 During prometaphase, dynamic 
MTs are importantly required for the correct attachment of chromosomes at their kinetochores 
to the spindle. During metaphase, they promote the complex movements of the chromosomes 
that bring them to their properly aligned positions at the metaphase plate. In anaphase and 
telophase, MTs are needed for the synchronous separation of the chromosomes. 
Remarkably, during prometaphase, MTs emanating from each of the two spindle poles 
make vast growing and shortening excursions, essentially probing the cytoplasm until they 
‘find’ and become attached to chromosomes at their kinetochores.151 Such MTs must be able 
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to grow for long distances (typically 5–10 µm), then shorten almost completely, then re-grow 
again until they successfully become attached. The presence of a single chromosome that is 
unable to achieve a bipolar attachment to the spindle is sufficient to prevent a cell from 
transitioning to anaphase; the cell then remains blocked in a metaphase/anaphase-like state 
and eventually undergoes cell death.152 
 
MT structures undergo significant marked morphological changes to mediate specific 
functions throughout the cell cycle (Figure 1.9). Their dynamics vary during the cell cycle, 
being least dynamic in interphase cells and most dynamic during mitosis,147,150 making this an 
important target especially for anticancer drug design.30 Indeed, most tubulin-binding agents 
(TBAs) act on spindle MT dynamics, which are important for normal spindle function.29 
Thus, disruption of spindle MTs results in mitotic arrest, which can lead to cell death through 
various mechanisms. 
 
 
  
Figure 1.9. MT changes during the cell cycle. MT structures are shown in green, DNA is 
shown in blue. TBAs = tubulin-binding agents.153 
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1.8 Tubulin-Binding Agents 
A large number of structurally different substances, generally originating from natural 
sources, bind to tubulin and/or MTs, thus altering MT dynamics in different ways.154 These 
agents can be divided into two major classes: the MT-destabilizing agents and the MT-
stabilizing agents, according to their effects on MT polymer mass at high concentration. The 
MT-destabilizing agents bind preferentially to depolymerized MTs and inhibit MT assembly 
at high concentration, while the MT-stabilizing drugs bind to polymerized MTs and inhibit 
MT disassembly. The result of these interactions is inevitably the failure of the cell to 
undergo a normal mitosis. 
The first group includes compounds like the Vinca alkaloids (vinblastine, vincristine, 
vinorelbine, vindesine and vinflunine), cryptophycins, eribulin, halichondrins, estramustine, 
colchicine and combretastatins, which are mostly used for treatment of cancer.29,155,156 In 
addition, this group includes a large number of compounds that have not undergone clinical 
development for cancer therapy, including the anti-tussive noscapine,157 maytansine, rhizoxin, 
spongistatins, podophyllotoxin, steganacins and curacins,156 several herbicides,158 antifungal 
and antihelmintic agents,159 and some psychoactive drugs.160−162 The second group includes 
paclitaxel (Taxol), docetaxel (Taxotere; Sanofi-Aventis), the epothilones, discodermolide, the 
eleutherobins, sarcodictyins, dictyostatin, laulimalide, rhazinalam, peloruside A and certain 
steroids and polyisoprenyl benzophenones.155,163 
The vast majority of the MT-binding agents act as antimitotic drugs and interfere with the 
normal dynamic equilibrium of MTs, thereby disrupting the function of the mitotic apparatus. 
The suppression of MT dynamics, which are essential to proper spindle function, result in the 
slowing or blocking of mitosis at the metaphase/anaphase transition and induction of 
apoptotic cell death. Furthermore, these compounds can affect MTs in interphase cells and 
have the potential to inhibit cell motility and normal subcellular organization. Interestingly, 
the effects of the drugs on dynamics are often more powerful than their effects on polymer 
mass. Thus, they can modulate MT dynamics at 10- to 100-fold lower concentrations than 
those required to affect (increase or decrease) the MT polymer mass. 
The effects of the major tubulin-binding drugs on MT dynamics and functions are 
described next.  
 
Vinca alkaloids 
The naturally occurring members of this family, vinblastine (1.1, Figure 1.10) and 
vincristine (1.2, Figure 1.10), were originally isolated from the leaves of the periwinkle plant 
Catharanthus rosea (Vinca rosea). In the late 1950s, the Eli Lilly Research Laboratories and 
the University of Western Ontario164,165 both discovered the antimitotic and, therefore, 
anticancer potential of these drugs that came into widespread use for the treatment of 
leukemias, lymphomas, and solid malignancies.166−168 Since that time, the clinical efficacy of 
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these drugs in several combination therapies has led to the development of various semi-
synthetic analogues, including vindesine (1.3, Figure 1.10), vinorelbine (1.6, Figure 1.10) and 
vinflunine (1.7, Figure 1.10), with the principal aims to obtain more efficacious congeners 
with a broad spectrum of antitumor activity and to reduce neurotoxicities and 
myelosuppression, which are the principle side effects.169 
The main structure of Vinca alkaloids is composed of a catharenthine moiety and vindoline 
nucleus, which are not able to inhibit MT assembly when alone. Structural modifications of 
the vinblastine molecule led to the development of several non-naturally occurring analogues. 
For example, vindesine (1.3, Figure 1.10), the first semisynthetic derivative discovered, was 
developed by changing the acetyl group at C23 of vindoline moiety to an amide group,170 
whereas introduction at C23 of a L-tryptophane residue led to the development of vintripole 
(1.4, Figure 1.10).171 Vinxaltin (1.5, Figure 1.10) is currently in phase II clinical trial for the 
treatment of advanced breast cancer showing an excellent antitumour profile. The 
semisynthetic analogue vinorelbine (1.6, Figure 1.10), showed promising activity against 
breast cancer172 and is now in clinical trial for the treatment of other types of tumors.173 
Further structural modifications of vinorelbine led to the discovery of vinflunine (1.7, Figure 
1.10), which showed significantly superior in vivo anticancer activity.174  
 
 
 
Figure 1.10. Vinca alkaloid site binding agents. 
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The interactions of Vinca alkaloids, especially vinblastine, with tubulin and MTs have 
been extensively studied.155,175−177 Vinblastine binds to the β-tubulin subunit at a distinct 
region, usually referred to as the “Vinca-binding domain”,178,179 which is located very close to 
the GTP site at the interface between β1-tubulin subunit and the adjacent α2-tubulin subunit. 
The binding of vinblastine to soluble tubulin is rapid and reversible, but relatively weak (Ka 
~2 × 104 M), and is not influenced by temperature.177,180,181 Remarkably, binding of 
vinblastine induces a conformational change in tubulin, which not only promotes tubulin self-
association, but it also results in an increased affinity of vinblastine for the tubulin.175,177,182 
Vinblastine also binds directly to MTs. In vitro, vinblastine binds to tubulin at the plus 
ends of the MT with very high affinity (1 µM) (Figure 1.11), but it binds with markedly 
reduced affinity to tubulin that is buried in the tubulin lattice.183,184  
The mechanism of action of the Vinca alkaloids on tubulin and MTs is highly dependent 
upon drug concentration.155 At substoichiometric concentrations (at concentrations well 
below the concentration of tubulin free in solution) these drugs bind to high-affinity sites at 
the ends of MTs (Ka 5.3 × 10−5 M) and do not decrease the polymer mass, but they prevent 
MT polymerization by blocking mitosis through the suppression of MT dynamics. At higher 
concentrations (for example, 10–100 nM in HeLa cells), these drugs bind to low affinity, high 
capacity sites (Ka 3–4 × 10−3 M) and destroy mitotic spindles therefore leaving the dividing 
cancer cells blocked in mitosis with condensed chromosomes.  
 
 
 
Figure 1.11. Binding of vinblastine to the MT plus end suffice.29 
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The structure of vinblastine bound to the tubulin/stathmin-like domain/vinblastine complex 
was determined at 4.1 Å resolution by X-ray diffraction (Figure 1.12).185  
 
 
  
Figure 1.12. Ribbon diagram of the X-ray structure of tubulin(α1β1α2β2)/stathmin-like 
domain/vinblastine complex (α1-, α2-tubulin in cyan, β1-, β2-tubulin in purple, GDP in green, 
GTP in yellow, stathmin-like in gray, vinblastine in white.185,186 
 
Colchicine  
Colchicine (1.8, Figure 1.13) was originally isolated from the meadow saffron Colchicum 
autumnale and it is used clinically in the treatment and prevention of gout,187 familial 
Mediterranean fever and liver cirrhosis.188 The toxicity profile of colchicine, as well as 
compounds that bind to the “colchicine site” on tubulin, prevented their use in other therapies, 
including cancer chemotherapy. The reasons for this are not completely clear, but might be 
related to their potent effect on MT assembly.29 
Because of the important toxicity profile of colchicine, hundreds of analogues have been 
discovered in the past decades. Thus, for example, colchicone (1.9, Figure 1.13), 
thiocolchicine (1.10, Figure 1.13), allocolchicine, (1.11, Figure 1.13), cornigerine (1.12, 
Figure 1.13), podophyllotoxin (1.13, Figure 1.13), etoposide (1.14, Figure 1.13), teniposide 
(1.15, Figure 1.13), combretastatin A-4 (1.16, Figure 1.13) and related congeners (1.17−1.19, 
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and 1.20, 1.21, Figure 1.13) are all derivatives of colchicine that share a common binding site 
on tubulin and mechanism of action together with a more favorable water solubility, more 
potent activity, and lower toxicity than colchicine. 
 
 
 
  
  
Figure 1.13. Colchicine binding site agents. 
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The colchicine-binding site on tubulin has been extensively studied.189,190 It is located at 
the αβ-tubulin heterodimer interface191 and, when colchicine is bound to tubulin, it forms 
complexes with tubulin dimers and copolymerizes into the MT lattice, suppressing MT 
dynamics (Figure 1.14).192 As with the Vinca alkaloids, colchicine promotes MT 
depolymerization at high concentrations and powerfully suppresses MT dynamics at low 
concentrations, without appreciably affecting the mass of assembled MTs.192,193 Colchicine 
first binds to soluble tubulin, induces slow conformational changes in the tubulin, and 
ultimately forms a final-state tubulin–colchicine complex, which poorly dissociates.175,194  
 
In contrast to vinblastine, which acts selectively at the plus ends, colchicine copolymerizes 
along with free tubulin into the MT at both ends,195 which remain competent to grow but their 
dynamics are suppressed.196 
 
 
 
Figure 1.14. Binding of colchicine to MTs.29 
 
 
The binding mode of colchicine was confirmed by the determination of a 3.58 Å X-ray 
structure of tubulin complexed with N-deacetyl-N-(2mercaptoacetyl)colchicine (DAMA-
colchicine), which is a close structural analogue of colchicine (Figure 1.15).191 
It has been reported that the β-tubulin subunit is mostly involved in colchicine binding. In 
particular, the A ring of colchicine (Figure 1.13) is involved in interactions with Cys-354 and 
Cys-239 residues and the C ring lying between the peptide region containing Cys-239, the 
terminal amino sequence, and the region containing aminoacids 1−36.197,198 The seven 
membered B ring is not believed to be crucial for tubulin binding,199,200 while the 
trimethoxyphenyl group on A ring and the α-methoxytropolone ring C are important 
structural features essential for inhibition of MT assembly. 
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Figure 1.15. Ribbon diagram of the X-ray structure of tubulin(α1β1α2β2)/stathmin-like 
domain/DAMA colchicine complex. α1-, α2-Tubulin in cyan, β1-, β2-tubulin in purple, GDP 
in green, GTP in yellow, stathmin-like in gray, DAMA-colchicine in white.191,201 
 
Taxanes 
Paclitaxel (1.22, Figure 1.16) and its more potent, semisynthetic derivative docetaxel (1.23, 
Figure 1.16) are among the most important antimitotic agents with broad antitumor activity. 
Paclitaxel was isolated from the pacific yew, Taxus brevifolia, by Wani and Wall in 1971.202 
The difficulties in limited supplies of the natural compound, formulation, poorly solubility, 
and toxicities initially prohibited its clinical development. The discovery by Peter Schiff and 
Susan Horwitz that, unlike the Vinca alkaloids, paclitaxel acts by stimulating MT 
polymerization,203 encourajed the development of procedures for its semi-synthesis and a 
more practical formulation that allowed paclitaxel to be approved for clinical purposes by 
1995. Paclitaxel is now semisynthesized from baccatin III (1.24, Figure 1.16), which is 
isolated from Taxus baccata,204 or fully synthesized205 and it is widely used to treat breast and 
ovarian cancer, non-small-cell lung cancer and Kaposi’s sarcoma. Principal side effects are 
represented by neurotoxicity and myelosuppression.206,207  
Extensive structure-activity relationship (SAR) studies provided the structural determinants 
responsible for the activity of paclitaxel. It is now established that the side chain at C13 
bearing a C2'-OH, as well as the benzoyl group at C2 and the oxetane ring at C4-C5 are 
essential for both cytotoxicity and stabilization of MTs.208,209 Remarkably, the oxetane ring 
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appeared to be an important feature, as analogues that bear an open oxetane ring showed a 
greatly reduced activity. The acetyl group at C4 did not appear to play a significant role in the 
biological activity, but it may contribute to the final conformation of the molecule. Finally, 
the C1-OH group imparts a significant contribution to the overall bioactivity.208 
 
  
Figure 1.16. Taxane site binding agents. 
 
 
Paclitaxel binds poorly to soluble tubulin itself, while binds directly with high affinity to 
tubulin along the length of the MT (Figure 1.17). In detail, paclitaxel acts on MTs by binding 
within the lumen of the MT at a site in the β-tubulin subunit on the inside surface of the MT, 
which is commonly referred to as the “taxane site”. Although the binding site is on the inside 
surface of the MT, paclitaxel is thought to gain access to its binding site by diffusing through 
small openings in the MT or fluctuations of the MT lattice.210 The interaction with β-tubulin 
results in conformational changes in the M-loop of β-tubulin that ultimately stabilize lateral 
interactions of adjacent protofilaments.6,211  
Like the Vinca alkaloids, the mechanism of action of paclitaxel, and taxanes in general, is 
dose-dependent.212 At low concentrations, taxanes induce a mitotic block without a 
significantly increase in MT polymer mass. These effects are associated with abnormalities in 
the metaphase plate and mitotic asters. At higher concentrations, taxanes induce 
polymerization of stable MTs. 
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Figure 1.17. A MT cut away to Taxol binding along the interior surface of the MT.29 
 
 
The structure of the tubulin-paclitaxel complex has been solved at 3.5 Å by electron 
crystallography (Figure 1.18).8 
 
 
  
Figure 1.18. Ribbon diagram of the X-ray structure of α,β-tubulin/paclitaxel complex (α-
tubulin in cyan, β-tubulin in purple, GDP in green, GTP in yellow, stathmin-like in gray, 
paclitaxel in white.8,18 
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The clinical success of the taxanes has led to a search for other drugs that enhance MT 
polymerization, yielding several promising compounds, including the epothilones, 
discodermolide, the sarcodictyins, eleutherobin and laulimalide. Some of these compounds 
compete with paclitaxel for binding to MTs and are said to bind at or near the taxane site 
(epothilones, discodermolide, eleutherobins and sarcodictyins), but others, such as 
laulimalide, seem to bind to unique sites on MT.213  
 
1.9 Resistance to Tubulin-Binding Agents  
Resistance to tubulin-binding drugs is mediated by several mechanisms, including drug 
efflux by membrane pumps, alterations in tubulin, cell cycle perturbations, changes in drug 
distribution and metabolism, and failed induction of the apoptotic signal (Figure 1.19). 
 
 
Figure 1.19. Potential mechanisms of resistance to tubulin-binding agents.214 
 
 
Overexpression of a class of membrane transporter proteins known as ABC-transporters 
(ATP-dependent drug efflux pumps or ATP-binding cassettes) produce decreased intracellular 
drug levels and lead to cross-resistance (multi-drug resistance (MDR)) to drugs of different 
chemical structures, such as taxanes and Vinca alkaloids.215 The first of many membrane 
pumps identified was P-glycoprotein (Pgp), a 170 kDa phosphoglycoprotein encoded by the 
human MDR1 gene.216−219 Considerable efforts are underway to understand these mechanisms 
of resistance, to develop Pgp inhibitors and MT-targeted drugs that are not removed by these 
pumps.220−223 
Cells have also many MT-related mechanisms that confer resistance or determine intrinsic 
insensitivity to antimitotic drugs29,223−231 MT-polymer levels and dynamics are regulated by a 
host of factors, including expression of regulatory proteins, PTMs of tubulin and expression 
of different tubulin isotypes. The levels of each of these isotypes, for example, differ among 
tissue and cell types, and there are several examples of changes in their levels that correlate 
with development of resistance to paclitaxel or Vinca alkaloids and other MT-interacting 
drugs.224,226,232−242 
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The ability of tubulin-binding agents to kill cells appears to require the cell to enter 
mitosis. Therefore, alterations that prevent entry into mitosis and determine cell cycle 
perturbations might be expected to result in drug resistance. Accordingly, Fojo and 
coworkers243 demonstrated that tumor cells that lose the G2 check point (p53, p21 
incompetent) do not delay proliferation following exposure to a DNA damaging drug 
(doxorubicin) and are readily killed by Vinca alkaloids and taxanes. In contrast, cells that 
maintain normal G2/M checkpoint control (p53/p21 competent) are resistant to killing by 
anti-MT drugs because they delay at G2/M following DNA damage. These data suggest that 
normal cells exposed to low doses of anthracyclines will become transiently resistant to anti-
MT agents whereas certain tumor cells will not, thereby improving the therapeutic index of 
tubulin-binding agents. However, this same strategy could potentially protect malignant cells 
with intact checkpoints. For example, Alli and coworkers244 found that breast cancer cell lines 
with mutant p53 overexpress stathmin and are less sensitive to Vinca alkaloids and taxanes; 
this decrease in sensitivity was associated with G2 arrest. 
Scientific evidence demonstrated that changes in drug metabolism, such as overexpression 
of CYP3A4, produce resistance to Vinca alkaloids and that treatment of several malignant cell 
lines with vincristine or vinblastine select for surviving cells that express the cytochrome 
p450 phenotype.245  
Finally, prolonged cell-cycle arrest, caused by the interaction of antimitotic drugs with 
tubulin, may induce death signals. Indeed, abrogation of the G2/M checkpoint by mutations in 
tubulin, as well as several antiapoptotic molecules including bcl-2, bcl-xL, bim, and p53 have 
been demonstrated to be involved in resistance to these drugs.246,247 For example, bcl-2 was 
first discovered as the gene on chromosome 18q21 at the breakpoint of the t(14;18) 
chromosomal translocation found in B-cell follicular lymphomas.248 This translocation places 
the bcl-2 gene next to the immunoglobulin heavy chain enhancer, leading to overexpression 
of the bcl-2 protein that gives B cells the ability to survive in the absence of a requisite 
growth factor, interleukin-3. Thus, bcl-2 promotes malignant transformation by prolonging 
cell survival independent of usual control factors rather than by increasing the rate of cell 
division.249 
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Chapter 2: New Indole Derivatives as Potent Inhibitors of Tubulin 
Polymerization 
2.1 Introduction 
The cytoskeleton of MTs is both an effective and a validated target in the therapy of 
cancer.1−4 Because of their crucial role in the formation of the mitotic spindle during cell 
division, drugs that bind to either unpolymerized tubulin or tubulin polymer interfere both 
with cell division and interphase functions, which require a normal MT cytoskeleton, and 
invariably lead to cell death. As discussed in chapter 1, a wide-range of natural products are 
known to interact with the tubulin/MT system displaying antimitotic and anticancer 
properties. In this respect, colchicine,5,6 combretastatin A-4 (CSA4)7 and the Catharanthus 
alkaloids vincristine, vinblastine and vinorelbine are tubulin assembly inhibitors that interact 
with α,β-tubulin dimers at distinct interfaces between the two subunits. This effect results in 
MT destabilization, arrest of mitotic progression, and subsequent apoptosis.8,9 In contrast, 
MT-stabilizing drugs, such as the toxoids paclitaxel and docetaxel, as well as epothilones, 
block MT disassembly by targeting a lumenal site on the β-subunit10,11 and entering the lumen 
through a binding site located at a pore on the MT surface formed by different tubulin 
dimers.12 Overall, these drugs (especially Vinca alkaloids and taxanes) have been broadly 
used in cancer therapy for the treatment of a variety of tumor types. However, although their 
notably efficacy in some patients, their clinical use is limited by resistance that occurs with 
high frequency either at the onset or during the course of therapy. Furthermore, toxicity and 
unwanted side effects still remain unsolved problems. Therefore, despite the progress 
achieved in the development of MT-targeting drugs with different mechanisms of action and 
improved afficacy the quest for new and potent anticancer agents remains mandatory.13 
 
2.2 Arylthioindoles as New Potent Anticancer Agents 
Over the years, a great number of indoles were found to be effective as inhibitors of 
tubulin assembly.14−17 In this context, Silvestri and coworkers recently discovered 
arylthioindoles (ATIs, Figure 2.1) as a new class of potent inhibitors of tubulin 
polymerization and the growth of MCF-7 human breast carcinoma cells.18−23 ATIs inhibit 
[3H]colchicine binding on β-tubulin close to its interface with α-tubulin within the α,β-
dimer.18 A number of ATIs proved to be more potent than other chemotypes so far presented, 
thus encouraging their development as new potential therapeutics in cancer therapy.22,23 
Structure-activity relationship (SAR) and molecular modeling studies on ATI derivatives 
highlighted three essential structural requirements: (a) aromatic ring at position 2 of the 
indole, which is important for activity and improves metabolic stability (b) 3,4,5-
trimethoxyphenyl moiety; (c) sulfur, ketone, or methylene bridging group at position 3 of the 
indole (Figure 2.1). 
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Accordingly, ATI 2.1 (Figure 2.1) was found to inhibit tubulin assembly with IC50 = 3.3 
µM and growth of MCF-7 human breast carcinoma cells with IC50 = 52 nM,23 whereas ATI 
2.2 (Figure 2.1), proved to be another potent analogue with tubulin assembly IC50 = 2.0 µM 
and MCF-7 IC50 = 13 nM.18 It should also be noted that major differences in SARs were 
found in comparing ATIs with the 3-aroylindoles reported by Hsieh and coworkers.24 These 
compounds are characterized by the presence of a methoxy group at position 6 of the indole.  
 
 
  
Figure 2.1. Most potent ATIs discovered in previous studies (2.1 and 2.2)18,23 and design of 
new ATI derivatives 2.3−2.42. Adapted from Ref. 25. 
 
2.3 Objective of the Study 
ATI derivatives bearing an aromatic ring at position 2 of the indole (A region, Figure 2.1) 
inhibit tubulin polymerization and cancer cell growth. These compounds hamper mitotic 
progression, thus causing cells to undergo apoptosis (i.e., ATI 2.1).22,23 In contrast, chemical 
modification of positions 4−7 of the indole (D region, Figure 2.1) were not exhaustively 
explored, although a few ATIs, such as 2.2, bearing a methoxycarbonyl functionality at 
position 2 and a halogen atom or a methoxy group at position 5 were found to be potent 
tubulin assembly inhibitors.18 
Docking studies of colchicine and compound 2.1 into the colchicine site of tubulin showed 
a good superimposition of the trimethoxyphenyl moieties and of the tropolone ring of 
colchicine with the phenyl core of the indole (Figure 2.2).22,23 
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Figure 2.2. Proposed binding modes of colchicine (cyan), 2.1 (gray), and 2.41 (orange). 
Tubulin is represented as a cartoon for the α-subunit (red) and β-subunit (green). Residues 
forming interactions with the ATI D region are depicted in white.25  
 
 
These findings suggested that appropriate substituents at positions 4−7 of the indole could 
resemble the methoxy and carbonyl groups of the tropolone ring of colchicine, respectively. 
Docking simulations with PLANTS,26 using a methodology previously described by Coluccia 
and coworkers,27 revealed binding poses consistent with the previous ATI series: (i) the 
trimethoxyphenyl group forms polar interactions with βCys241, βMet259, and βLeu255; (ii) 
the indole NH establishes a hydrogen bond with αThr179; (iii) the phenyl ring at position 2 of 
the indole imparts hydrophobic interactions with the βLys254 and βLeu248 side chains. In 
comparison with 2.1, the chlorine atom(s) of compounds 2.7, 2.15, 2.25, 2.34, and 2.41 fit 
into a new hydrophobic pocket formed by the βLys353, βAsn258, βMet259, and αVal181 
residue side chains (Figure 2.3). 
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Figure 2.3.	 Proposed binding mode of 2.7 (pink), 2.15 (magenta), 2.25 (violet), and 2.41 
(orange); colchicine is shown in cyan. Tubulin is represented as a cartoon for the α- (red) and 
β- (green) subunits. Residues forming interactions with the D region of the ATIs are depicted 
in white. HBs are indicated by yellow dashed lines.25 
 
The 7-fluoro atom of 2.37 behaves as a hydrogen bond acceptor with αVal181, while the 
methoxy group of 2.30 mimics the corresponding group at position 10 of colchicine, 
resembling its interaction with the εN of βLys353 (Figure2.4).  
 
 
Figure 2.4. Proposed binding modes of 2.30 (grey) and 2.37 (orange); colchicine is shown in 
cyan. Tubulin is represented as a cartoon for the α- (red) and β- (green) subunits. Residues 
forming interactions with the D region of the ATIs are depicted in white. HBs are indicated 
by yellow dashed lines.25 
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Starting from these observations we conducted SAR investigations of new 2-phenyl-1H-
indole derivatives bearing halogen or methoxy substitutent(s) at positions 4−7. We 
maintained the phenyl group at position 2 of the indole, because of the better metabolic 
profile compared to that of indole derivatives bearing an ester function at this position,23 and 
the trimethoxyphenyl moiety at position 3, because of its important role in binding at the 
colchicine site. Accordingly, we designed and synthesized 39 new ATI derivatives that were 
evaluated as inhibitors of tubulin polymerization, the growth of MCF-7 human breast cancer 
cells, and the binding of [3H]colchicine to tubulin. 
As a PhD student of Prof. R. Silvestri’s research group, I participated in the synthesis and 
characterization of compounds 2.3−2.42 (see Experimental Section, Chemistry 2.7.1). 
 
2.4 Chemistry 
2-Phenyl-3-((3,4,5-trimethoxyphenyl)thio)-1H-indoles 2.3, 2.5, 2.8, 2.10, 2.12, 2.15, 2.18, 
2.20, 2.22, 2.25, 2.28, 2.30, 2.32, 2.34, 2.37, 2.39, and 2.41 were prepared using a previously 
reported venting-while-heating microwave-assisted procedure28 by reacting 2-phenylindoles 
2.43−2.59 (prepared as described in Scheme 2.2) with bis(3,4,5-trimethoxyphenyl) disulfide18 
in the presence of sodium hydride (Scheme 2.1). Microwave-assisted Friedel−Crafts reaction 
of the indoles 2.43−2.59 with 3,4,5-trimethoxybenzoyl chloride in the presence of AlCl3 in 
1,2-dichloroethane yielded the corresponding methanones 2.4, 2.6, 2.9, 2.11, 2.13, 2.16, 2.19, 
2.21, 2.24, 2.26, 2.29, 2.31, 2.33, 2.35, 2.38, 2.40, and 2.42.21 Finally, reduction of the 
appropriate ketones with a borane−tetrahydrofuran complex29 in acetonitrile/methanol 
furnished the corresponding methylene derivatives 2.7, 2.17, 2.22, 2.27, and 2.36, whereas 
derivative 2.14 was obtained by reducing 2.13 with triethylsilane/trifluoroacetic acid in 1,2-
dichloroethane under microwave-assisted conditions (Scheme 2.1).30  
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Scheme 2.1. Synthesis of compounds 2.3−2.42. 
 
 
Synthesis of intermediates 2.43−2.59 was accomplished following synthetic scheme 
depicted in Scheme 2.2. Reaction of the appropriate 1-methyl-2-nitrobenzene with 
benzaldehyde in the presence of sodium ethoxide furnished the corresponding alcohols 
2.60−2.62. After oxidation of 2.60−2.62 to ketones 2.63−2.65 with pyridinium 
chlorochromate (PCC), the nitro group was reduced to amino using tin(II) chloride 
dihydrate/1 N HCl in acetic acid. Thus, the intermediate aminoketone underwent 
intramolecular cyclization to give the corresponding 2-phenylindoles 2.43, 2.51 and 2.53 
(Scheme 2.2A).31  
Preparation of 2-phenylindoles 2.44−2.46, 2.52, 2.54, and 2.58 was achieved by reaction of 
the N-(2-tolyl)benzamides 2.66−2.71 with tert-butyllithium in anhydrous tetrahydrofuran,32 
after obtaining intermediate amides 2.66−2.71 by treatment of an appropriate o-toluidine with 
N
H
R
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NaH, DMF
microwave 130 °C, 120 W, 2 min
20−77%
3,4,5-trimethoxybenzoyl chloride
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DCE
microwave 110 °C, 150 W, 2 min
                  20−78%
a) borane-tetrahydrofuran complex
     ACN/MeOH
     50 °C, 1 h
b) TES/TFA
    DCE
    microwave 250 °C, 250 W, 20 min
                      10−41%
Different synthetic procedures
depending on the commercial
availability of primary reactives
N
H
R
S
OMe
OMe
OMe
N
H
R
OMe
OMe
OMe
O
N
H
R
OMe
OMe
OMe
2.43−2.59 2.3, 2.5, 2.8, 2.10, 2.12, 2.15,
2.18,2.20, 2.22, 2.25, 2.28, 2.30,
2.32, 2.34, 2.37, 2.39, 2.41
2.4, 2.6, 2.9, 2.11, 2.13, 2.16,
2.19,2.21, 2.24, 2.26, 2.29, 2.31,
2.33, 2.35, 2.38, 2.40, 2.42
2.7, 2.14, 2.17, 2.22, 2.27, 2.36
2.3, 2.4, 2.43 R = 4-Br; 2.5−2.7, 2.44 R = 4-Cl; 2.8, 2.9, 2.45 R = 4-F; 2.10, 2.11, 2.46 R = 4-OMe;
2.12−2.14, 2.47 R = 5-Br; 2.15−2.17, 2.48 R = 5-Cl; 2.18, 2.19, 2.49 R = 5-F; 2.20−2.22, 2.50 R = 5-OMe;
2.23, 2.24, 2.51 R = 6-Br; 2.25−2.27, 2.52 R = 6-Cl; 2.28, 2.29, 2.53 R = 6-F; 2.30, 2.31, 2.54 R = 6-OMe;
2.32, 2.36, 2.55 R = 7-Br; 2.34−2.36, 2.56 R = 7-Cl; 2.37, 2.38, 2.57 R = 7-F; 2.39, 2.40, 2.58 R = 7-OMe; 
2.41, 2.42, 2.59 R = 6,7-Cl2.
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benzoyl chloride in the presence of triethylamine (Scheme 2.2B). Finally, polyphosphoric 
acid (PPA)-mediated cyclization of phenylhydrazones 2.72−2.77, prepared with a cooling-
while-heating microwave-assisted reaction conducted in an open vessel using the appropriate 
phenylhydrazine hydrochloride and acetophenone in the presence of sodium acetate in 
ethanol,33 furnished the corresponding 2-phenylindoles 2.47−2.49, 2.55, 2.57, and 2.59 
(Scheme 2.2C).34 
 
 
  
Scheme 2.2. Synthesis of intermediates 2.43−2.59. 
 
 
 
Me
NO2
R
NO2
R OH NO2
R O
N
H
R
2.43, 2.51, 2.53
benzaldehyde
EtONa, DMSO
RT, 12 h
40−44% 2.60−2.62 2.63−2.65
PCC, CH2Cl2
RT, 1.5 h
16−40%
SnCl2  2H2O/1N HCl
AcOH
reflux, 12 h
19−24%
Me
NH2
R
N
H
R
benzoyl chloride
Et3N, THF
reflux, 2 h
49−88%
2.66−2.71
OMe
N
H
R
2.44−2.46, 2.52, 2.54, 2.58
t-BuLi, THF
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110 °C, 1 h
25−82%
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2.60, 2.63 R = 2-Br; 2.61, 2.64 R = 4-Br; 2.62, 2.65 R = 4-F; 2.66 R = 3-Cl; 2.67 R = 3-F;
2.68 R = 3-OMe; 2.69 R = 5-Cl; 2.70 R = 5-OMe; 2.71 R = 2-OMe; 2.72 R = 4-Br;
2.73 R = 4-Cl; 2.74 R = 4-F; 2.75 R = 2-Br; 2.76 R = 2-F; 2.77 R = 5,6-Cl2.
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2.5 Results and Discussion 
SAR Analysis. Activities of compounds 2.3−2.42, colchicine, CSA4, and ATIs 2.1 and 2.2 
are shown in Table 2.1. The majority of the new derivatives (23 compounds: 2.5, 2.8, 2.9, 
2.12, 2.15, 2.18, 2.23−2.27, 2.30−2.35, and 2.37−2.42) inhibited tubulin polymerization with 
IC50 values in the 1.0−2.0 µM range, being comparable to the references colchicine and 
CSA4. 
Evaluation of the effect of different substitutions at position 4 of the indole (compounds 
2.3−2.11) reveals that the 4-chloro derivative 2.5 exhibits good tubulin assembly inhibitiory 
activity with an half maximal inhibitory concentration (IC50) value of 1.6 µM, being 2.2-fold 
more active compared to the corresponding ketone 2.6 (IC50 = 3.6 µM). The thio/keto 4-fluoro 
derivatives 2.8 and 2.9 are almost equipotent as tubulin assembly inhibitors and showed the 
greatest inhibition of MCF-7 cell growth in the nanomolar range. Neither the bromine atom 
nor the methoxy group was found among the most active 4-substituted indole derivatives in 
both the thio and ketone series. In terms of effects on MCF-7 cell growth, there is no evident 
major difference between the thio and ketone series, although the data are limited. 
 Among ATI derivatives 2.12−2.22, bearing a substituent at position 5 of the indole, four 
compounds (2.12, 2.15, 2.18, and 2.20) were found to be significantly more potent than the 
corresponding ketones (2.13, 2.16, 2.19, and 2.21, respectively) and slightly more active than 
the methylene analogues (2.14, 2.17, and 2.22, respectively). In general, the tubulin inhibitory 
activity of 5-substituted analogues seems to be weakly affected by the nature of the 
substituent. In contrast to the corresponding ester derivatives, all these compounds were 
found to be weak inhibitors of MCF-7 cell growth with IC50 ≥ 100 nM (cf., 2.2 with 2.20). 
Furthermore, within the limitations of the data, there are no major differences in the effects on 
MCF-7 cell growth dependent on the bridging group (thio, ketone, or methylene).  
All the derivatives bearing the substituent at position 6 of the indole (compounds 
2.23−2.31) inhibited tubulin polymerization with IC50 < 2.5 µM, with the possible exception 
of the 6-fluoro derivative 2.29, which showed an IC50 value of 10 µM. As inhibitors of MCF-
7 cell growth, ketones showed to be generally less potent than the corresponding thio 
derivatives (cf., 2.23 with 2.24, 2.30 with 2.31). Furthermore, among the thio-derivatives, the 
6-bromo derivative 2.23 and 6-methoxy derivative 2.30 showed the most potent cell growth 
inhibitory activity. 
With respect to the substitution at position 7 of the indole, all the derivatives (compounds 
2.32−2.40) showed to be essentially potent inhibitors of tubulin assembly with IC50 < 2.5 µM. 
With the exception of 2.36 and 2.40, these compounds potently inhibited the growth of the 
MCF-7 cells, with 2.33 and 2.35 being the most active analogues of the series (IC50 = 4 and 9 
nM, respectively). However, in contrast to what was observed for the 6-substituted indoles, 
the 7-substituted derivatives, particularly the bromo and chloro ketones appeared to be 
generally more potent than the corresponding thio-counterparts as inhibitors of MCF-7 cell 
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growth (cf., 2.23 and 2.24 with 2.32 and 2.33, 2.25 and 2.26 with 2.34 and 2.35). Finally, we 
tried to join the features of 2.25 and 2.26 with those of 2.34 and 2.35 to further enhance 
activity. This effort yielded the 6,7-dichlorinated derivatives 2.41 and 2.42, which showed to 
be highly potent inhibitors of tubulin polymerization and MCF-7 cell growth. 
 
 
Cmpd R X 
Tubulin assembly 
IC50 ± SDa (µM) 
MCF-7 
IC50 ± SDb (nM) 
Colchicine binding 
inhibitionb,c (% ± SD) 
2.3 4-Br S 2.4 ± 0.1 400 ± 70 33 ± 2 
2.4 4-Br C=O >20 (partial activity)d 430 ± 100 ND 
2.5 4-Cl S 1.6 ± 0.07 290 ± 50 48 ± 5 
2.6 4-Cl C=O 3.6 ± 0.2 260 ± 50 38 ± 3 
2.7 4-Cl CH2 17 ± 0.2 >5000 ND 
2.8 4-F S 1.7 ± 0.07 80 ± 30  80 ± 0.4 
2.9 4-F C=O 1.6 ± 0.08 65 ± 7 63 ± 1 
2.10 4-OMe S >20 (partial activity)d 1400 ± 300 ND 
2.11 4-OMe C=O >20 (no activity)e >5000 ND 
2.12 5-Br S 1.3 ± 0.1 320 ± 100 39 ± 3 
2.13 5-Br C=O >40 530 ± 100 ND 
2.14 5-Br CH2 4.0 ± 0.5 700 ± 300 31 ± 2 
2.15 5-Cl S 1.5 ± 0.2 280 ± 70 49 ± 5 
2.16 5-Cl C=O >20 330 ± 100 ND 
2.17 5-Cl CH2 4.4 ± 0.8 310 ± 10 38 ± 3 
2.18 5-F S 1.5 ± 0.1 300 ± 0 61 ± 4 
2.19 5-F C=O 13 ± 0.4 240 ± 90 ND 
2.20 5-OMe S 2.1 ± 0.01 200 ± 80 58 ± 0.5 
2.21 5-OMe C=O 8.3 ± 1 170 ± 60 ND 
2.22 5-OMe CH2 3.5 ± 0.4 100 ± 0 41 ± 0.9 
N
H
R X
OMe
OMe
OMe
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2.23 6-Br S 1.9 ± 0.2 9.0 ± 2 87 ± 0.6 
2.24 6-Br C=O 1.3 ± 0.2 30 ± 2 86 ± 0.4 
2.25 6-Cl S 1.2 ± 0.2 20 ± 10 88 ± 3 
2.26 6-Cl C=O 1.4 ± 0.06 35 ± 7 71 ± 5 
2.27 6-Cl CH2 1.6 ± 0.01 55 ± 20 72 ± 6 
2.28 6-F S 2.4 ± 0.2 80 ± 20 74 ± 2 
2.29 6-F C=O 10 ± 0.4 600 ± 0 ND 
2.30 6-OMe S 1.1 ± 0.1 1.3 ± 0.6 96 ± 1 
2.31 6-OMe C=O 1.2 ± 0.06 30 ± 10 95 ± 0.4 
2.32 7-Br S 1.6 ± 0.2 25 ± 5 82 ± 1 
2.33 7-Br C=O 1.7 ± 0.1 4.0 ± 0.5 72 ± 0.3 
2.34 7-Cl S 1.3 ± 0.2 50 ± 10 82 ± 0.3 
2.35 7-Cl C=O 1.8 ± 0.05 9.0 ± 1 69 ± 0.5 
2.36 7-Cl CH2 2.4 ± 0.2 200 ± 0 50 ± 4 
2.37 7-F S 1.0 ± 0.1 20 ± 9 92 ± 0.3 
2.38 7-F C=O 1.7 ± 0.1 30 ± 0 67 ± 3 
2.39 7-OMe S 1.2 ± 0.01 19 ± 10 87 ± 2 
2.40 7-OMe C=O 1.8 ± 0.1 200 ± 0 62 ± 3 
2.41 6,7-Cl2 S 1.2 ± 0.1 7.0 ± 3 92 ± 2 
2.42 6,7-Cl2 C=O 1.5 ± 0.03 15 ± 5 93 ± 0.7 
Colchicine − − 3.2 ± 0.4 5.0 ± 1 ND 
CSA4 − − 1.0 ± 0.1 13 ± 3 98 ± 0.6 
2.1f − − 3.3 ± 0.1 52 ± 7 ND 
2.2g − − 2.0 ± 0.2 13 ± 3 93 ± 0.8 
 
Table 2.1. Inhibition of tubulin polymerization, growth of MCF-7 human breast carcinoma 
cells, and binding of colchicine to tubulin by compounds 2.1−2.42 and references colchicine, 
and CSA4. aTubulin was at 10 µM in the assembly assay. bCompounds that inhibited tubulin 
assembly with IC50 ≤ 5 µM were tested in the cellular and colchicine binding assays. cTubulin 
was at 1 µM. Both [3H]colchicine and inhibitor were at 5 µM. dPartial inhibition at 20 µM. 
eLittle or no activity at 20 µM. fReference 23. gReference 18. ND = not determined. 
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The results obtained from the docking simulations described above provided us with a 
general binding mode that was able to justify the biological activity of compounds 2.3−2.42. 
However, we found some exceptions that could not be fully rationalized (2.4, 2.10, 2.11, 
and 2.13), and that did not show any correlation between docking scores and experimental 
data. This fact prompted us to further investigate the binding mode of ATIs with another set 
of docking simulations using a more recent tubulin structure (PDB code: 4O2A),35 
crystallized at higher resolution than the structure used in our previous simulations (2.50 Å 
vs. 3.58 Å, respectively).35 Furthermore, we performed the docking calculations using two 
other software programs, Glide36,37 and Autodock,38 which rely on a different search 
algorithm. The docking results obtained from these simulations showed a virtually identical 
binding pose for the ATIs, and were entirely consistent with the one obtained using 
PLANTS26 (Figure 2.5). 
 
 
Figure 2.5. Left panel. Binding mode of 2.37 furnished by: PLANTS (cyan), Glide (magenta) 
and Autodock (yellow) versus 1SA0 tubulin crystal structure. Right panel. Binding mode of 
2.37 furnished by: PLANTS (cyan), Glide (magenta) and Autodock (yellow) versus 42OA 
tubulin crystal structure.25 
 
The data presented Table 2.1 reveal that inhibition of tubulin polymerization is in good 
agreement with inhibition of colchicine binding, as demonstrated by comparing the MT 
assembly inhibitory concentrations (µM) with the percent inhibition of colchicine binding, 
which provide an indirect measure of the affinity of the compounds for the colchicine site 
(Figure 2.6). Compounds that inhibited tubulin assembly with IC50 values in the 1.0−1.5 µM 
range showed a colchicine binding inhibition mean value of 79%, whereas those with IC50 
values in the 1.6−2.0 µM range showed a mean value of 70%, and inhibitors with IC50 values 
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in the 2.1−3.0 µM range inhibited colchicine binding with a mean value of 53%. CSA4 has 
been used as reference compound (tubulin assembly inhibition, IC50 = 1.0 µM; colchicine 
binding inhibition, 98%). 
 
 
Figure 2.6. Correlation between inhibition of tubulin assembly (IC50 values, µM) and 
inhibition of colchicine binding (%). Data of ATI derivatives 2.3−2.42 are shown as open 
circles. The black circle represents the reference CSA4.25 
 
 
Same good correlation was observed beetween the MCF-7 cell growth inhibition (nM) of 
ATIs 2.3−2.42 and the percent inhibition on the binding of [3H]colchicine to tubulin (Figure 
2.7B).  
 
  
Figure 2.7. Correlation between the MCF-7 cytotoxicity data and inhibition of tubulin 
assembly (A) or inhibition of colchicine binding (B). Data of ATI derivatives 2.3−2.42 are 
shown as open circles. Black circle represents the reference CSA4.25 
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Cell Growth Inhibition. Two representative members of the series, 2.30 and 2.41, were 
found to uniformly inhibit the growth of a panel of cancer cells, including breast cancer 
(MDA-MB-468, MDA-MB-436, MDA-MB-231), human acute myelocytic leukemia 
(MV4−11, NB4), and human lung adenocarcinoma (A-549, NCI-H1975) cell lines (Table 
2.2). Paclitaxel was used as reference drug. As shown by the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay performed at 48 and 72 h, ATIs 2.30 and 2.41 
induce a dose- and time-dependent growth inhibition of each treated breast cancer cell line 
with IC50 values in the nanomolar range at 72 h. As inhibitors of the human acute myelocytic 
leukemia and the human lung adenocarcinoma cancer cells bearing the KRAS mutation and 
resistance to EGFR inhibitors, 2.30 and 2.41 yielded IC50 values in the nanomolar range at 48 
and 72 h, respectively.  
 
 
 IC50 ± SD (nM) 
Cmpd 
MDA-MB-
468a 
MDA-MB-
436a 
MDA-MB-
231a 
MV4−11b NB4b A-549a 
NCI-H19 
75a 
2.30 37 ± 0.5 62 ± 1 39 ± 1.2 2.5 ± 2.1 4 ± 1 28 ± 6 195 ± 158 
2.41 33 ± 0.3 75 ± 1.1 47 ± 0.1 10.5 ± 0.7 10 ± 4 120 ± 10 305 ± 122 
Paclitaxel 5 ± 1 8 ± 1.5 7 ± 2 ND 2.3 ± 0.3 7 ± 2 2.5 ± 5  
Table 2.2. Growth inhibition of the MDA-MB-468, MDA-MB-436, MDA-MB-231, A-549, 
MV4-11, NB4, and NCI-H1975 cell lines by compounds 2.30 and 2.41 and paclitaxel as 
reference. aIncubation time was 72 h. bIncubation time was 48 h. ND = not determined.  
 
 
Multi-Drug-Resistant (MDR) Cell Lines. ATIs 2.30 and 2.41 were assayed as growth 
inhibitors of the ovarian carcinoma cell line OVCAR-8 and its cognate P-glycoprotein (Pgp)-
over-expressing line NCI/ADR-RES and of the human uterine sarcoma cell line Messa and its 
cognate MDR line Messa/Dx5, using colchicine, CSA4, vinorelbine, vinblastine, and 
paclitaxel as reference compounds (Table 2.3). Compounds 2.30 and 2.41 showed particularly 
potent inhibitory activity against these MDR cell lines, being comparable to CSA4 as 
inhibitors of the NCI/ADR-RES and Messa/Dx5 cell lines, respectively. Conversely, the 
references colchicine, vinorelbine, vinblastine and paclitaxel appear to be generally weak 
inhibitors of the MDR cell lines. 
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 IC50 ± SD (nM) 
Cmpd OVCAR-8 
NCI/ 
ADR-RES 
Messaa Messa/Dx5a 
2.30 4.3 ± 1 2.5 ± 1 20.7 ± 1.7 28.0 ± 1 
2.41 14 ± 2 10 ± 4 3.5 ± 0.9 4.5 ± 1.9 
Colchicine 30 ± 1 420 ± 100 11 ± 6 329 ± 166 
CSA4 2.8 ± 1 1.8 ± 1 2.7 ± 2 2.6 ± 1 
Vinorelbine 300 ± 0 5000 ± 1000 ND ND 
Vinblastine 15 ± 7 200 ± 0 3 ± 2 144 ± 61 
Paclitaxel 3.7 ± 1 6000 ± 500 4 ± 1 1764 ± 477  
Table 2.3. Growth inhibition of the OVCAR-8 and NCI/ADR-RES, and Messa and Messa/Dx 
cell line pairs by compounds 2.30 and 2.41 and references colchicine, CSA4, vinorelbine, 
vinblastine, and paclitaxel. aIncubation time was 72 h. ND = not determined. 
 
Arrest of Mitotic Progression and Concomitant Cell Death Induction. To assess whether 
the growth-suppressive effect of 2.30 and 2.41 reflected their antimitotic activity, we 
evaluated their ability to induce mitotic arrest. In previous studies we found that treatment 
with 20 nM vinblastine effectively arrested the cell cycle of HeLa cells in mitosis; at lower 
concentrations vinblastine did not completely prevent mitotic progression, such that cells 
assemble defective mitotic spindles, “slip” through the mitotic checkpoint, and progress 
toward aberrant chromosome segregation.22  
 We examined HeLa cell cultures after treatment with increasing concentrations of 20, 50, 
and 100 nM 2.30 or 2.41 in DMSO, 20 nM vinblastine, and DMSO vehicle. Treatments were 
carried out for 24 h, allowing all cells to enter mitosis during the treatment. Cell cultures were 
then harvested, and their cell cycle profile was analyzed by flow cytometry after incubation 
with propidium iodide (PI) to reveal their genomic DNA content (linear scale). Similarly to 
what was observed with vinblastine, at concentration of 20 nM 2.30 and 2.41 induced >80% 
of HeLa cells to arrest with a G2/M genomic content, with very few cells progressing past the 
4N G2/M phase (Figure 2.8A). These results suggest that 2.30 and 2.41 stably arrest mitotic 
progression and prevent mitotic slippage, ensuing formation of hyperdiploid or polyploid 
cells. Furthermore, to assess whether G2/M-arrested cells underwent cell death over time, PI-
stained cell samples were analyzed by plotting their DNA content on a logarithmic scale to 
resolve the sub-G1 region, in which hypodiploid cells represent the terminal products of cell 
death. At 20 nM concentration 2.30 and 2.41 induced both cell death and concomitant G2/M 
phase arrest, being comparable to vinblastine; these effects were even more significant at 50 
nM (Figure 2.8B). Moreover, the induction of cell death by 2.30 appeared to be superior to 
2.41 at all tested concentrations. 
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Finally, biparametric analysis after simultaneous incubation of non-permeabilized cells 
with annexin V, which reacts with phosphatidylserine residues on the outer cell membrane 
during early apoptosis, and PI, to which viable cells are not spontaneously permeable, 
discriminates early and late stages of apoptotic cell death (Figure 2.8C) from necrotic cells, 
which are permeable to PI but do not react with annexin V. ATIs 2.30 and 2.41 were found to 
induce cell death with apoptotic-like phenotypic features with comparable effectiveness and 
early-to-late kinetics as observed with vinblastine.  
 
  
Figure 2.8. (A) Cell cycle profiles of HeLa cell cultures exposed to 2.30, 2.41, and 
vinblastine for 24 h at the indicated concentrations. The percentage of cells with 2C (G1 
phase, black bars), 4C (G2/M phases, white bars), or between 2C and 4C (S phase, dashed 
bars) genomic DNA content is shown. Mean values were calculated from three independent 
experiments. (B) Flow cytometry analysis of PI-stained cells with sub-G1 DNA content, 
representing terminal cell death, after 24 h. Mean values were calculated from four 
independent experiments. (C) Distribution of cells simultaneously processed for annexin V 
reactivity and PI incorporation, representing early (reactive to annexin V, not permeable to 
PI) and late (reactive to both annexin V and PI) stages of the cell death process in cultures 
treated for 24 h. Mean values were calculated from three independent experiments. Adapted 
from Ref. 25.  
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Inhibition of Mitotic MT Assembly. Immunofluorescence (IF) was employed to evaluate 
the effect of ATIs on tubulin and MTs and determine the correlation between the cell cycle 
arrest and cell death induction with inhibition of MT dynamics. HeLa cells were treated with 
20 or 50 nM 2.30 or 2.41 for 24 h in the same conditions that induced cell cycle arrest (Figure 
2.8). After 24 h, cells were processed for tubulin IF and examined under fluorescence 
microscopy. We found that at both concentrations 2.30 and 2.41 arrested cells in mitosis with 
a prometaphase-like appearance. Consistent with the absence of hyperdiploid cells in flow 
cytometry analysis, 2.30 and 2.41 prevented mitotic slippage. Interestingly, at 20 nM these 
two compounds inhibited MT polymerization and left tubulin foci and/or small asters of short 
MT fragments (Figure 2.9, right, middle panel). The proportion of mitotic cells with this MT 
phenotype appeared to be very similar to that observed with vinblastine (Figure 2.9, left). At 
higher concentration of 50 nM, 2.30 and 2.41 gave a phenotype with no recognizable mitotic 
MT remnants, but only tubulin aggregates that formed an unstructured meshwork throughout 
the mitotic cells (Figure 2.9, right, top panel). Taken together these results suggest that the 
new ATIs strongly affect MT polymerization, resulting in massive inhibition of formation of 
the mitotic apparatus, particularly when used at 50 nM. This phenotype was associated with a 
stable mitotic arrest and concomitant induction of cell death.  
 
  
Figure 2.9. Mitotic phenotypes in HeLa cell cultures exposed to ATIs 2.30 and 2.41 for 24 h 
and processed for tubulin IF (in red). The bar graph on the left indicates the statistical 
distribution of the cytological phenotypes depicted under the indicated conditions. The 
frequency of scored phenotypes is shown as the percentage of all counted mitotic figures 
(330−400 counted mitotic figures per condition). Gray bars represent the frequency of mitotic 
cells with severe inhibition of tubulin polymerization, no recognizable MTs and unstructured 
tubulin aggregates (top IF panel). Purple bars represent the frequency of mitotic cells with 
inhibited MT polymerization, yielding short MT stretches (middle panel). Black bars 
represent the frequency of normal mitoses with polymerized MT arrays forming a bipolar 
spindle (bottom panel). Adapted from Ref. 25. 
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Inhibition of PC-3, RD, and HepG2 Cancer Cell Growth. ATIs 2.30 and 2.41 were 
evaluated as growth inhibitors of prostate cancer PC-3, rhabdomyosarcoma RD, and human 
liver hepatocellular carcinoma HepG2 cell lines. After 48 h incubation in the presence of test 
compounds, 2.30 and 2.41 strongly inhibited the growth of these cell lines showing IC50 
values in the nanomolar range, being superior to the references vinblastine and paclitaxel. 
Furthermore, compound 2.30 showed to be particularly more potent than 2.41. 
 
 
 IC50 ± SD (nM) 
Cmpd PC3 RD HepG2 
2.30 0.3 ± 0.06 0.2 ± 0.04 0.1 ± 0.02 
2.41 19 ± 1 16 ± 1.3 62 ± 2 
Vinblastine 766 ± 1000 53 ± 2.5 81 ± 2.4 
Paclitaxel 4900 ± 1.3 >10000 2600 ± 1.5  
Table 2.4. Growth inhibition of PC-3, RD, and HepG2 cell lines by compounds 2.30 and 2.41 
and references vinblastine and paclitaxel. Incubation time was 48 h.  
 
 
To evaluate the ability of the new ATIs to induce mitotic arrest of this type of cells, PC-3, 
RD, and HEPG2 cell cultures were treated with 500, 1000, and 2000 nM 2.30, 2.41, and 
paclitaxel. After a 48 h exposure, cells and vehicle controls (0.1% DMSO) were incubated 
with PI to analyze their DNA content in flow cytometry assays. Interestingly, both ATIs 
arrested cell cycle progression in all cell lines at low concentrations. Similarly to what was 
observed with paclitaxel, 2.30 and 2.41 induced an accumulation in the G2/M phase in PC-3 
and RD cells, whereas in HepG2 cells the effect of these compounds on cell cyle progression 
appeared to be even stronger than the drug refence (Figure 2.10). 
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Figure 2.10. Cell cycle analysis of PC-3 (A), RD (B) and HepG2 (C) cells treated with 0.1% 
DMSO or 500, 1000 or 2000 nM 2.30, 2.41 or paclitaxel for 24 h. Representative cell cycle 
profiles from cytometric analysis following treatment with 2000 nM 2.30 or 2.41 are shown at 
the top of each panel. Histograms represent % of cells with G0/G1, S and G2/M DNA content 
expressed as mean values ± SD of three independent experiments. Adapted from Ref. 25. 
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After a 24 h exposure and subsequent incubation in drug-free medium for 24 h, the PC-3, 
RD, and HepG2 cell lines treated with 2.30 or 2.41 showed a strong accumulation of cells in 
G2/M (Figure 2.11). In addition, 2.30 and 2.41 induced an irreversible cell cycle arrest at 
concentrations of 500, 1000, and 2000 nM in the PC-3 and RD cells.  
 
 
Figure 2.11. Cell cycle analysis of PC-3 (A), RD (B), and HepG2 (C) cells treated with 0.1% 
DMSO or 500, 1000, or 2000 nM 2.30, 2.41, or paclitaxel for 24 h, followed by a 24 h 
recovery in drug-free medium. Histograms represent the percentage of cells with G0/G1, S, 
and G2/M DNA content expressed as mean values ± SD of three independent experiments. 
Adapted from Ref. 25.  
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A correlation between cell cycle arrest and cell death was investigated by exposing the 
cells to a 500, 1000, or 2000 nM concentration of 2.30, 2.41 or paclitaxel, followed by 
incubation with fluorescently conjugated annexin V and PI (Figure 2.12). All the cell lines 
treated with 500 nM 2.30 or 2.41 showed higher rates of cell death than the same populations 
treated with 500 nM paclitaxel. A dose−response trend in cell death was observed in the RD 
cell line after a 48 h exposure with either 2.30 or 2.41 (Figure 2.12B) and in the PC3 and 
HepG2 cell lines following treatment with paclitaxel (Figure 2.12A,C).  
 
  
Figure 2.12. Cell death cytometric analysis of PC-3 (A), RD (B), and HepG2 (C) cells treated 
with 0.1% DMSO or 500, 1000, or 2000 nM 2.30, 2.41, or paclitaxel for 48 h. Flow 
cytometric profiles of cell populations following treatment with DMSO or 2000 nM 2.30 or 
2.41 are at the top of each panel (annexin V−FITC staining on the x axis and PI on the y axis). 
Histograms represent the percentage of cells in early apoptosis (annexin V−FITC staining) 
and late apoptosis (annexin V−FITC and PI staining) expressed as mean values ± SD 
calculated from three independent experiments. Adapted from Ref. 25.  
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Inhibition of T98G and U343MG Cancer Cell Growth. Malignant gliomas develop from 
gradual accumulation of multiple genetic alterations, resulting in either activation of 
oncogenes or inactivation of tumor suppressor genes.39 Human glioblastoma multiforme 
T98G and U343MG cells exhibit typical hallmarks of glioblastoma multiforme tumors in 
patients and show different genetic profiles for the expression of key cell survival proteins, 
such as p53, MDM2, EGFR, RB, cyclin D, and MMPs.40 To evaluate the ability of 2.30 and 
2.41 to inhibit the growth of T98G and U343MG cancer cells, treatment of these cells with 
increasing concentrations of 2.30 or 2.41 was carried out for 24, 48, or 72 h. Compounds 2.30 
and 2.41 significantly inhibited cell growth in a dose- and time-dependent manner, as shown 
in Figure 2.13 and 2.14. 
 
 
 
Figure 2.13. Compounds 2.30 and 2.41 inhibit T98G cell growth/survival in a dose-
dependent manner following a 24 or 48 h drug treatment (A and B). The % of viable cells 
treated with 2.30 or 2.41 was calculated along with untreated control cells (value = 100%). 
Mean data ± SEM were obtained from three independent experiments performed in triplicate 
(*p < 0.05, **p < 0.01 and ***p < 0.001, Oneway Anova, Bonferroni’s corrected t-test for 
post-hoc pairwise comparisons). The relative IC50 curves (C). Adapted from Ref. 25. 
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Figure 2.14. Compounds 2.30 and 2.41 inhibit U343 cell growth/survival in a dose-dependent 
manner following a 24, 48 or 72 h drug treatment (A and B). The % of viable cells treated 
with 2.30 or 2.41 was calculated along with untreated control cells (value = 100%). Mean 
data ± SEM were obtained from three independent experiments performed in triplicate (*p < 
0.05, **p < 0.01 and ***p < 0.001, Oneway Anova, Bonferroni’s corrected t-test for post-hoc 
pairwise comparisons). The relative IC50 curves (C). Adapted from Ref. 25.  
 
 
The IC50 values were calculated taking into account the relative doubling time (CDT),41,42 
after 48 h for the T98G cells and after 72 h for the U343MG cells (Table 2.5). 
 
 
 IC50 ± SD (nM) 
Cmpd T98Ga U343b 
2.30 15.2 ± 1.6 0.5 ± 0.05 
2.41 16.3 ± 1.5 0.6 ± 0.05  
Table 2.5. Growth inhibition of T98G and U343MG cell lines by compounds 2.30 and 2.41. 
aIncubation time was 48 h. bIncubation time was 72 h. 
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Expression of MICA and MICB Ligands in HeLa Cells, Resulting in Enhanced Natural 
Killer (NK) Cell Degranulation. In previous studies,43 treatment of HeLa and HepG2 tumor 
cell lines with sodium butyrate, a potent repressor of histone deacetylases that causes spindle 
abnormalities and mitotic arrest, resulted in up-regulation of the expression of NK cell 
receptor-activating ligands MICA and MICB at both the mRNA and protein levels and in 
enhanced susceptibility of both cell lines to NK lysis. Accordingly, we first evaluated the 
inhibitory activity of 2.30, 2.34 and 2.41 on HeLa cell growth after 48 h treatment using a 
MTT assay and we found that these compounds act as potent growth inhibitors at sublethal 
doses (2.30, 2.41, IC50 = 10 nM; 2.34, IC50 = 76 nM). Biparametric analysis of HeLa cells 
showed only a weak increase of early apoptotic cells compared to control cultures (Figure 
2.15). 
 
 
Figure 2.15. Cell growth inhibition of HeLa cells after 48 h treatment with 10 nM 2.30, 2.34 
and 2.41. Adapted from Ref. 25.  
 
 
To evaluate whether the compounds could modulate the expression of NKG2D and 
DNAM-1 ligands in HeLa cells, we performed a NK cell receptor-activating ligand analysis 
by combined IF and flow cytometry. Our analysis revealed a different modulation of NKG2D 
and DNAM-1 ligands in ATI-treated HeLa cells after 48 h treatment with sublethal doses of 
10 nM, which did not severely affect cell viability. The new ATIs strongly up-regulated the 
expression of MICA, ULBP3, and PVR, while they behaved as only weak enhancers of 
MICB, ULBP1, and ULBP2 ligand expression (Figure 2.16). Interestingly, (1-(3-
aminophenyl)-1H-pyrrol-3-yl)(3,4,5-trimethoxyphenyl)-methanone, a potent tubulin 
polymerization inhibitor belonging to the ARAP class,44 was unable to induce the NKG2D 
and DNAM-1 ligands (data not shown). The expression of the ligand surface on treated HeLa 
cells was not accompanied by a corresponding increase in mRNA levels, as indicated by real-
time PCR data (Figure 2.17).  
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Figure 2.16. ATIs 2.30, 2.34 and 2.41 up-regulate DNAM-1 and NKG2D ligands in HeLa 
cells. NKG2D and DNAM-1 ligand surface expression was analyzed by flow cytometry after 
a 48 h treatment with the indicated ATI compound. Data are representative of one out of three 
independent experiments. Adapted from Ref. 25. 
 
 
 
Figure 2.17.	 mRNA abundance by real-time PCR after a 24 h treatment with the indicated 
ATI at 10 nM. Adapted from Ref. 25. 
 
 
These findings prompted us to evaluate whether ATIs 2.30 and 2.41 would increase NK 
cell degranulation toward HeLa cells. The expression of the lysosomal marker CD107a, 
which correlates with NK cell cytotoxicity,45 was evaluated by IF and flow cytometry 
analysis by gating on NK cells upon their interaction with treated or untreated HeLa cells, 
used as targets. The expression of CD107a on NK cells contacting treated HeLa target cells 
indicated that those cells were more susceptible to NK cell lysis (Figure 2.18).  
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Figure 2.18. NK cell-mediated killing of HeLa cells increased after a 48 h treatment with ATI 
2.30, or 2.41. Results are expressed as the percentage of CD107a+ cells after subtraction of 
the percentage of the control antibody and represent one of two independent experiments. The 
basal CD107a expression on NK cells was about 2%. Adapted from Ref. 25.  
 
 
Inhibition of Hedgehog (Hh) Signaling Pathway. There is an ever-growing interest in the 
development of inhibitors of the Hh signaling pathway as potential cancer therapeutics, 
especially in the case of Hh-dependent cancers, such as medulloblastomas.46 A variety of 
small molecules targeting key Hh components, (i.e., smoothened (Smo), sonic hedgehog 
protein (Shh), and Gli1) have shown to be potencially effective.47 Accordingly, some 
antagonists of Smo, the positive signaling transducer in the Hh pathway, have undergone 
clinical trials. However, the problem of drug resistance to Smo mutations, arising during 
clinical treatment, has led to a quest for new Hh inhibitors. We investigated whether ATI 
derivatives could behave as inhibitors of Hh signaling pathway by selecting three highly 
potent derivatives, 2.30, 2.41, and 2-(1H-imidazol-1-yl)-3-((3,4,5-trimethoxyphenyl)thio)-1H-
indole (2.78),23 and evaluating their effects with a luciferase assay performed in NIH3T3 Shh-
Light II (Shh-LII) cells. In these cells, in which is stably incorporated an Hh-responsive (Gli-
RE) reporter, the induction of the pathway occurs following treatment with the Smo agonist 
SAG. ATIs 2.30, 2.41, and 2.78 exhibited a strong and dose-dependent reduction of luciferase 
activity in cells treated with SAG showing IC50 values of 19, 72, and 38 nM, respectively 
(Figure 2.19). The treatment did not decrease the control Renilla luciferase activity, 
preventing any cytotoxicity-mediated effects on the inhibition of Hh signaling.  
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Figure 2.19. Inhibition of endogenous Hh signaling in Shh-LII cells by 2.30, 2.41, and 2.78. 
Dose−response curve of the indicated compounds in SAG-treated cells in comparison with 
untreated Shh-Light II cells as a control (CTR). The treatment was carried out for 48 h, and 
normalization was against Renilla luciferase. Data are from three independent experiments. 
Error bars indicate SD. *P = 0.05 vs CTR. Adapted from Ref. 25. 
 
 
Trypan blue count assay was used to determine the ability of 2.30, 2.41, and 2.78 to affect 
D283 medulloblastoma cell proliferation and survival. The in vitro results revealed that at 1 
µM these compounds impaired cell growth and the percentage of cell death (Figure 2.20). 
 
 
 
Figure 2.20. Effect of ATI derivatives 2.30, 2.41, and 2.78 on D283 cell growth. D283 cells 
were treated with these compounds (1 µM) or DMSO only, as control (CTR). After the 
indicated times, a trypan blue count was performed to determine the growth rate (A) and the 
percentage of cell death (B). Data show the mean ± SD of three independent experiments. 
Error bars indicate SD. *P = 0.05 vs CTR. Adapted from Ref. 25.  
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Metabolic Stability and Aqueous Solubility. Compounds 2.30 and 2.41 were examined in a 
microsomal stability assay, using both human and mouse liver microsomes, to estimate 
compound stability to phase I oxidative metabolism. 7-Ethoxy-coumarin and propranolol 
were used as controls (Table 2.6). Compound 2.41 showed metabolic stability of 25.6 and <3 
µL/min/mg of protein in mouse and human liver microsomes, respectively. Compound 2.30 
showed medium metabolic stability with human liver microsomes and low to medium 
metabolic stability with mouse liver microsomes (Table 2.6). Solubility of compounds 2.30 
and 2.41 was about 1 µM and 3.2 µM respectively, when measured in aqueous pH 7.4 buffer 
using a high-throughput screening solubility assay. In general, 2.41 showed higher metabolic 
stability in human and mouse liver microsomes and greater water solubility than 2.30 (Table 
2.6). 
 
 
Clearancea,b  
(µL/min/mg of protein) 
 
Compd Human liver microsomes 
Mouse liver 
microsomes 
Solubilityc at 
pH 7.4 (µM) 
2.30 15.2 ± 8.0 43.1 ± 7.9 0.99 ± 0.13 
2.41 <3 25.6 ± 1.7 3.18 ± 0.50 
7-ethoxy cumarin 209 ± 10.2 710.8 ± 1.2 − 
propanolol 19.1 ± 2.2 235.1 ± 24.1 −  
Table 2.6. Metabolic stability with human and mouse liver microsomes and aqueous 
solubility of compounds 2.30 and 2.41. Metabolic stability: <3, good; 3−60, medium; >60, 
low. aResults are expressed as the mean ± SD, n = 2. bThe standard compounds 7-
ethoxycoumarin and propranolol showed metabolic stability in agreement with the literature 
and internal validation data REF. cHigh-throughput screening solubility assay.  
 
2.6 Conclusions 
Our synthetic effort led to the preparation and SAR description of 39 new 2-phenylindole 
derivatives bearing a 3,4,5-trimethoxyphenyl moiety with a sulfur, ketone, or methylene 
bridging group at position 3 of the indole and a methoxy or halogen substituent at positions 
4−7 (SAR summary depicted in Figure 2.21). As inhibitors of tubulin polymerization, 23 
compounds showed IC50 values in the 1.0−2.0 µM range. They inhibited colchicine binding 
with a value >70% and the growth of MCF-7 human breast cancer cells with IC50 in the 
nanomolar range. Two representative examples, 2.30 and 2.41, uniformly inhibited a panel of 
cancer cells at nanomolar concentration, being comparable or superior to the drug references. 
Compounds 2.30 and 2.41 strongly inhibited the growth of the MDR cell lines NCI/ADR-
RES and Messa/Dx5. 
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Further biological characterization of new ATIs revealed an unexpected stimulation of the 
cytotoxic activity of NK cells. Thus, at sublethal doses of 10 nM, ATI derivatives increased 
NKG2D and DNAM-1 ligand up-regulation of HeLa cells and induced a stronger expression 
of NK cell receptor-activating ligand, leading to an increased propensity of NK cells to 
degranulate against tumor cells. 
At higher concentrations of 20−50 nM, new ATIs arrested >80% of HeLa cells in the 
G2/M phase of the cell cycle, prevented mitotic slippage and the ensuing formation of 
aneuploid cells (a hallmark of aggressive cancers), and produced a stable arrest of the mitotic 
progression with consecutive apoptotic death induction. These findings suggest that the new 
ATIs 2.30 and 2.41 can arrest proliferation of cancer cells with effectiveness comparable or 
superior to the drug reference vinblastine. Finally, we found that new ATI derivatives act as 
strong inhibitors of the Hedgehog signaling pathway showing nanomolar IC50 values against 
medulloblastoma D283 cells. 
In summary, new indole derivatives presented in this work behaved as good inhibitors of 
tubulin polymerization, for which they were originally designed, but they also showed an 
unexpected alternative cytotoxic response via NK cells at doses that do not allow ATIs to 
completely prevent the assembly of the mitotic apparatus. Compounds 2.30 and 2.41 
represent novel lead compounds that encourage the development of the ATI class to obtain 
new promising anticancer agents with enhanced stimulation of NK cell cytotoxic activity and 
repression of Hh-dependent cancers.  
 
 
 
Figure 2.21. General chemical structure of 2-phenylindole derivatives and SAR summary of 
tubulin polymerization inhibition (TPI) and inhibition of MCF-7 cell growth. 
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2.7 Experimental Section 
2.7.1 Chemistry 
Microwave-assisted reactions were performed on a CEM Discover SP single-mode reactor. 
The instrument settings were controlled with PC-running CEM Synergy 1.49 software. 
Closed vessel experiments were carried out in capped microwave-dedicated vials (10 mL) 
with a cylindrical stirring bar (length 8 mm, diameter 3 mm). Open vessel experiments were 
carried out in 100 mL round-bottom flasks equipped with a Dimroth reflux condenser and a 
cylindrical stirring bar (length 20 mm, diameter 6 mm). Stirring, temperature, irradiation 
power, maximum pressure (Pmax), PowerMAX (simultaneous cooling-while-heating), 
ActiVent (simultaneous venting-while-heating), and ramp and hold times were set as 
indicated. The temperature of the reaction was monitored by an external fiber optic 
temperature sensor. After completion of the reaction, the mixture was cooled to 25 °C via air-
jet cooling. Melting points (m.p.) were determined on a Stuart Scientific SMP1 apparatus and 
are uncorrected. IR spectra were run on a PerkinElmer SpectrumOne FT-ATR 
spectrophotometer. Band position and absorption ranges are given in inverse centimeters. 
Proton (1H) NMR spectra were acquired on a Bruker 400 MHz FT spectrometer in the 
indicated solvent by TopSpin 2.1 software and the files processed by MestreLab Research 
S.L. MestreReNova 6.2.1−769 software. Flash chromatography was carried out on an 
Interchim Spot II Flash system, using Merck SuperVarioFlash D26 cartridges packed with 
Merck Geduran 60 (0.040−0.063 mm) silica gel. Column chromatography was performed on 
columns packed with alumina from Merck (70−230 mesh) or silica gel from Macherey-Nagel 
(70−230 mesh). Aluminum oxide thin layer chromatography (TLC) cards from Fluka 
(aluminum oxide-precoated aluminum cards with fluorescent indicator visualizable at 254 
nm) and silica gel TLC cards from Macherey-Nagel (silica gel-precoated aluminum cards 
with fluorescent indicator visualizable at 254 nm) were used for TLC. Developed plates were 
visualized by a Spectroline ENF 260C/FE UV apparatus. Evaporation of solvents was carried 
out on a Büchi Rotavapor R-210 equipped with a Büchi V-850 vacuum controller and a Büchi 
V-700 or V-710 vacuum pump. All commercially available reagents were used without 
further purification. Elemental analyses of the compounds were found within ± 0.4% of the 
theoretical values. The purity of the tested compounds was determined by high-performance 
liquid chromatography (HPLC) and was >95%. The HPLC system (Dionex UltiMate 3000, 
Thermo Fisher Scientific Inc.) was equipped with an SR-3000 solvent rack, an LPG-3400SD 
quaternary analytical pump, a TCC-3000SD column compartment, a DAD-3000 diode array 
detectorn and an analytical manual injection valve with a 20 µL loop. Compounds were 
dissolved in acetonitrile (10 mg/mL). HPLC analysis was performed by using an Acclaim 120 
C18 reversed-phase column (5 µm, 4.6 × 250 mm, Thermo Fisher Scientific Inc.) at a 
temperature of 30 ± 1 °C, an isocratic gradient (acetonitrile/water 90:10), a flow rate of 1.0 
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mL/min, and detector signals 254 and 365 nm. Chromatographic data were acquired and 
processed by Chromeleon 6.80 software (Thermo Fisher Scientific Inc.).  
General Procedure A for the Synthesis of 2.3, 2.5, 2.8, 2.10, 2.12, 2.15, 2.18, 2.20, 2.23, 
2.25, 2.28, 2.30, 2.32, 2.34, 2.37, 2.39, and 2.41. A mixture of the appropriate substituted 2-
phenyl-1H-indole (1 equiv), bis(3,4,5-trimethoxyphenyl) disulfide (1.1 equiv), and sodium 
hydride (2.2 equiv; 60% in mineral oil) in anhydrous DMF (0.3 M) was placed into the 
microwave cavity (closed vessel mode, Pmax = 250 psi). Starting microwave irradiation of 120 
W was used, the temperature being ramped from 25 to 130 °C, with rapid stirring and venting 
(pressure set point 100 psi, times at set point 100, delta pressure 20 psi). Once 130 °C was 
reached, taking about 1 min, the reaction mixture was held at this temperature for 2 min. The 
mixture was diluted with water and extracted with EtOAc. The organic layer was washed with 
brine, dried over Na2SO4, filtered and concentrated in vacuo. The resulting material was 
putified by silica gel column chromatography to obtain the desired thio-indole derivative.  
General Procedure B for the Synthesis of 2.4, 2.6, 2.9, 2.11, 2.13, 2.16, 2.19, 2.21, 2.24, 
2.26, 2.29, 2.31, 2.33, 2.35, 2.38, 2.40, and 2.42. A mixture of the appropriate substituted 2-
phenyl-1H-indole (1 equiv), 3,4,5-trimethoxybenzoyl chloride (1 equiv), and anhydrous 
aluminum chloride (1 equiv) in anhydrous DCE (0.5 M) was placed into the microwave 
cavity (closed vessel mode, Pmax = 250 psi). A starting microwave irradiation of 150 W was 
used, the temperature being ramped from 25 to 110 °C, with stirring. Once 110 °C was 
reached, taking about 1 min, the reaction mixture was held at this temperature for 2 min. The 
reaction mixture was quenched on 1 M HCl/crushed ice and extracted with chloroform. The 
organic layer was washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. 
Removal of the solvent gave a residue that was purified by silica gel column chromatography 
to obtain the desired methanone derivative. 
General Procedure C for the Preparation of 2.7, 2.17, 2.22, 2.27, 2.36. A 
borane−tetrahydrofuran complex (0.24 M, 1.0 M in THF) was slowly added to a cold solution 
of the appropriate methanone (1 equiv) in anhydrous acetonitrile (0.17 M) containing 
anhydrous MeOH (12 M) under an Ar stream. The reaction was stirred for 1 h at 50 °C. After 
cooling, the mixture was carefully diluted with water and extracted with EtOAc. The organic 
layer was washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The 
resulting material was purified by silica gel column chromatography to obtain the 
corresponding methylene derivative. 
General Procedure D for the Synthesis of 2.43, 2.51, 2.53. A mixture of the appropriate 
ketone derivative (1 equiv), tin(II) chloride dihydrate (1.5 equiv), and 1 N HCl (0.43 M) in 
glacial acetic acid (0.08 M) was heated at reflux temperature for 12 h. After cooling, the 
reaction mixture was diluted with a saturated aqueous solution of potassium carbonate and 
extracted with EtOAc. The organic layer was washed with brine, dried over Na2SO4, and 
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filtered. Removal of the solvent gave a residue that was purified by silica gel column 
chromatography to furnish the corresponding 2-phenylindole derivative. 
General Procedure E for the Synthesis of 2.44−2.46, 2.52, 2.54, and 2.58. A solution of 
the appropriate N-(2-tolyl)benzamide (1 equiv) in anhydrous THF (0.07 M) was cooled at −40 
°C, and then a solution of tert-butyllithium (7.7 M in pentane, 0.5 M) was added dropwise 
under an Ar stream. The reaction mixture was stirred at 0 °C for 1 h and at 25 °C for 12 h, 
diluted with water, and extracted with EtOAc. The organic layer was washed with brine, dried 
over Na2SO4, filtered and concentrated in vacuo. Purification via silica gel column 
chromatography yielded the desired 2-phenylindole derivative. 
General Procedure F for the Synthesis of 2.47−2.49, 2.55, 2.57, and 2.59. The appropriate 
phenylhydrazone (1 equiv) was added by portions to polyphosphoric acid (29 equiv) 
preheated at 110 °C. The reaction mixture was stirred at the same temperature for 1 h and 
then quenched on crushed ice. The solid was filtered and crystallized to obtain the desired 2-
phenylindole derivative. 
General Procedure G for the Synthesis of 2.60−2.62. To a solution of benzaldehyde (1 
equiv) and appropriate 1-methyl-2-nitrobenzene (1.09 equiv) in anhydrous DMSO (0.22 M) 
was added a solution of sodium ethoxide in anhydrous EtOH (3.4 M). The reaction mixture 
was stirred at 25 °C for 12 h, carefully diluted with water, and extracted with EtOAc. The 
organic layer was washed with brine, dried over Na2SO4, and filtered. Removal of the solvent 
gave a residue that was purified by silica gel column chromatography to obtain the alcohol 
derivative. 
General Procedure H for the Synthesis of 2.63−2.65. A solution of appropriate alcohol 
derivative (1 equiv) in anhydrous CH2Cl2 (0.3 M) was added to a suspension of pyridinium 
chlorochromate (1.6 equiv) in CH2Cl2 (0.2 M). The reaction mixture was stirred at 25 °C for 
1.5 h and diluted with water. The layers were separated, and the organic phase was washed 
with brine, dried over Na2SO4, filtered and concentrated in vacuo. Purification via silica gel 
column chromatography furnished the ketone derivative. 
General Procedure I for the Synthesis of 2.66−2.71. A solution of benzoyl chloride (1.19 
equiv) in THF (2.8 M) was added dropwise to a solution of appropriate o-toluidine (1 equiv) 
and Et3N (1.19 equiv) at 0 °C in the same solvent (0.35 M). The reaction was heated at reflux 
for 2 h. After cooling, the mixture was diluted with water and extracted with ethyl acetate. 
The organic layer was washed with brine, dried, and filtered. Removal of the solvent gave a 
residue that was triturated with diethyl ether to furnish the desired amide derivative. 
General Procedure J for the Synthesis of 2.72−2.77. A mixture of appropriate 
phenylhydrazine hydrochloride (1.5 equiv), acetophenone (1 equiv), and sodium acetate (1.5 
equic) in EtOH (0.7 M) was placed into the microwave cavity (open vessel mode). 
Microwave irradiation of 250 W was used, the temperature being ramped from 25 to 80 °C. 
Once 80 °C was reached, taking about 1 min, the reaction mixture was held at this 
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temperature for 5 min, with stirring and cooling. The reaction mixture was cooled to 0 °C, 
filtered, washed with petroleum ether, and dried to obtain the desire phenylhydrazone. 
4-Bromo-2-phenyl-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (2.3). Following synthetic 
procedure A using 4-bromo-2-phenyl-1H-indole (0.035 g, 0.128 mmol), purification by silica 
gel column chromatography (hexanes/EtOAc 67:33) afforded the title compound as a yellow 
solid (0.017 g, 0.036 mmol, 28% yield). M.p. 202−205 °C (EtOH). 1H NMR (CDCl3) δ 3.66 
(s, 6H), 3.79 (s, 3H), 6.37 (s, 2H), 7.10 (t, J = 7.8 Hz, 1H), 7.38− 7.41 (m, 5H), 7.71 (d, J = 
6.7 Hz, 2H), 8.72 (br s, disappeared on treatment with D2O, 1H) ppm. IR ν 3344 cm−1. Anal. 
(C23H20BrNO3S (470.38)) C, H, Br, N, S.  
(4-Bromo-2-phenyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)methanone (2.4). Following 
synthetic procedure B using 4-bromo-2-phenyl-1H-indole (0.030 g, 0.110 mmol), purification 
by silica gel column chromatography (hexanes/EtOAc 50:50) afforded the title compound as 
a yellow solid (0.004 g, 0.193 mmol, 8% yield). M.p. 228−230 °C (EtOH). 1H NMR (CDCl3) 
δ 3.74 (s, 6H), 3.88 (s, 3H), 7.13−7.16 (m, 3H), 7.31−7.37 (m, 4H), 7.42−7.46 (m, 3H), 8.58 
(br s, disappeared on treatment with D2O, 1H) ppm. IR ν 1618, 3344 cm−1. Anal. 
(C24H20BrNO4 (466.32)) C, H, Br, N.  
4-Chloro-2-phenyl-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (2.5). Following synthetic 
procedure A using 4-chloro-2-phenyl-1H-indole (0.250 g, 1.10 mmol), purification by silica 
gel column chromatography (hexanes/EtOAc 67:33) afforded the title compound as a white 
solid (0.290 g, 0.681 mmol, 62% yield). M.p. 178−180 °C (EtOH). 1H NMR (DMSO-d6) δ 
3.54 (s, 6H), 3.57 (s, 3H), 6.26 s, 2H), 7.10−7.11 (m, 1H), 7.18−7.20 (m, 1H), 7.44−7.54 (m, 
4H), 7.77−7.80 (m, 2H), 12.51 (br s, disappeared on treatment with D2O, 1H) ppm. IR ν 3345 
cm−1. Anal. (C23H20ClNO3S (425.93)) C, H, Cl, N, S.  
(4-Chloro-2-phenyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)-methanone (2.6). Following 
synthetic procedure B using 4-chloro-2-phenyl-1H-indole (0.250 g, 1.10 mmol), purification 
by silica gel column chromatography (hexanes/EtOAc 50:50) afforded the title compound as 
a yellow solid (0.300 g, 0.711 mmol, 65% yield). M.p. 232−235 °C (EtOH). 1H NMR 
(CDCl3) δ 3.72 (s, 6H), 3.94 (s, 3H), 7.17 (s, 2H), 7.19−7.23 (m, 2H), 7.30−7.33 (m, 3H), 
7.38 (dd, J = 2.0 and 7.0 Hz, 1H), 7.45−7.48 (m, 2H), 8.73 (br s, disappeared on treatment 
with D2O, 1H) ppm. IR ν 1618, 3169 cm−1. Anal. (C24H20ClNO4 (421.87)) C, H, Cl, N.  
4-Chloro-2-phenyl-3-(3,4,5-trimethoxybenzyl)-1H-indole (2.7). Following synthetic 
procedure C using (4-chloro-2-phenyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)-methanone 
(0.100 g, 0.240 mmol), purification by silica gel column chromatography (hexanes/EtOAc 
67:33) afforded the title compound as a yellow solid (0.010 g, 0.024 mmol, 10% yield). M.p. 
178−180 °C (EtOH). 1H NMR (CDCl3) δ 3.74 (s, 6H), 3.84 (s, 3H), 4.45 (s, 2H), 6.44 (s, 2H), 
7.10−7.15 (m, 2H), 7.33 (dd, J = 2.2 and 6.8 Hz, 1H), 7.41−7−47 (m, 3H), 7.51−7.53 (m, 2H), 
8.29 (br s, disappeared on treatment with D2O, 1H) ppm. IR ν 3358 cm−1. Anal. 
(C24H22ClNO3 (407.89)) C, H, Cl, N.  
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4-Fluoro-2-phenyl-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (2.8). Following synthetic 
procedure A using 4-fluoro-2-phenyl-1H-indole (0.250 g, 1.18 mmol), purification by silica 
gel column chromatography (hexanes/EtOAc 80:20) afforded the title compound as a yellow 
solid (0.150 g, 0.366 mmol, 31% yield). M.p. 168−170 °C (EtOH). 1H NMR (DMSO-d6) δ 
3.53 (s, 6H), 3.56 (s, 3H), 6.28 (s, 2H), 6.80−6.85 (m, 1H), 7.14−7.19 (m, 1H), 7.32 (d, J = 
8.0 Hz, 1H), 7.44 (t, J = 7.1 Hz, 1H), 7.51 (t, J = 7.1 Hz, 2H), 7.80−7.82 (m, 2H), 12.30 (br s, 
disappeared on treatment with D2O, 1H) ppm. IR ν 3307 cm−1. Anal. (C23H20FNO3S (409.47)) 
C, H, F, N, S.  
(4-Fluoro-2-phenyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)-methanone (2.9). Following 
synthetic procedure B using 4-fluoro-2-phenyl-1H-indole (0.250 g, 1.18 mmol), purification 
by silica gel column chromatography (hexanes/EtOAc 80:20) afforded the title compound as 
a yellow solid (0.120 g, 0.295 mmol, 25% yield). M.p. 212−215 °C (toluene). 1H NMR 
(DMSO-d6) δ 3.62 (s, 6H), 3.64 (s, 3H), 6.84−6.89 (m, 1H), 6.99 (s, 2H), 7.18−7.22 (m, 1H), 
7.30− 7.35 (m, 4H), 7.42−7.44 (m, 2H), 12.34 (br s, disappeared on treatment with D2O, 1H) 
ppm. IR ν 1618, 3205 cm−1. Anal. (C24H20FNO4 (405.42)) C, H, F, N. 
4-Methoxy-2-phenyl-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (2.10). Following 
synthetic procedure A using 4-methoxy-2-phenyl-1H-indole (0.140 g, 0.627 mmol), 
purification by silica gel column chromatography (CH2Cl2/EtOAc 99:1) afforded the title 
compound as a white solid (0.110 g, 0.261 mmol, 42% yield). M.p. 133−136 °C (toluene). 1H 
NMR (CDCl3) δ 3.66 (s, 6H), 3.78 (s, 6H), 6.44 (s, 2H), 6.57−6.59 (m, 1H), 7.05 (d, J = 8.2 
Hz, 1H), 7.18 (t, J = 7.7 Hz, 1H), 7.38−7.48 (m, 3H), 7.73 (d, J = 7.2 Hz, 2H), 8.52 (br s, 
disappeared on treatment with D2O, 1H) ppm. IR ν 3261 cm−1. Anal. (C24H23NO4S (421.51)) 
C, H, N, S.  
(4-Methoxy-2-phenyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)-methanone (2.11). Following 
synthetic procedure B using 4-methoxy-2-phenyl-1H-indole (0.250 g, 1.12 mmol), 
purification by silica gel column chromatography (hexanes/EtOAc 67:33) afforded the title 
compound as a yellow solid (0.230 g, 0.551 mmol, 49% yield). M.p. 144−146 °C (toluene). 
1H NMR (DMSO-d6) δ 3.53 (s, 3H), 3.64 (s, 6H), 3.69 (s, 3H), 6.55−6.57 (m, 1H), 7.02 (s, 
2H), 7.09−7.16 (m, 2H), 7.29−7.39 (m, 3H), 7.49−7.51 (m, 2H), 11.95 (br s, disappeared on 
treatment with D2O, 1H) ppm. IR ν 1622, 3220 cm−1. Anal. (C25H23NO5 (417.45)) C, H, N.  
5-Bromo-2-phenyl-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (2.12). Following synthetic 
procedure A using 5-bromo-2-phenyl-1H-indole (0.250 g, 0.919 mmol), purification by silica 
gel column chromatography (hexanes/EtOAc 75:25) afforded the title compound as a yellow 
solid (0.080 g, 0.170 mmol, 18% yield). M.p. 152−155 °C (EtOH). 1H NMR (DMSO-d6) δ 
3.53 (s, 6H), 3.56 (s, 3H), 6.27 (s, 2H), 7.32−7.35 (m, 1H), 7.44−7.58 (m, 5H), 7.86−7.88 (m, 
2H), 12.29 (br s, disappeared on treatment with D2O, 1H) ppm. IR ν 3316 cm−1. Anal. 
(C23H20BrNO3S (470.38)) C, H, Br, N, S.  
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(5-Bromo-2-phenyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)-methanone (2.13). Following 
synthetic procedure B using 5-bromo-2-phenyl-1H-indole (0.250 g, 0.919 mmol), purification 
by silica gel column chromatography (hexanes/EtOAc 40:60) afforded the title compound as 
a brown solid (0.260 g, mmol, 61% yield). M.p. 200−203 °C (EtOH). 1H NMR (DMSO-d6) δ 
3.57 (s, 3H), 3.58 (s, 6H), 6.78 (s, 2H), 7.23−7.27 (m, 3H), 7.35−7.41 (m, 3H), 7.48 (d, J = 
8.3 Hz, 1H), 8.09 (s, 1H), 12.40 (br s, disappeared on treatment with D2O, 1H) ppm. IR ν 
1610, 3305 cm−1. Anal. (C24H20BrNO4 (466.32)) C, H, Br, N. 
5-Bromo-2-phenyl-3-(3,4,5-trimethoxybenzyl)-1H-indole (2.14). A mixture of (5-bromo-2-
phenyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)-methanone (0.250 g, 0.540 mmol), 
triethylsilane (0.140 g, 1.20 mmol), and trifluoroacetic acid (0.630 g, 5.50 mmol) in 1,2-
dichloroethane (2.0 mL) was placed into the microwave cavity (closed vessel mode, Pmax 
=250 psi). A starting microwave irradiation of 250 W was used, the temperature being 
ramped from 25 to 250 °C, with rapid stirring and cooling. Once 250 °C was reached, taking 
about 2 min, the reaction mixture was held at this temperature for 20 min. The reaction 
mixture was diluted with satd. aq. NaHCO3 and extracted with EtOAc. The organic layer was 
washed with brine, dried, and filtered. Removal of the solvent gave a residue that was purified 
by silica gel column chromatography (hexanes/EtOAc 75:25) to furnish the title compound as 
a colorless oil (0.040 g, 0.088 mmol, 15% yield) 1H NMR (CDCl3) δ 3.73 (s, 6H), 3.83 (s, 
3H), 4.17 (s, 2H), 6.42 (s, 2H), 7.28 (s, 2H), 7.37−7.47 (m, 3H), 7.53−7.55 (m, 2H), 7.62 (s, 
1H), 8.25 (br s, disappeared on treatment with D2O, 1H) ppm. IR ν 3338 cm−1. Anal. 
(C24H22BrNO3 (452.34)) C, H, Br, N.  
5-Chloro-2-phenyl-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (2.15). Following synthetic 
procedure A using 5-chloro-2-phenyl-1H-indole (0.250 g, 1.10 mmol), purification by silica 
gel column chromatography (hexanes/EtOAc 70:30) afforded the title compound as a pink 
solid (0.030 g, 0.070 mmol, 6% yield). M.p. 158−160 °C (EtOH). 1H NMR (CDCl3) δ 3.65 (s, 
6H), 3.78 (s, 3H), 6.33 (s, 2H), 7.21−7.24 (m, 1H), 7.36−7.49 (m, 4H), 7.66−7.67 (m, 1H), 
7.77−7.80 (m, 2H), 8.69 (br s, disappeared on treatment with D2O, 1H) ppm. IR ν 3319 cm−1. 
Anal. (C23H20ClNO3S (425.93)) C, H, Cl, N, S.  
(5-Chloro-2-phenyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)-methanone (2.16). Following 
synthetic procedure B using 5-chloro-2-phenyl-1H-indole (0.250 g, 1.10 mmol), purification 
by silica gel column chromatography (hexanes/EtOAc 60:40) afforded the title compound as 
a white solid (0.230 g, 0.545 mmol, 50% yield). M.p. 222−225 °C (EtOH). 1H NMR (CDCl3) 
δ 3.69 (s, 6H), 3.81 (s, 3H), 6.94 (s, 2H), 7.24−7.30 (m, 4H), 7.33−7.40 (m, 3H), 8.07−8.08 
(m, 1H), 8.81 (br s, disappeared on treatment with D2O, 1H) ppm. IR ν 1610, 3340 cm−1. 
Anal. (C24H20ClNO4 (421.87)) C, H, Cl, N.  
5-Chloro-2-phenyl-3-(3,4,5-trimethoxybenzyl)-1H-indole (2.17). Following synthetic 
procedure C using (5-chloro-2-phenyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)-methanone 
(0.100 g, 0.237 mmol), purification by silica gel column chromatography (hexanes/EtOAc 
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50:50) afforded the title compound as a yellow solid (0.040 g, 0.098 mmol, 41% yield). M.p. 
172−175 °C (EtOH). 1H NMR (CDCl3) δ 3.76 (s, 6H), 3.82 (s, 3H), 4.16 (s, 2H), 6.41 (s, 2H), 
7.15 (dd, J = 2.0 and 8.6 Hz, 1H), 7.31 (d, J = 8.6 Hz, 1H), 7.37−7.39 (m, 1H), 7.42−7.46 (m, 
3H), 7.51−7.54 (m, 2H), 8.23 (br s, disappeared on treatment with D2O, 1H) ppm. IR ν 3340 
cm−1. Anal. (C24H22ClNO3 (407.89)) C, H, Cl, N.  
 5-Fluoro-2-phenyl-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (2.18). Following synthetic 
procedure A using 5-fluoro-2-phenyl-1H-indole (0.250 g, 1.18 mmol), purification by silica 
gel column chromatography (CH2Cl2/EtOAc 99:1) afforded the title compound as a yellow 
solid (0.130 g, 0.317 mmol, 27% yield). M.p. 158−160 °C (toluene). 1H NMR (DMSO-d6) δ 
3.54 (s, 6H), 3.57 (s, 3H), 6.30 (s, 2H), 7.1 (t, J = 8.0 Hz, 1H), 7.16 (d, J = 9.2 Hz, 1H), 5.45 
(t, J = 7.2 Hz, 1H), 7.50−7.55 (m, 3H), 7.88 (d, J = 7.4 Hz, 2H), 12.21 (br s, disappeared on 
treatment with D2O, 1H) ppm. IR ν 3231 cm−1. Anal. (C23H20FNO3S (409.47)) C, H, F, N, S.  
(5-Fluoro-2-phenyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)-methanone (2.19). Following 
synthetic procedure B using 5-fluoro-2-phenyl-1H-indole (0.250 g, 1.18 mmol), purification 
by silica gel column chromatography (hexanes/EtOAc 67:33) afforded the title compound as 
a white solid (0.320 g, 0.789 mmol, 67% yield). M.p. 198−200 °C (toluene). 1H NMR 
(DMSO-d6) δ 3.58 (s, 3H), 3.59 (s, 6H), 6.78 (s, 2H), 7.10−7.15 (m, 1H), 7.24−7.27 (m, 3H), 
7.34− 7.37 (m, 2H), 7.51 (q, J = 4.6 Hz, 1H), 7.66 (dd, J = 2.5 and 10.1, 1H), 12.30 (br s, 
disappeared on treatment with D2O, 1H) ppm. IR ν 1620, 3225 cm−1. Anal. (C24H20FNO4 
(405.42)) C, H, F, N.  
5-Methoxy-2-phenyl-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (2.20). Following 
synthetic procedure A using 5-methoxy-2-phenyl-1H-indole (0.250 g, 1.12 mmol), 
purification by silica gel column chromatography (hexanes/EtOAc 70:30) afforded the title 
compound as a yellow oil (0.050 g, 0.119 mmol, 11% yield). 1H NMR (CDCl3) δ 3.63 (s, 
6H), 3.77 (s, 3H), 3.83 (s, 3H), 6.35 (s, 2H), 6.90−6.93 (m, 1H), 7.10−7.11 (m, 1H), 
7.32−7.46 (m, 4H), 7.76−7.77 (m, 2H), 8.58 (br s, disappeared on treatment with D2O, 1H) 
ppm. IR ν 3337 cm−1. Anal. (C24H23NO4S (421.51)) C, H, N, S.  
(5-Methoxy-2-phenyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)-methanone (2.21). Following 
synthetic procedure B using 5-methoxy-2-phenyl-1H-indole (0.250 g, 1.12 mmol), 
purification by silica gel column chromatography (hexanes/EtOAc 50:50) afforded the title 
compound as a green solid (0.360 g, 0.862 mmol, 77% yield). M.p. 202−205 °C (EtOH). 1H 
NMR (DMSO-d6) δ 3.58 (s, 3H), 3.59 (s, 6H), 3.78 (s, 3H), 6.78 (s, 2H), 6.90 (dd, J = 2.6 and 
8.8 Hz, 1H), 7.24−7.25 (m, 3H), 7.32−7.34 (m, 2H), 7.41 (d, J = 8.8 Hz, 1H), 7.48 (d, J = 2.4 
Hz, 1H), 12.11 (br s, disappeared on treatment with D2O, 1H) ppm. IR ν 1652, 3195 cm−1. 
Anal. (C25H23NO5 (417.45)) C, H, N.  
5-Methoxy-2-phenyl-3-(3,4,5-trimethoxybenzyl)-1H-indole (2.22). Following synthetic 
procedure C using (5-methoxy-2-phenyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)-methanone 
(0.200 g, 0.479 mmol), purification by silica gel column chromatography (hexanes/EtOAc 
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75:25) afforded the title compound as a white solid (0.050 g, 0.124 mmol, 26% yield). M.p. 
137−139 °C (EtOH). 1H NMR (DMSO-d6) δ 3.59 (s, 3H), 3.60 (s, 6H), 3.72 (s, 3H), 4.14 (s, 
2H), 6.48 (s, 2H), 6.76 (dd, J = 2.4 and 8.9 Hz, 1H), 6.97 (d, J = 2.4 Hz, 1H), 7.27 (d, J = 8.9 
Hz, 1H), 7.35−7.39 (m, 1H), 7.50 (t, J = 7.4 Hz, 2H), 7.61−7.64 (m, 2H), 11.12 (br s, 
disappeared on treatment with D2O, 1H) ppm. IR ν 3361 cm−1. Anal. (C25H25NO4 (403.47)) C, 
H, N.  
6-Bromo-2-phenyl-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (2.23). Following synthetic 
procedure A using 6-bromo-2-phenyl-1H-indole (0.060 g, 0.220 mmol), purification by silica 
gel column chromatography (hexanes/EtOAc 67:33) afforded the title compound as a yellow 
solid (0.023 g, 0.049 mmol, 22% yield). M.p. 200−203 °C (EtOH). 1H NMR (DMSO-d6) δ 
3.57 (s, 3H), 3.58 (s, 6H), 6.78 (s, 2H), 7.23−7.27 (m, 3H), 7.35−7.41 (m, 3H), 7.48 (d, J = 
8.3 Hz, 1H), 8.09 (s, 1H), 12.40 (br s, disappeared on treatment with D2O, 1H) ppm. IR ν 
3320 cm−1. Anal. (C23H20BrNO3S (470.38)) C, H, Br, N, S.  
(6-Bromo-2-phenyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)-methanone (2.24). Following 
synthetic procedure B using 6-bromo-2-phenyl-1H-indole (0.033 g, 0.121 mmol), purification 
by silica gel column chromatography (hexanes/EtOAc 50:50) afforded the title compound as 
a yellow oil (0.022 g, 0.047 mmol, 39% yield). 1H NMR (CDCl3) δ 3.68 (s, 6H), 3.81 (s, 3H), 
6.94 (s, 2H), 7.23− 7.27 (m, 3H), 7.33−7.36 (m, 3H), 7.59 (s, 1H), 7.87 (d, J = 8.6 Hz, 1H), 
8.84 (br s, disappeared on treatment with D2O, 1H) ppm. IR ν 1610, 3304 cm−1. Anal. 
(C24H20BrNO4 (466.32)) C, H, Br, N. 
6-Chloro-2-phenyl-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (2.25). Following synthetic 
procedure A using 6-chloro-2-phenyl-1H-indole (0.140 g, 0.615 mmol), purification by silica 
gel column chromatography (hexanes/EtOAc 67:33) afforded the title compound as a white 
solid (0.130 g, 0.305 mmol, 50% yield). M.p. 207−210 °C (EtOH). 1H NMR (DMSO-d6) δ 
3.54 (s, 6H), 3.57 (s, 3H), 6.29 (s, 2H), 7.14 (dd, J = 1.1 and 7.7 Hz, 1H), 7.43−7.55 (m, 5H), 
7.87 (d, J = 7.9 Hz, 2H), 12.23 (br s, disappeared on treatment with D2O, 1H) ppm. IR ν 3319 
cm−1. Anal. (C23H20ClNO3S (425.93)) C, H, Cl, N, S.  
(6-Chloro-2-phenyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)-methanone (2.26). Following 
synthetic procedure B using 6-chloro-2-phenyl-1H-indole (0.250 g, 1.10 mmol), purification 
by silica gel column chromatography (hexanes/EtOAc 67:33) afforded the title compound as 
a yellow solid (0.280 g, 0.657 mmol, 60% yield). M.p. 188−190 °C (EtOH). 1H NMR 
(CDCl3) δ 3.63 (s, 6H), 3.79 (s, 3H), 6.93 (s, 2H), 7.20−7.24 (m, 4H), 7.31−7.33 (m, 2H), 
7.41−7.43 (m, 1H), 7.91 (d, J = 8.6 Hz, 1H), 8.84 (br s, disappeared on treatment with D2O, 
1H) ppm. IR ν 3319, 1618 cm−1. Anal. (C24H20ClNO4 (421.87)) C, H, Cl, N.  
6-Chloro-2-phenyl-3-(3,4,5-trimethoxybenzyl)-1H-indole (2.27). Following synthetic 
procedure C using (6-chloro-2-phenyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)-methanone 
(0.100 g, 0.237 mmol), purification by silica gel column chromatography (hexanes/EtOAc 
67:33) afforded the title compound as a yellow solid (0.040 g, 0.098 mmol, 41% yield). M.p. 
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187−185 °C (EtOH). 1H NMR (CDCl3) δ 3.73 (s, 6H), 3.84 (s, 3H), 4.21 (s, 2H), 6.44 (s, 2H), 
7.07 (dd, J = 2.0 and 8.4 Hz, 1H), 7.38−7.42 (m, 3H), 7.45−7.49 (m, 2H), 7.53−7.56 (m, 2H), 
8.25 (br s, disappeared on treatment with D2O, 1H) ppm. IR ν 3332 cm−1. Anal. 
(C24H22ClNO3 (407.89)) C, H, Cl, N.  
6-Fluoro-2-phenyl-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (2.28). Following synthetic 
procedure A using 6-fluoro-2-phenyl-1H-indole (0.040 g, 0.189 mmol), purification by silica 
gel column chromatography (hexanes/EtOAc 67:33) afforded the title compound as a yellow 
oil (0.030 g, 0.073 mmol, 39% yield). 1H NMR (CDCl3) δ 3.64 (s, 6H), 3.78 (s, 3H), 6.35 (s, 
2H), 6.96 (t, J = 8.8 Hz, 1H), 7.14 (d, J = 9.0 Hz, 1H), 7.41−7.50 (m, 3H), 7.58−7.59 (m, 1H), 
7.78 (d, J = 8.0 Hz, 2H), 8.56 (br s, disappeared on treatment with D2O, 1H) ppm. IR ν 3320 
cm−1. Anal. (C23H20FNO3S (409.47)) C, H, F, N, S.  
(6-Fluoro-2-phenyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)-methanone (2.29). Following 
synthetic procedure B using 6-fluoro-2-phenyl-1H-indole (0.040 g, 0.189 mmol), purification 
by silica gel column chromatography (hexanes/EtOAc 67:33) afforded the title compound as 
a yellow oil (0.020 g, 0.049 mmol, 26% yield). 1H NMR (CDCl3) δ 3.68 (s, 6H), 3.80 (s, 3H), 
6.94 (s, 2H), 7.05 (t, J = 8.9 Hz, 1H), 7.14 (d, J = 9.0 Hz, 1H), 7.26−7.33 (m, 5H), 7.99− 8.02 
(m, 1H), 8.58 (br s, disappeared on treatment with D2O, 1H) ppm. IR ν 1621, 3265 cm−1. 
Anal. (C24H20FNO4 (405.42)) C, H, F, N. 
6-Methoxy-2-phenyl-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (2.30). Following 
synthetic procedure A using 6-methoxy-2-phenyl-1H-indole (0.250 g, 1.12 mmol), 
purification by silica gel column chromatography (CHCl3/EtOAc 95:5) afforded the title 
compound as a yellow solid (0.110 g, 0.261 mmol, 23% yield). M.p. 121−124 °C (toluene). 
1H NMR (DMSO-d6) δ 3.54 (s, 6H), 3.60 (s, 3H), 3.81 (s, 3H), 6.31 (s, 2H), 6.77 (dd, J = 2.2 
and 8.6 Hz, 1H), 6.97 (d, J = 2.0 Hz, 1H), 7.34−7.42 (m, 2H), 7.50 (t, J = 7.4 Hz, 2H), 7.85 
(d, J = 7.2 Hz, 2H), 11.88 (br s, disappeared on treatment with D2O, 1H) ppm. IR ν 3322 
cm−1. Anal. (C24H23NO4S (421.51)) C, H, N, S.  
(6-Methoxy-2-phenyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)-methanone (2.31). Following 
synthetic procedure B using 6-methoxy-2-phenyl-1H-indole (0.250 g, 1.12 mmol), 
purification by silica gel column chromatography (hexanes/EtOAc 67:33) afforded the title 
compound as a yellow solid (0.290 g, 0.695 mmol, 62% yield). M.p. 186−188 °C (toluene). 
1H NMR (DMSO-d6) δ 3.59 (s, 9H), 3.83 (s, 3H), 6.80 (s, 2H), 6.85 (dd, J = 2.3 and 8.8 Hz, 
1H), 6.97 (d, J = 2.2 Hz, 1H), 7.24−7.26 (m, 3H), 7.32−7.34 (m, 2H), 7.79 (d, J = 8.8 Hz, 
1H), 12.01 (br s, disappeared on treatment with D2O, 1H) ppm. IR ν 1610, 3302 cm−1. Anal. 
(C25H23NO5 (417.45)) C, H, N.  
7-Bromo-2-phenyl-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (2.32). Following synthetic 
procedure A using 7-bromo-2-phenyl-1H-indole (0.150 g, 0.551 mmol), purification by silica 
gel column chromatography (hexanes/EtOAc 75:25) afforded the title compound as a white 
solid (0.100 g, 0.213 mmol, 39% yield). M.p. 142−145 °C (toluene). 1H NMR (DMSO-d6) δ 
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3.54 (s, 6H), 3.57 (s, 3H), 6.29 (s, 2H), 7.08 (t, J = 7.7 Hz, 1H), 6.97 (d, J = 7.7 Hz, 1H), 
7.43−7.54 (m, 5H), 7.82 (d, J = 7.1 Hz, 1H), 12.11 (br s, disappeared on treatment with D2O, 
1H) ppm. IR ν 3335 cm−1. Anal. (C23H20BrNO3S (470.38)) C, H, Br, N, S.  
(7-Bromo-2-phenyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)-methanone (2.33). Following 
synthetic procedure B using 7-bromo-2-phenyl-1H-indole (0.150 g, 0.551 mmol), purification 
by silica gel column chromatography (hexanes/EtOAc 67:33) afforded the title compound as 
a yellow solid (0.150 g, 0.322 mmol, 58% yield). M.p. 188−190 °C (EtOH). 1H NMR 
(CDCl3) δ 3.71 (s, 6H), 3.82 (s, 3H), 6.97 (s, 2H), 7.18 (t, J = 7.8 Hz, 1H), 7.28−7.32 (m, 3H), 
7.42− 7.44 (m, 2H), 7.48 (d, J = 7.6 Hz, 1H), 7.99 (d, J = 8.0 Hz, 1H), 8.67 (br s, disappeared 
on treatment with D2O, 1H) ppm. IR ν 1618, 3258 cm−1. Anal. (C24H20BrNO4 (466.32)) C, H, 
Br, N.  
7-Chloro-2-phenyl-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (2.34). Following synthetic 
procedure A using 7-chloro-2-phenyl-1H-indole (0.140 g, 0.615 mmol), purification by silica 
gel column chromatography (hexanes/EtOAc 67:33) afforded the title compound as a white 
solid (0.200 g, 0.470 mmol, 76% yield). M.p. 62−65 °C (EtOH). 1H NMR (CDCl3) δ 3.66 (s, 
6H), 3.78 (s, 3H), 6.36 (s, 2H), 7.12−7.17 (m, 1H), 7.43−7.57 (m, 4H), 7.58−7.60 (m, 1H), 
7.83−7.85 (m, 2H), 8.72 (br s, disappeared on treatment with D2O, 1H) ppm. IR ν 3259 cm−1. 
Anal. (C23H20ClNO3S (425.93)) C, H, Cl, N, S. 
(7-Chloro-2-phenyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)-methanone (2.35). Following 
synthetic procedure B using 7-chloro-2-phenyl-1H-indole (0.250 g, 1.10 mmol), purification 
by silica gel column chromatography (hexanes/EtOAc 67:33) afforded the title compound as 
a brown solid (0.270 g, 0.640 mmol, 58% yield). M.p. 148−150 °C (EtOH). 1H NMR 
(DMSO-d6) δ 3.59 (s, 3H), 3.61 (s, 6H), 6.80 (s, 2H), 7.20−7.29 (m, 4H), 7.34 (dd, J = 1.0 
and 7.6 Hz, 1H), 7.38−7.41 (m, 2H), 7.88 (dd, J = 1.0 and 8.0 Hz, 1H), 12.41 (br s, 
disappeared on treatment with D2O, 1H) ppm. IR ν 1607, 3215 cm−1. Anal. (C24H20ClNO4 
(421.87)) C, H, Cl, N. 
7-Chloro-2-phenyl-3-(3,4,5-trimethoxybenzyl)-1H-indole (2.36). Following synthetic 
procedure C using (7-chloro-2-phenyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)-methanone 
(0.100 g, 0.237 mmol), purification by silica gel column chromatography (hexanes/EtOAc 
67:33) afforded the title compound as a yellow solid (0.040 g, 0.098 mmol, 41% yield). M.p. 
156−158 °C (EtOH). 1H NMR (CDCl3) δ 3.74 (s, 6H), 3.83 (s, 3H), 4.22 (s, 2H), 6.44 (s, 2H), 
7.05 (t, J = 7.8 Hz, 1H), 7.22−7−24 (m, 1H), 7.39− 7.45 (m, 2H), 7.48−7.51 (m, 2H), 
7.59−7.61 (m, 2H), 8.34 (br s, disappeared on treatment with D2O, 1H) ppm. IR ν 3347 cm−1. 
Anal. (C24H22ClNO3 (407.89)) C, H, Cl, N.    
7-Fluoro-2-phenyl-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (2.37). Following synthetic 
procedure A using 7-fluoro-2-phenyl-1H-indole (0.080 g, 0.379 mmol), purification by silica 
gel column chromatography (hexanes/EtOAc 67:33) afforded the title compound as a yellow 
solid (0.050 g, 0.122 mmol, 32% yield). M.p. 98−100 °C (toluene). 1H NMR (DMSO-d6) δ 
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3.54 (s, 6H), 3.57 (s, 3H), 6.30 (s, 2H), 7.05−7.10 (m, 2H), 7.31 (d, J = 7.1 Hz, 1H), 7.46 (t, J 
= 7.2 Hz, 1H), 7.53 (t, J = 7.1 Hz, 2H), 7.88 (d, J = 7.2 Hz, 2H), 12.46 (br s, disappeared on 
treatment with D2O, 1H) ppm. IR ν 3247 cm−1. Anal. (C23H20FNO3S (409.47)) C, H, F, N, S. 
(7-Fluoro-2-phenyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)-methanone (2.38). Following 
synthetic procedure B using 7-fluoro-2-phenyl-1H-indole (0.080 g, 0.379 mmol), purification 
by silica gel column chromatography (hexanes/EtOAc 67:33) afforded the title compound as 
a yellow solid (0.100 g, 0.247 mmol, 65% yield). M.p. 172−175 °C (toluene). 1H NMR 
(DMSO-d6) δ 3.59 (s, 3H), 3.61 (s, 6H), 6.81 (s, 2H), 7.07−7.18 (m, 2H), 7.26−7.27 (m, 3H), 
7.38− 7.40 (m, 2H), 7.72 (d, J = 7.8 Hz, 1H), 12.60 (br s, disappeared on treatment with D2O, 
1H) ppm. IR ν 1615, 3254 cm−1. Anal. (C24H20FNO4 (405.42)) C, H, F, N.   
7-Methoxy-2-phenyl-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (2.39). Following 
synthetic procedure A using 7-methoxy-2-phenyl-1H-indole (0.250 g, 1.12 mmol), 
purification by silica gel column chromatography (CH2Cl2/EtOAc 99:1) afforded the title 
compound as a white solid (0.270 g, 0.647 mmol, 58% yield). M.p. 158−160 °C (EtOH). 1H 
NMR (DMSO-d6) δ 3.53 (s, 6H), 3.57 (s, 3H), 3.97 (s, 3H), 6.29 (s, 2H), 6.79−6.81 (m, 1H), 
7.04−7.08 (m, 2H), 7.40−7.49 (m, 3H), 7.83−7.86 (m, 2H), 12.09 (br s, disappeared on 
treatment with D2O, 1H) ppm. IR ν 3300 cm−1. Anal. (C24H23NO4S (417.45)) C, H, N, S.  
(7-Methoxy-2-phenyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)-methanone (2.40). Following 
synthetic procedure B using 7-methoxy-2-phenyl-1H-indole (0.250 g, 1.12 mmol), 
purification by silica gel column chromatography (hexanes/Et2O 30:70) afforded the title 
compound as a yellow solid (0.030 g, 0.072 mmol, 6% yield). M.p. 185−188 °C (EtOH). 1H 
NMR (DMSO-d6) δ 3.59 (s, 3H), 3.60 (s, 6H), 3.98 (s, 3H), 6.79 (s, 2H), 6.83 (d, J = 7.4 Hz, 
1H), 7.11 (t, J = 7.9 Hz, 1H), 7.20−7.23 (m, 3H), 7.35−7.38 (m, 2H), 7.47−7.49 (m,1H), 
12.24 (br s, disappeared on treatment with D2O, 1H) ppm. IR ν 1606, 3270 cm−1. Anal. 
(C25H23NO5 (417.45)) C, H, N.  
6,7-Dichloro-2-phenyl-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (2.41). Following 
synthetic procedure A using 6,7-dichloro-2-phenyl-1H-indole (0.050 g, 0.191 mmol), 
purification by silica gel column chromatography (hexanes/EtOAc 67:33) afforded the title 
compound as a yellow solid (0.050 g, 0.109 mmol, 57% yield). M.p. 158−160 °C (EtOH). 1H 
NMR (DMSO-d6) δ 3.55 (s, 6H), 3.57 (s, 3H), 6.29 (s, 2H), 7.32 (d, J = 8.5 Hz, 1H), 
7.44−7.55 (m, 4H), 7.83−7.85 (m, 2H), 12.44 (br s, disappeared on treatment with D2O, 1H) 
ppm. IR ν 1610, 3268 cm−1. Anal. (C23H19Cl2NO3S (460.37)) C, H, Cl, N, S.  
(6,7-Dichloro-2-phenyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)-methanone (2.42). 
Following synthetic procedure B using 6,7-dichloro-2-phenyl-1H-indole (0.050 g, 0.191 
mmol), purification by silica gel column chromatography (hexanes/EtOAc 75:25) afforded 
the title compound as a green solid (0.020 g, 0.044 mmol, 23% yield). M.p. 218−220 °C 
(EtOH). 1H NMR (DMSO-d6) δ 3.59 (s, 3H), 3.61 (s, 6H), 6.81 (s, 2H), 7.25−7.32 (m, 3H), 
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7.39−7.42 (m, 3H), 7.86 (d, J = 8.5 Hz, 1H), 12.58 (br s, disappeared on treatment with D2O, 
1H) ppm. IR ν 1607, 3271 cm−1. Anal. (C24H19Cl2NO4S (456.32)) C, H, Cl, N, S. 
4-Bromo-2-phenyl-1H-indole (2.43). Following synthetic procedure D using 2-(2-bromo-6-
nitrophenyl)-1-phenylethanone (0.100 g, 0.400 mmol), purification by silica gel column 
chromatography (CHCl3) afforded the title compound as a solid (0.020 g, 0.073 mmol, 19% 
yield). M.p. 98−100 °C. Lit.48 100−102 °C.  
4-Chloro-2-phenyl-1H-indole (2.44). Following synthetic procedure E using N-(3-chloro-
2-methylphenyl)benzamide (2.00 g, 8.00 mmol), purification by silica gel column 
chromatography (CH2Cl2) afforded the title compound as a solid (0.56 g, mmol, 31% yield). 
M.p. 73−76 °C (EtOH). Lit.48 73−75 °C.  
4-Fluoro-2-phenyl-1H-indole (2.45). Following synthetic procedure E using N-(3-fluoro-2-
methylphenyl)benzamide (1.75 g, 7.63 mmol), purification by silica gel column 
chromatography (hexanes/EtOAc 80:20) afforded the title compound as a yellow solid (0.840 
g, 3.98 mmol, 52% yield). M.p. 60−62 °C (EtOH). Lit.48 62−64 °C.  
4-Methoxy-2-phenyl-1H-indole (2.46). Following synthetic procedure E using N-(3-
methoxy-2-methylphenyl)benzamide (2.4 g, 9.95 mmol), purification by silica gel column 
chromatography (hexanes/EtOAc 80:20) afforded the title compound as a yellow solid (0.750 
g, 3.36 mmol, 34% yield). M.p. 100−103 °C (EtOH). Lit.49 103−105 °C. 
5-Bromo-2-phenyl-1H-indole (2.47). Following synthetic procedure F using 1-(4-
bromophenyl)-2-(1-phenylethylidene)hydrazine (0.800 g, 2.77 mmol), crystallization from 
EtOH afforded the title compound as a brown solid (0.65 g, 2.39 mmol, 82% yield). M.p. 
190−192 °C. Lit.50 193−196 °C. 
5-Chloro-2-phenyl-1H-indole (2.48). Following synthetic procedure F using 1-(4-
chlorophenyl)-2-(1-phenylethylidene)hydrazine (0.500 g, 2.04 mmol), crystallization from 
EtOH afforded the title compound as a yellow solid (0.170 g, 0.747 mmol, 37% yield). M.p. 
198−200 °C. Lit.51 203−204 °C.  
5-Fluoro-2-phenyl-1H-indole (2.49). Following synthetic procedure F using 1-(4-
fluorophenyl)-2-(1-phenylethylidene)hydrazine (4.77 g, 21.0 mmol), purification by silica gel 
column chromatography afforded the title compound as a yellow solid (1.57 g, 7.43 mmol, 
35% yield). M.p. 180−185 °C. Lit.52 181−183 °C.  
5-Methoxy-2-phenyl-1H-indole (2.50) was synthesized according to a literature 
procedure.53 
6-Bromo-2-phenyl-1H-indole (2.51). Following synthetic procedure D using 2-(4-bromo-2-
nitrophenyl)-1-phenylethanone (0.250 g, 0.781 mmol), purification by silica gel column 
chromatography (hexanes/EtOAc 75:25) afforded the title compound as a yellow solid (0.100 
g, 0.367 mmol, 47% yield). M.p. 188−190 °C (EtOH). Lit.54 187 °C.  
6-Chloro-2-phenyl-1H-indole (2.52). Following synthetic procedure E using N-(5-chloro-
2-methylphenyl)benzamide (2.00 g, 8.14 mmol), purification by silica gel column 
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chromatography (hexanes/EtOAc 80:20) afforded the title compound as a white solid (0.315 
g, 1.38 mmol, 18% yield). M.p. 176−177 °C (EtOH). Lit.49 180−181 °C. 
6-Fluoro-2-phenyl-1H-indole (2.53). Following synthetic procedure D using 2-(4-fluoro-2-
nitrophenyl)-1-phenylethanone (0.050 g, 0.193 mmol), purification by silica gel column 
chromatography (hexanes/EtOAc 75:25) afforded the title compound as a solid (0.010 g, 
0.047 mmol, 25% yield). M.p. 170−171 °C (EtOH). Lit.55 171−172 °C.  
6-Methoxy-2-phenyl-1H-indole (2.54). Following synthetic procedure E using N-(5-
methoxy-2-methylphenyl)benzamide (2.00 g, 8.29 mmol), purification by silica gel column 
chromatography (CHCl3) afforded the title compound as a green solid (0.620 g, 2.78 mmol, 
33% yield). M.p. 170−173 °C (EtOH). Lit.56 173−176 °C. 
7-Bromo-2-phenyl-1H-indole (2.55). Following synthetic procedure F using 1-(2-
bromophenyl)-2-(1-phenylethylidene)hydrazine (2.49 g, 8.61 mmol), crystallization from 
EtOH afforded the title compound as a yellow solid (0.320 g, 1.18 mmol, 14% yield). M.p. 
115−117 °C. Lit.57 117−118 °C. 1H NMR (DMSO-d6) δ 6.97 (t, J = 7.7, 1H), 7.02 (s, 1H), 
7.31−7.38 (m, 2H), 7.47 (t, J = 7.5 Hz, 2H), 7.56 (d, J = 7.8 Hz, 1H), 7.98−8.00 (m, 2H), 
11.36 (br s, disappeared on treatment with D2O, 1H) ppm. IR ν 3436 cm−1.  
7-Chloro-2-phenyl-1H-indole (2.56) was synthesized according to a literature procedure.58 
7-Fluoro-2-phenyl-1H-indole (2.57). Following synthetic procedure F using 1-(2-
fluorophenyl)-2-(1-phenylethylidene)hydrazine (2.99 g, 13.0 mmol), purification by silica gel 
column chromatography (hexanes/acetone 80:20) afforded the title compound as a yellow 
solid (0.180 g, 0.852 mmol, 7% yield). M.p. 122−125 °C. 1H NMR (DMSO-d6) δ 6.91−7.00 
(m, 3H), 7.33−7.38 (m, 2H), 7.47 (t, J = 7.5 Hz, 2H), 7.95 (d, J = 7.4 Hz, 2H), 11.85 (br s, 
disappeared on treatment with D2O, 1H) ppm. IR ν 3436 cm−1.  
7-Methoxy-2-phenyl-1H-indole (2.58). Following synthetic procedure E using N-(2-
methoxy-6-methylphenyl)benzamide (2.88 g, 0.012 mmol), purification by silica gel column 
chromatography (hexanes/EtOAc 5:1) afforded the title compound as a yellow solid (0.760 g, 
3.40 mmol, 28% yield). M.p. 83−87 °C (EtOH). Lit.59,60 85−86 °C. 
6,7-Dichloro-2-phenyl-1H-indole (2.59). Following synthetic procedure F using 1-(2,3-
dichlorophenyl)-2-(1-phenylethylidene)hydrazine (1.11 g, 3.98 mmol), purification by silica 
gel column chromatography (hexanes/acetone 80:20) afforded the title compound as a yellow 
solid (0.120 g, 0.458 mmol, 12% yield). M.p. 105−108 °C. 1H NMR (DMSO-d6) δ 7.03 (s, 
1H), 7.21 (t, J = 8.4 Hz, 1H), 7.37 (t, J = 7.4 Hz, 1H), 7.46−7.55 (m, 3H), 7.99 (d, J = 8.0 Hz, 
2H), 11.71 (br s, disappeared on treatment with D2O, 1H) ppm. IR ν 3248 cm−1.  
2-(2-Bromo-6-nitrophenyl)-1-phenylethanol (2.60). Following synthetic procedure G using 
2-bromo-6-nitrotoluene (0.250 g, 1.16 mmol), purification by silica gel column 
chromatography (hexanes/EtOAc 75:25) afforded the title compound as a yellow oil (0.150 g, 
0.466 mmol, 40% yield). 1H NMR (DMSO-d6) δ 3.21−3.24 (m, 2H), 4.64 (d, J = 7.4 Hz, 1H), 
5.48 (br s, disappeared on treatment with D2O, 1H), 7.25−7.33 (m, 5H), 7.42 (t, J = 8.0 Hz, 
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1H), 7.84 (d, J = 2 8.0 Hz, 1H), 7.97 (d, J = 8.2 Hz, 1H) ppm. IR ν 2961, 3030, 3063, 3325, 
3560 cm−1. 
2-(4-Bromo-2-nitrophenyl)-1-phenylethanol (2.61). Following synthetic procedure G using 
4-bromo-1-methyl-2-nitrobenzene (0.250 g, 1.16 mmol), purification by silica gel column 
chromatography (hexanes/EtOAc 75:25) afforded the title compound as an oil (0.164 g, 0.509 
mmol, 44% yield). 1H NMR (DMSO-d6) δ 3.07−3.12 (m, 2H), 4.69−4.73 (m, 1H), 5.43 (d, J 
= 4.5 Hz, disappeared on treatment with D2O, 1H), 7.21−7.25 (m, 1H), 7.28−7.33 (m, 4H), 
7.39 (d, J = 8.3 Hz, 1H), 7.80 (dd, J = 1.7 and 8.2 Hz, 1H), 8.08−8.10 (m, 1H) ppm. IR ν 
2934, 3030, 3065, 3418 cm−1.  
2-(4-Fluoro-2-nitrophenyl)-1-phenylethanol (2.62). Following synthetic procedure G using 
4-fluoro-1-methyl-2-nitrobenzene (0.180 g, 1.16 mmol), purification by silica gel column 
chromatography (hexanes/EtOAc 75:25) afforded the title compound as an oil (0.100 g, 0.383 
mmol, 33% yield). 1H NMR (DMSO-d6) δ 3.12−3.14 (m, 2H), 4.68−4.73 (m, 1H), 5.40 (d, J 
= 4.4 Hz, disappeared on treatment with D2O, 1H), 7.22−7.33 (m, 5H), 7.46−7.51 (m, 2H), 
7.81 (dd, J = 2.3 and 9.0 Hz, 1H) ppm. IR ν 2932, 3032, 3087, 3404 cm−1. 
2-(2-Bromo-6-nitrophenyl)-1-phenylethanone (2.63). Following synthetic procedure H 
using 2-(2-bromo-6-nitrophenyl)-1-phenylethanol (0.100 g, 0.310 mmol), purification by 
silica gel column chromatography (CHCl3/petroleum ether 50:50) afforded the title compound 
as a solid (0.040 g, 0.125 mmol, 40% yield). M.p. 113−115 °C (EtOH). 1H NMR (DMSO-d6) 
δ 4.89 (s, 2H), 7.52−7.62 (m, 3H), 7.70 (t, J = 7.8 Hz, 1H), 8.05−8.10 (m, 4H) ppm. IR ν 1680 
cm−1.  
2-(4-Bromo-2-nitrophenyl)-1-phenylethanone (2.64). Following synthetic procedure H 
using 2-(4-bromo-2-nitrophenyl)-1-phenylethanol (0.100 g, 0.310 mmol), purification by 
silica gel column chromatography (CHCl3/petroleum ether 50:50) afforded the title compound 
as a solid (0.040 g, 0.125 mmol, 40% yield). M.p. 114−116 °C (EtOH). 1H NMR (DMSO-d6) 
δ 4.87 (s, 2H), 7.53−7.60 (m, 3H), 7.70 (t, J = 7.1 Hz, 1H), 7.96−7.98 (m, 1H), 8.05 (d, J = 
7.4 Hz, 2H), 8.28−8.30 (m, 1H) ppm. IR ν 1686 cm−1.  
2-(4-Fluoro-2-nitrophenyl)-1-phenylethanone (2.65). Following synthetic procedure H 
using 2-(4-fluoro-2-nitrophenyl)-1-phenylethanol (0.100 g, 0.383 mmol), purification by 
silica gel column chromatography (CHCl3/petroleum ether 50:50) afforded the title compound 
as a white solid (0.020 g, 0.077 mmol, 20% yield). M.p. 95−98 °C (EtOH). 1H NMR (DMSO-
d6) δ 4.88 (s, 2H), 7.56−7.72 (m, 5H), 8.03−8.06 (m, 3H) ppm. IR ν 1680 cm−1.  
N-(3-Chloro-2-methylphenyl)benzamide (2.66). Following synthetic procedure I using 3-
chloro-2-methylaniline (6.68 g, 47.2 mmol), treatment with diethyl ether furnished the title 
compound (5.66 g, 23.0 mmol, 49% yield). M.p. 168−170 °C. Lit.61 170 °C. 1H NMR 
(CDCl3) δ 2.40 (s, 3H), 7.21 (t, J = 8.0 Hz, 1H), 7.26−7.29 (m, 1H), 7.51−7.55 (m, 2H), 
7.58−7.62 (m, 1H), 7.75−7.80 (m, 2H; one proton disappeared after treatment with D2O), 
7.90−7.92 (m, 2H) ppm. IR ν 1647, 3244 cm−1. 
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N-(3-Fluoro-2-methylphenyl)benzamide (2.67). Following synthetic procedure I using 3-
fluoro-2-methylaniline (3.00 g, 24.0 mmol), purification by silica gel column chromatography 
(hexanes/EtOAc 67:33) afforded the title compound as a white solid (3.67 g, 16.0 mmol, 67% 
yield). M.p. 150−152 °C (EtOH). Lit.62 157−158 °C. 1H NMR (CDCl3) δ 2.25 (s, 3H), 6.93 (t, 
J = 9.0 Hz, 1H), 7.20−7.27 (m, 1H), 7.52 (t, J = 7.7 Hz, 2H), 7.59 (t, J = 7.3 Hz, 1H), 
7.71−7.75 (m, 2H; one proton disappeared after treatment with D2O), 7.88−7.91 (m, 2H) ppm. 
IR ν 1670, 3230 cm−1.  
N-(3-Methoxy-2-methylphenyl)benzamide (2.68). Following synthetic procedure I using 3-
methoxy-2-methylaniline (2.00 g, 14.6 mmol), purification by silica gel column 
chromatography (hexanes/EtOAc 75:25) afforded the title compound as a yellow solid (2.73 
g, 11.3 mmol, 77% yield). Mp: 173−175 °C (EtOH). Lit.63 177 °C. 1H NMR (DMSO-d6) δ 
2.06 (s, 3H), 3.82 (s, 3H), 6.89 (d, J = 8.2 Hz, 1H), 6.94 (d, J = 7.8 Hz, 1H), 7.19 (t, J = 8.1 
Hz, 1H), 7.53 (t, J = 7.6 Hz, 2H), 7.59 (t, J = 7.4 Hz, 1H), 7.98 (d, J = 7.2 Hz, 2H), 9.89 (br s, 
disappeared on treatment with D2O, 1H) ppm. IR ν 1649, 3229 cm−1.  
N-(5-Chloro-2-methylphenyl)benzamide (2.69). Following synthetic procedure I using 5-
chloro-2-methylaniline (7.16 g, 50.6 mmol), treatment with diethyl ether furnished the title 
compound as a white solid (7.25 g, 29.5 mmol, 58% yield). M.p. 125−127 °C (EtOH). Lit.64 
121−123 °C.  
N-(5-Methoxy-2-methylphenyl)benzamide (2.70). Following synthetic procedure I using 5-
methoxy-2-methylaniline (1.38 g, 10.0 mmol), purification by silica gel column 
chromatography (CHCl3/EtOAc 95:5) afforded the title compound as a pink solid (2.00 g, 
8.29 mmol, 83% yield). M.p. 113−115 °C (EtOH). 1H NMR (DMSO-d6) δ 2.17 (s, 3H), 3.74 
(s, 3H), 6.77 (dd, J = 2.6 and 8.4 Hz, 1H), 6.98 (d, J = 2.6 Hz, 1H), 7.17 (d, J = 8.4 Hz, 1H), 
7.53 (t, J = 7.6 Hz, 2H), 7.59 (t, J = 7.3 Hz, 1H), 7.98 (d, J = 7.1 Hz, 2H), 9.83 (br s, 
disappeared on treatment with D2O, 1H) ppm. IR ν 1650, 3299 cm−1.  
N-(2-Methoxy-6-methylphenyl)benzamide (2.71). Following synthetic procedure I using 2-
methoxy-6-methylaniline (2.00 g, 0.015 mmol), purification by silica gel column 
chromatography (hexanes/EtOAc 75:25) afforded the title compound as awhite solid (2.88 g, 
11.9 mmol, 80% yield). M.p. 127−130 °C (EtOH). 1H NMR (DMSO-d6) δ 2.50 (s, 3H), 3.74 
(s, 3H), 6.87−6.93 (m, 2H), 7.20 (t, J = 8.0 Hz, 1H), 7.49−7.60 (m, 3H), 8.00 (d, J = 7.3 Hz, 
2H), 9.57 (br s, disappeared on treatment with D2O, 1H) ppm. IR ν 1647, 3360 cm−1.  
1-(4-Bromophenyl)-2-(1-phenylethylidene)hydrazine (2.72). Following synthetic procedure 
J using (4-bromophenyl)hydrazine hydrochloride (3.71 g, 16.6 mmol), the title compound was 
obtained as a yellow solid (0.90 g, 0.311 mmol, 30% yield). M.p. 118−120 °C (EtOH). 1H 
NMR (CDCl3) δ 2.25 (s, 3H), 7.08 (d, J = 8.9 Hz, 2H), 7.35−7.41 (m, 6H; one proton 
disappeared after treatment with D2O), 7.83 (d, J = 8.5 Hz, 2H) ppm. IR ν 3353 cm−1. 
1-(4-Chlorophenyl)-2-(1-phenylethylidene)hydrazine (2.73). Following synthetic 
procedure J using (4-chlorophenyl)hydrazine hydrochloride (2.23 g, 15.6 mmol), the title 
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compound was obtained as a brown solid (0.500 g, 2.04 mmol, 25% yield). M.p. 105−107 °C 
(EtOH). Lit.65 100−102 °C. 1H NMR (CDCl3) δ 2.25 (s, 3H), 7.12 (d, J = 8.8 Hz, 2H), 7.24 
(d, J = 8.8 Hz, 2H), 7.31−7.35 (m, 2H; one proton disappeared after treatment with D2O), 
7.40 (t, J = 7.0 Hz, 2H), 7.79 (d, J = 7.1 Hz, 2H) ppm. IR ν 3352 cm−1.  
1-(4-Fluorophenyl)-2-(1-phenylethylidene)hydrazine (2.74). Following synthetic procedure 
J using (4-fluorophenyl)hydrazine hydrochloride (2.44 g, 15.0 mmol), the title compound was 
obtained as a yellow solid (2.44 g, 10.7 mmol, 95% yield). M.p. 110−112 °C (EtOH). Lit.66 
107 °C. 1H NMR (DMSO-d6) δ 2.25 (s, 3H), 7.00−7.10 (m, 2H), 7.22−7.29 (m, 3H), 7.38 (t, J 
= 7.3 Hz, 2H), 7.78 (d, J = 7.2 Hz, 2H), 9.31 (br s, disappeared on treatment with D2O, 1H) 
ppm. IR ν 3380 cm−1.  
1-(2-Bromophenyl)-2-(1-phenylethylidene)hydrazine (2.75). Following synthetic procedure 
J using (2-bromophenyl)hydrazine hydrochloride (3.35 g, 15.0 mmol), the title compound was 
obtained as a yellow solid (2.49 g, 8.61 mmol, 86% yield). M.p. >300 °C (EtOH). Spectral 
data were consistent with those reported in the literature.67 
1-(2-Fluorophenyl)-2-(1-phenylethylidene)hydrazine (2.76). Following synthetic procedure 
J using (2-fluorophenyl)hydrazine hydrochloride (2.44 g, 15.0 mmol), the title compound was 
obtained as a yellow solid (1.55 g, 6.79 mmol, 68% yield). M.p. >300 °C (EtOH). 1H NMR 
(DMSO-d6) δ 2.32 (s, 3H), 6.79−6.84 (m, 1H), 7.13−7.17 (m, 2H), 7.34−7.43 (m, 3H), 
7.56−7.59 (m, 1H), 7.80−7.83 (m, 2H), 8.64 (br s, disappeared on treatment with D2O, 1H) 
ppm. IR ν 3380 cm−1.  
1-(2,3-Dichlorophenyl)-2-(1-phenylethylidene)hydrazine (2.77). Following synthetic 
procedure J using (2,3-dichlorophenyl)hydrazine hydrochloride (1.60 g, 7.49 mmol), the title 
compound was obtained as a white solid (1.11 g, 0.398 mmol, 79% yield). M.p. 112−115 °C. 
1H NMR (DMSO-d6) δ 2.36 (s, 3H), 7.09 (dd, J = 1.4 and 7.9 Hz, 1H), 7.31 (t, J = 8.4, 1H), 
7.37−7.45 (m, 3H), 7.60 (dd, J = 1.3 and 8.4 Hz, 1H), 7.84−7.87 (m, 2H), 8.40 (br s, 
disappeared on treatment with D2O, 1H) ppm. IR ν 3270 cm−1.  
 
2.7.2 Molecular Modeling 
All molecular modeling studies were performed on a MacPro dual 2.66 GHz Xeon running 
Ubuntu 14. The tubulin structure was downloaded from the Protein Data Bank 
(http://www.rcsb.org/, PDB codes: 1SA06 and 4O2A29).6 Ligand structures were built with 
MOE68 and minimized using the MMFF94x force field until an RMSD gradient of 0.05 kcal 
mol−1 Å−1 was reached. The docking simulations were performed using PLANTS26 on the 
1SA0 crystal structure.  
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2.7.3 Biological Assay 
Tubulin Assembly. The reaction mixtures contained 0.8 M monosodium glutamate (pH 6.6 
with HCl in a 2 M stock solution), 10 µM tubulin, 4% (v/v) DMSO, and varying 
concentrations of drug. Following a 15 min preincubation at 30 °C, samples were chilled on 
ice, GTP to 0.4 mM was added, and turbidity development was followed at 350 nm in a 
temperature-controlled recording spectrophotometer for 20 min at 30 °C. The extent of 
reaction was measured. Full experimental details were previously reported.69 
[3H]Colchicine Binding Assay. The reaction mixtures contained 1.0 µM tubulin, 5.0 µM 
[3H]colchicine, and 5.0 µM inhibitor and were incubated for 10 min at 37 °C. Complete 
details were described previously.70  
Cell Cultures. Cell lines were obtained from the American Type Culture Collection 
(ATCC), unless otherwise specified. MCF-7 breast carcinoma, OVCAR-8, and NCI/ADR-
RES cells were obtained from the National Cancer Institute drug screening laboratory, and 
NB4 cells and MV4−11 cells from the Deutsche Sammlung von Mikroorganismen and 
Zellkulturen. All cell lines, except as indicated, were grown in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 20 mM HEPES, 100 
U/mL penicillin, 100 mg/mL streptomycin, and 1% L-glutamine; specific requirements 
include the addition of sodium pyruvate (1−2% for RD rhabdomyosarcoma, HepG2 
hepatoma, and the three MDA breast carcinoma cell lines) and glucose (1 g/L for RD and 
HepG2, 4.5 g/L for PC3 prostate carcinoma). Cell lines were cultured at 37 °C in 5% 
CO2/95% air in a humidified incubator. Treatments were initiated 24 h after cell seeding using 
ATI compound diluted in 0.1% DMSO, the indicated reference compound, or 0.1% DMSO 
vehicle, for 24−72 h as indicated.  
Cell Viability Assays. For MCF-7 breast carcinoma and OVCAR-8 and NCI/ADR-RES 
ovary carcinoma cells, the methodology for evaluation of growth was previously described, 
except that cells were grown for 96 h for IC50 determinations.71 
MV4−11, NB4, A-549, NCI-H1975, Messa, and Messa/Dx5 cells were seeded into 96-well 
plates (Corning Inc., Costar) at a density of 2 × 103 cells/well in 50 µL of the appropriate 
medium. For the MDA-MB-468, MDA-MB-436, and MDA-MB-231 breast carcinoma cell 
lines, the cells were plated in 100 µL of medium in 96-well plates at a density of 3.5 × 103 
cells/well for MDA-MB-468, 3 × 103 cells/well for MDA-MB-436, and 2 × 103 cells/well for 
MDA-MB-436. After 24 h, the cells were treated with the inhibitor (0.39−100 nM) and then 
evaluated in MTT assays as described.72 Statistical analysis was performed by analysis of 
variance (ANOVA) with Neumann−Keul’s multiple comparison test or the 
Kolmogorov−Smirnov test where appropriate.  
For the PC-3, HepG2, and RD cell lines, the cells were seeded in 24-well plates at a 
density of 95 × 103 cells/100 µL well (PC-3 and RD) or 120 × 103 cells/100 µL well (HepG2). 
After 24 h, the test compound was added (0.01−25 µM) for 48 h. After removal of the 
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medium, MTT was added (500 µM final concentration in 500 µL/well of phosphate-buffered 
saline (PBS)) and incubation continued at 37 °C for 2 h in the dark. The formazan crystals 
were dissolved in 2-propanol containing 0.04 N HCl (200 µL). A550 in the wells was 
determined using a Multiskan Spectrum Thermo Electron Corp. reader. IC50 values were 
calculated by nonlinear regression analysis (GraphPad Prism statistics software). Experiments 
were performed in triplicate. For HeLa cells, 7 × 103 cell aliquots were seeded in a flat-
bottom 96-well tissue culture plate and, after 24 h, were exposed to the inhibitor (10−100 nM) 
for 24 or 48 h. MTT (10 µL, 5 mg/mL) (Sigma-Aldrich) was added to each well, and the cells 
were further incubated for 3 h at 37 °C. After solubilization of the crystals with 2-
propanol/0.04 N HCl, A570 measurements were made with an ELISA reader, and IC50 values 
were derived from dose−response curves.  
For the MV4−11, NB4 (AML), A-549, and NCI-H1975 (lung adenocarcinoma) cell lines, 
cell growth was measured using CellTiter-Flor (Promega), a nonlytic, single-reagent-addition 
fluorescence assay that detects the relative number of living cells in samples after 
experimental manipulation. The CellTiter-Fluor cell viability assay measures the conserved 
and constitutive protease activity within live cells and, therefore, acts as a marker for cell 
viability. NB4 and MV4−11 cells in exponential growth were incubated for 48 h with 
different concentrations of the inhibitors. After 48 h, CellTiter-Fluor reagent was added to the 
cell culture medium (1:1, v/v) and incubated for at least 90 min at 37 °C. A549 and NCI-
H1975 cells were treated with the inhibitor for 72 h, and then CellTiter-Fluor reagent was 
added to one-fifth of the culture medium volume. Fluorescence was recorded (excitation 
wavelength, 360 nm; emission wavelength, 535 nm), and the IC50 was calculated using 
GraphPad software.  
For the Messa and Messa/Dx5 (resistant) sarcoma cell lines, the CellTiter-Glo luminescent 
cell viability assay was used (Promega, Madison, WI). Cells in exponential growth were 
incubated for 72 h with different concentrations of the inhibitor, and then the same volume of 
CellTiter-Glo reagent was added. The solution was stirred for 2 min to induce cell lysis. 
Luminescence was recorded after an additional 10 min. IC50 values were calculated using 
nonlinear regression analysis (GraphPad Prism statistics software).  
For T98G and U343MG cells, growth was measured by a colorimetric MTS conversion 
assay, as previously reported.23 
For D283 medulloblastoma cells, 3 × 105 D283 cells/well were plated in a 24-multiwell 
dish. After 24 h, ATI derivative 2.41 or 2.78 (1 µM) was added to the cells for the indicated 
time. Viability was evaluated with a trypan blue assay.  
Antibodies and Immunostaining. The following unconjugated monoclonal antibodies 
(mAb’s) were used for immunostaining: anti-MICA (MAB159227), anti-MICB 
(MAB236511), anti-ULBP1 (MAB170818), anti-ULBP2 (MAB165903), and anti-ULBP3 
(MAB166510) from R&D Systems (Minneapolis, MN), anti-PVR (SKII.4) kindly provided 
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by Prof M. Colonna (Washington University, St Louis, MO), anti-Nec-2 (R2.525) from BD 
Pharmingen (San Diego, CA), and allophycocyanin (APC)-conjugated goat affinity purified 
F(ab′)2 fragment to mouse IgG (GAM) from Jackson ImmunoResearch Laboratories (West 
Grove, PA).  
Flow Cytometry Analysis. A total of 3 × 105 HeLa cells were seeded in tissue culture 
dishes. After ATI treatment, cell numbers were counted using a Z1 Coulter particle counter 
(Beckman Coulter). Cell cycle phase distribution was analyzed in permeabilized cells 
incubated with PI (Sigma-Aldrich P4170, 0.04 mg/mL). SS and FL-3 parameters were 
acquired on a linear amplification scale, and FS and Fl2 on a log scale. Cell aggregates were 
gated out on the biparametric graph FL-3lin/ratio. Apoptosis was determined as the 
proportion of cells exhibiting a DNA content lower than 2 N after gating out cell debris on the 
biparametric graph FS/SS using the WinMDI software. Cell death was analyzed in 200 000 
cell aliquots in binding buffer (10 mM HEPES/NaOH, pH 7.4, 140 mM NaCl, 2.5 mM CaCl2) 
incubated with annexin V−FITC (Immunological Sciences, IK-11120) alone or annexin 
V−FITC in combination with PI in the absence of permeabilizing agents. Cell samples were 
analyzed in a Coulter Epics XL cytofluorometer (Beckman Coulter) equipped with EXPO 32 
ADC software. At least 10 000 cells per sample were acquired.  
IF and Image Analysis. Cells were seeded on sterile polylysine-coated coverslips placed in 
tissue culture plates. After treatment with ATI or vinblastine, as indicated, the cells were fixed 
with 3.7% para-formaldehyde in PBS for 10 min at room temperature and then permeabilized 
in 0.1% Triton-X100 in PBS for 5 min. Blocking and antibody reactions were carried out in 
PBS/0.05% Tween 20 containing 3% BSA at room temperature using mouse anti-α-tubulin 
(1:2000, B-5-1-2, Sigma-Aldrich) followed by FITC-conjugated goat antimouse IgG (Jackson 
ImmunoResearch Laboratories). Chromosomal DNA was stained with 4,6-diamidino-2-
phenylindole (DAPI; 0.1 µg/mL) and mounted in Vectashield (Vector Laboratories). Images 
were analyzed using a Nikon Eclipse 90i microscope equipped with a Qicam Fast 1394 CCD 
camera (Qimaging). To resolve MT remnants or unstructured tubulin foci, some of the 
acquired images were deconvoluted and analyzed using the extended depth of focus on Z-
serial optical sections using a Nis-Elements AR 4.2 (Nikon).  
IF and Flow Cytometry Ligand Analysis. NKG2D and DNAM-1 ligand surface expression 
on HeLa cells was analyzed by IF staining using anti-MICA, anti-MICB, anti-ULBP1/2/3, 
anti-PVR, or anti-Nec2 unconjugated mAb’s, followed by secondary GAM/APC. Samples 
were analyzed using a FACSCanto II (BD Biosciences, San Jose, CA). Flow cytometric 
analysis was performed using the FlowJo software, version 8.8.7 (TreeStar, Ashland, OR).  
Degranulation Assay. NK cell-mediated cytotoxicity was evaluated using the 
degranulation lysosomal marker CD107a as previously described.73 As a source of effector 
cells, we used human peripheral blood mononuclear cells (PBMCs) isolated from healthy 
donors by Lymphoprep (Nycomed, Oslo, Norway) gradient centrifugation and then 
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cocultured for 10 days with an irradiated (30 Gy) Epstein−Barr virus (EBV)-transformed B-
cell line. Cells were grown in RPMI 8866 at 37 °C in a humidified 5% CO2 atmosphere. On 
day 10, the cell population was routinely more than 90% CD56+CD16+CD3−, as assessed by 
IF and flow cytometric analysis. After a 48 h treatment with 2.30 or 2.41, HeLa cells were 
incubated with activated NK cells at effector:target (E:T) ratios of 1:1 in a flat-bottom 96-well 
tissue culture plate in complete medium (DMEM (Life Technologies, Gaithersburg, MD) 
supplemented with 10% FCS). The plates were incubated at 37 °C in a 5% CO2 atmosphere 
for 2 h. Thereafter, the cells were washed with PBS and incubated with anti-CD107a/APC (or 
cIgG/APC) for 45 min at 4 °C. The cells were also stained with anti-CD3/FITC and anti-
CD56/PE to gate the CD3−CD56+ NK cell population.  
Real-Time PCR. MICA, MICB, ULBP1, ULBP2, ULBP3, and PVR mRNA expression 
was analyzed by real-time PCR. Total RNA from HeLa cells was extracted using Trizol 
(Invitrogen) after a maximum of 24 h of drug treatment. Total RNA (1 µg) was used for 
cDNA first-strand synthesis using oligo-dT (Promega, Madison, WI) in a 25 µL reaction 
volume. To analyze ligand mRNA expression, the cDNA was amplified in triplicate with the 
following primers: Hs00792952_m1 for MICA, Hs00792952_m1 for MICB, 
Hs00197846_m1 for PVR, Hs00607609_m1 for ULBP2, Hs00225909_m1 for ULBP3, and 
Hs99999903_m1 for β-actin, all conjugated with fluorochrome FAM (Applied Biosystems). 
The level of ligand expression was measured using the threshold cycle value (Ct). The ΔCt 
was obtained by subtracting the Ct value of the gene of interest (MICA, MICB, or PVR) from 
the housekeeping gene (β-actin) Ct value. We used ΔCt of the NT sample as the calibrator. 
The fold change was calculated according to the formula 2−ΔΔCt, where ΔΔCt was the 
difference between ΔCt of the sample and that of the calibrator (according to the formula, the 
value of the calibrator in each run is 1).  
Hh-Dependent Luciferase Reporter Assay. The luciferase assay was performed in Shh-
Light II (Shh-LII) cells, stably incorporating a Gli-responsive luciferase reporter and the pRL-
TK Renilla (normalization control), treated for 48 h with SAG (200 nM) and the studied com- 
pounds. Luciferase and Renilla activity were assayed with a dual-luciferase assay system 
according to the manufacturer’s instructions (Promega, Madison, WI). The results are 
expressed as luciferase/Renilla ratios and represent the mean ± SD of three experiments, each 
performed in triplicate.  
LC−MS/MS Analytical Method. Samples were analyzed under the following conditions: 
UFLC (Shimadzu) AC20 coupled with an API 3200 triple-quadrupole (ABSciex); eluents, 
(phase A) 95% water, 5% acetonitrile + 0.1% formic acid, (phase B) 5% water, 95% 
acetonitrile + 0.1% formic acid; flow rate, 0.3 mL/min; column, Gemini-Nx 5 µm C18 110A 
(50 × 2.00 mm) at 35 °C; injection volume, 5 µL. LC−MS/MS analyses were carried out 
using an ESI(+) interface in multiple reaction monitoring mode.  
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Metabolic Stability. Compounds 2.30 and 2.41 were dissolved in DMSO in duplicate at a 
final concentration of 1 µM and preincubated for 10 min at 37 °C in potassium phosphate 
buffer (pH 7.4), 3 mM MgCl2, with human or mouse liver microsomes (Xenotech) at a final 
concentration of 0.5 mg/mL. After the preincubation period, the reactions were started by 
adding the cofactor mixture (NADP, Glc6P, G6P-DH). Samples were taken at times 0, 10, 20, 
30, and 60 min. Acetonitrile was added to stop the reaction and centrifuged. Supernatants 
were analyzed and quantified by LC−MS/MS. A control sample without cofactors was always 
added to check the stability of the test compounds in the reaction mixtures. The reference 
standards were 7-ethoxycoumarin and propranolol. A fixed concentration of verapamil was 
added in every sample as an internal standard for LC−MS/MS. The percentage of the area of 
the test compound remaining at the various incubation times was calculated with respect to 
the area of the compound at time 0 min. 
The rate constant, k (min-1), derived for the exponential decay equation (peak area/IS vs time) 
was used to calculate the rate of intrinsic clearance (CL) of the compound using the following 
equation:  
CL (µL/min /mg of protein) = (k/microsomal concn) × 103 
 
Aqueous Solubility. The solubilities of compounds 2.30 and 2.41 were measured using a 
high-throughput screening assay format. Samples prepared at the target concentration of 200 
µM were placed in a 96-well filter plate and incubated at room temperature for 90 min. The 
plate was then filtered, and solutions were analyzed by LC−MS/MS. Final concentrations 
were evaluated by comparing the area under the curve of the MeOH stock solution with those 
of the test compound solutions.  
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Chapter 3: Multitargeted Imidazoles: A Potential Tactic for 
Alzheimer’s and Other Neurodegenerative Diseases 
3.1 Introduction 
3.1.1 Alzheimer’s Disease 
Alzheimer’s disease (AD) is a progressive and irreversible disease of the central nervous 
system (CNS) that represents the major cause of dementia among older adults.1,2 Dementia is 
typically characterized by a gradual onset and progression of deficits in more than one area of 
cognition. The characteristic early symptoms of dementia are difficulty remembering recent 
conversations, names or events, apathy and depression. Later symptoms include impaired 
communication, disorientation, confusion, poor judgment, behavior changes and, ultimately, 
difficulty speaking, swallowing and walking.3	
To date, there are approximately 50 million people worldwide with AD, which is mostly 
diffused in developing countries. Every 3 seconds someone in the world develops dementia 
that, in final stages, is ultimately fatal with mortality of 60%. Patients require resource-
intensive care and the worldwide cost of care for a patient with AD was estimated 
approximately US$818 billion in 2015, and this number is tought to rise above a US$ trillion 
by 2018.4	
The cause of AD is poorly understood. Since the first description of presenile dementia by 
Alois Alzheimer in 1907, senile plaques (SPs) and neurofibrillary tangles (NFTs) are 
considered the key pathological hallmarks of AD and their presence in the brain parenchyma 
allows a definite diagnosis for AD following post-portem analysis. SPs are extracellular 
deposits comprised of Amyloid-β (Aβ) peptides, which are proteolytically-derived from the 
amyloid precursor protein (APP). NFTs are intracellular tau aggregates derived from the 
misfolding and aggregation of the microtubule (MT)-stabilizing protein tau, which role is 
fundamental for the organization and stability of MTs and, consequently, the axonal transport 
machinery. The progressive accumulation of these two lesions is eventually accompanied by 
damage and death of neurons. 
With the exception of cases of Alzheimer’s caused by genetic abnormalities (such as 
certain mutations to the APP or the genes for the presenilin 1 and presenilin 2 proteins and/or 
the extra copy of chromosome 21 that characterizes Down syndrome), which represent a 
small proportion of patients5 (< 1%) that tend to develop the disease at much younger age 
(∼45 years of age) resulting in a type known as early-onset familial AD (FAD), experts 
believe that Alzheimer’s develops as a result of multiple factors that affect the brain over 
time. Indeed, most patients with Alzheimer's (> 95%) have the sporadic form that is typically 
characterized by a late onset (80–90 years of age). Although Alzheimer's is not a normal part 
of growing older, increasing age is known as the greatest risk factor.6,7 After age 65, the risk 
of Alzheimer's doubles every five years; after age 85, the risk reaches nearly 50%. The 
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disease has an estimated prevalence of 10–30% in the population >65 years of age with an 
incidence of 1–3%. Other risk factors for late-onset AD are having a family history of 
Alzheimer’s and/or carrying the APOE-e4 gene. Accordingly, research has shown that those 
who have a parent, brother, or sister with Alzheimer's are more likely to develop the disease. 
The risk increases if more than one family member has the illness.8−12 
The apolipoprotein E (APOE) is a 34-kDa secreted protein that is synthesized 
predominantly in the liver but is also produced by glial cells in the brain. It acts as a 
lipoprotein-binding protein and mediates lipid metabolism by binding to the low-density 
lipoprotein superfamily of receptors. This gene has several forms (e.g., ε2, ε3 or ε4). One of 
them, APOE ε4, increases a person’s risk of developing AD and is also associated with an 
earlier age of disease onset.13−15 However, carrying the APOE ε4 form of the gene does not 
mean that a person will definitely develop AD, and some people with no APOE ε4 may also 
develop the disease. 
Beyond genetics, a number of different factors may also play a role in the development and 
course of AD. Although risk factors such as age, family history and genetic mutations cannot 
be changed, others, including cardiovascular conditions16,17 such as heart disease, stroke 
and high blood pressure,18−20 as well as metabolic conditions such as diabetes21−24 and 
obesity,25,26 represent factors that can be modulated to reduce risk of cognitive decline and 
dementia.27 
 
3.1.2 Current Drug Treatment 
None of the pharmacologic treatments available today for AD can slow, stop or reverse the 
progressive damage and destruction of neurons that cause Alzheimer’s symptoms and make 
the disease fatal. Current drug treatments that are used to temporarily alleviate symptoms 
include the acetylcholinesterase inhibitors donepezil (Aricept; Eisai/Pfizer, 3.1, Figure 3.1), 
galantamine (Razadyne; Johnson & Johnson, 3.2, Figure 3.1) and rivastigmine (Exelon; 
Novartis, 3.3, Figure 3.1), and the low-affinity NMDA (N-methyl-d-aspartate) receptor 
antagonist memantine (3.4, Figure 3.1) used for moderate to severe AD. The 
acetylcholinesterase inhibitors mediate their effects by increasing the amount of the 
neurotransmitter acetylcholinesterase in the brain, thus remediating, in part, the cholinergic 
deficit. The precise mechanism of action of memantine remains to be elucidated. 
Overall, the success of the therapy varies from person to person, although the effects of 
these drugs are limited as they do not treat the disease but modestly improve/delay symptoms 
and help people to maintain mental function and manage behavioral symptoms. Current 
strategies aim to develop therapies directed toward specific genetic, molecular and cellular 
mechanisms so that the actual underlying cause of the disease can be stopped or prevented. 
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Figure 3.1. Drug treatments for Alzheimer’s. 
 
 
3.1.3 Alzheimer’s Disease Pathogenesis 
The amyloid cascade hypothesis 
The lack of disease-modifying drug candidates with demonstrated efficacy in phase III 
clinical trials28 may be due to the fact that several neuropathological mechanisms are likely to 
provide potentially alternative or redundant pathways to drive/sustain the neurodegenerative 
process in AD. Thus, aggregated tau proteins and Aβ peptides are invariably associated with 
disease onset and progression. Moreover, other factors such as neuroinflammation and 
oxidative stress are thought to participate in the neurodegenerative process (Figure 3.2). 
 
 
Figure 3.2. Pathogenesis and multiple causes of Alzheimer’s. 
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A key pathological feature of the AD brain is the presence of SPs comprised of Aβ 
peptides, which proteolytically-derived from sequential cleavage of the APP by the β-cleaving 
amyloid precursor protein enzyme (BACE) and γ-secretase.29 These peptides vary in length, 
with Aβ40 (the 40-amino acid form of the peptide) being predominant. Amyloid plaques are 
deposits of insoluble Aβ in the parenchyma of the brain that can be diffuse or compact. If they 
are associated with dystrophic and degenerating neurons, they are often referred to as ‘neuritic 
plaques’. The amyloid cascade hypothesis posits that accumulation and aggregation of Aβ is 
the initial pathological trigger in AD, which subsequently results in the formation and 
deposition of SPs, neuronal cell death and dementia.30 Thus far, Aβ amyloidosis has been the 
target of choice in AD drug discovery, as most drug candidates have been designed to 
modulate Aβ homeostasis. There are currently three main therapeutic intervention strategies 
aimed at Aβ: reducing Aβ production, facilitating Aβ clearance, and preventing Aβ 
aggregation. However, in spite of generally strong preclinical data with such therapeutic 
candidates, the outcomes of late-stage AD clinical trials have thus far failed to demonstrate 
clinical efficacy. These disappointing results raise the possibility that AD treatments may 
have to interfere concurrently with more than one neuropathological mechanism to exert 
disease modifying benefits. 
 
Neuroinflammation 
Inflammatory eicosanoids have also been reported as key contributing factors to Aβ plaque 
deposition in AD.31 Indeed, the increased microglial activation in the vicinity of SPs32,33 
stimulates the activation of the arachidonic acid cascade (Figure 3.3) and the release of 
inflammatory molecules, including eicosanoids, cytokines and chemokines, as well as 
oxidizing molecules, contributing to exacerbate AD neuropathology.31,34 For example, it has 
been demonstrated that elevated levels of a lipid oxidation product, isoprostane F2αIII 
(iPF2αIII), in AD brain35,36 can activate the thromboxane A2 (TXA2)-prostanoid (TP) receptor 
in neurons with a resulting increase of APP mRNA stability that leads to enhanced APP 
expression and Aβ production.37,38 Similarly, activated microglia induces the production of 
TXA2, resulting in increased levels of this eicosanoid in AD brain.39 
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Figure 3.3. Schematic representation of the arachidonic acid cascade. 
 
 
Recent work from Brunden and coworkers40 indicates that the binding of cyclooxygenase 
(COX)- and 5-lipoxygenase (5-LOX)-derived eicosanoids to their cognate receptors in 
neurons results in increased production of APP and Aβ peptides (Figure 3.4). In particular, 
they demonstrated that the TP receptor regulation of APP expression depends on Gαq-
signaling and conventional protein kinase C (PKC) isoforms. Importantly, they discovered 
that Gαq-linked prostaglandin E2 (PGE2) and leukotriene D4 (LTD4) receptors also regulate 
APP expression. PGE2 and TXA2, as well as total APP levels, were found to be elevated in 
the brains of aged 5XFAD transgenic mice harbouring Aβ plaques and activated glia, 
suggesting that increased APP expression resulted from eicosanoid binding to Gαq-linked 
neuronal receptors. Notably, inhibition of eicosanoid synthesis significantly lowered brain 
APP protein levels in aged 5XFAD mice. 
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Figure 3.4. Aβ cyclic production. Aβ peptides induce inflammation and stimulate the 
production of prostaglandins (PGs), thromboxane A2 (TXA), and leukotrienes (LTs) that can 
activate their cognate receptors in neurons, increasing the APP production, and consequently 
Aβ formation.   
 
Overall, these findings provide novel potential AD therapeutic strategies. The most 
straightforward possible therapeutic strategy to prevent the eicosanoid-driven increases of 
APP and Aβ would be the inhibition of eicosanoid production. This approach has been 
already explored with varying results. COX inhibitors, such as the nonsteroidal anti-
inflammatory drug (NSAID) ibuprofen, have attracted considerable attention as potential 
candidates for AD treatment due to promising results in a series of preclinical studies in 
animal models with Aβ plaque pathology,41−45 coupled with compelling retrospective 
epidemiological data indicating that individuals who were on sustained regimens of COX-
inhibiting NSAIDs had reduced AD risk.42,46 However, NSAIDs have not generally proven 
effective in AD clinical trials yielding mostly disappointing results.42,47−49 There are possible 
explanations for this lack of clinical success, including issues with the particular candidate 
compounds used in the studies and/or trials that were conducted in patient populations with 
disease that was too advanced to respond to this therapeutic approach, or who had dementia 
that was not due to underlying AD pathology. Another possible mechanistic explanation may 
be that even if substantial COX inhibition is achieved within the AD brain, this may lead to 
shunting of arachidonic acid to the 5-LOX pathway, resulting in increased production of LTs 
(Figure 3.3).50,51 Different studies have shown that these 5-LOX products might cause 
CysLT1 receptor activation and increased APP and Aβ levels, as well as increased Aβ via 
enhanced γ-secretase cleavage of APP.40,52−55 Thus, the utilization of a combination of COX 
and 5-LOX inhibitors, or dual-acting COX/5-LOX inhibitors,56 may merit consideration for 
AD. It has been reported that 5-LOX and COX levels are increased in the AD brain52,57−59 and 
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combined COX/5-LOX inhibitors should reduce the production of PGs, TXs and LTs. 
Furthermore, whereas NSAIDs can cause gastrointestinal or cardiovascular complications, 
and were poorly tolerated by a percentage of AD patients,60 dual COX/5-LOX inhibitors, such 
as licofelone, appear to have decreased side-effects when compared to typical NSAIDs.61,62 
However, such an approach would result in a systemic reduction of PGs, TXs and LTs, some 
of which clearly play a beneficial role within the body, so as with all drugs, a benefit-to-risk 
assessment would be important if such a strategy were pursued. 
 
Microtubule organization in neurons and the tau hypothesis  
In neuronal axons, MTs are more stable than in other cell types. They are assembled to 
form polarized linear arrays with the plus ends directed toward the synapses and the minus 
ends directed toward the cell body, thus providing both structural support and directionality 
for the intracellular transport of proteins and vesicles to and from the cell body and the 
synapses (Figure 3.5).63 This cytoskeletal structure, together with molecular motors such as 
kinesins and dyneins, form a sophisticated machinery that is essential to provide an efficient 
axonal transport, which is critical to the viability of neurons.64 
Neurodegenerative tauopathies, of which AD is the most prominent and common example, 
are characterized by axonal transport deficits that are thought to arise, at least in part, from the 
misfolding and aggregation of the MT associated protein tau.65,66 The protein tau is expressed 
particularly in the axons of neurons with the primary function to promote MT stabilization.67 
Under physiological conditions, the vast majority of tau molecules are bound to MTs. 
Although the presence of tau on MTs presents a physical obstacle for vesicles and other 
cargoes that are moving along the axon, MT-bound tau is essential to maintain the MT 
integrity. Thus, relatively frequent cycles of tau–MT binding (promoted by dephosphorylation 
of tau) and detachment of tau from the MT (promoted by phosphorylation of tau) are needed 
for an effective axonal transport. However, when neurons are affected by tauopathies, the 
hyperphosphorylation of tau is thought to induce its progressive disengagment from the 
axons, thus reducing the binding affinity of this protein for the MTs (Figure 3.5).68−70 An 
abnormal disengagment of tau from the MTs is believed to alter the dynamics and 
organization of the axonal MTs, which in turn can trigger or exacerbate axonal transport 
defects, leading to neuronal dysfunction, neuron loss and cognitive decline.63,64 Furthermore, 
hyperphosphorylated tau becomes considerably more prone to misfolding and 
aggregation,71,72 facilitating the formation of insoluble tau aggregates known as NFTs and 
neuropil threads within the neuronal soma and dendritic processes, respectively.65,73 This 
event contributes further to the destabilization of axonal MTs.66 Thus, these evidences suggest 
that a possible therapeutic strategy for the treatment of AD and related tauopathies is to 
employ exogenous MT-stabilizing agents that might attenuate these deficits and compensate 
for loss of tau functions.74,75 
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Figure 3.5. Schematic representation of the axonal transport machinery and dynamic 
equilibrium of tau MT binding.63 
 
 
3.1.4 Microtubule-stabilizing agents as potential treatment for AD 
Over the past several decades, different classes of MT-stabilizing natural products 
(3.5−3.21, Figure 3.6) have been discovered and widely used in cancer chemotherapy due to 
their ability to trigger apoptosis in rapidly dividing cells.76 In contrast, the development of 
these agents for CNS-indications, such as in the context of neurodegenerative tauopathies,63 
has been challenging primarily due to issues related to insufficient brain penetration. Indeed, 
the blood−brain barrier (BBB) is equipped with relatively impermeable intercellular tight 
junctions and active transporters, such as the P-glycoprotein (Pgp),77 that are known to be a 
remarkable obstacles in the development of CNS-directed therapies.78 
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Figure 3.6. MT-stabilizing natural products. 
 
Another critical challenge in the development of CNS-directed MT-stabilizing therapies is 
identifying brain-penetrant compounds that would be effective at nontoxic doses. Indeed, 
MT-stabilizing drugs that are routinely used to treat cancer, are known to cause a number of 
debilitating side effects, including neutropenia79 and peripheral neuropathy,80 which are 
directly linked to their mechanism of action. Thus, even if brain-penetration issues were 
solved, dose-limiting toxicities might hinder long-term treatment of tauopathies with this 
class of therapeutics. 
Despite these important challenges, in recent years a growing number of molecules, 
including natural products, as well as non-naturally occurring small molecules, have been 
identified that exhibit both MT-stabilizing properties and excellent brain exposure. A series of 
different studies have validated their use as potential therapeutics for tauopathies. In vitro, 
MT-stabilizing agents have been found to protect cultured neurons against tau-81,82 and Aβ-
mediated83−85 neurotoxicity, while the first demonstration in vivo appeared in 2005,86 when 
paclitaxel (3.5, Figure 3.6) was found to product a series of beneficial effects in T44 tau 
transgenic (Tg) mice affected by spinal cord tau pathology. However, paclitaxel does not 
cross the BBB, thus resulting unsuitable as a therapeutic candidate for human brain 
tauopathies. More recent studies87−89 demonstrated that treatment of aged tau Tg mice, which 
manifest NFT-like inclusions, with low weekly doses of the brain-penetrant MT-stabilizing 
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natural product epothilone D (3.6, Figure 3.6), improved axonal transport, reduced axonal 
dystrophy, decreased tau neuropathology, reduced hippocampal neuron loss, and ultimately 
leads to a significant improvement of cognitive performance.87,88 Although 3.6 has since 
progressed to clinical trials in patients with AD and represents a promising drug candidate, it 
exhibits potentially significant deficiencies as drug candidate, including a generally preferred 
intravenous (iv) route of administration and, as in the case of many taxanes, the inhibition of 
the Pgp transporter,90 which upon prolonged dosing could be responsible for undesired CNS 
toxicities91 and/or drug−drug interactions. As a result, alternative brain-penetrant MT-
stabilizing agents, ideally those that could be readily synthesized and orally administered, are 
clearly desirable. 
In this context, non-naturally occurring small molecules triazolopyrimidines (TPDs, Figure 
3.7) have attracted particular interest since they were found to readily access the brains of 
mice. These compounds were initially identified as antifungal agents92 (due to their ability to 
promot tubulin polymerization) and investigated as potential agrochemicals. The 
pharmaceutical company Wyeth, later conducted an anticancer drug development program 
that resulted in the identification of a TPD clinical candidate, cevipabulin (3.22, Figure 3.7), 
which showed MT-stabilizing activity comparable to that of other well characterized MT-
stabilizing natural products, such as paclitaxel, and excellent drug-like properties, including 
oral bioavailability (61%), metabolic stability (T1/2 = 13 h in female nude mice), and water 
solubility (0.89 mg/mL).93 Although 3.22 showed good efficacy in murine tumor xenograft 
models93,94 it does not cross the BBB and thus it would not have therapeutic potential in 
neurodegenerative diseases. Interestingly, other closely related congeners, such as TPD 
analogues of 3.22 (3.23, Figure 3.7), phenylpyrimidines (PPDs, 3.24, Figure 3.7), pyridazines 
(3.25, Figure 3.7), diarylimidazoles (3.26, Figure 3.7), among others (3.26−3.33, Figure 3.7), 
appear to be potentially attractive starting points for CNS-active drug development due to 
their relatively simple structure and favorable pharmacokinetic properties, including brain 
penetration and oral bioavailability, as well as MT-stabilizing properties. 
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Figure 3.7. Representative examples from different classes of non-naturally occurring small 
molecules with reported MT-stabilizing activity.  
 
 
3.2 Objective of the Study 
The multifactorial pathogenesis of AD, as well as the disappointing results from AD 
clinical trials raise the possibility that candidate treatments may have to interfere concurrently 
with more than one neuropathological mechanism to affect disease progression. In this 
context, although the rational design of multitargeted compounds is challenging, especially 
when the aim is to merge multiple molecular pharmacophores in a single small molecule,95 a 
single multitargeted drug directed against multiple disease mechanisms could be 
advantageous in terms of efficacy and safety over drug combination therapies.96 As such, an 
increasing number of therapeutic strategies that are based on polypharmacology have been 
proposed for AD.97,98 However, there have been no reports of molecules that exhibit 
polypharmacology against targets that are likely involved in tau and Aβ neuropathology. 
Thus, as a part of ongoing efforts by Ballatore and coworkers to develop brain-penetrant MT-
stabilizing agents as potential treatments for tauopathies, we pursued the idea that the 
stabilization of axonal MTs, combined with a concurrent suppression of eicosanoid 
production, could attenuate both tau- and Aβ-mediated neurodegeneration, as well as MT 
deficiencies99 and/or neuroinflammation (Figure 3.8).100−106 
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Figure 3.8. Multitargeted approach directed against tau and Aβ neuropathology. 
 
 
Our studies began with the observation that, among the non-naturally occurring small 
molecules that are structurally and functionally related to the TPD (see section 3.1.4), selected 
diary-imidazoles (e.g., 3.26, Figure 3.9) and diaryl-pyrazoles (e.g., 3.27, Figure 3.9) with 
reported MT-stabilizing activity as antifungal agents107 exhibit tricyclic structures similar to 
those found in known NSAIDs, such as the dual COX/5-LOX inhibitor licofelone108 (3.34, 
Figure 3.9) and the potent COX-1 inhibitor SC560109 (3.35, Figure 3.9), suggesting a 
potentially significant overlap between these two pharmacophores. Molecular docking studies 
revealed that selected representative examples of these MT-stabilizing imidazoles, such as 
3.26, could fit within the arachidonic acid binding site of COX-1 with a predicted binding 
energy that is comparable (i.e., within 2 kcal/mol) to that of 3.35 (Figure 3.9B and C). Thus, 
although MT-stabilizing agents and NSAIDs are different classes of biologically active 
compounds that interact with unrelated targets, these evidences suggest that there may be 
significant degree of crosstalk between the different pharmacophores that could be exploited 
to identify multitargeted ligands.  
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Figure 3.9. (A) Representative examples of fungicidal diaryl-imidazoles (3.26) and diaryl-
pyrazoles (3.27) with reported MT-stabilizing activity, with known dual COX/5-LOX (3.34) 
and COX- (3.35) inhibitors. Molecular docking of 3.26 (B) and 3.35 (C) within the 
arachidonic acid binding site of COX-1. Adapted from Ref. 110. 
 
 
Toward this end, we conducted SAR studies of a series of 1,5-diarylimidazole congeners to 
identify potentially brain-penetrant compounds that act as MT-stabilizers and/or inhibitors of 
the COX- and/or 5-LOX pathways. Given that optimal broad-spectrum fungicidal activity is 
typically achieved with tetrasubstituted imidazoles, such as 3.26, and other related congeners 
that comprise a 4-chlorophenyl group at N1, a chlorine atom in position 4, and a di- or tri-
fluorinated phenyl group in position 5, we primarily evaluated (a) mono- and di-substitutions 
in the A ring, (b) chloro- and/or alkyl-substitutions in positions 2 and/or 4 of the imidazole 
ring (C ring), (c) the effect of varying the degree and pattern of fluorination in the B ring.  
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3.3 Chemistry 
A library of 81 diaryl-imidazoles has been synthesized, comprising 36 known compounds 
(i.e., 3.26, 3.56, 3.60–3.62, 3.66, 3.67, 3.69, 3.74–3.77, 3.82, 3.85, 3.86, 3.88, 3.89, 3.92, 
3.93, 3.95, 3.96, 3.98, 3.99, 3.101, 3.102, 3.104, 3.105, 3.114–3.117, 3.119, 3.123, 3.125, 
3.126, and 3.128, Table 3.1), with reported anti-fungal107 or anti-microbial activity, and 45 
new derivatives (i.e., 3.57–3.59, 3.63–3.65, 3.68, 3.70–3.73, 3.78–3.81, 3.83, 3.84, 3.87, 3.90, 
3.91, 3.94, 3.97, 3.103, 3.106–3.113, 3.118, 3.120–3.122, 3.124, 3.127, 3.129–3.135, Table 
3.1). 
In general, the synthesis of the 1,5-diarylimidazoles was achieved following the van 
Leusen imidazole synthesis.111 Accordingly, condensation of the appropriate aryl-amine and 
benzaldehyde was initially performed with the Dean–Stark apparatus and required 4 days to 
obtain a complete conversion of the starting materials into the resulting Schiff base (3.36–
3.55, Scheme 3.1). Thus, to accelerate the process, the same reaction was performed 
following the Taguchi method112 that allows a complete conversion in 48 hours (Scheme 3.1). 
The so obtained Schiff base was cyclized by treatment with toluenesulfonylmethyl 
isocyanide (TosMIC) to form the 1,5-diarylimidazole (3.56–3.59, 3.63, 3.64, 3.68–3.74, 3.78–
3.84, Scheme 3.1). Further derivatizations of the imidazole ring included the introduction of 
small alkyl groups and/or halogens in position 2 and/or 4 (3.26, 3.60–3.62, 3.65–3.67, 3.75–
3.77 and 3.85–3.135, Scheme 3.1). Imidazole derivatives bearing a methyl substituent at C4 
were obtained by employing the appropriately C substituted TosMIC reagent during the 
cyclization step (3.60, 3.66, 3.75), while treatment of the appropriate 1,5-diarylimidazole with 
LDA, followed by addition of the desired alkyliodide, gave the alkylated derivatives at C2 
(e.g., 3.65, 3.86, 3.117). Finally, N-chlorosuccinimide (NCS) was employed to obtain the 
halogenation of the imidazole ring. When the halogenation was carried out on imidazoles that 
were not substituted at C2 and C4, the reaction typically furnished separable mixtures of 
mono- and di-chlorinated imidazoles (e.g., 3.85, 3.87, 3.88). The two mono-chlorinated 
isomers bearing a proton at C2 or C4 can be distinguished via 1H NMR analysis (e.g., 3.129 
and 3.130, Figure 3.10A and B). Furthermore, recrystallization of one representative 
chlorinated isomer, compound 3.129, led to the formation of crystals that were suitable for X-
ray diffraction analysis and confirmed the NMR assignment (Figure 3.11). 
During the research experience as a visiting PhD student at the University of Pennsylvania, 
I accomplished the preparation and characterization of compounds 3.57, 3.59−3.62, 
3.64−3.67, 3.73−3.84, 3.90, 3.91, 3.112−3.135 (see Experimental Section, Chemistry 3.6.1). 
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Scheme 3.1. Synthesis of 1,5-diarylimidazoles 3.26 and 3.36−3.135 (R and R′ see Table 3.1). 
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Figure 3.10. 1H NMR spectra of imidazoles 3.129 (A) and 3.130 (B) recorded in deuterated 
chloroform (CDCl3) at 500 MHz.  
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Figure 3.11. X-ray structure determination of compound 3.129.110 
 
3.4 Results and Discussion 
Effects of diaryl-imidazoles 3.26, and 3.36−3.135 on MT-stabilization and inhibition of 
COX and 5-LOX pathways are shown in Table 3.1. 
The MT-stabilizing activity was assessed at 1 and 10 µM compound concentration in 
QBI293 cells by monitoring compound-induced elevation in acetylated α-tubulin (AcTub),113 
which is a known marker of stable MTs.114 Furthermore, as the MT-stabilizing imidazoles are 
believed to act on MTs in a manner similar to that described for the TPD,107 and considering 
that certain TPD have been found to induce a proteasome-dependent degradation of α-
tubulin,115 the effect of compound treatment on total α-tubulin was also monitored. 
Evaluation of compound inhibition of the biosynthesis of COX- and 5-LOX-derived 
eicosanoids was conducted at 10 µM compound concentration in a modified rat basophilic 
leukemia (RBL-1) cell assay,116 which was developed for the evaluatation of 5-LOX 
inhibition and we found can be suitable for the assessment of both PGs and LTs formed in the 
presence or absence of test compounds. Culture supernatants were subsequently collected and 
assessed for COX-derived prostaglandins PGD2 and PGE2 and 5-LOX-derived leukotrienes 
LTB4 by LC−MS/MS. In initial concentration−response testing (Table 3.1), LTB4 and 
combined PGD2 and PGE2, which coeluted under the chromatographic conditions, were 
quantified. In subsequent studies, selected compounds exhibiting evidence of multitargeted 
activity underwent further confirmatory studies in the RBL-1 assay using a refined 
LC−MS/MS protocol that permitted separate analysis of PGD2 and PGE2, as well as both 
LTB4 and LTC4. As the formation of each of these eicosanoids depends on separate 
enzymatic steps in the COX or 5-LOX pathways,117 concurrent analysis of all four of these 
eicosanoids provides a convenient and reliable method to evaluate the overall effect of test 
compounds on COX and 5-LOX pathways in a cellular milieu. 
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Finally, we evaluated the brain penetration of several diaryl-imidazoles monitoring the 
levels of compounds in mouse brain and plasma 1 h after intraperitoneal (i.p.) administration 
of 5 mg/kg test compound (Table 3.2). In general, the vast majority of CNS-active drugs 
typically exhibit brain-to-plasma (B/P) exposure ratios of ≥0.3, although there are 
exceptions.118 
 
MT-stabilizing activity: Evaluation of compounds activity revealed that 48 examples of 71 
overall tested compounds induced statistically significant changes in AcTub levels. Among 
them, seven examples (i.e., 3.26, 3.89, 3.96, 3.102, 3.116, 3.117, and 3.128) showed activity 
at 1 µM compound concentration, whereas the remaining 41 were active only at 10 µM. 
Consistent with the notion that the MT-stabilizing 1,5-diarylimidazoles may be acting on MTs 
in a similar manner as the TPDs,107 the data presented in Table 3.1 reveal that like the latter 
molecules, these imidazoles can be broadly divided into two subsets: one group of 15 entries, 
which cause a significant reduction in total α-tubulin levels at doses that induce an elevation 
in AcTub (i.e., 3.26, 3.61, 3.65, 3.89, 3.93, 3.94, 3.96, 3.97, 3.102, 3.104, 3.116, 3.125–
3.128); and a second group of 33 compounds that produce an elevation in AcTub at 1 or 10 
µM without decreasing α-tubulin level (3.60, 3.62, 3.66, 3.67, 3.75–3.77, 3.85, 3.86–3.88, 
3.90, 3.91, 3.95, 3.98–3.101, 3.103, 3.105, 3.109, 3.113–3.115, 3.117–3.119, 3.121–3.124, 
3.133, 3.135). Interestingly, we previously found that TPDs bearing an alkoxy side chain in 
the fluorinated phenyl ring (e.g., 3.23, Table 3.1) typically produce an unusual cellular 
phenotype that is characterized by a bell-shaped concentration-response relationship in the 
AcTub assay and proteasome-dependent degradation of α-tubulin.115 A similar effect is 
observed with the MT-active 1,5-diarylimidazoles bearing an alkoxy side chain in ring B (i.e., 
3.26, 3.89, 3.126–3.128, Table 3.1), which cause a reduction in α-tubulin levels at compound 
concentrations that are required to increase AcTub. However, our results with the 1,5-
diarylimidazoles clearly suggest that the substitution pattern of ring B may not be the only 
determining factor in whether α-tubulin is affected, as other substitutions in the A and C ring 
appear to play a role (cf., 3.60 with 3.61, and 3.85 with 3.104, Table 1). As was noted for the 
TPDs,115 MT-stabilizing imidazoles that cause a reduction in total α-tubulin may not be 
desirable for neurodegenerative diseases as this effect would be expected to ultimately 
compromise rather than restore axonal MT function. Conversely, certain multitargeted 
congeners (see Table 3.2) that do not appear to reduce total α-tubulin levels at concentrations 
that increase AcTub, may be more promising candidates for tauopathy treatment. 
Irrespective of whether or not test compounds cause a reduction in total α-tubulin, the 
AcTub SAR emerging from the data shown in Table 3.1 appears to be in general agreement 
with the anti-fungal activity SAR of 1,5-diarylimidazoles that was reported in prior studies.107 
Thus, our results indicate that ring A is preferably a 4-chloro-phenyl, although examples 
bearing other substituents in the para-position, such as a trifluoromethoxy (3.114), are also 
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active. Additional substitutions in the A ring, as in compound 3.108 and 3.109 in which a 
fluorine is present in the ortho-position, appear to impact negatively MT interactions of the 
compound (cf., 3.108 with 3.118, and 3.109 with 3.115). With respect to the B ring, the 
degree and pattern of fluorination appear to be generally important factors that determine the 
ability of these imidazoles to produce a significant elevation in the marker of stable MTs in 
QBI293 cells. Whereas derivatives with either one or no fluorination in the B ring (i.e., 3.81, 
3.82, 3.106, 3.107, 3.129–3.132) were found to be essentially devoid of MT activity in our 
assay conditions, other di- and tri-substituted congeners (e.g., 3.85, 3.99, 3.115) produced a 
significant increase in AcTub. Furthermore, a comparison between the inactive difluorinated 
derivative 3.111 and the active di- and tri-fluorinated compounds (i.e., 3.85, 3.99, and 3.115) 
suggests that the presence of two fluorine atoms in the ortho-positions of ring B is required 
for MT activity. Finally, with respect to the imidazole ring (ring C), our results indicate that 
1,5-diarylimidazoles that are not substituted in positions 2 and 4 (e.g., 3.56, 3.57, 3.73, 3.74, 
3.79, 3.80, 3.83 and 3.84) do not cause a detectable increase in AcTub, whereas 
tetrasubstituted imidazoles, including C2/C4 dihalogenated (e.g., 3.119) and dimethylated 
(e.g., 3.77) derivatives, as well as analogues bearing both a small alkyl- and a chloro-
substituent in either C2 or C4 positions (e.g., 3.116 and 3.76), are generally more active than 
corresponding derivatives bearing a single substitution in either position 2 or 4 (cf., 3.118, 
3.119, and 3.75, 3.77). These results also suggest that MT activity does not strictly require a 
halogen in position 4 of the imidazole ring, as was required for optimal anti-fungal activity,107 
because congeners halogenated at C2 appear to retain comparable MT activity (cf., 3.85, 3.87 
and 3.115, 3.118).110  
 
Inhibition of prostaglandin biosynthetic pathway: Evaluation of test compounds as 
potential inhibitors of COX-dependent formation of PGD2/PGE2 in RBL-1 cells revealed that 
optimal inhibition of PG synthesis is typically achieved when ring A is substituted in the 
para-position with either a chloride (e.g., 3.85) or methoxy group (e.g., 3.90). With respect to 
ring B, comparison of 3.85, 3.99, 3.107, 3.110, 3.115, and 3.129 clearly suggests that the 
presence of fluorine substituents is not detrimental, nor necessary, for inhibition of PG 
production. Evaluation of the effect of different substitutions in the imidazole ring reveal that, 
with the possible exception of compound 3.135, which shows a >50% inhibition in the 
PGD2/PGE2 assay, tetrasubstituted compounds (e.g., 3.76, 3.77, 3.116, 3.119) are generally 
devoid of inhibitory activity against PG synthesis. Conversely, 1,5-diarylimidazole congeners 
with one substitution at either C2 or C4 are generally active, with the presence of a substituent 
at C4 being possibly preferred over the C2 position (cf., 3.93 with 3.94, 3.95 with 3.97, 3.115 
with 3.118, and 3.123 with 3.124). Among 1,5-diarylimidazoles that are not substituted at C2 
and C4, although these compounds appear to be generally less active than the corresponding 
compounds bearing a substituent at C2 or C4, selected examples, such as 3.82, have been 
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identified that produce a near complete inhibition of the combined PGD2/PGE2 synthesis in 
the RBL-1 assay when tested at 10 µM.110  
 
Inhibition of leukotriene biosynthetic pathway: Evaluation of compound inhibitory activity 
in the LTB4 assay revealed that whereas a number of substitutions in the para-position of ring 
A appeared to be well tolerated, the presence of a 2-chloro-pyridine (see 3.104 and 3.105) 
prevented inhibition of LTB4 synthesis. In addition, similarly to what was observed for the 
SAR of PGD2/PGE2 synthesis inhibition, the fluorination of the B ring did not impact activity, 
as both fluorinated (e.g., 3.90, 3.111 and 3.115) and non-fluorinated (e.g., 3.129) congeners 
exhibit comparable inhibitory activity in the LTB4 assay. However, in contrast to what was 
observed for inhibitory activity against PG synthesis, the choice of substituents at C2 and/or 
C4 of the imidazole ring did not play a critical role as examples of di- (e.g., 3.78), tri- (e.g., 
3.120 and 121) and tetra-substituted (e.g., 3.122) imidazoles were found to exhibit 
comparable suppression of LTB4 synthesis in RBL-1 cells at 10 µM.110  
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Change in 
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Relative 
Change in 
α-Tubd 
3.26 Me Cl  
 
39 88 
× 7.1 
(1 µM)** 
× 2.9 
(10 µM)** 
× 0.6 
(1 µM)** 
× 0.3 
(10 µM)** 
3.56 H H  
 
44 24 NS NS 
3.57 H H  
 
65 25 NS NS 
3.60 H Me  
 
59 71 
× 3.5 
(10 µM)** 
NS 
3.61 Cl Me  
 
<10 54 
× 9.2 
(10 µM)** 
× 0.5 
(10 µM)** 
3.62 Me Me  
 
<10 51 
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(10 µM)** 
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3.66 H Me  
 
74 74 
× 3.4 
(10 µM)** 
× 1.2 (1 
µM)** 
3.67 Cl Me  
 
<10 58 
× 14.3 
(10 µM)** 
NS 
3.73 H H  
 
38 55 NS NS 
3.74 H H  
 
15 46 NS 
× 1.2 
(1 µM)* 
3.75 H Me  
 
72 44 
× 1.6 
(10 µM)** 
NS 
3.76 Cl Me  
 
<10 42 
× 4.1 
(10 µM)** 
NS 
3.77 Me Me  
 
<10 40 
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× 1.2 
(1 µM)* 
3.78 H H  
 
31 52 NS 
× 1.2 
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3.79 H H  
 
66 84 NS NS 
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<10 78 NS NS 
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3.82 H H   94 <10 NS NS 
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19 <10 NS NS 
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3.89 Cl Cl  
 
12 38 
× 3.3 
(1 µM)** 
× 2.5 
(10 µM)** 
× 0.6 
(1 µM)** 
× 0.3 
(10 µM)** 
3.90 H Cl  
 
93 86 
× 4.1 
(10 µM)** 
NS 
3.91 Cl H  
 
85 75 
× 3.4 
(10 µM)** 
NS 
3.93 H Cl  
 
79 78 
× 2.2 
(10 µM)** 
× 0.8 
(10 µM)** 
3.94 Cl H  
 
<10 69 
× 2.3 
(10 µM)** 
× 0.8 
(1 µM)** 
× 0.9 
(10 µM)** 
3.95 H Cl  
 
71 63 
× 2.4 
(10 µM)** 
NS 
3.96 Me Cl  
 
34 84 
× 1.7 
(1 µM)** 
× 9.7 
(10 µM)** 
× 0.6 
(10 µM)** 
3.97 Cl H  
 
<10 88 
× 2.2 
(10 µM)** 
× 0.8 
(10 µM)** 
3.98 H Cl  
 
54 78 
× 2.1 
(10 µM)** 
NS 
3.99 H Cl  
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× 2.0 
(10 µM)** 
NS 
3.100 Cl H  
 
26 24 
× 2.4 
(10 µM)** 
NS 
3.101 H Cl 
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× 1.9 
(10 µM)** 
NS 
3.102 Me Cl 
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× 3.9 
(1 µM)** 
× 2.4 
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(1 µM)** 
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(10 µM)** 
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3.104 H Cl  
 
65 <10 
× 1.9 
(10 µM)** 
× 0.8 
(10 µM)** 
3.105 Me Cl  
 
<10 26 
× 4.4 
(10 µM)** 
NS 
3.106 Cl H   87 57 NS NS 
3.107 H Cl   85 59 NS NS 
3.108 Cl H 
  
<10 49 NS NS 
3.109 H Cl 
  
36 14 
× 2.6 
(10 µM)** 
NS 
3.110 Cl H  
 
76 96 NS NS 
3.111 H Cl  
 
46 69 NS NS 
3.112 H Cl  
 
46 78 NS NS 
3.113 Cl H  
 
19 61 
× 2.2 
(10 µM)** 
NS 
3.114 Cl Cl  
 
19 81 
× 6.1 
(10 µM)** 
NS 
3.115 H Cl  
 
94 76 
× 4.0 
(10 µM)** 
NS 
3.116 Me Cl  
 
45 87 
× 2.5 
(1 µM)* 
× 15.7 
(10 µM)** 
× 0.8 
(10 µM)** 
3.117 Et Cl  
 
30 81 
× 1.8 
(1 µM)** 
× 5.0 
(10 µM)** 
NS 
3.118 Cl H  
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× 4.8 
(10 µM)** 
NS 
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3.121 Cl H  
 
58 80 
× 3.4 
(10 µM)** 
NS 
3.122 Cl Cl  
 
40 56 
× 6.3 
(10 µM)** 
NS 
3.123 H Cl  
 
90 75 
× 3.6 
(10 µM)** 
NS 
3.124 Cl H  
 
42 73 
× 5.7 
(10 µM)** 
NS 
3.125 Cl Cl  
 
<10 63 
× 18.2 
(10 µM)** 
× 0.7 
(10 µM)** 
3.126 H Cl  
 
48 91 
× 4.0 
(10 µM)** 
× 0.8 
(10 µM)** 
3.127 Cl H  
 
<10 68 
× 8.2 
(10 µM)** 
× 0.6 
(10 µM)** 
3.128 Cl Cl  
 
17 88 
× 5.1 
(1 µM)** 
× 10.1 
(10 µM)** 
× 0.9 
(1 µM)** 
× 0.4 
(10 µM)** 
3.129 H Cl   94 71 NS NS 
3.130 Cl H   75 52 NS 
× 1.2 
(10 µM)** 
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3.133 H Cl 
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(10 µM)** 
NS 
3.134 Cl H 
  
28 38 NS NS 
3.135 Cl Cl 
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(10 µM)** 
NS 
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TPD (3.137) 
 
ND ND 
× 2.5 (1 
µM)∧     
× 4.9 (10 
µM)∧ 
NS 
TPD (3.23) 
 
ND ND 
× 6.0 (1 
µM)∧ 
× 0.5 (10 
µM)∧ 
× 0.7 (1 
µM)           
× 0.4 (10 
µM)  
Table 3.1. Evaluation of test compounds as MT-stabilizing agents and inhibitors of COX- and 
5-LOX pathways. aInhibition of COX pathway was determined by monitoring via 
LC−MS/MS analyses the combined production of COX-derived PGD2 and PGE2 in RBL-1 
cells upon stimulation with arachidonic acid in the presence or absence of test compounds, 
with all samples run in at least triplicate. bInhibition of 5-LOX pathway was determined by 
monitoring via LC−MS/MS analyses the production of 5-LOX-derived LTB4 in RBL-1 cells 
upon stimulation with arachidonic acid in the presence or absence of test compounds, with all 
samples run in at least triplicate. cMT-stabilizing activity in QBI-293 cells was determined by 
monitoring via ELISA the changes in acetylated α-tubulin levels relative to vehicle treatment 
in response to 4 h treatment with 1 and 10 µM test compounds, with all samples run in at least 
triplicate. The compound concentrations causing a significant change in AcTub are listed, 
along with the fold-change in AcTub. dRelative changes in total α-tubulin, as determined by 
tubulin ELISA, in response to 1 and 10 µM compound treatment, with all samples run in at 
least triplicate. The compound concentrations causing a significant change in α-Tub are listed, 
along with the fold-change in α-Tub. §Compound tested at 10 nM. ∧Previously published 
data.115 *P < 0.05. **P < 0.01 compared with vehicle (DMSO)-treated controls as determined 
using an two-tailed unpaired t test. NS = not significant. ND = not determined. 
 
 
 
Thus, in light of the observed elements of SAR for the three biological targets, we found 
that the particular substitution pattern decorating the 1,5-diarylimidazole scaffold can result in 
compounds with different activity profiles, including multitargeted activity on MTs and/or 
eicosanoid biosynthesis (Figure 3.12). 
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Figure 3.12. Representative structures exemplifying the different activity profiles exhibited 
by the 1,5-diarylimidazoles. Adapted from Ref. 110. 
 
 
Selected representative examples of multitargeted compounds were evaluated further to 
determine the IC50 values in the RBL-1 assays and brain penetration (Table 3.2). Moreover, 
the compounds in Table 3.2 were also examined with improved LC−MS/MS methodologies 
for their ability to inhibit the individual COX-derived products PGE2 and PGD2, as well as a 
second 5-LOX-derived product, LTC4 (Figure 3.13). Finally, four example compounds (3.95, 
3.101, 3.110, 3.136) underwent full concentration−response analyses in the RBL-1 cell assay 
(Figure 3.14).  
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3.60 
 
12.1 13.4 
× 3.5 
(10 µM) 
600^ 
± 200 
500^ 
± 300 
1.4 
± 0.3 
3.66 
 
4.7 23.7 
× 3.4 
(10 µM) 
400^ 
± 200 
200^ 
± 100 
1.9 
± 0.2 
3.90 
 
2.4 9.7 
× 4.1 
(10 µM) 
ND ND ND 
3.91 
 
9.8 20.8 
× 3.4 
(10 µM) 
210^ 
± 90 
210^ 
± 80 
0.9 
± 0.1 
3.95 
 
2.2 9.5 
× 2.4 
(10 µM) 
400# 
± 200 
190# 
± 90 
2.1 
± 0.5 
3.98 
 
6.5 7.8 
× 2.1 
(10 µM) 
240# 
± 100 
260# 
± 90 
0.9# 
± 0.2 
3.99 
 
2.9 2.4 
× 2.0 
(10 µM) 
700# 
± 500 
300#  
± 200 
2.8 
± 0.8 
3.101 
 
4.6 6.0 
× 1.9 
(10 µM) 
700# 
± 200 
240# 
± 50 
3.0 
± 1.0 
3.115 
 
2.4 13.8 
× 4.0 
(10 µM) 
700^ 
± 400 
400^ 
± 200 
1.9 
± 0.2 
3.118 
 
15.0 10.7 
× 4.8 
(10 µM) 
900# 
± 300 
480# 
± 60 
1.9 
± 0.4 
3.123 
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× 3.6 
(10 µM) 
300^ 
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110^ 
± 60 
2.5 ± 
0.1 
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3.110 
 
2.2 2.5 NS 
200^ 
± 80 
60^ 
 ± 30 
3.3 
± 0.1 
3.129 
 
1.0 12.5 NS 
200^ 
± 60 
80^ 
 ± 20 
2.4 
± 0.1 
 
Table 3.2. Further evaluation of test compounds with multitargeted activity as MT-stabilizing 
agents and/or inhibitors of COX and 5-LOX pathways. aAll concentration−response analyses 
were conducted at multiple concentrations with triplicate samples per concentration. bThe 
change in AcTub was assessed as described in Table 3.1. #Study conducted after a 5 mg/kg 
i.p. injection of test compound. ∧Study conducted after a 2 mg/kg i.p. injection of test 
compound with drug concentrations adjusted proportionally upward to allow comparison to 5 
mg/kg doses. ND = not determined. NS = not significant. ± errors represent standard 
deviations. All analyses were conducted with groups of three mice.  
 
 
 
Figure 3.13. Analysis of the ability of diaryl-imidazoles to reduce multiple COX and 5-LOX 
products. The compounds listed in Table 3.2 were tested at 50 µM in the RBL-1 assay, and 
COX-derived PGE2 and PGD2, as well as 5-LOX-derived LTB4 and LTC4, were assessed by 
LC−MS/MS. All compounds caused appreciable inhibition of all of the measured eicosanoids. 
Adapted from Ref. 110.  
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Figure 3.14. Representative dose−response curves in the RBL-1 cell assays. Adapted from 
Ref. 110. 
 
Collectively, these studies confirmed that all Table 3.2 compounds effectively inhibited 
both COX and 5-LOX biosynthetic pathways with multiple compounds exhibiting balanced 
multitargeted activity in the low µM range. It has to be noted that, with respect to the ability 
of these compounds to act as inhibitors of the COX and/or 5-LOX pathways, although the 
IC50 values in the COX biosynthetic pathway assay are much higher than the IC50 of COX 
inhibitor 3.35 (i.e., ~1 nM), the activity level displayed by these molecules is closely 
comparable to that of the over-the-counter drug, ibuprofen (3.136, Table 3.1). Unlike 3.136 or 
3.35, however, these multitargeted 1,5-diarylimidazoles (e.g., 3.110, Table 3.2) exhibit 
inhibition activity against the leukotriene biosynthetic pathway, while other derivatives are 
also capable of affecting MT stability in vitro, with several examples (e.g., 3.99, 3.101, 3.118) 
exhibiting relatively balanced multitargeted activity and brain penetration (Table 3.2). Indeed, 
the evaluation of the brain penetration of these molecules revealed that, consistent with the 
relatively small size of these molecules, they are generally capable of reaching significant 
brain concentrations after peripheral administration, suggesting that compounds of this type 
may be appropriate for further evaluation in the context of CNS diseases.  
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3.5 Conclusions 
Given that MT dynamics are believed to be affected in AD and other neurodegenerative 
disorders,99,119 and considering the involvement of both COX- and 5-LOX derived 
eicosanoids, a normalization of axonal MT dynamics, combined with a suppression of 
eicosanoid production, may provide a potential novel multitargeted strategy to mitigate 
concurrent disease mechanisms in Alzheimer’s and other neurodegenerative conditions. 
Starting from a series of 1,5-diarylimidazoles with reported MT-stabilizing activity and 
structural similarities with known NSAIDs, the SAR studies reported here demonstrated that 
relatively small changes in the substitution pattern of 1,5-diarylimidazole scaffold can have 
profound effect in the activity profile of these molecules and ultimately led to the 
identification of a series of congeners (e.g., 3.99, 3.101, 3.115) that exhibit improved and 
balanced low µM in vitro multitargeted activity as MT-stabilizing agents and/or inhibitors of 
the COX and 5-LOX pathways (SAR summary depicted in Figure 3.15). Taken together, 
these results indicate that 1,5-diarylimidazoles comprise a promising scaffold for the 
evaluation of CNS-directed multitargeted strategies directed against two or more disease 
mechanisms involved in the complex and multifactorial disease of Alzheimer’s, as well as in 
the context of other neurodegenerative conditions. Further studies, however, will be necessary 
to confirm that these compounds can produce beneficial effects in an animal model of tau 
pathology. 
 
 
 MT-stabilization COX Inhibition 5-LOX Inhibition 
Ring 
A 
• monosubstitution in para-position 
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• highest activity with para-
chloro substitution 
• monosubstitution in para-
position preferred (except -F) 
• 2-chloro pyridine ring 
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Ring 
B 
• degree of fluorination generally 
important 
• 2 ortho-fluorine atoms preferred 
• degree and pattern of fluorination not necessary for inhibitory 
activity 
Ring 
C 
• unsubstituted imidazoles in 2 and 4 
positions generally inactive 
• halogen or small alkyl group in 
position 2 or 4 lead to active 
analogues 
• tetrasubstituted imidazoles most 
active 
• unsubstituted imidazoles 
in 2 and 4 positions active 
• tetrasubstituted 
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• substitution of imidazoles 
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position 2 and/or 4 
 
Figure 3.15. SAR summary of multitargeted 1,5-diarylimidazoles. 
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3.6 Experimental Section 
3.6.1 Chemistry 
All solvents were reagent grade. All reagents were purchased from Aldrich or Acros and 
used as received. Thin layer chromatography (TLC) was performed with 0.25 mm E. Merck 
precoated silica gel plates. Silica gel column chromatography was performed with silica gel 
60 (particle size 0.040−0.062 mm) supplied by Silicycle and Sorbent Technologies. TLC 
spots were detected by viewing under a UV light. Melting points (m.p.) were acquired on a 
Thomas−Hoover apparatus and are uncorrected. Infrared (IR) spectra were recorded on a 
Jasco model FT/IR-480 Plus spectrometer. Proton (1H) and carbon (13C) NMR spectra were 
recorded on a Bruker AMX-500 spectrometer. Chemical shifts were reported relative to 
solvents. High-resolution mass spectra were measured at the University of Pennsylvania Mass 
Spectrometry Center on either a VG Micromass 70/70H or VG ZAB-E spectrometer. Single-
crystal X-ray structure determinations were performed at the University of Pennsylvania with 
an Enraf Nonius CAD-4 diffractometer. Analytical reverse-phase (Sunfire C18; 4.6 mm × 50 
mm, 5 mL) HPLC was performed with a Waters binary gradient module 2525 equipped with 
Waters 2996 PDA and Waters micromass ZQ. All samples were analyzed employing a linear 
gradient from 10% to 90% of CH3CN in water over 8 min and flow rate of 1 mL/min, and 
unless otherwise stated, the purity level was >95%. Preparative reverse-phase HPLC 
purifications were performed on a Gilson instrument (i.e., Gilson 333 pumps, a 215 liquid 
handler, 845Z injection module, and PDA detector) employing Waters SunFire preparative 
C18 OBD columns (5 µm 19 mm × 50 mm or 19 mm × 100 mm). Purifications were carried 
out employing a linear gradient from 10% to 90% of CH3CN in water for 15 min with a flow 
rate of 20 mL/min. Unless otherwise stated, all final compounds were found to be >95% pure 
as determined by HPLC/MS and NMR.  
General procedure A for the synthesis of imines 3.37, 3.39, 3.41, 3.47, 3.48−3.52. A 
solution of aniline (1 equiv) and benzaldehyde (1 equiv) in toluene (0.2 M) was heated at 110 
˚C in a Dean−Stark apparatus for 4 days. The reaction mixture was then cooled and 
evaporated in vacuo to obtain the title compound, which was used in the next step without 
further purification. 
General procedure B for the synthesis of imines 3.53−3.55. To a solution of a primary 
amine (1 equiv) in anhydrous Et2O (0.3 M) in the presence of molecular sieves (4 Å, 1.6 mm 
pellets, 7 g/mmol) was added an aldehyde (1 equiv) according to the Taguchi’s method. The 
mixture was heated and stirred at 30 °C for 48 h. Molecular sieves were then removed by 
filtration and the solvent was evaporated in vacuo to afford the desired imine in quantitative 
yields. 
General procedure C for the synthesis of imidazoles 3.57, 3.59, 3.64, 3.73, 3.74, 
3.78−3.84. To a solution of imine (1 equiv) in a mixture of DMF (0.26 M) and 1,2-
dimethoxyethane (0.32 M) were added toluenesulfonylmethyl isocyanide (1.5 equiv) and 
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anhydrous K2CO3 (2.08 equiv). The reaction mixture was heated for 16 h at 100 °C, then 
cooled to room temperature, filtered, and evaporated in vacuo. The resulting material was 
adsorbed on Celite® 545 AW and purified by silica gel column chromatography to obtain the 
desired compound. 
General procedure D for the synthesis of 4-alkylated imidazoles 3.60, 3.66, 3.75. To a 
solution of imine (1 equiv) in a mixture of DMF (0.14 M) and 1,2-dimethoxyethane (0.17 M) 
were added 1-((1-isocyanoethyl)sulfonyl)-4-methylbenzene (1.5 equiv) and anhydrous K2CO3 
(2.08 equiv). The reaction mixture was heated for 16 h at 100 °C, then cooled to room 
temperature, filtered through a pad of Celite® 545 AW, and evaporated in vacuo. The 
resulting material was purified by silica gel column chromatography to obtain the desired 
compound. 
General procedure E for the mono and di-chlorination of 1,5-diarylimidazoles 3.61, 3.67, 
3.76, 3.90, 3.91, 3.112−3.115, 3.118−3.135. To a solution of imidazole (1 equiv) in CHCl3 
(0.16 M) was added N-chlorosuccinimide (1.06 equiv). The reaction mixture was heated at 
60 °C for 16 h, then cooled to room temperature and diluted with EtOAc. The organic layer 
was washed with brine (×3), dried over MgSO4, filtered, and evaporated in vacuo. 
Purification via silica gel column chromatography furnished the mono- and di-chlorinated 
imidazoles. 
General procedure F for alkylation of 1,5-diarylimidazoles 3.62, 3.77, 3.116, 3.117. To a 
solution of diisopropylamine (1.5 equiv) in THF (0.3 M) at –20 °C was added n-BuLi (2.5 M 
in hexanes, 1.5 equiv), and the mixture was stirred for 10 min. A solution of imidazole (1 
equiv) in THF (0.15 M) was added, and after stirring for 30 min, methyliodide or ethyliodide 
(3 equiv) was added. The mixture was stirred for 30 min at –20 °C and for 30 min at room 
temperature. Water was then added to the reaction mixture. The aqueous phase was extracted 
with EtOAc, and the combined organic layers were washed with brine (×3), dried over 
MgSO4, filtered, and concentrated in vacuo. Purification via silica gel column 
chromatography furnished the desired alkylated imidazoles. 
(E)-N-(4-methoxyphenyl)-1-(2,4,6-trifluorophenyl)methanimine (3.37). Following 
synthetic procedure A using 4-methoxyaniline (0.370 g, 3.00 mmol) and 2,4,6-
trifluorobenzaldehyde (0.480 g, 3.00 mmol), the title compound was obtained as a brown 
solid (0.814 g, 3.07 mmol, 99% yield). 1H NMR (500 MHz, CDCl3) δ 8.59 (s, 1H), 7.25–7.22 
(m, 2H), 6.97–6.90 (m, 2H), 6.81–6.72 (m, 2H), 3.84 (s, 3H) ppm. 
(E)-1-(3-chloro-2,6-difluorophenyl)-N-(4-chlorophenyl)methanimine (3.39). Following 
synthetic procedure A using 4-chloro-aniline (0.383 g, 3.00 mmol) and 3-chloro-2,6-
difluorobenzaldehyde (0.530 g, 3.00 mmol), the title compound was obtained as a brown solid 
(0.850 g, 2.97 mmol, 99% yield). 1H NMR (500 MHz, CDCl3) δ 8.60 (s, 1H), 7.47 (td, J = 
8.4, 5.5 Hz, 1H), 7.37 (app d, J = 8.5 Hz, 2H), 7.17 (app d, J = 8.5 Hz, 2H), 7.00–6.96 (m, 
1H) ppm; 13C NMR (126 MHz, CDCl3) δ 159.87 (dd, J = 390.8, 5.6 Hz), 157.80 (dd, J = 
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393.2, 5.6 Hz), 150.87, 150.42, 132.72 (d, J = 10.3 Hz), 132.65, 129.47, 122.29, 117.77 (dd, J 
= 18.0, 3.9 Hz), 115.03 (t, J = 12.9 Hz), 112.80 (dd, J = 23.0, 4.4 Hz) ppm. 
 (E)-N-(4-chlorophenyl)-1-(2,3,6-trifluorophenyl)methanimine (3.41). Following synthetic 
procedure A using 4-chloro-aniline (0.383 g, 3.00 mmol) and 2,3,6-trifluorobenzaldehyde 
(0.337 mL, 3.00 mmol), the title compound was obtained as a brown solid (0.778 g, 
2.88 mmol, 96% yield). 1H NMR (500 MHz, CDCl3) δ 8.58 (s, 1H), 7.34 (app d, J = 8.3 Hz, 
2H), 7.26–7.20 (m, 1H), 7.16 (app d, J = 8.2 Hz, 2H), 6.92 (app t, J = 9.0 Hz, 1H) ppm; 13C 
NMR (126 MHz, CDCl3) δ 158.28, 156.26, 150.76, 150.19, 148.36–148.23 (m), 146.34 (dd, J 
= 12.5, 3.6 Hz), 132.51, 129.30, 122.18, 119.33 (dd, J = 19.4, 10.4 Hz), 115.07 (dd, J = 14.2, 
9.0 Hz), 111.42 (dt, J = 24.4, 5.3 Hz) ppm. 
(E)-1-(2,6-difluorophenyl)-N-(4-(trifluoromethoxy)phenyl)methanimine (3.47). Following 
synthetic procedure A using 4-(trifluoromethoxy)aniline (0.531 g, 3.00 mmol) and 2,6-
difluorobenzaldehyde (0.426 g, 3.00 mmol), the title compound was obtained as a brown 
liquid (1.03 g, 3.43 mmol, 99% yield). 1H NMR (500 MHz, CDCl3) δ 8.65 (s, 1H), 7.46–7.39 
(m, 1H), 7.26–7.22 (m, 4H), 7.01 (t, J = 8.6 Hz, 2H) ppm. 
 (E)-N-(4-chlorophenyl)-1-(2,6-difluorophenyl)methanimine (3.48). Following synthetic 
procedure A using 4-chloroaniline (0.829 g, 6.50 mmol) and 2,6-difluorobenzaldehyde 
(0.924 g, 6.50 mmol) the title compound was obtained as a brown liquid (1.62 g, 6.45 mmol, 
99% yield). 1H NMR (500 MHz, CDCl3) δ 8.64 (s, 1H), 7.46–7.40 (m, 1H), 7.40–7.34 (m, 
2H), 7.20–7.14 (m, 2H), 7.04–6.96 (m, 2H) ppm. 
 (E)-N-(4-(trifluoromethoxy)phenyl)-1-(2,3,6-trifluorophenyl)methanimine (3.49). 
Following synthetic procedure A using 4-(trifluoromethoxy)aniline (0.531 g, 3.00 mmol) and 
2,3,6-trifluorobenzaldehyde (0.480 g, 3.00 mmol), the title compound was obtained as a 
brown solid (1.08 g, 3.47 mmol, 99% yield). 1H NMR (500 MHz, CDCl3) δ 8.62 (s, 1H), 
7.45–7.25 (m, 2H), 7.27–7.22 (m, 2H), 7.20–7.11 (m, 1H), 7.02–6.93 (m, 1H) ppm.  
 (E)-N-(4-chlorophenyl)-1-(2,6-difluoro-4-methylphenyl)methanimine (3.50). Following 
synthetic procedure A using 4-chloroaniline (0.157 g, 1.23 mmol) and 2,6-difluoro-4-
methylbenzaldehyde (0.192 g, 3.00 mmol), the title compound was obtained as a brown solid 
(0.183 g, 0.689 mmol, 56% yield). 1H NMR (500 MHz, CDCl3) δ 8.59 (s, 1H), 7.36 (d, J = 
8.2 Hz, 2H), 7.15 (d, J = 8.2 Hz, 2H), 6.82 (d, J = 10.1 Hz, 2H), 2.40 (s, 3H) ppm. 
 (E)-N-(4-chlorophenyl)-1-(2,6-difluoro-3-methoxyphenyl)methanimine (3.51). Following 
synthetic procedure A using 4-chloroaniline (0.383 g, 3.00 mmol) and 2,6-difluoro-3-
methoxybenzaldehyde (0.468 g, 3.00 mmol), the title compound was obtained as a brown 
solid (0.745 g, 2.64 mmol, 88% yield). 1H NMR (500 MHz, CDCl3) δ 8.63 (s, 1H), 7.39–7.32 
(m, 2H), 7.20–7.11 (m, 2H), 7.07–6.98 (m, 1H), 6.96–6.87 (m, 1H), 3.90 (s, 3H) ppm. 
 (E)-N-(4-chlorophenyl)-1-phenylmethanimine (3.52). Following synthetic procedure A 
using 4-chloroaniline (0.383 g, 3.00 mmol) and benzaldehyde (0.318 g, 3.00 mmol), the title 
compound was obtained as a brown solid (0.702 g, 3.25 mmol, 99% yield). 1H NMR 
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(500 MHz, CDCl3) δ 8.44 (s, 1H), 7.96–7.87 (m, 2H), 7.57–7.45 (m, 3H), 7.36 (d, J = 8.3 Hz, 
2H), 7.16 (d, J = 8.3 Hz, 2H) ppm. 
 (E)-N-(4-chlorophenyl)-1-(4-methoxyphenyl)methanimine (3.53). Following synthetic 
procedure B using 4-chloroaniline (0.765 g, 6.00 mmol) and 4-methoxybenzaldehyde 
(0.817 g, 6.00 mmol), the title compound was obtained as a yellow solid (1.37 g, 5.58 mmol, 
93% yield). 1H NMR (500 MHz, CDCl3) δ 8.35 (s, 1H), 7.84 (d, J = 8.4 Hz, 2H), 7.37–7.31 
(m, 2H), 7.13 (d, J = 8.5 Hz, 2H), 6.98 (d, J = 8.4 Hz, 2H), 3.87 (s, 3H) ppm. 
(E)-1-(2,6-difluorophenyl)-N-phenylmethanimine (3.54). Following synthetic procedure B 
using aniline (0.559 g, 6.00 mmol) and 2,6-difluorobenzaldehyde (0.853 g, 6.00 mmol), the 
title compound was obtained as a yellow liquid (0.637 g, 2.93 mmol, 49% yield). 1H NMR 
(500 MHz, CDCl3) δ 8.65 (s, 1H), 7.44–7.34 (m, 3H), 7.26–7.19 (m, 3H), 7.02–6.95 (m, 2H) 
ppm. 
 (E)-N-(2-chlorophenyl)-1-(2,6-difluorophenyl)methanimine (3.55). Following synthetic 
procedure B using 2-chloroaniline (0.765 g, 6.00 mmol) and 2,6-difluorobenzaldehyde 
(0.853 g, 6.00 mmol), the title compound was obtained as a yellow liquid (1.41 g, 5.58 mmol, 
93% yield). 1H NMR (500 MHz, CDCl3) δ 8.62 (s, 1H), 7.49–7.39 (m, 2H), 7.32–7.27 (m, 
1H), 7.20–7.14 (m, 1H), 7.06–6.98 (m, 3H) ppm. 
1-(4-Methoxyphenyl)-5-(2,4,6-trifluorophenyl)-1H-imidazole (3.57). Following synthetic 
procedure C using (E)-N-(4-methoxyphenyl)-1-(2,4,6-trifluorophenyl)methanimine (0.814 g, 
3.07 mmol), purification by silica gel column chromatography (hexanes/EtOAc 60:40) 
afforded the title compound as an orange solid (0.065 g, 0.214 mmol, 7% yield). 1H NMR 
(500 MHz, CDCl3) δ 7.76 (s, 1H), 7.25 (s, 1H), 7.09–7.04 (m, 2H), 6.88–6.83 (m, 2H), 6.66–
6.59 (m, 2H), 3.79 (s, 3H) ppm. 13C NMR (126 MHz, CDCl3) δ 163.05 (dt, J = 251.4, 15.1 
Hz), 160.93 (ddd, J = 251.1, 14.8, 8.6 Hz), 159.50, 139.30, 131.76, 129.27, 126.21, 119.50, 
114.58, 104.15 (td, J = 20.4, 4.9 Hz), 101.30–99.76 (m), 55.61 ppm. IR (KBr) ν 3102, 3008, 
2935, 2840, 1689, 1644, 1599, 1564, 1515, 1489, 1465, 1439, 1301, 1250, 1172, 1123, 1033 
cm-1. HRMS (ES+) calculated for C16H12F3N2O [M + H]+ 309.0902, found 309.0908. 
5-(3-Chloro-2,6-difluorophenyl)-1-(4-chlorophenyl)-1H-imidazole (3.59). Following 
synthetic procedure C using (E)-1-(3-chloro-2,6-difluorophenyl)-N-(4-
chlorophenyl)methanimine (0.429 g, 1.50 mmol), purification by silica gel column 
chromatography (hexanes/EtOAc 100:0 to 60:40) afforded the title compound as a white solid 
(0.298 g, 0.916 mmol, 61% yield). 1H NMR (500 MHz, CDCl3) δ 7.77 (d, J = 0.5 Hz, 1H), 
7.32–7.27 (m, 4H), 7.06–7.04 (m, 2H), 6.78 (td, J = 8.7, 1.4 Hz, 1H) ppm. 13C NMR 
(126 MHz, CDCl3) δ 158.27 (dd, J = 251.2, 4.4 Hz), 155.38 (dd, J = 252.0, 6.3 Hz), 138.97, 
134.65, 134.11, 132.45, 130.90, 130.83, 129.57, 125.53, 119.00, 116.96 (dd, J = 18.6, 4.2 
Hz), 112.05 (dd, J = 23.5, 4.1 Hz), 108.51 (t, J = 20.1 Hz) ppm. MS (ES+) calculated for 
C15H9Cl2F2N2 [M + H]+ 325.01, found 324.93. 
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5-(3-Chloro-2,6-difluorophenyl)-1-(4-chlorophenyl)-4-methyl-1H-imidazole (3.60). 
Following synthetic procedure D using (E)-1-(3-chloro-2,6-difluorophenyl)-N-(4-
chlorophenyl)methanimine (0.800 g, 2.80 mmol), purification by silica gel column 
chromatography (hexanes/EtOAc 65:35) afforded the title compound as an orange solid 
(0.433 g, 1.28 mmol, 46% yield). 1H NMR (500 MHz, CDCl3) δ 7.72 (s, 1H), 7.37 (ddd, J = 
9.0, 8.0, 5.6 Hz, 1H), 7.34–7.27 (m, 2H), 7.08–7.01 (m, 2H), 6.84 (ddd, J = 9.0, 8.2, 1.8 Hz, 
1H), 2.20 (s, 3H) ppm. 13C NMR (126 MHz, CDCl3) δ 158.82 (dd, J = 250.6, 4.6 Hz), 155.87 
(dd, J = 251.8, 6.6 Hz), 140.71, 138.02, 135.11, 134.20, 131.25 (d, J = 9.6 Hz), 129.79, 
125.77, 117.22 (dd, J = 18.7, 4.2 Hz), 115.41, 112.29 (dd, J = 23.6, 4.3 Hz), 109.12 (t, J = 
20.3 Hz), 13.48 ppm. IR (KBr) ν 3077, 3036, 2960, 2925, 1625, 1568, 1498, 1477, 1453, 
1352, 1282, 1269, 1218, 1091, 1003 cm-1. HRMS (ES+) calculated for C16H11Cl2F2N2 [M + 
H]+ 339.0267, found 339.0273. 
2-Chloro-5-(3-chloro-2,6-difluorophenyl)-1-(4-chlorophenyl)-4-methyl-1H-imidazole 
(3.61). Following synthetic procedure E using 5-(3-chloro-2,6-difluorophenyl)-1-(4-
chlorophenyl)-4-methyl-1H-imidazole (0.150 g, 0.442 mmol), purification by silica gel 
column chromatography (hexanes/EtOAc 80:20) afforded the title compound as a white solid 
(0.071 g, 0.190 mmol, 43% yield). 1H NMR (500 MHz, CDCl3) δ 7.39–7.31 (m, 3H), 7.14–
7.06 (m, 2H), 6.86–6.75 (m, 1H), 2.17 (s, 3H) ppm. 13C NMR (126 MHz, CDCl3) δ 158.94 
(dd, J = 250.9, 4.3 Hz), 156.02 (dd, J = 252.1, 6.2 Hz), 139.23, 135.37, 133.53 (d, J = 11.2 
Hz), 131.74 (d, J = 9.8 Hz), 129.85, 129.61, 128.57, 117.71, 117.16 (dd, J = 18.3, 3.5 Hz), 
112.23 (dd, J = 23.6, 4.3 Hz), 108.57 (t, J = 20.1 Hz), 13.43 ppm. IR (KBr) ν 3074, 2924, 
2848, 1627, 1572, 1494, 1474, 1455, 1388, 1283, 1218, 1092, 1007 cm-1. HRMS (ES+) 
calculated for C16H10Cl3F2N2 [M + H]+ 372.9878, found 372.9874. 
5-(3-Chloro-2,6-difluorophenyl)-1-(4-chlorophenyl)-2,4-dimethyl-1H-imidazole (3.62). 
Following synthetic procedure F using 5-(3-chloro-2,6-difluorophenyl)-1-(4-chlorophenyl)-4-
methyl-1H-imidazole (0.050 g, 0.147 mmol), purification by silica gel column 
chromatography (hexanes/EtOAc 60:40) afforded the title compound as a orange solid 
(0.029 g, 0.082 mmol, 56% yield). 1H NMR (500 MHz, CDCl3) δ 7.34–7.29 (m, 2H), 7.31–
7.26 (m, 1H), 7.03 (d, J = 8.4 Hz, 2H), 6.82–6.74 (m, 1H), 2.29 (s, 3H), 2.14 (s, 3H) ppm. 13C 
NMR (126 MHz, CDCl3) δ 158.99 (dd, J = 249.9, 4.9 Hz), 156.01 (dd, J = 251.2, 6.6 Hz), 
146.28, 138.04, 135.07, 134.66, 130.99 (d, J = 9.7 Hz), 129.62, 128.34, 116.96 (dd, J = 19.0, 
3.9 Hz), 115.69, 112.05 (dd, J = 23.9, 4.3 Hz), 109.60 (t, J = 20.7 Hz), 14.04, 13.13 ppm. IR 
(KBr) ν 3052, 2962, 2922, 2849, 1693, 1629, 1593, 1571, 1495, 1474, 1402, 1266, 1218, 
1092, 1004 cm-1. HRMS (ES+) calculated for C17H13Cl2F2N2 [M + H]+ 353.0424, found 
353.0413. 
1-(4-Chlorophenyl)-5-(2,3,6-trifluorophenyl)-1H-imidazole (3.64). Following synthetic 
procedure C using (E)-N-(4-chlorophenyl)-1-(2,3,6-trifluorophenyl)methanimine (0.405 g, 
1.50 mmol), purification by silica gel column chromatography (hexanes/EtOAc 100:0 to 
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60:40) afforded the title compound as a brown solid (0.350 g, 1.13 mmol, 76% yield). 1H 
NMR (500 MHz, CDCl3) δ 7.80 (s, 1H), 7.34–7.31 (m, 3H), 7.15–7.11 (m, J = 9.0, 5.0 Hz, 
1H), 7.09 (d, J = 8.6 Hz, 2H), 6.82–6.78 (m, 1H) ppm. MS (ES+) calculated for C15H8ClF3N2 
[M + H]+ 309.04, found 309.18. 
1-(4-Chlorophenyl)-2-methyl-5-(2,3,6-trifluorophenyl)-1H-imidazole (3.65). To a solution 
of diisopropylamine (0.020 mL, 0.146 mmol, 1.50 equiv) in THF (0.5 mL) at –20 °C was 
added n-BuLi (2.5 M in hexanes, 0.060 mL, 0.146 mmol, 1.50 equiv), and the mixture was 
stirred for 10 min. A solution of 1-(4-chlorophenyl)-5-(2,3,6-trifluorophenyl)-1H-imidazole 
(0.030 g, 0.097 mmol, 1.00 equiv) in THF (1 mL) was added, and after stirring for 30 min, 
methyliodide (0.009 mL, 0.146 mmol, 1.50 equiv) was added. The mixture was stirred for 
30 min at –20 °C and for 30 min at room temperature. H2O was added to the reaction mixture, 
the aqueous phase was extracted with EtOAc, and the combined organic layers were washed 
with brine (×3), dried over MgSO4, filtered, and concentrated. The mixture was purified by 
silica gel column chromatography (hexanes/EtOAc 65:35) afforded the title compound as a 
yellow solid (0.009 g, 0.028 mmol, 29% yield). 1H NMR (500 MHz, CDCl3) δ 7.38–7.33 (m, 
2H), 7.19 (s, 1H), 7.11–7.04 (m, 3H), 6.78–6.73 (m, 1H), 2.34 (s, 3H) ppm. 13C NMR 
(126 MHz, CDCl3) δ 155.73 (dt, J = 246.7, 3.2 Hz), 148.24 (ddd, J = 251.2, 14.2, 6.5 Hz), 
147.45, 147.13 (ddd, J = 245.9, 13.2, 3.6 Hz), 134.95, 134.80, 130.14, 129.73, 128.32, 
125.88, 119.63, 117.77–117.37 (m), 110.88 (ddd, J = 24.7, 6.9, 4.3 Hz), 109.67 (dd, J = 21.8, 
16.1 Hz), 14.24 ppm. IR (KBr) ν 3098, 3061, 2961, 2924, 2850, 1641, 1494, 1402, 1237, 
1093 cm-1. HRMS (ES+) calculated for C16H11ClF3N2 [M + H]+ 323.0563, found 323.0568. 
1-(4-Chlorophenyl)-4-methyl-5-(2,3,6-trifluorophenyl)-1H-imidazole (3.66). Following 
synthetic procedure D using (E)-N-(4-chlorophenyl)-1-(2,3,6-trifluorophenyl)methanimine 
(0.500 g, 1.85 mmol), purification by silica gel column chromatography (hexanes/EtOAc 
60:40) afforded the title compound as an orange solid (0.190 g, 0.589 mmol, 32% yield). 1H 
NMR (500 MHz, CDCl3) δ 7.72 (s, 1H), 7.33–7.29 (m, 2H), 7.15 (qd, J = 9.1, 5.0 Hz, 1H), 
7.07–7.02 (m, 2H), 6.85–6.79 (m, 1H), 2.22 (s, 3H) ppm. 13C NMR (126 MHz, CDCl3) δ 
155.69 (dt, J = 247.2, 3.4 Hz), 148.15 (ddd, J = 252.2, 14.3, 6.4 Hz), 147.28 (ddd, J = 246.6, 
12.8, 4.1 Hz), 140.74, 138.07, 135.11, 134.20, 129.79, 125.77, 117.83 (dd, J = 19.4, 9.7 Hz), 
115.33 (d, J = 2.3 Hz), 111.14 (ddd, J = 24.4, 6.9, 4.2 Hz), 109.45 (dd, J = 22.0, 16.2 Hz), 
13.48 ppm. IR (KBr) ν 3094, 2925, 1642, 1595, 1500, 1472, 1353, 1269, 1250, 1231, 1092, 
1002, 973 cm-1. HRMS (ES+) calculated for C16H11ClF3N2 [M + H]+ 323.0563, found 
323.0557. 
2-Chloro-1-(4-chlorophenyl)-4-methyl-5-(2,3,6-trifluorophenyl)-1H-imidazole (3.67). 
Following synthetic procedure E using 1-(4-chlorophenyl)-4-methyl-5-(2,3,6-
trifluorophenyl)-1H-imidazole (0.100 g, 0.310 mmol), purification by silica gel column 
chromatography (hexanes/EtOAc 80:20) afforded the title compound as a white solid 
(0.079 g, 0.221 mmol, 71% yield). 1H NMR (500 MHz, CDCl3) δ 7.36–7.31 (m, 2H), 7.17–
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7.07 (m, 3H), 6.82–6.76 (m, 1H), 2.17 (s, 3H) ppm. 13C NMR (126 MHz, CDCl3) δ 155.82 
(dt, J = 247.3, 2.9 Hz), 148.29 (ddd, J = 251.9, 14.1, 7.0 Hz), 147.12 (ddd, J = 246.7, 13.0, 
3.9 Hz), 139.27, 135.37, 133.55 (d, J = 5.2 Hz), 129.85, 129.60, 128.57, 118.34 (dd, J = 19.3, 
9.9 Hz), 117.60 (d, J = 2.3 Hz), 111.11 (ddd, J = 24.7, 6.9, 4.4 Hz), 108.90 (dd, J = 22.0, 16.2 
Hz), 13.44 ppm. IR (KBr) ν 3052, 2983, 2918, 2849, 1494, 1448, 1265, 1236, 1092, 1001 cm-
1. HRMS (ES+) calculated for C16H10Cl2F3N2 [M + H]+ 357.0173, found 357.0170. 
5-(2,6-Difluorophenyl)-1-(4-(trifluoromethoxy)phenyl)-1H-imidazole (3.73). Following 
synthetic procedure C using (E)-1-(2,6-difluorophenyl)-N-(4-
(trifluoromethoxy)phenyl)methanimine (1.03 g, 3.43 mmol), purification by silica gel column 
chromatography (hexanes/EtOAc 60:40) afforded the title compound as a white solid 
(0.644 g, 1.89 mmol, 55% yield). 1H NMR (500 MHz, DMSO-d6) δ 8.20 (s, 1H), 7.54–7.47 
(m, 1H), 7.45 (d, J = 8.5 Hz, 2H), 7.35 (d, J = 8.5 Hz, 2H), 7.32 (s, 1H), 7.15 (t, J = 8.2 Hz, 
2H) ppm. 13C NMR (126 MHz, DMSO-d6) δ 159.54 (dd, J = 248.4, 6.0 Hz), 147.54–147.48 
(m), 139.64, 135.08, 131.88, 131.76 (t, J = 5.2 Hz), 126.09, 122.12, 119.91 (q, J = 256.9 Hz), 
118.93, 111.98 (dd, J = 20.4, 5.1 Hz), 106.56 (t, J = 19.7 Hz) ppm. IR (KBr) ν 3059, 2917, 
2849, 1632, 1580, 1562, 1514, 1472, 1448, 1262, 1212, 1169 cm-1. HRMS (ES+) calculated 
for C16H10F5N2O [M + H]+ 341.0713, found 341.0714. 
1-(4-Chlorophenyl)-5-(2,6-difluorophenyl)-1H-imidazole (3.74). Following synthetic 
procedure C using (E)-N-(4-chlorophenyl)-1-(2,6-difluorophenyl)methanimine (1.62 g, 
6.45 mmol), purification by silica gel column chromatography (hexanes/EtOAc 65:35) 
afforded the title compound as a yellow solid (1.18 g, 4.04 mmol, 63% yield). 1H NMR 
(500 MHz, CDCl3) δ 8.86 (s, 1H), 7.60 (s, 1H), 7.49–7.44 (m, 1H), 7.44–7.40 (m, 2H), 7.21–
7.17 (m, 2H), 6.99–6.93 (m, 2H) ppm. 13C NMR (126 MHz, CDCl3) δ 160.46 (dd, J = 253.1, 
5.2 Hz), 136.99, 136.90, 133.44 (t, J = 10.2 Hz), 132.54, 130.41, 126.30, 123.71, 122.62, 
112.21 (dd, J = 20.4, 4.2 Hz), 103.71 (t, J = 19.4 Hz) ppm. IR (KBr) ν 3104, 2919, 2851, 
2612, 1987, 1680, 1590, 1536, 1491, 1469, 1414, 1348, 1148 cm-1. HRMS (ES+) calculated 
for C15H10ClF2N2 [M + H]+ 291.0501, found 291.0503. 
1-(4-Chlorophenyl)-5-(2,6-difluorophenyl)-4-methyl-1H-imidazole (3.75). Following 
synthetic procedure D using (E)-N-(4-chlorophenyl)-1-(2,6-difluorophenyl)methanimine 
(0.618 g, 2.46 mmol), purification by silica gel column chromatography (hexanes/EtOAc 
65:35) afforded the title compound as an orange solid (0.292 g, 0.958 mmol, 39% yield). 1H 
NMR (500 MHz, CDCl3) δ 7.72 (s, 1H), 7.36–7.28 (m, 1H), 7.32–7.25 (m, 2H), 7.08–7.01 
(m, 2H), 6.93–6.83 (m, 2H), 2.21 (s, 3H) ppm. 13C NMR (126 MHz, CDCl3) δ 160.61 (dd, J = 
250.3, 6.3 Hz), 140.19, 137.61, 135.40, 133.91, 131.00 (t, J = 10.2 Hz), 129.63, 125.7, 
116.13, 111.74 (dd, J = 20.1, 5.3 Hz), 107.53 (t, J = 20.0 Hz), 13.44 ppm. IR (KBr) ν 3105, 
2921, 2851, 1692, 1630, 1590, 1569, 1498, 1479, 1461, 1274, 1235, 1091, 997 cm-1. HRMS 
(ES+) calculated for C16H12ClF2N2 [M + H]+ 305.0657, found 305.0661. 
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2-Chloro-1-(4-chlorophenyl)-5-(2,6-difluorophenyl)-4-methyl-1H-imidazole (3.76). 
Following synthetic procedure E using 1-(4-chlorophenyl)-5-(2,6-difluorophenyl)-4-methyl-
1H-imidazole (0.150 g, 0.492 mmol), purification by silica gel column chromatography 
(hexanes/EtOAc 80:20) afforded the title compound as a yellow oil (0.079 g, 0.232 mmol, 
47% yield). 1H NMR (500 MHz, CDCl3) δ 7.31 (d, J = 8.6 Hz, 2H), 7.30–7.26 (m, 1H), 7.12–
7.07 (m, 2H), 6.88–6.81 (m, 2H), 2.16 (s, 3H) ppm. 13C NMR (126 MHz, CDCl3) δ 160.70 
(dd, J = 250.6, 6.0 Hz), 138.71, 135.08, 133.82, 132.88, 131.46 (t, J = 10.2 Hz), 129.41, 
128.60, 118.49, 111.65 (dd, J = 20.6, 5.1 Hz), 107.02 (t, J = 19.8 Hz), 13.37 ppm. IR (KBr) ν 
3056, 2959, 2923, 2850, 1633, 1590, 1571, 1495, 1467, 1448, 1387, 1280, 1236, 1092, 998 
cm-1. HRMS (ES+) calculated for C16H11Cl2F2N2 [M + H]+ 339.0267, found 339.0277. 
1-(4-Chlorophenyl)-5-(2,6-difluorophenyl)-2,4-dimethyl-1H-imidazole (3.77). Following 
synthetic procedure F using 1-(4-chlorophenyl)-5-(2,6-difluorophenyl)-4-methyl-1H-
imidazole (0.050 g, 0.164 mmol), purification by silica gel column chromatography 
(hexanes/EtOAc 65:35) afforded the title compound as a colorless liquid (0.025 g, 
0.078 mmol, 48% yield). 1H NMR (500 MHz, CDCl3) δ 7.31–7.27 (m, 2H), 7.25–7.18 (m, 
1H), 7.06–7.01 (m, 2H), 6.81 (t, J = 7.6 Hz, 2H), 2.29 (s, 3H), 2.14 (s, 3H) ppm. 13C NMR 
(126 MHz, CDCl3) δ 160.79 (dd, J = 249.7, 6.3 Hz), 145.79, 137.59, 135.43, 134.38, 130.69 
(t, J = 10.2 Hz), 129.44, 128.40, 116.41, 111.49 (dd, J = 20.3, 5.3 Hz), 108.12 (t, J = 20.1 
Hz), 14.09, 13.12 ppm. IR (KBr) ν 2958, 2923, 2851, 1633, 1594, 1572, 1495, 1464, 1403, 
1274, 1235, 1092 cm-1. HRMS (ES+) calculated for C17H14ClF2N2 [M + H]+ 319.0814, found 
319.0807. 
1-(4-(Trifluoromethoxy)phenyl)-5-(2,3,6-trifluorophenyl)-1H-imidazole (3.78). Following 
synthetic procedure C using (E)-N-(4-(trifluoromethoxy)phenyl)-1-(2,3,6-
trifluorophenyl)methanimine (1.08 g, 3.37 mmol), purification by silica gel column 
chromatography (hexanes/EtOAc 65:35) afforded the title compound as a brown solid 
(0.587 g, 1.64 mmol, 49% yield). 1H NMR (500 MHz, CDCl3) δ 7.83 (s, 1H), 7.36 (s, 1H), 
7.26–7.17 (m, 4H), 7.14 (qd, J = 9.1, 4.9 Hz, 1H), 6.86–6.77 (m, 1H) ppm. 13C NMR 
(126 MHz, CDCl3) δ 155.51 (dt, J = 247.8, 3.2 Hz), 149.06–148.90 (m), 148.12 (ddd, J = 
261.9, 15.9, 9.2 Hz), 147.33 (ddd, J = 246.6, 12.7, 4.1 Hz), 139.36, 134.80, 132.76, 126.15, 
122.02, 120.40 (q, J = 258.6 Hz), 119.39, 117.84 (dd, J = 19.1, 9.6 Hz), 111.17 (ddd, J = 
24.6, 6.7, 4.2 Hz), 109.03 (dd, J = 21.9, 15.9 Hz) ppm. IR (KBr) ν 3097, 2917, 2850, 1734, 
1642, 1599, 1563, 1514, 1494, 1448, 1383, 1260, 1211, 1167, 1103, 1027, 1016, 994 cm-1. 
HRMS (ES+) calculated for C16H9F6N2O [M + H]+ 359.0619, found 359.0621.  
1-(4-Chlorophenyl)-5-(2,6-difluoro-4-methylphenyl)-1H-imidazole (3.79). Following 
synthetic procedure C using (E)-N-(4-chlorophenyl)-1-(2,6-difluoro-4-
methylphenyl)methanimine (0.183 g, 0.689 mmol), purification by silica gel column 
chromatography (hexanes/EtOAc 60:40) afforded the title compound as a yellow solid 
(0.127 g, 0.417 mmol, 61% yield). 1H NMR (500 MHz, CDCl3) δ 7.76 (s, 1H), 7.31 (d, J = 
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8.2 Hz, 2H), 7.26 (s, 1H), 7.08 (d, J = 8.3 Hz, 2H), 6.67 (d, J = 8.2 Hz, 2H), 2.32 (s, 3H) ppm. 
13C NMR (126 MHz, CDCl3) δ 160.10 (dd, J = 249.8, 7.0 Hz), 142.34 (t, J = 9.8 Hz), 138.65, 
135.27, 134.11, 132.11, 129.68, 125.88, 120.32, 112.32 (dd, J = 19.8, 5.3 Hz), 104.03 (t, J = 
19.8 Hz), 21.58 ppm. IR (KBr) ν 3113, 3073, 3037, 2923, 2854, 1642, 1572, 1499, 1464, 
1323, 1277, 1249, 1215, 1205, 1091 cm-1. HRMS (ES+) calculated for C16H12ClF2N2 [M + 
H]+ 305.0657, found 305.0658.  
1-(4-Chlorophenyl)-5-(2,6-difluoro-3-methoxyphenyl)-1H-imidazole (3.80). Following 
synthetic procedure C using (E)-N-(4-chlorophenyl)-1-(2,6-difluoro-3-
methoxyphenyl)methanimine (0.745 g, 2.64 mmol), purification by silica gel column 
chromatography (hexanes/EtOAc 60:40) afforded the title compound as a yellow solid 
(0.278 g, 0.867 mmol, 33% yield). 1H NMR (500 MHz, CDCl3) δ 7.79 (s, 1H), 7.35–7.29 (m, 
3H), 7.10 (d, J = 8.1 Hz, 2H), 6.94–6.85 (m, 1H), 6.79 (t, J = 8.8 Hz, 1H), 3.83 (s, 3H) ppm. 
13C NMR (126 MHz, CDCl3) δ 153.72 (dd, J = 243.6, 4.1 Hz), 149.74 (dd, J = 250.3, 5.9 Hz), 
144.52 (dd, J = 11.1, 3.0 Hz), 138.92, 135.18, 134.20, 132.42, 129.73, 125.86, 120.12, 113.94 
(dd, J = 9.4, 2.9 Hz), 110.40 (dd, J = 23.1, 4.3 Hz), 108.08 (dd, J = 21.4, 16.8 Hz), 56.86 
ppm. IR (KBr) ν 3098, 2941, 2842, 1592, 1500, 1441, 1318, 1281, 1247, 1172, 1110, 1049 
cm-1. HRMS (ES+) calculated for C16H12ClF2N2O [M + H]+ 321.0606, found 321.0606. 
1-(4-Chlorophenyl)-5-phenyl-1H-imidazole (3.81). Following synthetic procedure C using 
(E)-N-(4-chlorophenyl)-1-phenylmethanimine (0.702 g, 3.25 mmol), purification by silica gel 
column chromatography (hexanes/EtOAc 60:40) afforded the title compound as a orange 
solid (0.088 g, 0.345 mmol, 11% yield). 1H NMR (500 MHz, CDCl3) δ 7.67 (s, 1H), 7.36 (d, 
J = 8.0 Hz, 2H), 7.30–7.26 (m, 4H), 7.16–7.09 (m, 4H) ppm. 13C NMR (126 MHz, CDCl3) δ 
138.80, 135.25, 134.08, 133.08, 129.77, 129.19, 129.15, 128.66, 128.28, 127.80, 126.84 ppm. 
IR (KBr) ν 3115, 3062, 2957, 2921, 2851, 1604, 1495, 1468, 1269, 1117, 1093 cm-1. HRMS 
(ES+) calculated for C15H12ClN2 [M + H]+ 255.0689, found 255.0690. 
1-(4-Chlorophenyl)-5-(4-methoxyphenyl)-1H-imidazole (3.82). Following synthetic 
procedure C using (E)-N-(4-chlorophenyl)-1-(4-methoxyphenyl)methanimine (0.100 g, 
0.407 mmol), purification by silica gel column chromatography (hexanes/EtOAc 65:35) 
afforded the title compound as a orange solid (0.065 g, 0.228 mmol, 56% yield). 1H NMR 
(500 MHz, CDCl3) δ 7.64 (s, 1H), 7.38–7.30 (m, 2H), 7.18 (s, 1H), 7.14–7.07 (m, 2H), 7.08–
6.99 (m, 2H), 6.85–6.75 (m, 2H), 3.78 (s, 3H) ppm. 13C NMR (126 MHz, CDCl3) δ 159.35, 
138.30, 135.38, 134.01, 132.95, 129.74, 128.50, 126.88, 121.62, 114.17, 55.35 ppm. IR (KBr) 
ν 3118, 3046, 2960, 2916, 2836, 1614, 1557, 1497, 1466, 1297, 1271, 1250, 1178, 1113, 
1093, 1063, 1030 cm-1. HRMS (ES+) calculated for C16H14ClN2O [M + H]+ 285.0795, found 
285.0798. 
5-(2,6-Difluorophenyl)-1-phenyl-1H-imidazole (3.83). Following synthetic procedure C 
using (E)-1-(2,6-difluorophenyl)-N-phenylmethanimine (0.600 g, 2.76 mmol), purification by 
silica gel column chromatography (hexanes/EtOAc 65:35) afforded the title compound as an 
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orange solid (0.193 g, 0.753 mmol, 27% yield). 1H NMR (500 MHz, CDCl3) δ 7.84 (s, 1H), 
7.41–7.34 (m, 3H), 7.34 (s, 1H), 7.34–7.25 (m, 1H), 7.21–7.15 (m, 2H), 6.91–6.83 (m, 2H) 
ppm. 13C NMR (126 MHz, CDCl3) δ 160.55 (dd, J = 250.5, 6.2 Hz), 138.99, 136.71, 132.15, 
130.67 (t, J = 10.2 Hz), 129.46, 128.25, 124.59, 120.06, 111.61 (dd, J = 20.4, 5.0 Hz), 107.65 
(t, J = 19.7 Hz) ppm. IR (KBr) ν 3103, 3070, 3045, 2916, 2848, 1631, 1597, 1563, 1498, 
1470, 1447, 1278, 1255, 1236, 1216, 1116, 1077, 998 cm-1. HRMS (ES+) calculated for 
C15H11F2N2 [M + H]+ 257.0890, found 257.0881. 
1-(2-Chlorophenyl)-5-(2,6-difluorophenyl)-1H-imidazole (3.84). Following synthetic 
procedure C using (E)-N-(2-chlorophenyl)-1-(2,6-difluorophenyl)methanimine (0.600 g, 
2.38 mmol), purification by silica gel column chromatography (hexanes/EtOAc 65:35) 
afforded the title compound as a yellow solid (0.478 g, 1.64 mmol, 69% yield). 1H NMR 
(500 MHz, CDCl3) δ 7.72 (s, 1H), 7.41–7.37 (m, 1H), 7.32–7.24 (m, 2H), 7.25–7.14 (m, 3H), 
6.82–6.74 (m, 2H) ppm. 13C NMR (126 MHz, CDCl3) δ 160.49 (dd, J = 250.9, 6.1 Hz), 139.5, 
134.11, 131.55, 131.53, 130.68 (t, J = 10.2 Hz), 130.54, 130.13, 129.00, 127.44, 121.01, 
111.52 (dd, J = 20.3, 5.0 Hz), 107.32 (t, J = 19.4 Hz) ppm. IR (KBr) ν 3104, 3062, 1632, 
1587, 1566, 1491, 1467, 1444, 1275, 1235, 1213, 1110, 1089, 1045, 999 cm-1. HRMS (ES+) 
calculated for C15H10ClF2N2 [M + H]+ 291.0501, found 291.0494. 
4-Chloro-1-(4-methoxyphenyl)-5-(2,4,6-trifluorophenyl)-1H-imidazole (3.90). Following 
synthetic procedure E using 1-(4-methoxyphenyl)-5-(2,4,6-trifluorophenyl)-1H-imidazole 
(0.086 g, 0.283 mmol), purification by silica gel column chromatography (hexanes/EtOAc 
80:20) afforded the title compound as a yellow solid (0.043 g, 0.127 mmol, 45% yield). 1H 
NMR (500 MHz, CDCl3) δ 77.64 (s, 1H), 7.06 (d, J = 8.6 Hz, 2H), 6.88–6.82 (m, 2H), 6.71–
6.61 (m, 2H), 3.79 (s, 3H) ppm. 13C NMR (126 MHz, CDCl3) δ 163.80 (dt, J = 252.7, 15.1 
Hz), 161.21 (ddd, J = 252.7, 15.3, 8.6 Hz), 159.90, 137.20, 131.91, 128.82, 126.27, 115.50, 
114.71, 102.27 (td, J = 20.4, 4.7 Hz), 101.15–100.40 (m), 55.62 ppm. IR (KBr) ν 3149, 3047, 
2983, 2941, 2916, 2838, 1644, 1595, 1564, 1517, 1468, 1439, 1249, 1179, 1128, 1028 cm-1. 
HRMS (ES+) calculated for C16H11ClF3N2O [M + H]+ 339.0512, found 339.0481. 
2-Chloro-1-(4-methoxyphenyl)-5-(2,4,6-trifluorophenyl)-1H-imidazole (3.91). Following 
synthetic procedure E using 1-(4-methoxyphenyl)-5-(2,4,6-trifluorophenyl)-1H-imidazole 
(0.086 g, 0.283 mmol), purification by silica gel column chromatography (hexanes/EtOAc 
80:20) afforded the title compound as a yellow solid (0.015 g, 0.044 mmol, 16% yield). 1H 
NMR (500 MHz, CDCl3) δ 7.14 (s, 1H), 7.11–7.06 (m, 2H), 6.89–6.84 (m, 2H), 6.64–6.56 
(m, 2H), 3.81 (s, 3H) ppm. 13C NMR (126 MHz, CDCl3) δ 163.34 (dt, J = 252.7, 15.4 Hz), 
161.13 (ddd, J = 251.5, 15.0, 8.5 Hz), 160.07, 134.94, 130.16, 128.51, 127.52, 121.78, 
114.42, 103.86 (td, J = 20.3, 4.7 Hz), 101.08–100.00 (m), 55.59 ppm. IR (KBr) ν 3053, 2962, 
2917, 2847, 1645, 1596, 1570, 1514, 1485, 1448, 1253, 1171, 1124, 1035 cm-1. HRMS (ES+) 
calculated for C16H11ClF3N2O [M + H]+ 339.0512, found 339.0499. 
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4-Chloro-5-(2,6-difluorophenyl)-1-(4-(trifluoromethoxy)phenyl)-1H-imidazole (3.112). 
Following synthetic procedure E using 5-(2,6-difluorophenyl)-1-(4-
(trifluoromethoxy)phenyl)-1H-imidazole (0.400 g, 1.17 mmol), purification by silica gel 
column chromatography (hexanes/EtOAc 85:15) afforded the title compound as a white solid 
(0.192 g, 0.512 mmol, 44% yield). 1H NMR (500 MHz, CDCl3) δ 7.70 (s, 1H), 7.43–7.33 (m, 
1H), 7.24–7.16 (m, 4H), 6.91 (t, J = 7.8 Hz, 2H) ppm. 13C NMR (126 MHz, CDCl3) δ 160.71 
(dd, J = 252.1, 6.0 Hz), 149.23–149.16 (m), 136.84, 134.52, 132.53, 132.20 (t, J = 10.2 Hz), 
126.25, 122.01, 120.39 (q, J = 238.7 Hz), 116.18, 111.88 (dd, J = 20.5, 5.1 Hz), 105.32 (t, J = 
19.7 Hz) ppm. IR (KBr) ν 3121, 3088, 1632, 1588, 1565, 1513, 1473, 1330, 1259, 1212, 
1169, 1099 cm-1. HRMS (ES+) calculated for C16H9ClF5N2O [M + H]+ 375.0324, found 
375.0334. 
2-Chloro-5-(2,6-difluorophenyl)-1-(4-(trifluoromethoxy)phenyl)-1H-imidazole (3.113). 
Following synthetic procedure E using 5-(2,6-difluorophenyl)-1-(4-
(trifluoromethoxy)phenyl)-1H-imidazole (0.400 g, 1.17 mmol), purification by silica gel 
column chromatography (hexanes/EtOAc 85:15) afforded the title compound as a white solid 
(0.033 g, 0.088 mmol, 8% yield). 1H NMR (500 MHz, CDCl3) δ 7.34–7.25 (m, 1H), 7.27–
7.20 (m, 4H), 7.20 (s, 1H), 6.88–6.82 (m, 2H) ppm. 13C NMR (126 MHz, CDCl3) δ 160.59 
(dd, J = 251.3, 5.8 Hz), 149.51–149.44 (m), 134.36, 133.35, 131.57 (t, J = 10.2 Hz), 130.53, 
128.96, 122.52, 121.41, 120.39 (q, J = 259.6 Hz), 111.67 (dd, J = 21.2, 4.6 Hz), 106.84 (t, J = 
19.5 Hz) ppm. IR (KBr) ν 3077, 2920, 2852, 1632, 1586, 1511, 1469, 1436, 1388, 1261, 
1211, 1172, 1001 cm-1. HRMS (ES+) calculated for C16H8ClF5N2NaO [M + Na]+ 397.0143, 
found 397.0149. 
2,4-Dichloro-5-(2,6-difluorophenyl)-1-(4-(trifluoromethoxy)phenyl)-1H-imidazole (3.114). 
Following synthetic procedure E using 5-(2,6-difluorophenyl)-1-(4-
(trifluoromethoxy)phenyl)-1H-imidazole (0.400 g, 1.17 mmol), purification by silica gel 
column chromatography (hexanes/EtOAc 85:15) afforded the title compound as a white solid 
(0.028 g, 0.068 mmol, 6% yield). 1H NMR (500 MHz, CDCl3) δ 7.40–7.30 (m, 1H), 7.27–
7.19 (m, 4H), 6.91–6.84 (m, 2H) ppm. 13C NMR (126 MHz, CDCl3) δ 160.74 (dd, J = 252.3, 
5.6 Hz), 149.85–149.77 (m), 132.76, 132.65, 132.61 (t, J = 10.3 Hz), 130.50, 128.96, 121.54, 
120.34 (q, J = 258.7 Hz), 118.60, 111.81 (dd, J = 21.0, 4.3 Hz), 104.93 (t, J = 19.4 Hz) ppm. 
IR (KBr) ν 3079, 2921, 2851, 1633, 1590, 1570, 1511, 1468, 1439, 1388, 1263, 1213, 1174 
cm-1. HRMS (ES+) calculated for C16H8Cl2F5N2O [M + H]+ 408.9934, found 408.9940. 
4-Chloro-1-(4-chlorophenyl)-5-(2,6-difluorophenyl)-1H-imidazole (3.115). Following 
synthetic procedure E using 1-(4-chlorophenyl)-5-(2,6-difluorophenyl)-1H-imidazole 
(0.400 g, 1.38 mmol), purification by silica gel column chromatography (hexanes/EtOAc 
85:15) afforded the title compound as a white solid (0.265 g, 0.815 mmol, 59% yield). 1H 
NMR (500 MHz, CDCl3) δ 7.69 (s, 1H), 7.41–7.35 (m, 1H), 7.33 (d, J = 8.0 Hz, 2H), 7.12–
7.05 (m, 2H), 6.91 (t, J = 7.9 Hz, 2H) ppm. 13C NMR (126 MHz, CDCl3) δ 160.67 (dd, J = 
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252.0, 5.9 Hz), 136.75, 134.89, 134.65, 132.40, 132.12 (t, J = 10.1 Hz), 129.91, 125.93, 
116.10, 111.88 (dd, J = 21.1, 4.3 Hz), 105.36 (t, J = 19.5 Hz) ppm. IR (KBr) ν 3128, 2917, 
2849, 1631, 1587, 1564, 1497, 1470, 1453, 1383, 1265, 1236, 1091, 998 cm-1. HRMS (ES+) 
calculated for C15H9Cl2F2N2 [M + H]+ 325.0111, found 325.0122. 
4-Chloro-1-(4-chlorophenyl)-5-(2,6-difluorophenyl)-2-methyl-1H-imidazole (3.116). 
Following synthetic procedure F using 4-chloro-1-(4-chlorophenyl)-5-(2,6-difluorophenyl)-
1H-imidazole (0.050 g, 0.154 mmol), purification by silica gel column chromatography 
(hexanes/EtOAc 80:20) afforded the title compound as a white solid (0.020 g, 0.059 mmol, 
38% yield). 1H NMR (500 MHz, CDCl3) δ 7.37–7.31 (m, 2H), 7.31–7.27 (m, 1H), 7.08 (d, J 
= 8.6 Hz, 2H), 6.89–6.82 (m, 2H), 2.31 (s, 3H) ppm. 13C NMR (126 MHz, CDCl3) δ 160.83 
(dd, J = 250.5, 6.9 Hz), 145.60, 135.23, 134.48, 131.79 (t, J = 10.1 Hz), 130.20, 129.75, 
128.37, 116.02, 111.63 (dd, J = 20.4, 4.8 Hz), 105.96 (t, J = 17.7 Hz), 14.13 ppm. IR (KBr) ν 
3064, 2960, 2921, 2850, 1634, 1576, 1494, 1467, 1402, 1278, 1238, 1093, 999 cm-1. HRMS 
(ES+) calculated for C16H11Cl2F2N2 [M + H]+ 339.0267, found 339.0265. 
4-Chloro-1-(4-chlorophenyl)-5-(2,6-difluorophenyl)-2-ethyl-1H-imidazole (3.117). 
Following synthetic procedure F using 4-chloro-1-(4-chlorophenyl)-5-(2,6-difluorophenyl)-
1H-imidazole (0.040 g, 0.123 mmol), purification by silica gel column chromatography 
(hexanes/EtOAc 85:15) afforded the title compound as a white solid (0.015 g, 0.042 mmol, 
35% yield). 1H NMR (500 MHz, CDCl3) δ 7.36–7.30 (m, 2H), 7.30–7.27 (m, 1H), 7.09 (d, J 
= 8.5 Hz, 2H), 6.87–6.81 (m, 2H), 2.58 (q, J = 7.5 Hz, 2H), 1.26 (t, J = 7.4 Hz, 3H) ppm. 13C 
NMR (126 MHz, CDCl3) δ 160.87 (dd, J = 251.5, 5.8 Hz), 150.43, 135.27, 134.34, 131.77 (t, 
J = 10.3 Hz), 130.33, 129.71, 128.59, 115.90, 111.61 (dd, J = 20.7, 5.4 Hz), 105.96 (t, J = 
20.3 Hz), 21.16, 12.21 ppm. IR (KBr) ν 3070, 2973, 2923, 2852, 1633, 1586, 1494, 1468, 
1411, 1276, 1238, 1092, 1001 cm-1. HRMS (ES+) calculated for C17H13Cl2F2N2 [M + H]+ 
353.0424, found 353.0429. 
2-Chloro-1-(4-chlorophenyl)-5-(2,6-difluorophenyl)-1H-imidazole (3.118). Following 
synthetic procedure E using 1-(4-chlorophenyl)-5-(2,6-difluorophenyl)-1H-imidazole 
(0.400 g, 1.38 mmol), purification by silica gel column chromatography (hexanes/EtOAc 
85:15) afforded the title compound as a white solid (0.056 g, 0.172 mmol, 12% yield). 1H 
NMR (500 MHz, CDCl3) δ 7.36–7.31 (m, 2H), 7.31–7.23 (m, 1H), 7.18 (s, 1H), 7.12 (d, J = 
8.2 Hz, 2H), 6.84 (t, J = 7.9 Hz, 2H) ppm. 13C NMR (126 MHz, CDCl3) δ 160.33 (dd, J = 
251.1, 5.8 Hz), 135.10, 134.03, 133.32, 131.24 (t, J = 10.3 Hz), 130.21, 129.27, 128.36, 
122.21, 111.39 (dd, J = 20.4, 4.8 Hz), 106.64 (t, J = 19.5 Hz) ppm. IR (KBr) ν 3098, 3063, 
2919, 2847, 1632, 1585, 1564, 1495, 1468, 1434, 1384, 1315, 1276, 1235, 1092, 1001 cm-1. 
HRMS (ES+) calculated for C15H8Cl2F2N2Na [M + Na]+ 346.9930, found 346.9933. 
2,4-Dichloro-1-(4-chlorophenyl)-5-(2,6-difluorophenyl)-1H-imidazole (3.119). Following 
synthetic procedure E using 1-(4-chlorophenyl)-5-(2,6-difluorophenyl)-1H-imidazole 
(0.400 g, 1.38 mmol), purification by silica gel column chromatography (hexanes/EtOAc 
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85:15) afforded the title compound as a white solid (0.026 g, 0.072 mmol, 5% yield). 1H 
NMR (500 MHz, CDCl3) δ 7.39–7.30 (m, 3H), 7.13 (d, J = 8.1 Hz, 2H), 6.88 (t, J = 8.0 Hz, 
2H) ppm. 13C NMR (126 MHz, CDCl3) δ 160.75 (dd, J = 252.3, 5.6 Hz), 135.94, 133.03, 
132.59, 132.54 (t, J = 10.2 Hz), 130.43, 129.75, 128.57, 118.55, 111.81 (dd, J = 21.2, 4.2 Hz), 
105.00 (t, J = 19.7 Hz) ppm. IR (KBr) ν 2961, 2918, 2850, 1632, 1589, 1568, 1495, 1468, 
1434, 1384, 1262, 1236, 1092, 1003 cm-1. HRMS (ES+) calculated for C15H8Cl3F2N2 [M + 
H]+ 358.9721, found 358.9725. 
4-Chloro-1-(4-(trifluoromethoxy)phenyl)-5-(2,3,6-trifluorophenyl)-1H-imidazole (3.120). 
Following synthetic procedure E using 1-(4-(trifluoromethoxy)phenyl)-5-(2,3,6-
trifluorophenyl)-1H-imidazole (0.500 g, 1.40 mmol), purification by silica gel column 
chromatography (hexanes/EtOAc 85:15) afforded the title compound as a yellow oil (0.198 g, 
0.504 mmol, 36% yield). 1H NMR (500 MHz, CDCl3) δ 7.72 (s, 1H), 7.25–7.17 (m, 5H), 
6.88–6.82 (m, 1H) ppm. 13C NMR (126 MHz, CDCl3) δ 155.78 (dt, J = 248.9, 3.1 Hz), 
149.38 – 149.32 (m), 148.35 (ddd, J = 253.2, 14.1, 6.8 Hz), 147.23 (ddd, J = 247.2, 12.8, 3.7 
Hz), 137.27, 134.21, 132.94, 126.29, 122.13, 120.36 (q, J = 258.7 Hz), 119.05 (dd, J = 19.2, 
9.6 Hz), 115.30, 111.35 (ddd, J = 24.2, 6.8, 4.2 Hz), 107.15 (dd, J = 21.7, 15.8 Hz) ppm. IR 
(KBr) ν 3095, 2918, 2850, 1568, 1513, 1493, 1467, 1383, 1162, 1110, 999 cm-1. HRMS (ES+) 
calculated for C16H7ClF6N2NaO [M + Na]+ 415.0049, found 415.0059. 
2-Chloro-1-(4-(trifluoromethoxy)phenyl)-5-(2,3,6-trifluorophenyl)-1H-imidazole (3.121). 
Following synthetic procedure E using 1-(4-(trifluoromethoxy)phenyl)-5-(2,3,6-
trifluorophenyl)-1H-imidazole (0.500 g, 1.40 mmol), purification by silica gel column 
chromatography (hexanes/EtOAc 85:15) afforded the title compound as a yellow solid 
(0.047 g, 0.120 mmol, 9% yield). 1H NMR (500 MHz, CDCl3) δ 7.29–7.24 (m, 5H), 7.16 (qd, 
J = 9.1, 5.0 Hz, 1H), 6.86–6.78 (m, 1H) ppm. 13C NMR (126 MHz, CDCl3) δ 155.69 (dt, J = 
248.0, 3.1 Hz), 149.67–149.59 (m), 148.28 (ddd, J = 252.4, 14.7, 5.9 Hz), 147.13 (ddd, J = 
246.5, 12.4, 3.6 Hz), 134.96, 133.11, 130.95, 128.93, 121.59, 121.52, 120.37 (q, J = 258.7 
Hz), 118.40 (dd, J = 19.2, 9.7 Hz), 111.10 (ddd, J = 24.3, 6.7, 4.1 Hz), 108.67 (dd, J = 21.8, 
15.9 Hz) ppm. IR (KBr) ν 3081, 2920, 1511, 1493, 1460, 1433, 1387, 1260, 1211, 1172, 
1113, 1018, 998 cm-1. HRMS (ES+) calculated for C16H8ClF6N2O [M + H]+ 393.0229, found 
393.0232. 
2,4-Dichloro-1-(4-(trifluoromethoxy)phenyl)-5-(2,3,6-trifluorophenyl)-1H-imidazole 
(3.122). Following synthetic procedure E using 1-(4-(trifluoromethoxy)phenyl)-5-(2,3,6-
trifluorophenyl)-1H-imidazole (0.500 g, 1.40 mmol), purification by silica gel column 
chromatography (hexanes/EtOAc 85:15) afforded the title compound as a yellow solid 
(0.010 g, 0.023 mmol, 2% yield). 1H NMR (600 MHz, DMSO-d6) δ 7.72 – 7.63 (m, 1H), 7.57 
(d, J = 8.8 Hz, 2H), 7.53 – 7.48 (m, 2H), 7.27 – 7.21 (m, 1H). ppm. 13C NMR (151 MHz, 
DMSO-d6) δ 155.16 (dt, J = 248.0, 3.1 Hz), 148.96 (q, J = 2.0 Hz), 147.29 (ddd, J = 252.1, 
14.5, 6.2 Hz), 146.31 (ddd, J = 244.4, 12.4, 4.1 Hz), 133.01, 132.51, 129.62, 129.15, 122.11, 
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120.66 (dd, J = 19.3, 9.7 Hz), 119.87 (q, J = 258.7 Hz), 119.55, 112.27 (ddd, J = 24.2, 7.6, 
4.4 Hz), 105.61 (dd, J = 22.5, 16.2 Hz) ppm. IR (KBr) ν 2919, 2850, 1642, 1383, 1247, 1179 
cm-1. HRMS (ES+) calculated for C16H7Cl2F6N2O [M + H]+ 426.9840, found 426.9850. 
4-Chloro-1-(4-chlorophenyl)-5-(2,6-difluoro-4-methylphenyl)-1H-imidazole (3.123). 
Following synthetic procedure E using 1-(4-chlorophenyl)-5-(2,6-difluoro-4-methylphenyl)-
1H-imidazole (0.100 g, 0.328 mmol), purification by silica gel column chromatography 
(hexanes/EtOAc 85:15) afforded the title compound as a yellow solid (0.070 g, 0.206 mmol, 
63% yield). 1H NMR (500 MHz, CDCl3) δ 7.67 (s, 1H), 7.35–7.29 (m, 2H), 7.11–7.05 (m, 
2H), 6.71 (d, J = 8.4 Hz, 2H), 2.35 (s, 3H) ppm. 13C NMR (126 MHz, CDCl3) δ 160.37 (dd, J 
= 251.2, 6.9 Hz), 143.68 (t, J = 9.9 Hz), 136.56, 134.77, 134.75, 132.25, 129.86, 125.96, 
116.31, 112.46 (dd, J = 20.3, 4.9 Hz), 102.16 (t, J = 19.8 Hz), 21.74 ppm. IR (KBr) ν 3064, 
2922, 1644, 1568, 1496, 1412, 1321, 1265, 1205, 1086, 1037 cm-1. HRMS (ES+) calculated 
for C16H11Cl2F2N2 [M + H]+ 339.0267, found 339.0259. 
2-Chloro-1-(4-chlorophenyl)-5-(2,6-difluoro-4-methylphenyl)-1H-imidazole (3.124). 
Following synthetic procedure E using 1-(4-chlorophenyl)-5-(2,6-difluoro-4-methylphenyl)-
1H-imidazole (0.100 g, 0.328 mmol), purification by silica gel column chromatography 
(hexanes/EtOAc 85:15) afforded the title compound as a yellow solid (0.009 g, 0.026 mmol, 
8% yield). 1H NMR (500 MHz, CDCl3) δ 7.38–7.31 (m, 2H), 7.18–7.10 (m, 3H), 6.65 (d, J = 
8.5 Hz, 2H), 2.31 (s, 3H) ppm. 13C NMR (126 MHz, CDCl3) δ 160.30 (dd, J = 250.0, 6.7 Hz), 
143.00 (t, J = 9.9 Hz), 135.27, 134.04, 133.66, 130.31, 129.52, 128.68, 122.73, 112.24 (dd, J 
= 21.0, 4.4 Hz), 103.73 (t, J = 19.4 Hz), 21.68 ppm. IR (KBr) ν 2918, 2850, 1644, 1494, 
1440, 1383, 1315, 1205, 1094, 1039 cm-1. HRMS (ES+) calculated for C16H11Cl2F2N2 [M + 
H]+ 339.0267, found 339.0263. 
2,4-Dichloro-1-(4-chlorophenyl)-5-(2,6-difluoro-4-methylphenyl)-1H-imidazole (3.125). 
Following synthetic procedure E using 1-(4-chlorophenyl)-5-(2,6-difluoro-4-methylphenyl)-
1H-imidazole (0.100 g, 0.328 mmol), purification by silica gel column chromatography 
(hexanes/EtOAc 85:15) afforded the title compound as a yellow solid (0.024 g, 0.064 mmol, 
20% yield). 1H NMR (500 MHz, CDCl3) δ 7.35 (d, J = 8.3 Hz, 2H), 7.12 (d, J = 8.3 Hz, 2H), 
6.68 (d, J = 8.5 Hz, 2H), 2.33 (s, 3H) ppm. 13C NMR (126 MHz, CDCl3) δ 160.45 (dd, J = 
251.3, 6.7 Hz), 144.17 (t, J = 9.9 Hz), 135.85, 133.15, 132.32, 130.31, 129.72, 128.61, 
118.80, 112.40 (dd, J = 20.2, 4.1 Hz), 101.84 (t, J = 20.0 Hz), 21.79 ppm. IR (KBr) ν 3065, 
2924, 2853, 1645, 1573, 1493, 1436, 1385, 1324, 1263, 1237, 1206, 1093, 1040 cm-1. HRMS 
(ES+) calculated for C16H10Cl3F2N2 [M + H]+ 372.9878, found 372.9869. 
4-Chloro-1-(4-chlorophenyl)-5-(2,6-difluoro-3-methoxyphenyl)-1H-imidazole (3.126). 
Following synthetic procedure E using 1-(4-chlorophenyl)-5-(2,6-difluoro-3-methoxyphenyl)-
1H-imidazole (0.132 g, 0.412 mmol), purification by silica gel column chromatography 
(hexanes/EtOAc 80:20) afforded the title compound as white foam (0.065 g, 0.183 mmol, 
45% yield). 1H NMR (500 MHz, CDCl3) δ 7.67 (s, 1H), 7.32 (d, J = 8.7 Hz, 2H), 7.09 (d, J = 
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8.3 Hz, 2H), 6.96 (td, J = 9.2, 5.0 Hz, 1H), 6.85–6.77 (m, 1H), 3.83 (s, 3H) ppm. 13C NMR 
(126 MHz, CDCl3) δ 153.82 (dd, J = 244.9, 3.7 Hz), 149.93 (dd, J = 251.9, 5.9 Hz), 144.49 
(dd, J = 10.6, 2.7 Hz), 136.77, 134.84, 134.59, 132.37, 129.88, 125.92, 116.10, 114.96 (dd, J 
= 9.5, 2.1 Hz), 110.52 (dd, J = 22.6, 4.3 Hz), 106.13 (dd, J = 21.1, 16.7 Hz), 56.81 ppm. IR 
(KBr) ν 3097, 2925, 2843, 1591, 1563, 1495, 1463, 1440, 1328, 1257, 1203, 1094, 1070 cm-1. 
HRMS (ES+) calculated for C16H11Cl2F2N2O [M + H]+ 355.0217, found 355.0203. 
2-Chloro-1-(4-chlorophenyl)-5-(2,6-difluoro-3-methoxyphenyl)-1H-imidazole (3.127). 
Following synthetic procedure E using 1-(4-chlorophenyl)-5-(2,6-difluoro-3-methoxyphenyl)-
1H-imidazole (0.132 g, 0.412 mmol), purification by silica gel column chromatography 
(hexanes/EtOAc 80:20) afforded the title compound as a yellow solid (0.015 g, 0.042 mmol, 
10% yield). 1H NMR (500 MHz, CDCl3) δ 7.38–7.31 (m, 2H), 7.18 (s, 1H), 7.16–7.11 (m, 
2H), 6.88 (td, J = 9.1, 5.0 Hz, 1H), 6.80–6.72 (m, 1H), 3.82 (s, 3H) ppm. 13C NMR 
(126 MHz, CDCl3) δ 153.85 (dd, J = 243.6, 4.2 Hz), 149.92 (dd, J = 250.9, 5.9 Hz), 144.38 
(dd, J = 11.0, 3.4 Hz), 135.36, 134.38, 133.55, 130.48, 129.57, 128.66, 122.51, 114.40 (dd, J 
= 9.5, 3.2 Hz), 110.34 (dd, J = 23.3, 4.4 Hz), 107.70 (dd, J = 21.2, 16.9 Hz), 56.84 ppm. IR 
(KBr) ν 3096, 2923, 2849, 1590, 1493, 1459, 1438, 1383, 1318, 1244, 1175, 1123, 1093, 
1058 cm-1. HRMS (ES+) calculated for C16H11Cl2F2N2O [M + H]+ 355.0217, found 355.0219. 
2,4-Dichloro-1-(4-chlorophenyl)-5-(2,6-difluoro-3-methoxyphenyl)-1H-imidazole (3.128). 
Following synthetic procedure E using 1-(4-chlorophenyl)-5-(2,6-difluoro-3-methoxyphenyl)-
1H-imidazole (0.132 g, 0.412 mmol), purification by silica gel column chromatography 
(hexanes/EtOAc 80:20) afforded the title compound as a yellow solid (0.009 g, 0.023 mmol, 
6% yield). 1H NMR (500 MHz, CDCl3) δ 7.37 – 7.34 (m, 2H), 7.15 – 7.12 (m, 2H), 6.94 (td, J 
= 9.2, 5.0 Hz, 1H), 6.81– 6.77 (m, 1H), 3.83 (s, 3H) ppm. 13C NMR (126 MHz, CDCl3) δ 
153.94 (dd, J = 244.9, 4.0 Hz), 150.12 (dd, J = 252.5, 5.6 Hz), 144.45 (dd, J = 10.6, 3.4 Hz), 
135.95, 133.06, 132.65, 130.49, 129.78, 128.61, 118.59, 115.43 (dd, J = 9.8, 3.0 Hz), 110.51 
(dd, J = 22.8, 4.3 Hz), 105.84 (dd, J = 21.4, 16.8 Hz), 56.88 ppm. IR (KBr) ν 2921, 2850, 
1639, 1494, 1440, 1384, 1331, 1251, 1090 cm-1. HRMS (ES+) calculated for C16H10Cl3F2N2O 
[M + H]+ 388.9827, found 388.9832. 
4-Chloro-1-(4-chlorophenyl)-5-phenyl-1H-imidazole (3.129). Following synthetic 
procedure E using 1-(4-chlorophenyl)-5-phenyl-1H-imidazole (0.070 g, 0.275 mmol), 
purification by silica gel column chromatography (hexanes/EtOAc 80:20) afforded the title 
compound as a yellow solid (0.061 g, 0.211 mmol, 77% yield). X-ray quality crystals were 
obtained by slow evaporation from a CH2Cl2/hexanes solution (see Supporting Information): 
mp (CH2Cl2/hexanes) 126–128˚C. 1H NMR (500 MHz, CDCl3) δ 7.58 (s, 1H), 7.36–7.29 (m, 
5H), 7.22–7.16 (m, 2H), 7.09–7.02 (m, 2H) ppm. 13C NMR (126 MHz, CDCl3) δ 135.72, 
134.91, 134.49, 129.89, 129.75, 129.24, 128.62, 128.44, 127.28, 127.09, 126.61 ppm. IR 
(KBr) ν 3121, 3096, 3034, 2917, 2849, 1607, 1558, 1497, 1483, 1467, 1413, 1329, 1259, 
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1199, 1090 cm-1. HRMS (ES+) calculated for C15H11Cl2N2 [M + H]+ 289.0299, found 
289.0300. 
2-Chloro-1-(4-chlorophenyl)-5-phenyl-1H-imidazole (3.130). Following synthetic 
procedure E using 1-(4-chlorophenyl)-5-phenyl-1H-imidazole (0.070 g, 0.275 mmol), 
purification by silica gel column chromatography (hexanes/EtOAc 80:20) afforded the title 
compound as a yellow solid (0.007 g, 0.025 mmol, 9% yield). 1H NMR (500 MHz, CDCl3) δ 
7.45–7.38 (m, 2H), 7.27–7.22 (m, 3H), 7.20–7.12 (m, 3H), 7.10–7.03 (m, 2H) ppm. 13C NMR 
(126 MHz, CDCl3) δ 135.32, 134.09, 133.77, 129.85, 129.37, 128.95, 128.76, 128.12, 127.94, 
127.21, 125.13 ppm. IR (KBr) ν 2956, 2918, 2850, 1487, 1457, 1432, 1383, 1307, 1256, 
1146, 1146, 1093 cm-1. HRMS (ES+) calculated for C15H11Cl2N2 [M + H]+ 289.0299, found 
289.0324. 
2,4-Dichloro-1-(4-chlorophenyl)-5-phenyl-1H-imidazole (3.131). Following synthetic 
procedure E using 1-(4-chlorophenyl)-5-phenyl-1H-imidazole (0.070 g, 0.275 mmol), 
purification by silica gel column chromatography (hexanes/EtOAc 80:20) afforded the title 
compound as a yellow solid (0.008 g, 0.024 mmol, 9% yield). 1H NMR (500 MHz, CDCl3) δ 
7.40–7.36 (m, 2H), 7.30–7.27 (m, 3H), 7.16–7.12 (m, 2H), 7.12–7.08 (m, 2H) ppm. 13C NMR 
(126 MHz, CDCl3) δ 135.64, 133.57, 131.34, 129.89, 129.59, 129.21, 128.71, 128.65, 127.20, 
127.05 ppm. IR (KBr) ν 2956, 2917, 2849, 1493, 1452, 1381, 1230, 1091 cm-1. HRMS (ES+) 
calculated for C15H10Cl3N2 [M + H]+ 322.9910, found 322.9906. 
4-Chloro-1-(4-chlorophenyl)-5-(4-methoxyphenyl)-1H-imidazole (3.132). Following 
synthetic procedure E using 1-(4-chlorophenyl)-5-(4-methoxyphenyl)-1H-imidazole (0.220 g, 
0.773 mmol), purification by silica gel column chromatography (hexanes/EtOAc 80:20) 
afforded the title compound as a yellow solid (0.159 g, 0.498 mmol, 65% yield). 1H NMR 
(500 MHz, CDCl3) δ 7.55 (s, 1H), 7.36–7.31 (m, 2H), 7.11 (d, J = 8.1 Hz, 2H), 7.06 (d, J = 
7.9 Hz, 2H), 6.84 (d, J = 8.3 Hz, 2H), 3.79 (s, 3H) ppm. 13C NMR (126 MHz, CDCl3) δ 
159.66, 135.29, 135.02, 134.43, 131.15, 129.87, 128.71, 127.05, 126.64, 119.49, 114.17, 
55.36 ppm. IR (KBr) ν 3116, 3004, 2960, 2836, 1713, 1614, 1556, 1497, 1467, 1290, 1253, 
1179, 1087 cm-1. HRMS (ES+) calculated for C16H12Cl2N2NaO [M + Na]+ 341.0224, found 
341.0229. 
4-Chloro-1-(2-chlorophenyl)-5-(2,6-difluorophenyl)-1H-imidazole (3.133). Following 
synthetic procedure E using 1-(2-chlorophenyl)-5-(2,6-difluorophenyl)-1H-imidazole 
(0.260 g, 0.894 mmol), purification by silica gel column chromatography (hexanes/EtOAc 
75:25) afforded the title compound as a white solid (0.187 g, 0.575 mmol, 64% yield). 1H 
NMR (500 MHz, CDCl3) δ 7.63 (s, 1H), 7.42 (d, J = 7.9 Hz, 1H), 7.36–7.29 (m, 2H), 7.29–
7.26 (m, 2H), 6.85 (t, J = 8.6 Hz, 2H) ppm. 13C NMR (126 MHz, CDCl3) δ 160.77 (dd, J = 
252.5, 5.9 Hz), 137.58, 133.55, 131.88 (t, J = 10.2 Hz), 131.70, 131.67, 130.73, 130.61, 
129.10, 127.60, 117.02, 111.64 (dd, J = 21.8, 3.6 Hz), 105.35 (t, J = 19.5 Hz) ppm. IR (KBr) 
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ν 3129, 3052, 2988, 2922, 2846, 1633, 1589, 1568, 1492, 1471, 1455, 1266, 1238, 1003 cm-1. 
HRMS (ES+) calculated for C15H9Cl2F2N2 [M + H]+ 325.0111, found 325.0111. 
2-Chloro-1-(2-chlorophenyl)-5-(2,6-difluorophenyl)-1H-imidazole (3.134). Following 
synthetic procedure E using 1-(2-chlorophenyl)-5-(2,6-difluorophenyl)-1H-imidazole 
(0.260 g, 0.894 mmol), purification by silica gel column chromatography (hexanes/EtOAc 
75:25) afforded the title compound as a white solid (0.026 g, 0.080 mmol, 9% yield). 1H 
NMR (500 MHz, CDCl3) δ 7.40 (d, J = 8.0 Hz, 1H), 7.36–7.27 (m, 3H), 7.25–7.16 (m, 2H), 
6.79 (t, J = 7.7 Hz, 2H) ppm. 13C NMR (126 MHz, CDCl3) δ 160.72 (dd, J = 251.5, 5.8 Hz), 
134.75, 133.21, 132.81, 131.34 (t, J = 10.2 Hz), 131.06, 130.51, 130.44, 130.32, 127.44, 
122.84, 111.53 (dd, J = 20.6, 5.1 Hz), 106.87 (t, J = 19.5 Hz) ppm. IR (KBr) ν 2916, 2852, 
1633, 1587, 1487, 1468, 1435, 1383, 1313, 1277, 1235, 1000 cm-1. HRMS (ES+) calculated 
for C15H9Cl2F2N2 [M + H]+ 325.0111, found 325.0119. 
2,4-Dichloro-1-(2-chlorophenyl)-5-(2,6-difluorophenyl)-1H-imidazole (3.135). Following 
synthetic procedure E using 4-chloro-1-(2-chlorophenyl)-5-(2,6-difluorophenyl)-1H-
imidazole (0.060 g, 0.184 mmol), purification by silica gel column chromatography 
(hexanes/EtOAc 80:20) afforded the title compound as a white solid (0.047 g, 0.131 mmol, 
71% yield). 1H NMR (500 MHz, CDCl3) δ 7.44 (d, J = 7.9 Hz, 1H), 7.40–7.27 (m, 4H), 6.88 
(t, J = 8.5 Hz, 1H), 6.82 (t, J = 8.6 Hz, 1H) ppm. 13C NMR (126 MHz, CDCl3) δ 161.07 (dd, J 
= 254.4, 5.9 Hz), 133.11, 133.08, 132.37 (t, J = 11.2 Hz), 131.53, 130.56, 130.39, 130.24, 
130.22, 127.62, 118.89, 111.95 (dd, J = 21.7, 3.5 Hz), 111.41 (dd, J = 21.8, 3.7 Hz), 104.92 
(t, J = 19.8 Hz) ppm. IR (KBr) ν 3073, 2918, 2853, 1633, 1588, 1487, 1466, 1439, 1384, 
1278, 1237, 1002 cm-1. HRMS (ES+) calculated for C15H8Cl3F2N2 [M + H]+ 358.9721, found 
358.9717. 
 
3.6.2 Biological Assay 
Acetyl-Tubulin Assay. QBI-293 cells (ATCC, Manassas, VA, USA) were maintained in 
Dulbecco’s Modified Eagle’s Medium (DMEM, Mediatech Inc., Manassas, VA, USA) 
containing 10% fetal bovine serum (FBS) (Atlanta Biologicals, Lawrenceville, GA, USA), 2 
mM L-glutamine (Mediatech), 50 units/mL penicillin, and 50 µg/mL streptomycin (1% 
penicillin/streptomycin; Thermo Fisher Scientific, Waltham, MA, USA). Cells were 
maintained at 37 °C in a humidified atmosphere (5% CO2) for all experiments. For compound 
testing, cells were dissociated with trypsin/EDTA (Thermo Fisher Scientific) and plated at 6 × 
105 cells/well in 6-well plates. The medium was aspirated after overnight incubation and fresh 
medium containing vehicle or test compound was added. After incubating for 4 h, cells were 
washed once with 1× phosphate-buffered saline (PBS), pH 7.4 and then lysed in 200 µL RIPA 
buffer containing protease inhibitor cocktail, 1 mM PMSF, and 1 µM TSA. Lysed cells were 
scraped into 1.5 mL Beckman ultracentrifuge tubes (Beckman, Brea, CA, USA) and 
centrifuged at 100000g for 30 min at 4 °C. Following centrifugation, the supernatant from 
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each sample was collected and analyzed for protein content by BCA assay. The samples 
subsequently underwent analysis for acetyl-tubulin and α-tubulin levels by ELISA, as 
previously described.115 
RBL-1 Cell PG and LT Assay. Inhibition of PG and LT synthesis by test compounds was 
determined through the utilization of an established RBL-1 cell assay.116 Briefly, RBL-1 cells 
(ATCC) were maintained in RPMI 1640 medium (Mediatech Inc., Manassas, VA) containing 
10% FBS (Atlanta Biologicals, Lawrenceville, GA), 1 mM L-glutamine (Mediatech), 50 
U/mL penicillin, and 0.05 mg/mL streptomycin (Thermo Fisher Scientific). For analysis of 
PG and LT production, RBL-1 cells were plated at a density of 9 × 105 cells/well in 24-well 
plates. After 2 h incubation at 37 °C, cells were added with indicated concentrations of test 
compounds. Following 2 h incubation with test compounds, cells were incubated with 12 µM 
calcium ionophore, A23187, for 15 min to induce arachidonic acid production. Cell culture 
supernatants (200 µL/well) were then collected and treated with 600 µL of MeOH containing 
0.01% BHT (butylated hydroxytoluene) to extract eicosanoids. After centrifugation, the 
supernatant was dried with a vacuum centrifugation and redissolved in 200 µL of 50% 
acetonitrile. Enzyme products were quantified with an Acquity UPLC-TQ MS system 
(Waters Corporation, Milford, MA). Injections (10 µL) were separated on an Acquity BEH 
C18, 1.7 µm, 2.1 mm × 50 mm column at 37 °C using a gradient from 5 to 95% acetonitrile 
with 10 mM ammonium formate over 2 min at 0.6 mL/min. Combined PGD2+PGE2, as well 
as LTB4, were detected in negative ion mode using compound specific collision induced mass 
transitions (PGD2 and PGE2, 351 > 315; LTB4, 335 > 195). To separate the isomeric PGD2 
and PGE2, a higher resolution gradient from 5 to 60% acetonitrile over 3 min at 0.6 mL/min 
was used. The cysteinyl leukotriene LTC4 was separated using a gradient from 5 to 95% 
acetonitrile with 0.1% formic acid over 2 min at 0.6 mL/min. LTC4 was detected using 
electrospray ionization in positive mode while monitoring for a compound specific mass 
transition (626 > 189). Chromatograms are integrated and peak areas used to quantitate 
unknowns against a curve of standards (Cayman Chemical, Ann Arbor, MI) from 1 to 50 
ng/mL in 50% acetonitrile. The IC50 values and 95% confidence intervals of compound 
concentration-response curves were determined in GraphPad Prism from triplicate samples at 
each concentration using a sigmoidal fit allowing for variable slope. 
Brain and Plasma Compound Determinations. All animal protocols were approved by the 
University of Pennsylvania Institutional Animal Care and Use Committee (IACUC). Test 
compounds were administered to groups of three 2−5 month old CD-1 or B6SJL mice, with 
both female and male mice used but not mixed within experimental groups. For standard 
single time-point brain and plasma determinations, mice were injected i.p. with a single dose 
of 5 mg/kg compound dissolved in DMSO, or a dose of 2 mg/kg if two or three compounds 
were dosed concurrently (cassette dosing). Compounds were quantified in plasma and brain 
homogenates as previously described.115  
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Chapter 4: CNS-Active Microtubule-Stabilizing Agents as Potential 
Leads for Human African Trypanosomiasis and Other Neuroparasitic 
Infections 
4.1 Introduction 
4.1.1 Human African Trypanosomiasis 
Human African trypanosomiasis (HAT), also known as sleeping sickness, is a debilitating 
and deadly vector-borne parasitic disease caused by protozoans hemoflagellates of the genus 
Trypanosoma that are transmitted to humans by Tsetse flies (Glossina genus).1−4 The three 
principal trypanosome species are Trypanosoma vivax and Trypanosoma congolense, which 
infect livestock causing annual losses in excess of US$ 4.5 billion,5 and Trypanosoma brucei. 
T. brucei has three sub-species: T. b. gambiense and T. b. rhodesiense infect humans, whereas 
T. b. brucei infects domestic and wild animals.3,6−8 T. b. rhodesiense is found in 13 countries 
in eastern and southern Africa, with approximately 12.3 million people at risk of contracting 
the infection, mainly in Uganda, Tanzania and Kenya,9 whereas T. b. gambiense is found in 
24 countries in western and central Africa, where it threatens approximately 57 million people 
with the Democratic Republic of the Congo carrying the greatest risk at 36 million.9,10  
HAT clinically evolves in two stages (Figure 4.1). In the first stage (Stage 1 or 
haemo−lymphatic stage), trypanosomes replicate at the tsetse fly bite site before 
disseminating from the skin through the hemolymphatic system where they replicate in 
subcutaneous tissues, blood and lymph.3,11 After a variable period, trypanosomes cross the 
blood-brain barrier (BBB) arriving at the central nervous system (CNS) and causing 
progressive neurological damage (Stage 2 or meningo−encephalitic stage).3,11   
The disease caused by T. b. rhodesiense, known as rhodesiense HAT (rHAT), usually 
follows a more acute clinical progression than the T. b. gambiense disease (gHAT). First signs 
and symptoms of rHAT are usually observed a few months or weeks after infection, with 
parasites rapidly arriving at the CNS. In the case of gHAT, a person can be infected for 
months or even years without major signs or symptoms of the disease. When more evident 
symptoms emerge, the patient is often already in an advanced disease stage where the CNS is 
affected. However, both forms generate symptoms that include changes of behaviour, 
confusion, psychosis, tremor and ataxia.12,13 Disturbance of the sleep cycle is an important 
feature of Stage 2 and it can proceed until convulsions, coma and death, which is inevitable if 
the infection is left untreated or is inadequately treated.12−14 
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Figure 4.1. Schematic representation of the human infection by trypanosomes.15 
 
4.1.2 Current Drug Treatment 
In the absence of a vaccine, the type of treatment depends on the disease stage. Drugs that 
are used to treat the Stage 1 are safier and easier to administer than those used for Stage 2. 
Indeed, treatment success of Stage 2 relies on drugs that cross the BBB to reach the parasite. 
Such drugs are toxic and require supervised parenteral administration regimens of days or 
weeks.13 
The aromatic diamidine, pentamidine (4.1, Figure 4.2), is used for the treatment of Stage 1 
gHAT, whereas suramin (4.2, Figure 4.2), a polysulfonated naphthylamine derivative of urea, 
is employed for Stage 1 rHAT. For Stage 2 gHAT, the regimen of choice is a combination of 
the injectable nitrofuran, nifurtimox (4.3, Figure 4.2), with the oral ornithine decarboxylase 
inhibitor, eflornithine (4.4, Figure 4.2). For Stage 2 rHAT, therapy relies on the trivalent 
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arsenical, melarsoprol (4.5, Figure 4.2), which has many undesirable side effects, the most 
dramatic of which is reactive encephalopathy that can be fatal (3−10%).13,16,17 Cross-
resistance to pentamidine and melarsoprol is well known18,19 and treatment failures with 
suramin have also been recorded.20 Two drug candidates, the oxaborole, SCYX-7158 (4.6, 
Figure 4.2), and the nitroimidazole, fexinidazole (4.7, Figure 4.2), are currently in phase I and 
III clinical trials, respectively.21 Although this is encouraging progress, the focus for 
fexinidazole has been on gHAT treatment, without primary evidence of efficacy to treat 
rHAT. Accordingly, there is an urgent need for new safer and effective treatments, especially 
for Stage 2 of gHAT and ideally also rHAT. 
 
 
Figure 4.2. Current drug treatment for HAT. 
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4.1.3 The Life Cycle of African Trypanosomes  
Three major environments characterize the African trypanosome’s life cycle: mammalian 
host blood stream, tsetse mid-gut, and tsetse salivary glands (Figure 4.3).22 In these 
transitions, parasites undergo four developmental stages: the non-infective procyclic and 
epimastigote forms in the tsetse fly, the long slender bloodstream form, and the short stumpy 
form in the mammalian host. 
Infection of a mammalian host begins with the formation of a trypanosome-chancre in the 
site of the fly’s bite that appears after a minimum of about five days and is generally 
accompanied by regional lymphadenopathy, from which growth-arrested metacyclic 
trypomastigotes enter the mammalian bloodstream and diffuse through other body tissues.23 
Metacyclic trypomastigotes then differentiate into proliferating long slender forms that 
establish and maintain the bloodstream infection (Figure 4.3). Parasites eventually penetrate 
the blood vessel endothelium and invade extravascular tissues, including the CNS. In the 
bloodstream, long slender forms differentiate into short stumpy forms that do not multiply 
and exhibit several pre-adaptations for survival in the next environment in the tsetse fly. 
When an infected host is bitten by a tsetse fly, parasites are taken up with the blood meal into 
the midgut, where short stumpy forms turn into procyclic trypomastigotes that resume cell 
division and establish a midgut infection (Figure 4.3). Midgut procyclic trypomastigotes then 
migrate through the peritrophic matrix, along the foregut to the proventriculus, and from there 
onwards through the mouthparts, salivary ducts and ultimately into the salivary gland, where 
they attach to the salivary gland epithelium. In the proventriculus, procyclic trypomastigotes 
undergo one more developmental stage to generate one long epimastigote and one short 
epimastigote. The short epimastigote forms use their flagella for attachment to surfaces in the 
salivary gland. Attached epimastigotes replicate and ultimately complete the life cycle via an 
asymmetric division to generate metacyclic trypomastigotes that are free in the salivary gland 
lumen and uniquely adapted to survive in the mammalian host. Indeed, trypanosomes rely on 
antigenic variation of their surface coat for survival. This coat is mainly composed of a single 
protein species, the variant surface glycoprotein (VSG), which is made in sufficient quantity 
to form a dense, homogeneous protective barrier that covers the entire trypanosome surface. 
The VSG glycoprotein is repeatedly changed in a fraction of the population, thus protecting 
parasites from the attack of the hosts’s immune system on the outer membrane constituents. 
Accordingly, on entering the cell cycle, trypanosomes start to express the bloodstream VSG 
coat and adopt a slender morphology.22 While in their hosts, they continue to express the 
metacylic VSGs for as long as seven days and then switch to the expression of non-
metacyclic, bloodstream VSGs.24 Avoiding destruction by antibody-mediated killing, 
trypanosomes can repopulate the host, resulting in a a long-lasting chronic infection.25,26 
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Figure 4.3. Stages of life cycle of trypanosomes.27 
 
4.1.4 Microtubules in Trypanosomes 
The cytoskeleton of trypanosomes plays essential roles in the parasites’s life cycle, as the 
parasites must migrate between different tissues in the mammalian host. Thus, the 
cytoskeleton is particularly important for development and maintenance of cell shape, 
motility, cell division, and attachment to host cell surfaces. 
Microtubules (MTs) are major structural components of the cytoskeleton of trypanosomes, 
together with the axoneme, the basal body, the paraflagellar rod (PFR), and the attached 
flagellum. MTs in trypanosomes are generally distinguished in four structurally different 
classes: subpellicular, flagellar, cytoplasmic, and mitotic.22 
Subsurface MTs are important to support and maintain cell form and shape, whereas the 
subpellicular MTs form a unique corset-like structure lying right underneath the plasma 
membrane. This structure is not found in mammalian cells and, in trypanosomes, it has been 
attributed to the subpellicular MT-associated proteins (MAPs) that cross-link tubulin 
polymers and connect the MT network to the plasma membrane (Figure 4.4).28 Subpellicular 
MTs have a defined polarity with the fast-growing plus ends orientated towards the posterior 
of the cell.22 
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Flagellar MTs play a pivotal role in trypanosomes locomotion, which is an essential 
function for parasites to survive. African trypanosomes possess a flagellum that protrudes 
from the cell at the flagellar pocket area and it is attached to the cell body along its length 
(Figure 4.4). In trypanosomes, the flagellar pocket is the only site of entry for external 
macromolecules. Receptors for macromolecules, such as transferrin and lipoproteins from the 
surrounding plasma, escape the host’s immune response by being located in the flagellar 
pocket. The flagellum has a typical 9 + 2 MT axoneme (Figure 4.5) in association with a PFR 
that is a large, highly organized structure mainly composed of two proteins with molecular 
mass of 68,000 and 72,000 Da, respectively (Figure 4.5). The PFR runs alongside the 
axoneme starting at the level where the flagellum emerges from the cell body (Figure 4.4).22,26 
The flagellar attachment zone (FAZ) is the region where the flagellum and cell body meet 
(Figure 4.5) and it is composed of specialized MTs, together with a complex, non-MT 
filament.22 
The cytoplasmic MTs in trypanosomes originate from the posterior end of the cell, close to 
the basal bodies in the flagellar pocket, and run around the flagellar pocket. They possess 
structural and biochemical functions, as they are closely associated with a smooth membrane 
vesicle that makes them resistant to high salt treatments that depolymerize the other MTs of 
the subpellicular array.22,26 
Finally, mitotic MTs are crucial for trypanosomes cell division and replication. The cell 
division cycle of trypanosomes follows the typical eukaryotic cell cycle regulatory sequence, 
although it also possesses several unique features. A Trypanosoma cell contains a number of 
single-copy organelles and cytoskeletal structures, such as the nucleus, mitochondrion, 
kinetoplast (mitochondrial DNA network), basal body, Golgi apparatus, and flagellum, all of 
which need to be accurately duplicated and segregated prior to cell division (Figure 4.4). 
Therefore, well-regulated organelle segregation is crucial for a correct cell division, which 
occurs longitudinally from the anterior toward the posterior end of the cell.29 
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Figure 4.4. Schematic representation of Trypanosoma morphology.30 
 
 
Figure 4.5. The trypanosome flagellum. (A) Scanning electron micrograph (EM) of a 
procyclic trypanosome. (B) Transmission EM of a cross-section of the flagellum and its 
attachment to the cell body. (C) Schematic representation of the flagellar MT axoneme. DRC, 
dynein regulatory complex; IFT = intraflagellar transport; FAZ = flagellar attachment zone.31 
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4.1.5 Tubulin in Trypanosomes 
The α- and β-tubulins of flagellar and cytoskeletal MTs in unicellular parasites share 
~85−95% amino-acid sequence identity with their mammalian counterparts. As with most 
tubulins, the α-tubulin gene of trypanosomes codes for a C-terminal tyrosine residue, but 
surprisingly, the β-tubulin gene also codes for a C-terminal tyrosine. This has not been found 
in any other cell or tissue.26,32 
The assembly and stability of MTs are favorited by a number of molecules that bind to 
tubulins, such as guanine nucleotides, Mg2+, Ca2+ and MAPs. In contrast, tubulin-binding 
anti-mitotic agents, such as colchicine and benzimidazoles, destabilize and prevent MT 
assembly.33 
In trypanosomes, both α- and β-tubulins undergo post-translational modifications (PTMs). 
Acetylation occurs at lysine 40 of α-tubulin, which in this acetylated form is found in both the 
subpellicular and the axonemal MTs. Acetylation occurs with assembly of axonemal MTs, 
and the modification can be reversed upon MT disassembly.22 Detyrosination of α-tubulin 
occurs after MT assembly, and tyrosinated α-tubulin acts as a molecular marker for new 
MTs.26 β-Tubulin can also be detyrosinated, and both tyrosinated and detyrosinated α- and β-
tubulins are extensively glutamylated. Polyglutamylation adds a number of negative charges 
to the already very acidic carboxyl termini of the tubulins.22,26 
In addition to the α- and β-tubulins there are several isoforms that are expressed at much 
reduced levels and that show special localizations.26 γ-Tubulin is generally associated with 
basal bodies and spindle poles and its assembly with a group of other proteins forms the γ-
TuRCs, which constitute key components of the MT-organizing center (MTOC) and promote 
MT assembly. Trypanosomes also contain three other tubulin forms: δ, ε and ζ, but their 
functions remain to be elucidated.22 
 
4.2 Objective of the Study  
The cytoskeleton of trypanosomes, and tubulin in particular, has long been considered a 
drug target.32,34 Over the past several years, inhibitors of tubulin polymerization have been 
evaluated as novel anti-parasitics,34−37 and, interestingly, trypanosome and mammalian 
tubulins were found to exhibit different reactivities in the colchicine binding site to these type 
of compounds.35 However, in spite of generally promising in vitro activity with such 
therapeutic candidates, they were not pursued due to a rapid metabolism/elimination.38 
Furthermore, there are no data about brain penetration and metabolic stability, and there is 
only one demonstration of in vivo efficacy against T. brucei Lister 427 in a mouse model of 
Stage 1 infection.37 In contrast, tubulin polymerization promoters, such as MT-stabilizing 
agents, have not been investigated. Thus, we reason that promoters of tubulin polymerization 
should also be explored as potential candidates.  
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As previously described in section 3.1.4, the evaluation and development of MT-
stabilizing agents for CNS-indications such as brain tumor39 and neurodegenerative diseases40 
have been challenging due to issues of insufficient brain penetration. This situation changed 
with the discovery that selected MT-stabilizing natural products, such as epothilone D,41 as 
well as synthetic heterocyclic molecules,42,43 including several triazolopyrimidines (TPDs), 
phenylpyrimidines (PPDs) and related congeners, can readily access the brain of mice. 
Interestingly, competitive binding studies using radioactive [3H]-labeled vinblastine, 
colchicine and paclitaxel showed that these TPDs and related congeners do not effectively 
inhibit the binding of colchicine or paclitaxel. Instead, somewhat surprisingly, these agents 
were found to inhibit the binding of the tubulin polymerization inhibitor, vinblastine.44 Until 
recently, it was not clear, however, whether the observed competition with [3H]-vinblastine 
results from overlapping binding sites or a distinct allosteric site. Either way, these findings 
suggested that the mechanism of action of these molecules is completely distinct from other 
known MT-stabilizing compounds. Recent studies from Díaz and coworkers45 revealed the 
innovative molecular mode of action of this class of compounds: instead of stabilizing lateral 
contacts between tubulin subunits in MTs, as tubulin polymerization promoters typically do, 
these compounds stabilize longitudinal contacts by binding to the vinca-site that is normally 
targeted by classical MT-destabilizing agents, such as vinblastine and eribulin. 
Over the years, as part of ongoing studies in the context of Alzheimer’s disease an related 
neurodegenerative tauopathies, Dr. Ballatore and coworkers worked on the development and 
evaluation of structurally related non-naturally occurring small molecules as CNS-active MT-
stabilizing agents.42,43,46 Using a library of more than two-hundred synthetic molecules, their 
studies noted that MT-stabilizing agents can be divided into two general classes. One group, 
that is usually referred to as “phenotype I compounds”, increase markers of stable MTs in a 
concentration-dependent manner in dividing cells and neurons without affecting total tubulin 
levels or disrupting MT architecture. The second group, the so called “phenotype II 
compounds”, produce a bell-shaped concentration-response effect on markers of MT 
stabilization in cellular assays. Moreover, these compounds induced proteasome-dependent 
degradation of α- and β-tubulin and cause altered MT morphology in both dividing cells and 
neuron cultures.43 As a result, phenotype II compounds, which were found to cause a 
reduction in total tubulin, may not be desirable for neurodegenerative diseases as this effect 
would be expected to ultimately compromise rather than restore axonal MT function. 
However, regardless of whether these compounds elicit a phenotype I or II, both groups of 
MT-stabilizing agents may be of potential use in the context of neuroparasitic infection, such 
as the HAT. Accordingly, we propose the evaluation of CNS-active MT-stabilizing agents 
against T. brucei that could lead to the identification of viable candidates for in vivo proof-of-
concept studies. 
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4.3 Results and Discussion 
To assess the potential anti-parasitic activity of MT-stabilizing agents, we performed a 
preliminary screening of selected representative examples, which included the natural product 
epothilone D (4.8, Table 4.1), as well as several compounds from different classes of non 
naturally-occurring small molecules previously synthesized in the laboratory of Dr. Ballatore, 
such as diaryl-imidazoles 4.9 and 4.10, pyridopyrazine 4.11, pyridazine 4.12, TPDs 4.13 and 
4.14, and PPD 4.15. Preliminary data are shown in Table 4.1. 
The anti-parasitic activity of test compounds was determined with a SYBR Green-based 
whole-cell assay developed for T. brucei in a 96-well format using 20,000 parasites/well.47 
SYBR Green is a cyanine fluorescent dye that binds to nucleic acids, preferably to double-
stranded DNA, thus providing an indirect assessment of cell number in a population. Plates 
were incubated for 72 h at 37 °C and 5% CO2, at which point the trypanosomes were lysed by 
the addition of lysis solution containing the SYBR Green I dye and incubated in the dark for 1 
h at room temperature, followed by reading on a Envision plate reader. All test compounds 
were initially screened at the highest concentration of 4 µM in the SYBR Green assay, using 
pentamidine (4.1, Table 4.1) as a positive control. 
In trypanosomes, pentamidine interferes with DNA biosynthesis by binding to adenine-
thymine-rich regions of the parasite DNA, forming a cross-link between two adenines four to 
five base pairs apart.48 Furthermore, pentamidine inhibits the type II topoisomerase in the 
mitochondria of trypanosomes that results in the rupture and destruction of circulating 
mitochondrial DNA.49 
The data presented in Table 4.1 reveal that 4.8, as well as TPDs 4.13 and 4.14 and PPD 
4.15 have potent anti-trypanosomal activity, showing IC50 values comparable to that of the 
drug standard pentamidine, whereas the remaining heterocyclic compounds 4.9−4.12 were 
inactive or very weakly active. These results suggest that TPDs and PPDs may be promising 
scaffolds for further investigation. Moreover, considering the cellular phenotype elicited by 
these compounds in prior studies, these results suggest that phenotype II compounds may be 
preferred as anti-trypanosome agents over phenotype I analogues (see Table 4.1). Thus, to 
confirm this assessment, we evaluated a larger set of molecules under the same assay 
conditions described above, including primarily phenotype II compounds. 
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   T. brucei viability assay 
Cmpd Structure Cellular phenotype IC50 ± SD (nM) MIC ± SD (nM) 
4.8 
 
I 202 ± 80.0* 296 ± 95.5* 
4.9 
 
II >4 µM** − 
4.10 
 
II >4 µM** − 
4.11 
 
weak activity on MTs >4 µM** − 
4.12 
 
weak activity on MTs 3327 ± 1822** 12691 ± 17116** 
4.13 
 
I 922 ± 150** 1489 ± 247** 
4.14 
 
II 160 ± 31.6* 292 ± 23.6* 
4.15 
 
II 124 ± 46.9§ 201 ± 103§ 
Pentamidine 
(4.1)  
− 65.4 ± 28.8# 145 ± 88.0# 
 
Table 4.1. Anti-trypanosomal activity of compounds 4.8−4.15 and the reference pentamidine 
against T. brucei. All concentration−response analyses were conducted in a SYBR Green 
viability assay at 8-point concentrations ranging from 0.87 nM to 4 µM, with duplicate 
samples per concentration. Concentration needed to inhibit cell growth by 50% (IC50) and the 
minimum inhibitory concentration (MIC) ± standard deviation (SD) are used to indicate the 
potency of the compounds. Incubation time was 72 h. *Data are means of n = 4 separate 
determinations. **Data are means of n = 3 separate determinations. §Data are means of n = 6 
separate determinations. #Data are means of n = 12 separate determinations. 
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The increasing killing effect of compounds 4.13−4.52 on T. brucei cells is shown in Table 
4.2. We screened overall 40 test compounds, which included 14 TPD (4.13, 4.14, 4.16, 4.22, 
4.23, 4.25, 4.27−4.29, 4.35, 4.36, 4.38, 4.43, 4.47) and 26 PPD (4.15, 4.17−4.21, 4.24, 4.26, 
4.30−4.34, 4.37, 4.39−4.42, 4.44−4.46, 4.48−4.52) derivatives. 
Previous evaluation of the 40 compounds in the QBI-293 cell MT assay43 showed that six 
examples (i.e., 4.13, 4.16, 4.23, 4.25, 4.27, and 4.29) cause the cellular phenotype I, whereas 
31 others cause the phenotype II (i.e., 4.14, 4.15, 4.17−4.19, 4.24, 4.26, 4.28, 4.30−4.52). 
Moreover, we examined compounds 4.20−4.22 that were found to be inactive or weakly 
active in the QBI-293 cell MT assay and were tested as controls. 
The majority of the MT-stabilizing agents (23 compounds: 4.13−4.15, 4.33−4.52) killed T. 
brucei cells with IC50 values <1 µM, whereas five derivatives (i.e., 4.28−4.32) showed IC50 
values in the 1−4 µM range, and twelve (i.e., 4.16−4.27) showed activity at >4 µM compound 
concentration. 
Consistent with data from the preliminary assay, compounds that cause a phenotype II and 
alter the normal MT morphology were generally more active than phenotype I congeners (see 
Table 4.2). This observation paves the way to consider the therapeutic potential of phenotype 
II compounds for neuroparasitic infections. 
In general, the anti-parasitic SAR emerging from these studies appears to be generally 
consistent with the anticancer SAR analysis reported by Wyeth.44,50 In detail, data shown in 
Table 4.2 indicate that the central aromatic system is preferably a PPD. Accordingly, PPDs 
exhibited a generally more potent anti-trypanosomal activity than TPDs (see Table 4.2), with 
the most active PPD found, 4.52, being approximately 30–fold more potent than the most 
active TPD, 4.47. Furthermore, five PPD analogues (i.e., 4.48−4.52) were found to be active 
in the low nanomolar range, being about 6 to 26-fold more potent than the drug reference 
pentamidine (IC50 = 65.4 nM, Table 4.1). With respect to the heteroaryl group attached to the 
position 2 of the pyrimidine ring, 2-pyrazinyl or 2-pyridinyl heterocycles were preferred over 
different heterocyclic substitutions (cf., 4.15, 4.45 with 4.21, 4.31, 4.39, 4.41). Evaluation of 
the effect of substitution at C4 of the PPD scaffold revealed that, although a variety of amines 
can be tolerated, fluorinated alkyl amine appeared to be generally preferred. Specifically, (S)-
2,2,2-triﬂuoro-1-methylethylamine seems to provide the best activity, as demonstrated by the 
comparison between the inactive PPDs 4.17, 4.18 or the weakly active analogues 4.30, 
4.32−4.34, 4.37 and the activity of compounds 4.15 and 4.45. Furthermore, the chirality of the 
fluorinated amine appeared to be an important factor, as the R-enantiomer, 4.24, was much 
less active than the corresponding S-enantiomer, 4.15. In contrast, removal of the chirality did 
not significantly affect ability of compounds to kill parasites (cf., 4.15 with 4.44, and 4.45 
with 4.46). With respect to the fluorinated phenyl ring, the degree and pattern of fluorination 
appear to be generally important factors that determine the ability of the MT-stabilizing 
compounds to significantly kill T. brucei cells. Accordingly, whereas derivative 4.19 with no 
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fluorination on the phenyl ring was found to be essentially devoid of killing activity in our 
assay conditions, other di- and tri-fluorinated analogues (i.e., 4.15, 4.40, 4.42) were more 
potently parasiticidal. Furthermore, a comparison between the di-fluorinated analogues, 4.26, 
4.40, 4.42, suggest that the presence of either one or two fluorine atoms in the ortho-positions 
of the phenyl ring is required for anti-trypanosomal activity. However, the highest activity 
was observed with tri-fluorinated derivative 4.15 that killed T. brucei with potency 
comparable to that of pentamidine. Finally, replacement of the fluorine atom in the para-
position of the phenyl ring with an alkoxy side chain led to a boost in activity, regardless of 
whether the general scaffold is a TPD or a PPD (cf., 4.25 with 4.14, 4.47, and 4.15 with 4.48, 
4.50). High potency was achieved when the alkoxy side chain bears an oxygen linkage, a 
three-carbon spacer and a terminal secondary or tertiary amine (e.g., 4.47, 4.52). Accordingly, 
compounds with a two-, four- or no methylene unit tether instead of a three-methylene unit 
tether (i.e., 4.28, 4.35, 4.38), as well as derivatives with terminal hydroxyl or heterocyclic 
amino groups (i.e., 4.36, 4.43) showed much lower activity. Finally, replacement of the 
chlorine atom on the pyrimidine ring with an azetidine led to a loss in activity regardless of 
the nature of the scaffold (cf., 4.14 with 4.22, and 4.15 with 4.20). 
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Cmpd Structure 
Cellular 
phenotype 
IC50 ± SD (nM) MIC ± SD (nM) 
4.16 
 
I >4 µM* − 
4.17 
 
II >4 µM* − 
4.18 
 
II >4 µM* − 
4.19 
 
II >4 µM* − 
4.20 
 
inactive >4 µM* − 
4.21 
 
weak activity on 
MTs 
>4 µM* − 
4.22 
 
weak activity on 
MTs 
>4 µM* − 
4.23 
 
I >4 µM* − 
4.24 
 
II >4 µM* − 
4.25 
 
I >4 µM* − 
4.26 
 
II >4 µM* − 
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4.27 
 
I >4 µM* − 
4.28 
 
II 3403 ± 1263* 6382 ± 5856* 
4.29 
 
I 2142 ± 2050* 35456 ± 75213* 
4.30 
 
II 1435 ± 1198* 69736 ± 119232* 
4.31 
 
II 1223 ± 225* 1500 ± 98.2* 
4.32 
 
II 1121 ± 70.3* 1958 ± 1227* 
4.13 
 
I 922 ± 150* 1489 ± 247* 
4.33 
 
II 853 ± 310* 646 ± 601* 
4.34 
 
II 697 ± 277* 1108 ± 105* 
4.35 
 
II 627 ± 282* 513 ± 9.2* 
4.36 
 
II 506 ± 173* 743 ± 311* 
4.37 
 
II 489 ± 104* 659 ± 367* 
4.38 
 
II 449 ± 22.2* 788 ± 218* 
4.39 
 
II 403 ± 9.2* 530 ± 120* 
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4.40 
 
II 313 ± 120* 417 ± 116* 
4.41 
 
II 273 ± 62.8* 366 ± 9.2* 
4.42 
 
II 268 ± 78.7* 389 ± 28.6* 
4.43 
 
II 264 ± 43.5* 336 ± 26.0* 
4.44 
 
II 241 ± 68.4* 303 ± 54.2* 
4.14 
 
II 160 ± 31.6* 292 ± 23.6* 
4.45 
 
II 140 ± 148* 179 ± 157* 
4.15 
 
II 124 ± 46.9§ 201 ± 103§ 
4.46 
 
II 109 ± 13.4* 182 ± 54.4* 
4.47 
 
II 81.3 ± 14.5* 105 ± 3.8* 
4.48 
 
II 10.9 ± 6.8** 13.1 ± 8.3** 
4.49 
 
II 6.8 ± 4.7** 9.8 ± 7.3** 
4.50 
 
II 7.2 ± 1.5* 9.2 ± 0.9* 
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4.51 
 
II 3.8 ± 0** 27.3 ± 29.5** 
4.52 
 
II 2.5 ± 2.5** 3.5 ± 3.6** 
 
Table 4.2. Anti-trypanosomal activity of the MT-stabilizing agents 4.13−4.52 against T. 
brucei. All concentration−response analyses were conducted in a SYBR Green viability assay 
at 8-point concentrations ranging from 0.87 nM to 4 µM for compounds 4.13−4.47 and from 
0.08 nM to 50 nM for compounds 4.48−4.52, with duplicate samples per concentration. 
Concentration needed to inhibit cell growth by 50% (IC50) and the minimum inhibitory 
concentration (MIC) ± standard deviation (SD) are used to indicate the potency of the 
compounds. Incubation time was 72 h.  *Data are means of n = 3 separate determinations. 
**Data are means of n = 4 separate determinations. §Data are means of n = 6 separate 
determinations. 
 
 
 
Several compounds in Table 4.3 were assessed for their brain-to-plasma (B/P) exposure 
levels after peripheral administration to mice and were found to reach significant nanomolar 
concentrations in the brain. 
 
Cmpd Brain (nM) Plasma (nM) B/P ratio 
4.14 1300 ± 200* 4900 ± 500* 0.27 ± 0.02* 
4.15 2900 ± 100* 5000 ± 200* 0.58 ± 0.01* 
4.45 1500 ± 400* 4300 ± 900* 0.34 ± 0.04* 
4.48 860 ± 130* 2500 ± 200* 0.35 ± 0.06* 
4.49 701 ± 41 2120 ± 160 0.33 ± 0.03 
 
Table 4.3. Brain and plasma compound concentration, 1 h after an intra-peritoneal (i.p.) 
injection of 5 mg/kg of test compound. Means and SD are shown. All analyses were 
conducted with groups of three mice. *Previously published data.42  
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Among the CNS-active MT-stabilizing compounds in Table 4.3, which represent some of 
the most promising anti-trypanosome agents identified in our screening, 4.15 was selected as 
lead molecule. Although 4.15 is not the most active compound within the series, it showed 
killing activity against T. brucei equivalent to the drug standard in our assay conditions. 
Furthermore, extensive pharmacokinetic (PK) profiling in mice previously conducted in the 
laboratory of Dr. K. Brunden, demonstrated that 4.15 is not only brain-penetrant, but it also 
exhibits favorable PK properties after a single i.p. injection or oral administration (Figure 
4.6A and B).42 To more accurately estimate the BBB permeability of this compound, an 
evaluation of brain and plasma exposure over a 16 h time period after i.p. administration of 5 
mg/kg to mice showed that the area under the curve brain-to-plasma (AUC B/P) ratio is 0.72 
(Figure 4.6A). Correction of these values for the unbound fractions (fu) in plasma and brain, 
as determined by equilibrium dialysis,41 clearly suggests that the free fraction of 4.15 can 
readily partition across the BBB (i.e., B(fu)/P(fu) ratios of ~1). Moreover, 4.15 is 
metabolically stable, as demonstrated by the relatively prolonged elimination half-life (T1/2) in 
both plasma and brain (~15 h) (Figure 4.6A). Finally, an evaluation of the oral bioavailability 
of 4.15 showed that this compound can reach micromolar levels in both plasma and brain 
after 2 h post oral administration (Figure 4.6B). Interestingly, these results suggest that a 
single oral dose of 10 mg/kg administered to mice, achieves a 3−5 µM compound 
concentrations in the both plasma and brain,42 (i.e., concentrations that are greater than the 
parasiticidal concentration). Furthermore, animals that received the treatment did not show 
evident signs of toxicity. Based on these results, we anticipate that the in vivo efficacy studies 
of 4.15 will be likely based upon single or repeated administrations of ≤ 10 mg/kg. With these 
assumptions, we estimated that <100 mg of 4.15 will be sufficient to complete the in vivo 
studies. Thus, to ensure adequate supply, a re-synthesis of 4.15 was carried out at a 0.5 g scale 
(Scheme 4.1). Using this fresh material, we plan to obtain in vivo proof of principle that short-
term, tolerable treatments with brain-penetrant MT-stabilizing compounds can be effective in 
murine models of HAT. 
During my research activity as a visiting PhD student at the University of California, San 
Diego, I worked on the in vitro screening and determination of the parasiticidal effect of 
compounds 4.13−4.52 on T. brucei. Furthermore, I was responsible for the re-synthesis of 
4.15 for the in vivo proof-of-concept studies. In addition, I accomplished the synthesis and 
characterization of compounds 4.19, 4.21, 4.24, 4.26, 4.32, 4.33, 4.34, 4.40, 4.42, 4.45, 4.50 
(see Experimental Section, Chemistry 4.6.1). 
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Figure 4.6. (A) Brain/plasma PK of 4.15 after 5 mg/kg i.p. dosing to CD1 mice; (B) brain and 
plasma levels of 4.15 2 h after oral administration of 10 mg/kg. All analyses were conducted 
with groups of three mice. Adapted from Ref. 42. 
 
Taken together these studies suggest that tubulin polymerization promoters that disrupt MT 
architecture, such as the phenotype II PPD 4.15, kill T. brucei with potencies the equivalent of 
or better than the drug standard pentamidine. The combination, therefore, of 4.15’s potency, 
favourable drug-like properties, synthetic accessibility and straightforward dosing regimen 
encourages the further investigation of the therapeutic potential of CNS-active MT-stabilizing 
agents as a treatment for parasitic infections of the brain.  
In this regard, we preliminary evaluated 4.15 for its effect against another parasite involved 
in human infections that can affect the brain, specifically, the brain-eating ameba, Naegleria 
fowleri.51 Preliminary in vitro data obtained in the laboratory of Dr. A. Debnath at the 
University of California, San Diego, revealed that 4.15 (IC50 = 3 µM, Figure 4.7) is less 
effective against N. fowleri than T. brucei, but it is 18-fold more potent than miltefosine52 
(4.53, IC50 = 54 µM, Figure 4.7), the current drug for primary amebic meningoencephalitis 
(PAM). 
 
  
Figure 4.7. Dose−response curves in N. fowleri assays that employ the CellTiter-Glo reagent 
to measure ATP. Concentration−response analyses were conducted at 8-point concentrations 
ranging from 0.39 µM to 50 µM for 4.15 and from 1.56 µM to 200 µM for miltefosine, with 
triplicate samples per concentration. Points are means and SD values from three experiments.  
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To conclude, effective treatment of Stage 2 HAT requires drugs that can cross the BBB 
and reach brain concentrations sufficient to affect CNS-resident parasites upon administration 
of tolerable, oral doses. Compounds like 4.15 possess the requisite in vitro biological activity 
and PK properties to potentially achieve complete anti-parasitic efficacy in vivo. 
For PAM, the optimum treatment has not been clinically defined: >95% of cases are fatal 
and the disease progresses quickly with death occurring within a week of infection.53 
Therefore, new drugs to treat this deadly pathogen are a critical unmet need to prevent future 
deaths of children and young adults. Also, as PAM is a rare disease in the United States, in 
vivo proof-of-principle efficacy with 4.15 will encourage us to apply to the US Food and 
Drug Administration for Orphan Drug Status for the treatment of PAM. 
 
 
4.4 Chemistry  
Synthesis of PPDs, typified here by 4.15 (Scheme 4.1), was accomplished following the 
synthetic procedure described by Wyeth.44 Related TPD derivatives were synthetised as 
previusly described.42,43,50 
Coupling of 1-bromo-2,4,6-trifluorobenzene with diethyl malonate, in the presence of 
CuBr and sodium hydride, yielded diethyl 2,4,6-trifluorophenylmalonate 4.54. Condensation 
of 4.54 with the appropriate amidine, followed by chlorination with phosphorus oxychloride 
led to the formation of the dichlorinated phenylpyrimidine 4.55. Treatment of 4.55 with the 
appropriate fluorinated alkyl amine, in the presence of N,N-diisopropylethylamine (DIPEA), 
provided the replacement of one of the two equivalent chlorine atoms and yielded 
phenylpyrimidine 4.15. 
The purity of compound was determined via 1H and 13C NMR analyses (Figure 4.8A and 
B). Finally, recrystallization from C2H4Cl2/pentane led to the formation of crystals that were 
suitable for X-ray diffraction analysis and confirmed the final structure (Figure 4.9). 
 
 
 
 
Scheme 4.1. Synthesis of compound 4.15. 
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Figure 4.8. (A) 1H NMR spectrum of 4.15 recorded in deuterated chloroform (CDCl3) at 600 
MHz. (B) 13C NMR spectrum of 4.15 recorded in CDCl3 at 151 MHz.  
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Figure 4.9. X-ray structure determination of compound 4.15. 
 
4.5 Conclusions 
HAT is a debilitating and deadly disease caused by the flagellate Trypanosoma parasite 
that threatens millions of people in Sub-Saharan Africa. In the absence of a vaccine, therapy 
relies heavily on pre-1950 drugs with poor safety profiles, limited effectiveness and high 
costs.54 Therefore, new drugs are urgently needed, particularly to treat Stage 2 disease, in 
which parasites invade the brain and CNS. Until recently, the development of MT-targeting 
therapies for CNS-indications has been challenging due to issues of limited brain penetration. 
This situation changed with the discovery of natural products and non-naturally occurring 
small molecules that possess potent MT-stabilizing activity and can readily access the brain.43 
Accordingly, through an integrated drug discovery approach, we evaluated the anti-parasitic 
activity of CNS-active MT-stabilizing agents. The majority of the compounds killed T. brucei 
in vitro with IC50 values in the nanomolar concentration range (SAR summary depicted in 
Figure 4.10). These studies led to the identification of one preferred drug candidate, 
compound 4.15, which exhibits a promising combination of anti-parasitic activity and PK 
properties, including brain penetration and oral bioavailability. Finally, preliminary screening 
against another CNS-invasive parasite, Naegleria fowleri, indicated that this class of 
compounds hold promise as novel leads. 
 
 
Figure 4.10. Anti-trypanosomal activity SAR summary represented by compound 4.48. 
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4.6 Experimental Section 
4.6.1 Chemistry 
All solvents were reagent grade. All reagents were purchased from Aldrich or Fisher 
Scientific and used as received. Thin layer chromatography (TLC) was performed with 0.25 
mm E. Merck pre-coated silica gel plates. Silica gel column chromatography was performed 
with silica gel 60 (particle size 0.040–0.062 mm) supplied by Silicycle and Sorbent 
Technologies. TLC spots were detected by viewing under a UV light (254 nm). Melting 
points (m.p.) were acquired on a Thomas-Hoover apparatus and are uncorrected. Infrared (IR) 
spectra were recorded on a Jasco Model FT/IR-480 Plus spectrometer. Proton (1H) and carbon 
(13C) NMR spectra were recorded on a Bruker AMX-500 or BMA-600 spectrometer. 
Chemical shifts were reported relative to the residual solvent’s peak. High-resolution mass 
spectra were measured at the University of California, San Diego Molecular Mass 
Spectrometry Facility on either a Thermo LCQdeca-MS spectrometer. The single crystal X-
ray diffraction studies were performed at the Unversity of California, San Diego and carried 
out on a Bruker D8 Platinum135 CCD diffractometer equipped with Cu Ka radiation (λ = 
1.5478). Crystals of the subject compound were grown by dissolving approximately 1mg of 
sample in 350 µL of DCE, which was then vapor diffused with pentane over 3 days. 
Analytical reverse-phase (SunfireTM C18; 4.6 × 50 mm, 5 mL) high-performance liquid 
chromatography (HPLC) was performed with a Waters binary gradient module 2525 
equipped with Waters 2996 PDA and Waters micromass ZQ. All samples were analyzed 
employing a linear gradient from 10% to 90% of CH3CN in H2O over 8 min and flow rate of 
1 mL/min, and unless otherwise stated, the purity level was >95%. Preparative reverse-phase 
HPLC purifications were performed on a Gilson instrument (i.e., Gilson 333 pumps, a 215 
liquid handler, 845Z injection module, and PDA detector) employing Waters SunFireTM 
preparative C18 OBDTM columns (5 µm 19 × 50 or 19 × 100 mm). Purifications were carried 
out employing a linear gradient from 10% to 90% of CH3CN in H2O for 15 min with a flow 
rate of 20 mL/min. Unless otherwise stated, all final compounds were found to be >95% pure 
as determined by HPLC/MS and NMR.  
General procedure A for the synthesis of 4-amino derivatives 4.15, 4.19, 4.21, 4.24, 4.26, 
4.40, 4.42, 4.45. To a solution of di-chlorinated derivative (1 equiv) in anhydrous DMF (0.1 
M) the appropriate amine hydrochloride (4 equiv) and N,N-diisopropylethylamine (4 equiv) 
were added. Reaction mixture was stirred at 90 °C for 18 h. Then, water was added and 
extracted with EtOAc (×2). The combined organic layers were washed with brine (x3), dried 
over MgSO4, filtered and concentrated in vacuo. Purification via silica gel column 
chromatography or via preparative reverse phase HPLC furnished the desired product. 
General procedure B for the synthesis of 4-amino derivatives 4.32, 4.33, 4.34. To a 
solution of di-chlorinated derivative (1 equiv) in anhydrous DMF (0.1 M) the appropriate 
amine (2.1 equiv) was added and the reaction mixture was stirred at room temperature for 1h. 
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Then water was added and extracted with EtOAc (×2). The combined organic layers were 
washed with brine (x3), dried over MgSO4, filtered and concentrated in vacuo. Then, water 
was added and extracted with EtOAc (×2). The combined organic layers were washed with 
brine (x3), dried over MgSO4, filtered and concentrated in vacuo. Purification via silica gel 
column chromatography furnished the desired product. 
General procedure C for the installment of side chain (e.g., 4.50). To a solution of the 7-
amino derivative (1 equiv) and the appropriate aminoalcohol (5.17 eq) in DMSO (0.2 M) was 
added sodium hydride (60% mineral oil, 5.17 equiv) at room temperature. Reaction mixture 
was stirred at 60 °C for 2 h, cooled to room temperature, dissolved in additional DMSO, 
filtered and purified by preparative reverse phase HPLC to obtain the desired product. 
General procedure D for the synthesis of diethylmalonate derivatives (e.g., 4.54). To a 
suspension of NaH (60 % in mineral oil, 1.00 equiv) in anhydrous 1,4-dioxane (previously 
degassed with N2) (1.75 mol/L from aryl bromide derivate) at 60 °C under N2 was slowly 
added diethyl malonate (3.00 equiv). After addition, the reaction was stirred at 60 °C for 10 
minutes. Then, CuBr (1.20 equiv) and appropriate aryl bromide derivate (3 equiv) were added 
and the reaction was heated at reflux overnight. Then, at room temperature the reaction was 
quenched with HCl 12N (1.40 equiv). The mixture was filtrated and washed with water. The 
filtrate was extracted with EtOAc (x3). The combined organic extracts were washed with 
brine, then dried over MgSO4, filtered and concentrated in vacuo. Purification via silica gel 
column chromatography furnished the desired product. 
General procedure E for the synthesis of di-chlorinated derivative 4.55−4.61. A mixture 
of the diethylmalonate derivate (1.00 equiv), appropriate amidine (1.05 equiv) and 
tributylamine (1.08 equiv) was stirred in a sealed tube at 180 °C for 1 h. After cooling at 110 
°C, phosphorus oxychloride (3 equiv) was added dropwise and the mixture was stirred at 100 
°C for 16 h. Then, the reaction was cooled to room temperature and slowly diluted with a 
mixture of CH2Cl2 and water (1:1). The aqueous phase was extracted with CH2Cl2 (x1), the 
combined organic layers were washed with brine (x3), dried over MgSO4, filtered and 
concentrated in vacuo. Purification via silica gel column chromatography furnished the 
desired di-chlorinated product. 
(S)-6-chloro-2-(pyrazin-2-yl)-5-(2,4,6-trifluorophenyl)-N-(1,1,1-trifluoropropan-2-
yl)pyrimidin-4-amine (4.15). Following synthetic procedure A using 4,6-dichloro-2-(pyrazin-
2-yl)-5-(2,4,6-trifluorophenyl)pyrimidine (0.500 g, 1.40 mmol) and (S)-1,1,1-trifluoropropan-
2-amine hydrochloride (0.837 g, 5.60 mmol), purification by silica gel column 
chromatography (hexanes/EtOAc 100:0 to 80:20) afforded the title compound as a beige solid 
(0.296 g, 0.682 mmol, 49% yield). X-ray quality crystals were obtained by slow evaporation 
from a C2H4Cl2/pentane solution: m.p. 190–192 °C (C2H4Cl2/pentane). 1H NMR (600 MHz, 
CDCl3) δ 9.62 (s, 1H), 8.78 (s, 1H), 8.70 (s, 1H), 6.89–6.81 (m, 2H), 5.38–5.27 (m, 1H), 4.85 
(d, J = 9.3 Hz, 1H), 1.42 (d, J = 7.0 Hz, 3H) ppm. 13C NMR (151 MHz, CDCl3) δ 164.24 (dt, 
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J = 254.1, 15.1 Hz), 161.64, 161.51, 161.11, 160.87 (ddd, J = 252.2, 9.1, 4.0 Hz), 160.77 
(ddd, J = 253.3, 9.4, 4.0 Hz), 149.01, 146.11, 145.60, 144.57, 125.36 (q, J = 281.9 Hz), 
104.85 (td, J = 21.1, 20.6, 5.1 Hz), 104.74, 101.74 (tdd, J = 26.1, 22.7, 4.0 Hz), 48.27 (q, J = 
31.7 Hz), 14.49 ppm. IR (KBr) ν 3279, 2923, 1638, 1579, 1556 cm-1. HRMS (ES+) calculated 
for C17H11ClF6N5 [M + H]+ 434.0602, found 434.0601. 
(S)-6-chloro-5-phenyl-2-(pyrazin-2-yl)-N-(1,1,1-trifluoropropan-2-yl)pyrimidin-4-amine 
(4.19). Following synthetic procedure A using 4,6-dichloro-5-phenyl-2-(pyrazin-2-
yl)pyrimidine (0.100 g, 0.330 mmol) and (S)-1,1,1-trifluoropropan-2-amine hydrochloride 
(0.163 g, 1.09 mmol, 3.30 equiv), purification by silica gel column chromatography 
(hexanes/EtOAc 60:40) afforded the title compound as an brown solid (0.012 g, 0.033 mmol, 
10% yield). 1H NMR (600 MHz, CDCl3) δ 9.63 (s, 1H), 8.79 (s, 1H), 8.70 (s, 1H), 7.61–7.54 
(m, 1H), 7.55–7.49 (m, 1H), 7.38–7.32 (m, 2H), 7.27–7.11 (m, 1H), 5.32–5.20 (m, 1H), 4.80 
(d, J = 9.3 Hz, 1H), 1.35 (d, J = 7.0 Hz, 3H) ppm. 13C NMR (151 MHz, CDCl3) δ 160.95, 
160.22, 159.17, 149.38, 145.83, 145.50, 144.56, 131.39, 130.07, 129.96, 129.83, 129.72, 
129.49, 125.49 (q, J = 282.1 Hz), 117.14, 48.06 (q, J = 31.5 Hz), 14.56 ppm. IR (KBr) ν 
3420, 2920. 1722, 1578, 1552 cm-1. HRMS (ES+) calculated for C17H14ClF3N5 [M + H]+ 
380.0884, found 380.0883. 
(S)-6-chloro-2-(thiophen-2-yl)-5-(2,4,6-trifluorophenyl)-N-(1,1,1-trifluoropropan-2-
yl)pyrimidin-4-amine (4.21). Following synthetic procedure A using 4,6-dichloro-2-
(thiophen-2-yl)-5-(2,4,6-trifluorophenyl)pyrimidine (0.140 g, 0.387 mmol) and (S)-1,1,1-
trifluoropropan-2-amine (0.232 g, 1.55 mmol), purification by silica gel column 
chromatography (hexanes/EtOAc 99:1) afforded the title compound as an white solid (0.022 
g, 0.050 mmol, 13% yield). 1H NMR (600 MHz, CDCl3) δ 8.02 (d, J = 3.7 Hz, 1H), 7.51 (d, J 
= 5.0 Hz, 1H), 7.14 (t, J = 4.4 Hz, 1H), 6.92–6.84 (m, 2H), 5.31–5.19 (m, 1H), 4.44 (d, J = 
9.4 Hz, 1H), 1.39 (d, J = 7.0 Hz, 3H) ppm. 13C NMR (151 MHz, CDCl3) δ 164.07 (dt, J = 
253.4, 15.2 Hz), 160.99 (ddd, J = 252.8, 9.7, 5.5 Hz), 160.88 (ddd, J = 246.8, 8.3, 5.9 Hz), 
160.87, 160.46, 160.30, 142.02, 131.04, 130.39, 128.37, 125.44 (q, J = 281.6 Hz), 105.28 (td, 
J = 21.1, 4.2 Hz), 101.66 (qd, J = 25.8, 25.0, 4.2 Hz), 48.02 (q, J = 31.7 Hz), 14.61 ppm. IR 
(KBr) ν 3353, 2923, 1637, 1556, 1527 cm-1. HRMS (ES+) calculated for C17H11ClF6N3S [M + 
H]+ 438.0261, found 438.0262. 
(R)-6-chloro-2-(pyrazin-2-yl)-5-(2,4,6-trifluorophenyl)-N-(1,1,1-trifluoropropan-2-
yl)pyrimidin-4-amine (4.24). Following synthetic procedure A using 4,6-dichloro-2-(pyrazin-
2-yl)-5-(2,4,6-trifluorophenyl)pyrimidine (0.065 g, 0.182 mmol) and (S)-1,1,1-
trifluoropropan-2-amine hydrochloride (0.109 g, 0.728 mmol), purification by reverse phase 
afforded the title compound as a white solid (0.011 g, 0.682 mmol, 14% yield). 1H NMR (600 
MHz, CDCl3) δ 9.63 (s, 1H), 8.79 (s, 1H), 8.71 (s, 1H), 6.95–6.83 (m, 2H), 5.38–5.26 (m, 
1H), 4.70 (d, J = 9.3 Hz, 1H), 1.42 (d, J = 7.0 Hz, 3H) ppm. 13C NMR (151 MHz, CDCl3) δ 
164.31 (dt, J = 253.6, 15.0 Hz), 161.74, 161.55, 161.09, 160.81 (ddd, J = 245.6, 15.5, 9.0 Hz), 
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149.05, 146.15, 145.65, 144.61, 125.35 (q, J = 281.7 Hz), 104.82 (td, J = 20.7, 4.7 Hz), 
104.75, 101.83 (tdd, J = 26.1, 22.7, 4.0 Hz), 48.28 (q, J = 31.7 Hz), 14.57 ppm. IR (KBr) ν 
3280, 2917, 1637, 1579, 1554 cm-1. HRMS (ES+) calculated for C17H11ClF6N5 [M + H]+ 
434.0602, found 434.0604. 
(S)-6-chloro-5-(3,5-difluorophenyl)-2-(pyrazin-2-yl)-N-(1,1,1-trifluoropropan-2-
yl)pyrimidin-4-amine (4.26). Following synthetic procedure A using 4,6-dichloro-5-(3,5-
difluorophenyl)-2-(pyrazin-2-yl)pyrimidine (0.075 g, 0.221 mmol) and (S)-1,1,1-
trifluoropropan-2-amine hydrochloride (0.132 g, 0.885 mmol), purification by reverse phase 
HPLC afforded the title compound as a beige solid (0.020 g, 0.048 mmol, 22% yield). 1H 
NMR (600 MHz, CDCl3) δ 9.60 (s, 1H), 8.79 (s, 1H), 8.70 (d, J = 2.4 Hz, 1H), 7.00–6.93 (m, 
1H), 6.90 (d, J = 7.6 Hz, 2H), 5.35–5.23 (m, 1H), 4.79 (d, J = 9.3 Hz, 1H), 1.39 (d, J = 7.0 
Hz, 3H) ppm. 13C NMR (151 MHz, CDCl3) δ 163.98 (dd, J = 249.8, 10.5 Hz), 163.91 (dd, J = 
251.3, 13.1 Hz), 160.81, 160.49, 159.26, 149.00, 146.07, 145.53, 144.59, 134.49 (t, J = 9.8 
Hz), 125.40 (q, J = 281.9 Hz), 114.94, 113.24 (dd, J = 22.0, 3.6 Hz), 112.96 (dd, J = 22.3, 3.7 
Hz), 105.58 (t, J = 24.9 Hz), 48.18 (q, J = 31.6 Hz), 14.53 ppm. IR (KBr) ν 3289, 2921, 1621, 
1579, 1554 cm-1. HRMS (ES+) calculated for C17H12ClF5N5 [M + H]+ 416.0696, found 
416.0699. 
6-chloro-N-isopropyl-2-(pyrazin-2-yl)-5-(2,4,6-trifluorophenyl)pyrimidin-4-amine  (4.32). 
Following synthetic procedure B using 4,6-dichloro-2-(pyrazin-2-yl)-5-(2,4,6-
trifluorophenyl)pyrimidine (0.030 g, 0.084 mmol) and isopropylamine (0.010 g, 0.176 mmol), 
the title compound was used with no further purification, beige solid (0.134 g, 0.328 mmol, 
96%), purification by silica gel column chromatography (hexanes/EtOAc 70:30) afforded the 
title compound as a beige solid (0.025 g, 0.066 mmol, 78% yield). 1H NMR (600 MHz, 
CDCl3) δ 9.65 (s, 1H), 8.77 (s, 1H), 8.67 (s, 1H), 6.88–6.81 (m, 2H), 4.59–4.55 (m, 1H), 
4.55–4.47 (m, 1H), 1.24 (d, J = 6.5 Hz, 6H) ppm. 13C NMR (151 MHz, CDCl3) δ 163.94 (dt, 
J = 253.2, 15.2 Hz), 161.74, 160.98, 160.87 (ddd, J = 252.3, 15.0, 8.9 Hz), 160.39, 149.61, 
145.76, 145.60, 144.46, 105.68 (td, J = 20.9, 4.2 Hz), 103.75, 101.57 (td, J = 25.6, 3.6 Hz), 
43.85, 22.61 ppm. IR (KBr) ν 3310, 2922, 1639, 1579, 1556 cm-1. HRMS (ES+) calculated for 
C17H14ClF3N5 [M + H]+ 380.0884, found 380.0885. 
6-chloro-N-isopropyl-2-(pyridin-2-yl)-5-(2,4,6-trifluorophenyl)pyrimidin-4-amine (4.33). 
Following synthetic procedure B using 4,6-dichloro-2-(pyridin-2-yl)-5-(2,4,6-
trifluorophenyl)pyrimidine (0.060 g, 0.168 mmol) and isopropylamine (0.040 g, 0.674 mmol), 
purification by silica gel column chromatography (hexanes/EtOAc 60:40) afforded the title 
compound as a white solid (0.051 g, 0.135 mmol, 80% yield). 1H NMR (600 MHz, CDCl3) δ 
8.81 (d, J = 4.6 Hz, 1H), 8.43 (d, J = 7.9 Hz, 1H), 7.82 (td, J = 7.7, 1.7 Hz, 1H), 7.41–7.35 
(m, 1H), 6.85–6.78 (m, 2H), 4.59–4.49 (m, 2H), 1.23 (d, J = 6.2 Hz, 6H) ppm. 13C NMR (151 
MHz, CDCl3) δ 163.77 (dt, J = 252.8, 15.1 Hz), 163.32, 161.02, 160.88 (ddd, J = 252.4, 15.1, 
9.2 Hz), 160.31, 154.23, 149.98, 136.84, 125.11, 123.89, 106.02 (td, J = 21.1, 4.6 Hz), 
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102.97, 101.43 (td, J = 25.7, 4.1 Hz), 43.62, 22.67 ppm. IR (KBr) ν 3272, 2917, 1639, 1575, 
1556 cm-1. HRMS (ES+) calculated for C18H15ClF3N4 [M + H]+ 379.0932, found 379.0931. 
(R)-6-chloro-N-(3-methylbutan-2-yl)-2-(pyridin-2-yl)-5-(2,4,6-trifluorophenyl)pyrimidin-
4-amine (4.34). Following synthetic procedure B using 4,6-dichloro-2-(pyrazin-2-yl)-5-
(2,4,6-trifluorophenyl)pyrimidine (0.122 g, 0.342 mmol) and (R)-3-methylbutan-2-amine 
(0.063 g, 0.717 mmol), the title compound was used with no further purification, orange wax 
(0.134 g, 0.328 mmol, 96% yield). 1H NMR (600 MHz, CDCl3) δ 9.64 (s, 1H), 8.79 (s, 1H), 
8.68 (s, 1H), 6.92–6.85 (m, 2H), 4.50 (s, 1H), 4.38–4.28 (m, 1H), 1.87–1.78 (m, 1H), 1.15 (d, 
J = 6.6 Hz, 3H), 0.89 (d, J = 6.8 Hz, 6H) ppm. 13C NMR (151 MHz, CDCl3) δ 163.99 (dt, J = 
253.6, 15.3 Hz), 161.70, 161.34, 161.00 (ddd, J = 252.8, 15.2, 9.7 Hz), 160.79 (ddd, J = 
251.7, 14.6, 9.1 Hz), 160.44, 149.69, 145.63, 145.46, 144.55, 105.65 (td, J = 21.5, 5.2 Hz), 
103.65, 101.64 (qd, J = 25.8, 4.2 Hz), 52.35, 33.01, 18.61, 18.43, 17.41 ppm. IR (KBr) ν 
3305, 2962, 1637, 1580, 1557 cm-1. HRMS (ES+) calculated for C19H18ClF3N5 [M + H]+ 
408.1197, found 408.1199. 
6-chloro-5-(2,4-difluorophenyl)-2-(pyrazin-2-yl)-N-((S)-1,1,1-trifluoropropan-2-
yl)pyrimidin-4-amine (4.40). Following synthetic procedure A using 4,6-dichloro-5-(2,4-
difluorophenyl)-2-(pyrazin-2-yl)pyrimidine (0.100 g, 0.295 mmol) and (S)-1,1,1-
trifluoropropan-2-amine hydrochloride (0.176 g, 1.18 mmol), purification by reverse phase 
HPLC afforded the title compound as a mixture of atropisomers, uncolorless oil (0.015 g, 
0.036 mmol, 12% yield). 1H NMR (600 MHz, CDCl3) mixture of atropisomers δ 9.62 (s, 1H), 
8.78 (s, 1H), 8.70 (d, J = 2.4 Hz, 1H), 7.36–7.28 (m, 1H), 7.13–7.05 (m, 1H), 7.08–7.00 (m, 
1H), 5.35–5.23 (m, 1H), 4.71 (d, J = 9.4 Hz, 1H), 1.39 (dd, J = 7.0, 4.6 Hz, 3H) ppm. 13C 
NMR (151 MHz, CDCl3) mixture of atropisomers δ 165.05, 165.02, 164.97, 164.94, 163.37, 
163.34, 163.29, 163.26, 161.27, 161.24, 161.19, 161.16, 161.07, 161.02, 161.00, 160.62, 
160.54, 159.60, 159.57, 159.52, 159.49, 149.14, 146.02, 145.56, 144.58, 132.86, 132.84, 
132.80, 132.77, 132.68, 132.65, 132.61, 132.59, 128.26, 128.14, 126.40, 126.27, 124.53, 
124.40, 122.66, 122.53, 115.06, 115.03, 115.01, 114.99, 114.95, 114.92, 114.90, 114.88, 
113.40, 113.37, 113.25, 113.23, 113.21, 113.09, 113.06, 110.46, 105.92, 105.86, 105.76, 
105.69, 105.59, 105.53, 48.53, 48.46, 48.32, 48.25, 48.11, 48.04, 47.90, 47.83, 14.55 ppm. IR 
(KBr) ν 3280, 2997, 1732, 1619, 1557 cm-1. HRMS (ES+) calculated for C17H12ClF5N5 [M + 
H]+ 416.0696, found 416.0698. 
(S)-6-chloro-5-(2,6-difluorophenyl)-2-(pyrazin-2-yl)-N-(1,1,1-trifluoropropan-2-
yl)pyrimidin-4-amine (4.42). Following synthetic procedure A using 4,6-dichloro-5-(2,6-
difluorophenyl)-2-(pyrazin-2-yl)pyrimidine (0.100 g, 0.295 mmol) and (S)-1,1,1-
trifluoropropan-2-amine (0.133 g, 1.08 mmol), purification by silica gel column 
chromatography (hexanes/EtOAc 65:35) afforded the title compound as an orange solid 
(0.034 g, 0.082 mmol, 28% yield). 1H NMR (600 MHz, CDCl3) δ 9.60 (d, J = 1.5 Hz, 1H), 
8.78–8.74 (m, 1H), 8.68 (d, J = 2.5 Hz, 1H), 7.49–7.41 (m, 1H), 7.06–7.01 (m, 2H), 5.37–
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5.28 (m, 1H), 4.99 (d, J = 9.3 Hz, 1H), 1.40 (d, J = 7.0 Hz, 3H) ppm. 13C NMR (151 MHz, 
CDCl3) δ 161.38, 161.19, 161.05, 160.41 (dd, J = 251.3, 4.3 Hz), 160.37 (dd, J = 252.0, 4.9 
Hz), 149.10, 145.95, 145.52, 144.47, 132.46 (t, J = 10.0 Hz), 125.42 (q, J = 282.0 Hz), 112.57 
(dd, J = 21.4, 3.5 Hz), 112.37 (dd, J = 21.4, 3.5 Hz), 108.46 (t, J = 20.3 Hz), 105.63, 48.22 (q, 
J = 31.7 Hz), 14.41 ppm. IR (KBr) ν 3281, 2922, 1626, 1582, 1556 cm-1. HRMS (ES+) 
calculated for C17H12ClF5N5 [M + H]+ 416.0696, found 416.0698. 
(S)-6-chloro-2-(pyridin-2-yl)-5-(2,4,6-trifluorophenyl)-N-(1,1,1-trifluoropropan-2-
yl)pyrimidin-4-amine (4.45). Following synthetic procedure A using 4,6-dichloro-2-(pyridin-
2-yl)-5-(2,4,6-trifluorophenyl)pyrimidine (0.500 g, 1.40 mmol) and (S)-1,1,1-trifluoropropan-
2-amine hydrochloride (0.840 g, 5.62 mmol), purification by silica gel column 
chromatography (hexanes/EtOAc 80:20 to 70:30) afforded the title compound as a white solid 
(0.106 g, 0.245 mmol, 17% yield). 1H NMR (600 MHz, CDCl3) δ 8.83 (s, 1H), 8.42 (d, J = 
7.6 Hz, 1H), 7.87 (t, J = 7.5 Hz, 1H), 7.43 (dd, J = 7.6, 3.8 Hz, 1H), 6.86–6.78 (m, 2H), 5.42–
5.32 (m, 1H), 4.83 (d, J = 9.2 Hz, 1H), 1.41 (d, J = 6.9 Hz, 3H) ppm. 13C NMR (151 MHz, 
CDCl3) δ 164.07 (dt, J = 253.8, 15.4, 14.9 Hz), 163.14, 161.38, 161.09, 160.90 (ddd, J = 
251.7, 8.8, 4.6 Hz), 160.80 (ddd, J = 253.8, 9.3, 4.2 Hz), 153.56, 150.09, 137.12, 125.52, 
125.50 (q, J = 282.1 Hz), 124.11, 105.19 (td, J = 21.8, 21.0, 4.4 Hz), 104.00, 101.60 (tdd, J = 
26.0, 22.0, 3.9 Hz), 48.14 (q, J = 31.5 Hz), 14.51 ppm. IR (KBr) ν 3259, 2919, 1635, 1575, 
1548 cm-1. 
 (S)-6-chloro-5-(2,6-difluoro-4-(3-(methylamino)propoxy)phenyl)-2-(pyrazin-2-yl)-N-
(1,1,1-trifluoropropan-2-yl)pyrimidin-4-amine (4.50). Following synthetic procedure C using 
(S)-6-chloro-2-(pyrazin-2-yl)-5-(2,4,6-trifluorophenyl)-N-(1,1,1-trifluoropropan-2-
yl)pyrimidin-4-amine (0.050 g, 0.115 mmol) and 3-(methylamino)propan-1-ol (0.053 g, 0.596 
mmol), purification by reverse phase HPLC afforded the title compound as a yellow solid 
(0.008 g, 0.016 mmol, 14% yield). 1H NMR (600 MHz, CDCl3) δ 9.63 (d, J = 1.5 Hz, 1H), 
8.83–8.79 (m, 1H), 8.71 (d, J = 2.4 Hz, 1H), 8.19 (s, 2H), 6.59 (d, J = 9.5 Hz, 2H), 5.83 (d, J 
= 9.2 Hz, 1H), 5.40–5.28 (m, 1H), 4.18–4.09 (m, 2H), 3.28–3.17 (m, 2H), 2.73 (s, 3H), 2.32–
2.24 (m, 2H), 1.41 (d, J = 7.0 Hz, 4H) ppm. 13C NMR (151 MHz, CDCl3) δ 166.49, 162.00 
(d, J = 9.7 Hz), 161.72, 161.38, 161.24 (t, J = 14.5, 13.5 Hz), 161.14, 160.34 (d, J = 9.3 Hz), 
149.16, 146.01, 145.57, 144.45, 125.63 (q, J = 282.2 Hz), 105.58, 101.19 (t, J = 21.3 Hz), 
99.54 (ddd, J = 29.0, 25.7, 2.5 Hz), 65.30, 48.14 (q, J = 31.5 Hz), 46.65, 33.46, 25.67, 14.18 
ppm. IR (KBr) ν 3411, 2919, 1639, 1580, 1556 cm-1. HRMS (ES+) calculated for 
C21H21ClF5N6O [M + H]+ 503.1380, found 503.1377. 
Diethyl 2-(2,4,6-trifluorophenyl)malonate (4.54). Following synthetic procedure D using 
diethyl malonate (9.13 g, 57.0 mmol) and 2-bromo-1,3,5-trifluorobenzene (4.00 g, 19.0 
mmol), purification by silica gel column chromatography (hexanes/EtOAc 70:30) afforded 
the title compound as a colourless oil (3.67 g, 12.6 mmol, 66% yield). 1H NMR (500 MHz, 
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CDCl3) δ 6.71 (t, J = 8.8 Hz, 2H), 4.90 (s, 1H), 4.26 (q, J = 7.1 Hz, 4H), 1.28 (t, J = 7.2 Hz, 
6H) ppm. 
4,6-dichloro-2-(pyrazin-2-yl)-5-(2,4,6-trifluorophenyl)pyrimidine (4.55). Following 
synthetic procedure E using diethyl 2-(2,4,6-trifluorophenyl)malonate (0.679 g, 2.34 mmol) 
and pyrazine-2-carboximidamide hydrochloride (0.390 g, 2.46 mmol), purification by silica 
gel column chromatography (hexanes/EtOAc 100:0 to 77:23) afforded the title compound as a 
brown solid (0.252 g, 0.706 mmol, 30% yield). 1H NMR (600 MHz, CDCl3) δ 9.74 (d, J = 1.3 
Hz, 1H), 8.84 (dd, J = 2.5, 1.5 Hz, 1H), 8.77 (d, J = 2.4 Hz, 1H), 6.91–6.83 (m, 2H) ppm. 13C 
NMR (151 MHz, CDCl3) δ 164.31 (dt, J = 254.0, 15.1 Hz), 163.71, 162.40, 160.24 (ddd, J = 
252.7, 15.2, 8.9 Hz), 147.44, 146.98, 146.05, 144.95, 122.30, 106.76 (td, J = 20.6, 4.9 Hz), 
101.47–100.97 (m) ppm. 
4,6-dichloro-5-phenyl-2-(pyrazin-2-yl)pyrimidine (4.56). Following synthetic procedure E 
using diethyl 2-phenylmalonate (0.500 g, 2.12 mmol) and pyrazine-2-carboximidamide 
hydrochloride (0.352 g, 2.22 mmol), purification by silica gel column chromatography 
(hexanes/EtOAc 70:30) afforded the title compound as a brown solid (0.117 g, 0.386 mmol, 
18% yield). 1H NMR (600 MHz, CDCl3) δ 9.73 (s, 1H), 8.83 (s, 1H), 8.76 (s, 1H), 7.57–7.49 
(m, 3H), 7.38–7.34 (m, 2H) ppm. 13C NMR (151 MHz, CDCl3) δ 162.37, 160.76, 147.73, 
146.67, 145.82, 144.87, 133.49, 132.68, 129.65, 129.31, 128.92 ppm. 
4,6-dichloro-2-(thiophen-2-yl)-5-(2,4,6-trifluorophenyl)pyrimidine (4.57). Following 
synthetic procedure E using diethyl 2-(2,6-difluorophenyl)malonate (0.850 g, 2.93 mmol) and 
thiophene-2-carboximidamide hydrochloride (0.500 g, 3.07 mmol), purification by silica gel 
column chromatography (hexanes/EtOAc 98:2) afforded the title compound as a white solid 
(0.430 g, 1.19 mmol, 41% yield). 1H NMR (600 MHz, CDCl3) δ 8.13 (d, J = 2.6 Hz, 1H), 7.61 
(d, J = 4.4 Hz, 1H), 7.18 (t, J = 4.4 Hz, 1H), 6.87–6.81 (m, 2H) ppm. 13C NMR (151 MHz, 
CDCl3) δ 164.04 (dt, J = 252.9, 15.1 Hz), 162.48, 161.64, 160.41 (ddd, J = 252.0, 15.1, 8.9 
Hz), 140.12, 132.90, 132.16, 128.87, 118.45, 107.29 (td, J = 20.6, 4.9 Hz), 101.26–100.79 
(m) ppm. 
4,6-dichloro-5-(3,5-difluorophenyl)-2-(pyrazin-2-yl)pyrimidine (4.58). Following synthetic 
procedure E using diethyl 2-(3,5-difluorophenyl)malonate (0.500 g, 1.84 mmol) and pyrazine-
2-carboximidamide hydrochloride (0.306 g, 1.93 mmol), purification by silica gel column 
chromatography (hexanes/EtOAc 70:30 to 65:35) afforded the title compound as a brown 
solid (0.082 g, 0.242 mmol, 13% yield). 1H NMR (600 MHz, CDCl3) δ 9.72 (s, 1H), 8.84 (s, 
1H), 8.77 (d, J = 2.5 Hz, 1H), 7.01–6.94 (m, 1H), 6.93–6.88 (m, 2H) ppm. 13C NMR (151 
MHz, CDCl3) δ 164.03 (d, J = 12.8 Hz), 162.37 (d, J = 12.8 Hz), 162.07, 161.50, 147.42, 
146.93, 145.95, 144.95, 135.35 (t, J = 10.3 Hz), 131.34 (t, J = 2.3 Hz), 112.85 (dd, J = 21.0, 
5.9 Hz), 105.44 (t, J = 25.0 Hz) ppm; 13C NMR (151 MHz, Chloroform-d) δ 163.20 (dd, J = 
250.9, 12.8 Hz), 162.07, 161.50, 147.42, 146.93, 145.95, 144.95, 135.35 (t, J = 10.3 Hz), 
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131.34 (t, J = 2.3 Hz), 112.85 (dd, J = 21.0, 5.9 Hz), 105.44 (t, J = 25.0 Hz) ppm. HRMS 
(ES+) calculated for C14H7Cl2F2N4 [M + H]+ 339.0010, found 339.0010. 
4,6-dichloro-2-(pyridin-2-yl)-5-(2,4,6-trifluorophenyl)pyrimidine (4.59). Following 
synthetic procedure E using diethyl 2-(2,4,6-trifluorophenyl)malonate (0.871 g, 3.00 mmol) 
and pyridine-2-carboximidamide hydrochloride (0.496 g, 3.15 mmol), purification by silica 
gel column chromatography (hexanes/EtOAc 100:0 to 75:25) afforded the title compound as a 
yellow solid (0.350 g, 0.983 mmol, 33% yield). 1H NMR (600 MHz, CDCl3) δ 8.92–8.87 (m, 
1H), 8.55 (dt, J = 7.9, 1.1 Hz, 1H), 7.90 (td, J = 7.7, 1.8 Hz, 1H), 7.48 (ddd, J = 7.6, 4.7, 1.2 
Hz, 1H), 6.89–6.81 (m, 2H) ppm. 13C NMR (151 MHz, Chloroform-d) δ 164.18 (dt, J = 
254.0, 15.1 Hz), 163.98, 163.44, 160.27 (ddd, J = 252.4, 15.1, 8.8 Hz), 151.93, 150.65, 
137.37, 126.33, 124.80, 121.35, 107.06 (td, J = 20.4, 4.8 Hz), 101.43–100.82 (m) ppm. 
4,6-dichloro-5-(2,4-difluorophenyl)-2-(pyrazin-2-yl)pyrimidine (4.60). Following synthetic 
procedure E using diethyl 2-(2,4-difluorophenyl)malonate (0.500 g, 1.84 mmol) and pyrazine-
2-carboximidamide hydrochloride (0.306 g, 1.93 mmol), purification by silica gel column 
chromatography (hexanes/EtOAc 70:30 to 63:35) afforded the title compound as a brown 
solid (0.133 g, 0.392 mmol, 21%). 1H NMR (600 MHz, CDCl3) δ 9.73 (s, 1H), 8.84 (s, 1H), 
8.77 (d, J = 2.4 Hz, 1H), 7.37–7.29 (m, 1H), 7.07 (td, J = 8.3, 2.5 Hz, 1H), 7.01 (td, J = 9.1, 
2.5 Hz, 1H) ppm. 13C NMR (151 MHz, CDCl3) δ 164.17 (dd, J = 253.2, 11.6 Hz), 163.12, 
161.69, 159.87 (dd, J = 252.1, 12.4 Hz), 147.53, 146.87, 145.96, 144.91, 132.12 (dd, J = 10.0, 
3.7 Hz), 127.46, 116.71 (dd, J = 16.1, 4.0 Hz), 112.33 (dd, J = 21.8, 3.6 Hz), 104.98 (t, J = 
25.3 Hz) ppm. 
4,6-dichloro-5-(2,6-difluorophenyl)-2-(pyrazin-2-yl)pyrimidine (4.61). Following synthetic 
procedure E using diethyl 2-(2,6-difluorophenyl)malonate (0.330 g, 1.21 mmol) and pyrazine-
2-carboximidamide hydrochloride (0.201 g, 1.27 mmol), purification by silica gel column 
chromatography (hexanes/EtOAc 70:30) afforded the title compound as an orange solid 
(0.114 g, 0.336 mmol, 28% yield). 1H NMR (600 MHz, CDCl3) δ 9.75 (s, 1H), 8.85 (s, 1H), 
8.78 (d, J = 2.4 Hz, 1H), 7.57–7.48 (m, 1H), 7.09 (t, J = 7.9 Hz, 2H) ppm. 13C NMR (151 
MHz, CDCl3) δ 163.58, 162.24, 159.86 (dd, J = 251.8, 6.1 Hz), 147.56, 146.93, 146.04, 
144.94, 132.57 (t, J = 10.1 Hz), 123.16, 112.03 (dd, J = 20.8, 4.0 Hz), 110.26 (t, J = 19.9 Hz) 
ppm. 
4.6.2 Biological Assay 
Cell culture. T. b. brucei Lister 427 were cultured in HMI-9 medium55 with 10% heat-
inactivated fetal bovine serum (FBS; Gibco, Carlsbad, CA) and 10% serum plus medium 
supplement (Sigma-Aldrich), in vented flasks in a humidified atmosphere of 5% CO2 at 37 
°C. Parasites were maintained in log-phase growth (between 1×105 and 1×106 parasites/mL) 
and subcultured every 48 h. Trophozoites of N. fowleri strain KUL were axenically cultured 
in Nelson's medium supplemented with 10% FBS at 37 °C.56 
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In vitro activity against T. brucei (SYBR Green assay). SYBR Green assay was used to 
determine the killing effect of tubulin polymerization promoters on T. b. brucei cell 
viability.47 For the in vitro screening, compounds were serially diluted in duplicate to test at 
8-point concentrations ranging from 4 µM to 0.8 nM. Trypanosomes in log-phase growth 
were suspended at 2×105 trypanosomes/mL in complete HMI-9 medium under continuous 
agitation. Then, they were dispensed into 96-well plates (100 µL/well) containing 1 µL of test 
compound in 0.5% DMSO and 100 µL/well of fresh HMI-9 medium. Plates were incubated 
for 72 h at 37 °C and 5% CO2, at which point the trypanosomes were lysed by the addition of 
50 µL/well of lysis solution [30 mM Tris pH 7.5, 7.5 mM EDTA, 0.012% saponin, and 0.12% 
Triton X-100, modified from Co et al.;57 saponin was obtained from Sigma-Aldrich (Cat. No. 
S9430)] containing 0.3 µL/mL SYBR Green I (10,000× in DMSO; Invitrogen, Carlsbad, CA). 
The plates were agitated at 1700 rpm for 45 s using the MixMate plate mixer (Eppendorf, 
Hamburg-Eppendorf, Germany) and incubated in the dark for 1 h at room temperature, 
followed by reading on the 2104 EnVision® multilabel plate reader (PerkinElmer, Waltham, 
MA), with excitation at 485 nm/emission at 535 nm during 1 min per plate. The activity of 
test compounds was normalized against controls from the same plate according to the 
following formula: Activity (%) = [1 − (FCpd − blank) / (FNeg − blank)] × 100, where FCpd 
corresponds to the emitted fluorescent signal expressed in arbitrary fluorescence units for the 
test compound; and FNeg and blank correspond to the mean fluorescent signal of the negative 
control wells and the background signal, respectively. Data are means of three separate 
determinations. In each experiment, the whole library of test compounds was screened in a 
single day for each duplicate. Dose–response curves and IC50 values were calculated using the 
function asymmetrical sigmoidal, 5PL, X from the GraphPad Prism software, version 6.00 for 
Apple Macintosh.  
In vitro activity against N. fowleri. For primary screening, 0.5 µL of each 10 µM stock 
compound was transferred in duplicate to a 96-well microtiter plate to achieve a final 
concentration of 50 µM. Screening was carried out with 10,000 trophozoites/well. Plates were 
incubated at 37 °C for 48 h in an oxygenated environment and in the absence of the GasPak 
EZ anaerobe gas-generating pouch system (VWR).58 0.5% DMSO was used as a vehicle 
control and 200 µM miltefosine as a positive control. After 48 h incubation, the activity of the 
compounds was measured using a luminometer (EnVision multilabel plate reader, 
PerkinElmer) using an ATP bioluminescence-based CellTiter-Glo luminescent cell viability 
assay (Promega) technology.59,60 Compound 4.15, which showed more than 50% inhibition in 
primary screening at 50 µM, underwent secondary screening to confirm the activity and to 
determine IC50. For the secondary screening 4.15 was serially diluted in triplicate to test at 8-
point concentrations ranging from 0.39 µM to 50 µM. Dose–response curves and IC50 of 4.15 
were determined using GraphPad Prism software, version 6.00 for Apple Macintosh. 
Brain and Plasma Compound Determinations. Test compounds were quantified in plasma 
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and brain homogenates as previously described.42  
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Chapter 5: 1,1′-Biphenyl-4-sulfonamides as Potent Inhibitors of 
Carbonic Anhydrases 
5.1 Introduction 
Carbonic anhydrases (CAs) are metal containing enzymes that catalyze the production of 
monohydrogen carbonate from carbon dioxide and water.1 These enzymes are involved in 
many physiological processes, such as pH homeostasis, cell differentiation and proliferation, 
and neurotransmission. Consequently, their defective expression and/or abnormal activity 
may have important pathological consequences. Among fifteen well described human CA 
(hCA) isoforms belonging to the α-class family,2,3 the isoform XIV has been described as a 
new potential target for the treatment of epilepsy4 and some retinopathies.5 
 
5.2 Objective of the Study 
Despite the variety of CA inhibitors developed in the last few years,4,6,7 selective inhibitors 
of CA XIV have not been exhaustively explored. The region of the active site, containing 
residues 127−136 and indicated as a “hot zone”, makes the hCA XIV different from other 
human isoforms.8 In order to obtain selective hCA XIV inhibitors, molecular modeling 
studies hypothesised that the unexplored 1,1′-biphenyl-4-sulfonamide scaffold could interact 
with the active region. Thus, we designed and synthesised 21 1,1′-biphenyl-4-sulfonamide 
analogues (Figure 5.1) that were evaluated as inhibitors of hCA isoforms I, II, IX, XII and 
XIV. 
 
  
Figure 5.1. General chemical structure of the 1,1′-biphenyl-4-sulfonamide scaffold. 	
5.3 Chemistry 
Synthesis of 1,1′-biphenyl-4-sulfonamides 5.1−5.21 was accomplished following the 
general synthetic approach depicted in Scheme 5.1. Starting from the 4-(4,4,5,5-tetramethyl-
1,3,2-dioxaborolan-2-yl)-benzenesulfonamide 5.22,9 treatment with the appropriate aryl 
bromide (prepared as shown in Scheme 5.2 and 5.3), potassium phosphate tribasic and 
dichloro[1,1′-bis-(diphenylphosphino)ferrocene]palladium(II) complex with DCM (1:1) 
[PdCl2(dppf)·CH2Cl2] in DMF, furnished compounds 5.1 and 5.11−5.13. Hydrolysis of the 
esters 5.1 and 5.11−5.13 in the presence of lithium hydroxide in aqueous THF led to the 
corresponding carboxylic acids 5.3, 5.14−5.16, respectively. Sulfonamides 5.2, 5.4−5.10, 5.17 
and 5.19 were prepared using a microwave reaction, in which benzenesulfonamide 5.229 
reacted with the appropriate aryl bromide in the presence of cesium carbonate and Pd(II) 
S
H2N
linker
O
O 1
4
1′
4′
tail
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acetate in aqueous 1-methyl-2-pyrrolidinone (NMP). The alcohol 5.18 was obtained after 
treatment of 5.17 with sodium borohydride in aqueous THF. Finally, reduction of the nitro 
compounds 5.17 and 5.19 with tin(II) chloride dihydrate yielded the corresponding amino 
derivatives 5.20 and 5.21. As a PhD student of Prof. R. Silvestri’s research group, I 
participated in the synthesis and characterization of compounds 5.1−5.21 (see Experimental 
Section, Chemistry 5.6.1). 
 
 
  
Scheme 5.1. Synthesis of 1,1′-biphenyl-4-sulfonamides 5.1−5.21. 
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1-Bromo-4-nitrobenzene (5.24) was obtained by oxidation of 4-bromoaniline (5.23) with 
m-chloroperbenzoic acid (m-CPBA) in toluene (Scheme 5.2). Activation of 4-bromobenzoic 
acid (5.25) with 1,1′-carbonyldiimidazole (CDI) in anhydrous THF and subsequent treatment 
with potassium tert-butoxide or ammonium hydroxide solution furnished compounds 5.26 
and 5.27, respectively. Intermediates 5.28 and 5.29 were prepared by treating 5.25 with 2-
aminoethanol or N,O-dimethylhydroxylamine hydrochloride (CH3NHOCH3·HCl) in the 
presence of (benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 
(BOP reagent) and triethylamine in anhydrous DMF (Scheme 5.2). 
 
 
  
Scheme 5.2. Synthesis of intermediates 5.24−5.29. 
 
Treatment of 5.29 with phenyllithium in anhydrous Et2O furnished compound 5.30, 
whereas ketones 5.31 and 5.32 were obtained by reacting bromobenzene with nitrobenzene or 
toluene in the presence of AlCl3 (Scheme 5.3). Oxidation of 5.32 with potassium 
permanganate in aqueous tert-butanol furnished the carboxylic acid 5.33, which, after 
treatment with methanol in the presence of sulfuric acid gave the corresponding methyl ester 
5.34. Finally, alcohols 5.35−5.37 that were prepared as above reported by sodium 
borohydride reduction of ketones 5.30, 5.31 and 5.34, were converted into the corresponding 
methylene derivatives 5.38−5.40 by reaction with triethylsilane (TES) and 
trifluoromethanesulfonic acid in chloroform (Scheme 5.3).  
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Scheme 5.3. Synthesis of intermediates 5.30−5.40. 	
5.4 Results and Discussion 
Sulfonamides 5.1−5.21 were assayed for their ability to inhibit the hCA isoforms I, II, IX, 
XII and XIV, using acetazolamide (AAZ) as reference compound. The inhibitory constant 
(Ki) values of 5.1−5.21 and hCA XIV selectivity indexes (SI) are shown in Table 5.1. 
Ki values were measured by a stopped-flow screening assay that monitors the hydration of 
carbon dioxide catalyzed by each hCA isoform.10 Sulfonamides 5.1−5.21 were found to 
inhibit hCA isoforms I, II, IX and XII with Ki values in the nanomolar range, being superior 
to AAZ. Remarkably, they uniformly inhibited hCA XIV at nano/subnanomolar 
concentration. The SAR emerging from our data revealed a different inhibition profile for 
each hCA isoform. Thus, for example, alcohols 5.12 and 5.18 are the most potent inhibitors of 
hCA I (Ki = 6.3 and 8.9 nM, respectively), while ketones 5.8 and 5.14 showed to be the most 
active compounds against hCA II (Ki = 4.3 and 4.8 nM, respectively). Eight compounds, 5.1, 
5.3, 5.5, 5.6, 5.9, 5.14, 5.20, and 5.21, inhibited hCA IX with Ki < 10 nM, with the highest 
inhibition that was achieved with compounds bearing either a carboxylic acid or an amino 
group as the terminal function on the biphenylsulfonamide scaffold (e.g., 5.3 and 5.21, 
respectively). Nine compounds, 5.4, 5.6, 5.7, 5.8, 5.11, 5.12, 5.18, 5.19, and 5.21 inhibited 
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hCA XII with Ki values within the range of 6−9 nM, with the alcohol 5.12 being the most 
potent inhibitor against this isoform. Finally, twelve derivatives, 5.1−5.3, 5.5, 5.6, 5.8, 5.9, 
5.12, 5.14, 5.16, 5.20, and 5.21 showed to be exceptionally potent toward hCA XIV with Ki 
values in the subnanomolar range. Compound 5.20, which bears a terminal amino group, was 
found to be the most selective inhibitor of hCA XIV with Ki value of 0.26 nM. 
 
 
Ki (nM)a/SIb 
Cmpd R X hCA I hCA II hCA IX 
hCA 
XII 
hCA 
XIV 
5.1  - 
77.0 
1145 
9.0 
13 
9.3 
14 
35.2 
53 
0.67 
− 
5.2 
 
- 
78.8 
232 
42.0 
124 
71.4 
210 
44.9 
132 
0.34 
− 
5.3  - 
340 
453 
6.2 
8.3 
3.6 
4.8 
52.3 
70 
0.75 
− 
5.4 
 
- 
67.5 
4.9 
5.3 
0.4 
823 
60 
8.3 
0.6 
13.8 
− 
5.5 
 
- 
46.7 
68 
11.5 
17 
8.4 
12 
26.2 
40 
0.69 
− 
5.6  - 
62.2 
152 
11.6 
28 
9.6 
23 
7.4 
18 
0.41 
− 
5.7  - 
78.5 
21 
9.1 
2.5 
605 
164 
7.7 
2.1 
3.7 
− 
5.8  C=O 
1635 
1946 
4.3 
5.1 
63.8 
76 
7.4 
8.8 
 
0.84 
− 
5.9  CH(OH) 
52.7 
68 
4.9 
6.4 
8.9 
11.6 
81.1 
105 
0.77 
− 
5.10  CH2 
75.3 
4.6 
454 
27.9 
519 
31.8 
77.2 
4.7 
16.3 
− 
5.11  C=O 
73.8 
11 
7.8 
1.2 
42.3 
6.3 
7.3 
1.1 
6.7 
− 
5.12  CH(OH) 
6.3 
15 
6.6 
15.7 
710 
1690 
6.7 
16 
0.42 
− 
5.13  CH2 
122 
27 
50.6 
11 
76.7 
17 
237 
52 
4.6 
− 
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5.14  C=O 
263 
283 
4.8 
5.2 
8.5 
9.1 
45.5 
48.9 
0.93 
− 
5.15  CH(OH) 
72.5 
18 
814 
204 
450 
113 
93.9 
23 
4.0 
− 
5.16 
 
CH2 
236 
284 
6.9 
8.3 
31.4 
38 
90.8 
109 
0.83 
− 
5.17  C=O 
80.1 
23 
63.3 
18 
85.6 
24 
70.6 
20 
3.6 
− 
5.18  CH(OH) 
8.9 
1.0 
5.9 
0.7 
678 
80 
8.1 
0.9 
8.5 
− 
5.19  CH2 
70.5 
19 
39.7 
11 
705 
191 
9.3 
2.5 
3.7 
− 
5.20  C=O 
62.0 
238 
86.2 
332 
9.2 
35 
25.4 
98 
0.26 
− 
5.21  CH2 
589 
879 
5.2 
7.8 
6.0 
9 
8.1 
13 
0.67 
− 
AAZ 
 
250 
6 
12 
0.3 
25 
0.7 
5.7 
0.1 
41 
− 
 
Table 5.1. Inhibition of hCA I, II, IX, XII and XIV by 1,1′-biphenyl-4-sulfonamides 5.1−5.21 
and reference compound acetazolamide (AAZ). CO2 hydrase, stopped-flow method, mean 
from three different assays. aStandard deviations (SD) went from ±5% to ±10% of the 
indicated inhibitory constant (Ki) values. 
bhCA XIV selectivity indexes (SI) were obtained as 
ratio between the Kis of the indicated hCA and the corresponding hCA XIV Kis. 
 
X-ray crystallography and molecular modeling studies furnished the molecular basis 
responsible for the high selectivity of the most potent hCA XIV inhibitor within the series 
(compound 5.20) toward the target enzyme. Crystals of the hCA XIV/5.20 adduct were 
obtained by cocrystallization experiments as previously reported for other sulfonamide CA 
inhibitors.8 Data collected from crystallography studies revealed that the sulfonamide group 
of 5.20 coordinates the catalytic zinc ion and forms two hydrogen bonds with residue Thr199, 
as tipically observed in all CA/sulfonamide complexes (Figure 5.2).11 The biphenyl scaffold 
is located in the hydrophobic part of the active site8 and established several van der Waals 
interactions (<4.0 Å) with enzyme residues (Figures 5.3A and 5.3B). In one of the two 
conformations observed for the carbonyl group, it forms a hydrogen bond with the Ser132OG 
atom located in the “hot zone”, whereas in its second conformation, the side chain of Ser132 
is hydrogen bonded with the Ser130OG atom. Finally, the 4-aminophenyl moiety forms only 
weak binding interaction with the enzyme, thus resulting rather disordered.  
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Figure 5.2. Plants proposed binding mode (yellow) and crystallographic pose (cyan) of 
derivative 5.20 to hCA XIV. The active region, comprising residues 127−136, is reported as a 
cartoon; hydrogen bond and Zn coordinations are reported as yellow dot lines; residues of the 
binding site are also depicted.12 
 
 
 
Figure 5.3. Active-site region of the hCA XIV/5.20 (A) and solvent accessible surface of 
hCA XIV (B). (A) The inhibitor is shown in association with a σA-weighted |2Fo − Fc| map 
(contoured at 1.0 σ). Hydrogen bonds, residues involved in van der Waals interactions 
(distance <4.0 Å), and the active-site Zn2+ ion coordination are also shown. Conf.1 and Conf.2 
indicate the two conformations of Ser132 in the adduct. (B) The inhibitor molecule is shown 
in ball and stick representation. The hydrophobic and hydrophilic parts of the active site are 
colored in blue and red, respectively.12 
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Analysis of the adduct of 5.20 with hCA isoform II showed that many interactions 
observed in the hCA XIV/5.20 adduct are conserved, while the carbonyl group of 5.20 does 
not form any hydrogen bond with the hCA II enzyme due to the substitution of Ser132 with a 
glycine residue (Figure 5.4A). Indeed, rotation of the residue of about 120° with respect to the 
corresponding pose in the hCA XIV/5.20 adduct, leads to a different orientation of the 
aminophenyl tail that, in the hCA II/5.20 adduct, interacts with a water molecule present 
within the active site cavity (Figure 5.4B). 
 
 
Figure 5.4. Active-site region of the hCA II/5.20 adduct (A) and superposition of the hCA 
XIV/5.20 (green) and hCA II/5.20 (yellow) complexes (B). (A) The inhibitor is shown in 
association with a σA-weighted |2Fo − Fc| map (contoured at 1.0 σ). Hydrogen bonds, residues 
involved in van der Waals interactions (distance < 4.0 Å), and the active-site Zn2+ ion 
coordination are also shown. Conf.1 and Conf.2 indicate the two conformations of Ser132 in 
the adduct. (B) The inhibitor is represented in ball-and-stick, while the protein region 
127−136 is represented in red.12 	
To investigate the role of the protein region of residues 127-136 in the interaction of 5.20 
with the other hCA isoforms I, IX and XII, docking studies were performed by using the 
programs Plants13,14 and Autodock.15 Superimposition of hCA XIV/5.20 and the other 
hCAs/5.20 complexes highlighted important amino acid substitutions in the active-site that 
slightly change the 5.20 binding mode. We can conclude that only hCA XIV is capable to 
form favorable interactions between the active region and the inhibitor, therefore 
discriminating the binding of 1,1’-biphenyl-4-sulfonamides to hCA XIV (Figure 5.5). 
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Figure 5.5. Superposition of the binding poses proposed by Plants of 5.20 in the catalytic site 
of (A) hCA I (green), (B) hCA IX (silver), and (C) hCA XII (brown) with hCA XIV 
(magenta)/5.20 (cyan) crystallographic complex. hCA XIV residue numbers are shown out of 
brackets.12 			
5.5 Conclusions 
We explored 1,1′-biphenylsulfonamide as a potential scaffold directed toward the 
inhibition of the ubiquitous hCA isoforms I, II, IX, XII and XIV. With this aim, we designed, 
synthesized and evaluated 21 new biphenylsulfonamide analogues obtaining Ki values at 
nanomolar concentration for the entire hCAs panel. Moreover, we conducted crystallography 
and molecular modeling studies to understand the molecular basis responsible for the high 
affinity of the most potent hCA XIV inhibitor found (compound 5.20, Ki = 0.26 nM) toward 
the target enzymes. Taken together our results suggest that each hCA isoform shows different 
inhibition profiles and highlight the importance of the interaction between the Ser132 of the 
active region and the carbonyl group of the inhibitor 5.20, which discriminates the selective 
binding to hCA XIV. These results encourage the development of 1,1′-biphenylsulfonamides 
as a new class of selective and potent hCA XIV inhibitors. 
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5.6 Experimental Section 
5.6.1 Chemistry 
General description of common materials and instrumentation has been previously 
discussed in section 2.7.1. 
General Procedure A for the Synthesis of Compounds 5.1 and 5.11−5.13. A mixture of 4-
(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-benzenesulfonamide (1.3 equiv), appropriate 
aryl bromide (1 equiv), and potassium phosphate tribasic (3 equiv) in DMF (0.2 M) was 
degassed for 30 min. PdCl2(dppf)·CH2Cl2 (0.03 equiv) was added under Ar stream, and the 
reaction mixture was heated at 60 °C for 2 h. After cooling, water and EtOAc were added and 
the resulting mixture was filtered through a pad of silica gel. The organic layer was washed 
with brine, dried over Na2SO4, filtered anc concentrated in vacuo. The resulting material was 
purified by silica gel column chromatography to obtain the desired compound. 
General Procedure B for the Synthesis of Compounds 5.2, 5.4−5.10, 5.17, and 5.19. A 
mixture of 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-benzenesulfonamide (1.3 equiv), 
appropriate arylbromide (1 equiv), cesium carbonate (1.3 equiv), and Pd(II) acetate (0.13 
equiv) in 1-methyl-2-pyrrolidinone (2.3 mL) and water (5 M) was placed into the microwave 
cavity (closed vessel mode, Pmax = 250 PSI). Starting MW irradiation of 100 W was used, the 
temperature being ramped from 25 to 110 °C. Once 110 °C was reached, taking about 2 min, 
the reaction mixture was held at the same temperature for 15 min while highly stirring and 
cooling. The mixture was diluted with water and extracted with EtOAc. The organic layer was 
washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. Purification via 
silica gel column chromatography yielded the desired product. 
General Procedure C for the Synthesis of Compounds 5.3, 5.14−5.16. A mixture of the 
appropriate 1,1′-biphenylsulfonamide (1 equiv) and lithium hydroxide hydrate (3 equiv) in 
THF (0.1 M) and water (0.1 M) was stirred at 25 °C overnight. The reaction mixture was 
made acidic (pH = 2) with 1 N HCl and extracted with EtOAc. The organic layer was washed 
with brine, dried over Na2SO4, and filtered. Removal of the solvent furnished the desired 
product. 
General Procedure D for the Synthesis of Compounds 5.18 and 5.35−5.37. A mixture of 
the appropriate 1,1′-biphenylsulfonamide (1 equiv) and sodium borohydride (1 equiv) in THF 
(0.2 M) and water (4 M) was heated at reflux for 2 h. After cooling, cold water and EtOAc 
were added and layers were separated. The organic layer was washed with brine, dried over 
Na2SO4, filtered and concentrated in vacuo. The resulting material was purified by silica gel 
column chromatography to obtain the desired compound. 
General Procedure E for the Synthesis of Compounds 5.20 and 5.21. A mixture of the 
appropriate 1,1′-biphenylsulfonamide (1 equiv) and tin(II) chloride dihydrate (5 equiv) in 
EtOAc (0.1 M) was refluxed for 3 h. After cooling, the reaction mixture was made basic (pH 
= 10) with satd. aq. NaHCO3 and extracted with EtOAc. The organic layer was dried over 
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Na2SO4 and filtered. Removal of the solvent furnished the desired product. 
General Procedure F for the Synthesis of Compounds 5.38−5.40. 
Trifluoromethanesulfonic acid (11 equiv) was added dropwise to a cold solution of the 
appropriate 4-bromoderivative (1 equiv) and triethylsilane (4 equiv) in CHCl3 (0.2 mL). The 
reaction mixture was stirred for 1 h at 25 °C, then diluted with water and extracted with 
CHCl3. The organic layer was washed with satd. aq. NaHCO3 and brine, dried over Na2SO4 
and filtered. Removal of the solvent gave a residue that was purified by silica gel column 
chromatography to obtain the desired compound. 
Methyl 4-sulfamoyl-1,1'-biphenyl-4'-carboxylate (5.1). Following synthetic procedure A 
using methyl ester of the 4-bromobenzoic acid (0.210 g, 1.00 mmol), purification by silica gel 
column chromatography (hexanes/EtOAc 50:50) afforded the title compound as a brown solid 
(0.170 g, 0.583 mmol, 58% yield). M.p. 240−243 °C (EtOH). 1H NMR (400 MHz, DMSO-d6) 
δ 3.89 (s, 3H), 7.44 (broad s, 2H, disappeared on treatment with D2O), 7.88−7.96 (m, 6H), 
8.07 (d, J = 8.2 Hz, 2H) ppm. IR ν 1701, 3231, 3232 cm−1. Anal. (C14H13NO4S (291.32)) C, 
H, N, S. 
tert-Butyl 4-sulfamoyl-1,1'-biphenyl-4'-carboxylate (5.2). Following synthetic procedure B 
using tert-butyl 4-bromobenzoate (0.070 g, 0.272 mmol), purification by silica gel column 
chromatography (CH2Cl2/EtOH 95:5) afforded the title compound as a green solid (0.025 g, 
0.075 mmol, 28% yield). M.p. 178−181 °C (EtOH). 1H NMR (400 MHz, DMSO-d6) δ 1.57 
(s, 9H), 7.45 (broad s, 2H, disappeared on treatment with D2O), 7.87 (d, J = 7.9 Hz, 2H), 
7.90−7.93 (m, 4H), 8.01 (d, J = 7.9 Hz, 2H) ppm. IR ν 1683, 3232, 3281 cm−1. Anal. 
(C17H19NO4S (333.40)) C, H, N, S.  
4-Sulfamoyl-1,1'-biphenyl-4'-carboxylic acid (5.3). Following synthetic procedure C using 
methyl 4-sulfamoyl-1,1′-biphenyl-4′-carboxylate (0.100 g, 0.340 mmol), the title compound 
was obtained as a brown solid (0.090 g, 0.324 mmol, 95% yield). M.p. >280 °C (EtOH). 1H 
NMR (400 MHz, DMSO-d6) δ 7.43 (broad s, 2H, disappeared on treatment with D2O), 7.86 
(d, J = 8.2 Hz, 2H), 7.93 (m, 4H), 8.05 (d, J = 8.3 Hz, 2H), 12.75 (broad s, 1H, disappeared 
on treatment with D2O) ppm. IR ν 1670, 3258, 3374 cm−1. Anal. (C13H11NO4S (277.30)) C, 
H, N, S.  
4-sulfamoyl-1,1'-biphenyl-4'-carboxamide (5.4). Following synthetic procedure B using 4-
bromobenzamide (0.054 g, 0.270 mmol), purification by silica gel column chromatography 
(EtOAc) afforded the title compound as a white solid (0.070 g, 0.253 mmol, 94% yield). M.p. 
>280 °C (EtOH). 1H NMR (400 MHz, DMSO-d6) δ 7.43 (broad s, 2H, disappeared on 
treatment with D2O), 7.83 (d, J = 8.3 Hz, 2H), 7.90−7.95 (m, 4H), 8.00 (d, J = 8.1 Hz, 2H), 
8.07 (broad s, 2H, disappeared on treatment with D2O) ppm. IR ν 1643, 3163, 3367 cm−1. 
Anal. (C13H12N2O3S (276.31)) C, H, N, S.  
N-(2-Hydroxyethyl)-4-sulfamoyl-1,1'-biphenyl-4'-carboxamide (5.5). Following synthetic 
procedure B using 4-bromo-N-(2-hydroxyethyl)-benzamide (0.066 g, 0.270 mmol), 
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purification by silica gel column chromatography (CH2Cl2/EtOH 80:20) afforded the title 
compound as a white solid (0.060 g, 0.187 mmol, 69% yield). M.p. 187−190 °C (EtOH). 1H 
NMR (400 MHz, DMSO-d6) δ 3.31−3.38 (m, 2H), 3.51−3.54 (m, 2H), 4.75 (t, J = 5.5 Hz, 
1H), 7.43 (broad s, 2H, disappeared on treatment with D2O), 7.84 (d, J = 8.6 Hz, 2H), 
7.90−7.95 (m, 4H), 7.99 (d, J = 8.2 Hz, 2H), 8.53 (broad s, 1H, disappeared on treatment with 
D2O) ppm. IR ν 1637, 2922, 3068, 3316, 3389 cm−1. Anal. (C15H16N2O4S (320.36)) C, H, N, 
S.  
4'-Nitro-1,1'-biphenyl-4-sulfonamide (5.6). Following synthetic procedure B using 1-
bromo-4-nitrobenzene (0.054 g, 0.267 mmol), purification by silica gel column 
chromatography (hexanes/EtOAc 50:50) afforded the title compound as a yellow solid (0.030 
g, 0.108 mmol, 40% yield). M.p. 143−145 °C (EtOH). Lit.16 m.p. 145 °C. 
4'-Amino-1,1'-biphenyl-4-sulfonamide (5.7). Following synthetic procedure B using 4-
bromoaniline (0.172 g, 1.00 mmol), purification by silica gel column chromatography 
(hexanes/EtOAc 50:50) afforded the title compound as a yellow solid (0.110 g, 0.443 mmol, 
45% yield). M.p. 271−274 °C (EtOH). Lit.17 266−267 °C. 1H NMR (400 MHz, DMSO-d6) δ 
5.38 (broad s, 2H, disappeared on treatment with D2O), 6.65 (d, J = 8.6 Hz, 2H), 7.29 (broad 
s, 2H, disappeared on treatment with D2O), 7.44 (d, J = 8.5 Hz, 2H), 7.71 (d, J = 8.7 Hz, 2H), 
7.78 (d, J = 8.4 Hz, 2H) ppm. IR ν 1588, 3276, 3434 cm−1. Anal. (C12H12N2O2S (248.30)) C, 
H, N, S.  
4'-Benzoyl-1,1'-biphenyl-4-sulfonamide (5.8). Following synthetic procedure B using (4-
bromophenyl)(phenyl)methanone (0.070 g, 0.268 mmol), purification by silica gel column 
chromatography (hexanes/EtOAc 50:50) afforded the title compound as a white solid (0.070 
g, 0.207 mmol, 77% yield). M.p. 262−265 °C (EtOH). 1H NMR (400 MHz, DMSO-d6) δ 7.44 
(broad s, 2H, disappeared on treatment with D2O), 7.57−7.61 (m, 2H), 7.68−7.98 (m, 11H) 
ppm. IR ν 1649, 3234, 3299 cm−1. Anal. (C19H15NO3S (337.39)) C, H, N, S.  
4'-(Hydroxy(phenyl)methyl)-1,1'-biphenyl-4-sulfonamide (5.9). Following synthetic 
procedure B using (4-bromophenyl)(phenyl)methanol (0.071 g, 0.270 mmol), purification by 
silica gel column chromatography (hexanes/EtOAc 50:50) afforded the title compound as a 
white solid (0.055 g, 0.162 mmol, 60 % yield). M.p. 195−197 °C (from EtOH). 1H NMR (400 
MHz, DMSO-d6) δ 5.76 (d, J = 3.82 Hz, 1H), 5.96 (d, J = 4 Hz, 1H), 7.19−7.23 (m, 1H), 
7.29−7.33 (m, 2H), 7.36 (broad s, 2H, disappeared on treatment with D2O), 7.40−7.42 (m, 
2H), 7.50 (d, J = 8.1 Hz, 2H), 7.67 (d, J = 8.2 Hz, 2H), 7.81−7.88 (m, 4H) ppm. IR ν 1595, 
2923, 3337 cm−1. Anal. (C19H17NO3S (339.41)) C, H, N, S.  
4'-Benzyl-1,1'-biphenyl-4-sulfonamide (5.10). Following synthetic procedure B using 1-
benzyl-4-bromobenzene (0.067 g, 0.271 mmol), purification by silica gel column 
chromatography (hexanes/EtOAc 50:50) afforded the title compound as a white solid (0.050 
g, 0.154 mmol, 57% yield). M.p. 165−168 °C (EtOH). 1H NMR (400 MHz, DMSO-d6) δ 4.00 
(s, 2H), 7.19−7.32 (m, 5H; m, 3H after treatment with D2O), 7.35−7.37 (m, 4H), 7.65 (d, J = 
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8.1 Hz, 2H), 7.81−7.88 (m, 4H) ppm. IR ν 3271, 3375 cm−1. Anal. (C19H17NO2S (323.41)) C, 
H, N, S.  
Methyl 4-(4-Sulfamoyl-1,1′-biphenyl-4′-carbonyl)benzoate (5.11). Following synthetic 
procedure A using methyl 4-(4-bromobenzoyl)benzoate (0.319 g, 1.00 mmol), purification by 
silica gel column chromatography (hexanes/EtOAc 50:50) afforded the title compound as a 
white solid (0.277 g, 0.700 mmol, 70% yield). M.p. 283−286 °C (EtOH). 1H NMR (400 MHz, 
DMSO-d6) δ 3.92 (s, 3H), 7.45 (broad s, 2H, disappeared on treatment with D2O), 7.87−7.90 
(m, 4H), 7.94−7.99 (m, 6H), 8.13−8.15 (m, 2H) ppm. IR ν 1644, 1720, 3277, 3375 cm−1. 
Anal. (C21H17NO5S (395.43)) C, H, N, S.  
Methyl 4-(4-Sulfamoyl-1,1′-biphenyl-4′-hydroxymethyl)benzoate (5.12). Following 
synthetic procedure A using methyl 4-(hydroxy(4-bromophenyl)methyl)benzoate (1.17 g, 
3.64 mmol), purification by silica gel column chromatography (CHCl3/EtOAc 50:50) 
afforded the title compound as a white solid (0.350 g, 0.881 mmol, 24% yield). M.p. 163−165 
°C (EtOH). 1H NMR (400 MHz, DMSO-d6) δ 3.83 (s, 3H), 5.85 (d, J = 3.7 Hz, 1H), 6,16 (d, J 
= 3.9 Hz, 1H), 7.38 (broad s, 2H, disappeared on treatment with D2O) 7.51 (d, J = 8.2 Hz, 
2H), 7.57 (d, J = 8.1 Hz, 2H), 7.68 (d, J = 8.3 Hz, 2H), 7.81−7.88 (m, 4H), 7.92 (d, J = 8.4 
Hz, 2H) ppm. IR ν 1721, 3277, 3379, 3506 cm−1. Anal. (C21H19NO5S (397.44)) C, H, N, S.  
Methyl 4-(4-Sulfamoyl-1,1′-biphenyl-4′-methyl)benzoate (5.13). Following synthetic 
procedure A using methyl 4-(4-bromobenzyl)benzoate (0.880 g, 2.88 mmol), purification by 
silica gel column chromatography (CHCl3/EtOAc 50:50) afforded the title compound as a 
white solid (0.240 g, 0.629 mmol, 22% yield). M.p. 150−153 °C (EtOH). 1H NMR (400 MHz, 
DMSO-d6) δ 3.82 (s, 3H), 4.08 (s, 2H), 7.36−7.38 (m, 4H), 7.40−7.42 (m, 2H) 7.66 (d, J = 7.9 
Hz, 2H), 7.81−7.91 (m, 6H) ppm. IR ν 1704, 3258, 3353 cm−1. Anal. (C21H19NO4S (381.44)) 
C, H, N, S.  
4-(4-Sulfamoyl-1,1′-biphenyl-4′-carbonyl)benzoic Acid (5.14). Following synthetic 
procedure C using methyl 4-(4-sulfamoyl-1,1′-biphenyl-4′-carbonyl)benzoate (0.050 g, 0.126 
mmol), the title compound was obtained as a white solid (0.030 g, 0.079 mmol, 62% yield). 
M.p. >280 °C (EtOH). Lit.18 351−352 °C. 1H NMR (400 MHz, DMSO-d6) δ 7.45 (broad s, 
2H, disappeared on treatment with D2O), 7.86−7.90 (m, 4H), 7.93−7.99 (m, 6H) 8.11−8.13 
(m, 2H), 12.85 (broad s, 1H, disappeared on treatment with D2O) ppm. IR ν 1687, 2845, 
3273, 3370 cm−1. Anal. (C20H15NO5S (381.40)) C, H, N, S.  
4-(4-Sulfamoyl-1,1′-biphenyl-4′-hydroxymethyl)benzoic Acid (5.15). Following synthetic 
procedure C using methyl 4-(4-sulfamoyl-1,1′-biphenyl-4′-hydroxymethyl)benzoate (0.050 g, 
0.126 mmol), purification by silica gel column chromatography (EtOAc/EtOH 90:10) the title 
compound was obtained as a white solid (0.043 g, 0.112 mmol, 89% yield). M.p. >280 °C 
(EtOH). 1H NMR (400 MHz, DMSO-d6) δ 5.79 (d, J = Hz, 1H), 6.03 (d, J = Hz, 1H), 
7.39−7.42 (m, 4H; m, 2H after treatment with D2O), 7.50 (d, J = 8.2 Hz, 2H), 7.67 (d, J = 8.0 
Hz, 2H), 7.81−7.89 ppm (m, 6H), 12.83 (broad s, 1H, disappeared on treatment with D2O) 
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ppm. IR ν 1685, 2845, 3360, 3365, 3568 cm−1. Anal. (C20H17NO5S (383.42)) C, H, N, S.  
4-(4-Sulfamoyl-1,1′-biphenyl-4′-methyl)benzoic Acid (5.16). Following synthetic procedure 
C using methyl 4-(4-sulfamoyl-1,1′-biphenyl-4′-methyl)benzoate (0.050 g, 0.131 mmol), the 
title compound was obtained as a white solid (0.047 g, 0.127 mmol, 98% yield). M.p. >280 
°C (EtOH). 1H NMR (400 MHz, DMSO-d6) δ 4.08 (s, 2H), 7.31−7.43 (m, 6H; m, 4H after 
treatment with D2O), 7.67 (d, J = 8.2 Hz, 2H), 7.82−7.89 (m, 6H), 12.79 (broad s, 1H, 
disappeared on treatment with D2O) ppm. IR ν 3346, 3258, 1681 cm−1. Anal. (C20H17NO4S 
(367.42)) C, H, N, S.  
4-Sulfamoyl-4′-(4-nitrobenzoyl)-1,1′-biphenyl (5.17). Following synthetic procedure B 
using (4-bromophenyl)(4-nitrophenyl)methanone (0.083 g, 0.271 mmol), purification by 
silica gel column chromatography (hexanes/EtOAc 50:50) afforded the title compound as a 
white solid (0.031 g, 0.081 mmol, 30% yield). M.p. 222−225 °C (EtOH). 1H NMR (400 MHz, 
DMSO-d6) δ 7.46 (broad s, 2H, disappeared on treatment with D2O), 7.89−7.94 (m, 3H), 
7.95−8.02 (m, 7H), 8.38−8.41 (m, 2H) ppm. IR ν 1641, 3103, 3211, 3380 cm−1. Anal. 
(C19H14N2O5S (382.39)) C, H, N, S.  
4-Sulfamoyl-4′- hydroxymethyl(4-nitrophenyl)-1,1′-biphenyl (5.18). Following synthetic 
procedure D using 4-sulfamoyl-4′-(4-nitrobenzoyl)-1,1′-biphenyl (0.190 g, 0.497 mmol), 
purification by silica gel column chromatography (hexanes/EtOAc 50:50) afforded the title 
compound as a white solid (0.070 g, 0.182 mmol, 37% yield). M.p. 169−172 °C (EtOH). 1H 
NMR (400 MHz, DMSO-d6) δ 5.94 (d, J = 2.5 Hz, 1H), 6.31 (d, J = 3.5 Hz, 1H), 7.37 (broad 
s, 2H, disappeared on treatment with D2O), 7.53 (d, J = 8.2 Hz, 2H), 7.68−7.72 (m, 4H), 
7.82−7.89 (m, 4H), 8.19−8.21 (m, 2H) ppm. IR ν 3258, 3362, 3571 cm−1. Anal. 
(C19H16N2O5S (384.41)) C, H, N, S.  
4-Sulfamoyl-4′-methyl(4-nitrophenyl)-1,1′-biphenyl (5.19). Following synthetic procedure 
B using 1-bromo-4-(4-nitrobenzyl)benzene (0.079 g, 0.270 mmol), purification by silica gel 
column chromatography (CHCl3/EtOAc 50:50) afforded the title compound as a yellow solid 
(0.060 g, 0.163 mmol, 60% yield). M.p. 165−168 °C (EtOH). 1H NMR (400 MHz, DMSO-d6) 
δ 4.16 (s, 2H), 7.39−7.41 (m, 4H; m, 2H after treatment with D2O), 7.56 (d, J = 8.7 Hz, 2H), 
7.68 (d, J = 8.2 Hz, 2H), 7.82−7.89 (m, 4H), 8.18 (d, J = 8.8 Hz, 2H) ppm. IR ν 3270, 3367 
cm−1. Anal. (C19H16N2O4S (368.41)) C, H, N, S.  
4-Sulfamoyl-4′-(4-aminobenzoyl)-1,1′-biphenyl (5.20). Following synthetic procedure D 
using 4-sulfamoyl-4′-(4-nitrobenzoyl)-1,1′-biphenyl (0.150 g, 0.390 mmol), the title 
compound was obtained as a yellow solid (0.080 g, 0.226 mmol, 58% yield). M.p. 140−145 
°C (EtOH). 1H NMR (400 MHz, DMSO-d6) δ 6.20 (broad s, 2H, disappeared on treatment 
with D2O), 6.62 (d, J = 8.7 Hz, 2H), 7.44 (broad s, 2H, disappeared on treatment with D2O), 
7.57 (d, J = 8.7 Hz, 2H), 7.72 (d, J = 7.9 Hz, 2H), 7.87 (d, J = 7.9 Hz, 2H), 7.86−7.96 (m, 4H) 
ppm. IR ν 1638, 3264, 3340 cm−1. Anal. (C19H16N2O3S (352.41)) C, H, N, S.  
4-Sulfamoyl-4′-methyl(4-aminophenyl)-1,1′-biphenyl (5.21). Following synthetic procedure 
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D using 4-sulfamoyl-4′-methyl(4-nitrophenyl)-1,1′-biphenyl (0.084 g, 0.228 mmol), the title 
compound was obtained as a yellow solid (0.040 g, 0.118 mmol, 52% yield). M.p. 235 °C 
with decomposition (EtOH). 1H NMR (400 MHz, DMSO-d6) δ 3.80 (s, 2H), 4.87 (broad s, 
2H, disappeared on treatment with D2O), 6.50 (d, J = 8.2 Hz, 2H), 6.90 (d, J = 8.2 Hz, 2H), 
7.30 (d, J = 8.1 Hz, 2H), 7.36 (broad s, 2H, disappeared on treatment with D2O), 7.63 (d, J = 
8.1 Hz, 2H), 7.81−7.88 (m, 4H) ppm. IR ν 3310, 3410 cm−1. Anal. (C19H18N2O2S (338.42)) C, 
H, N, S.  
1-Bromo-4-nitrobenzene (5.24). 3-Chloroperbenzoic acid (10.3 g, 60.0 mmol) was added 
to a mixture of 4-bromoaniline (2.00 g, 12.0 mmol) in toluene (50 mL). The reaction was 
refluxed for 3 h, and after cooling was diluted with water and extracted with EtOAc. The 
organic layer was washed with 1 N NaOH and with brine, dried over Na2SO4 and filtered. 
Removal of the solvent furnished the desired product as a solid (2.30 g, 11.4 mmol, 95% 
yield). M.p. 123−125 °C (EtOH). Lit.19 m.p. 126−128 °C.  
tert-Butyl 4-bromobenzoate (5.26). 1,1'-Carbonyldiimidazole (2.43 g, 15.0 mmol) was 
added to a solution of 4-bromobenzoic acid (2.00 g, 10.0 mmol) in THF (20 mL). The 
reaction mixture was stirred for 2 h at 25 °C. A solution of potassium tert-butoxide (3.37 g, 
30.0 mmol) in THF (30 mL) was added dropwise and the reaction mixture was stirred for 2 h 
at 25 °C. Water was added and the resulting solution was extracted with EtOAc. The organic 
layer was washed with brine, dried over Na2SO4 and filtered. Removal of the solvent gave a 
residue that was purified by silica gel column chromatography (CH2Cl2) to furnish the title 
compound as a yellow oil (2.29 g, 8.91 mmol, 89% yield).20  
4-Bromobenzamide (5.27). Following synthetic procedure described for 5.26 using an 
NH4OH solution (≥25% in water), purification by silica gel column chromatography (EtOAc) 
afforded the title compound as a white solid (1.86 g, 9.30 mmol, 93% yield). M.p. 198−200 
°C (EtOH). Lit.21 m.p. 199−200 °C.  
4-Bromo-N-(2-hydroxyethyl)benzamide (5.28). To a solution of 4-bromobenzoic acid (2.00 
g, 10.0 mmol), 2-aminoethanol (1.83 g, 30.0 mmol) and Et3N (3.0 g, 30.0 mmol) in DMF (20 
mL) wad added (benzotriazol-1-yloxy)tris(dimethylamino) phosphonium 
hexafluorophosphate (4.42 g, 10.0 mmol). The reaction mixture was stirred for 2 h at 25 °C, 
diluted with water and extracted with EtOAc. The organic layer was washed with brine, dried 
over Na2SO4 and filtered. Removal of the solvent gave a residue that was triturated with n-
hexane to obtain the desired product as a white solid (1.60 g, 6.55 mmol, 66% yield). M.p. 
131−134 °C (EtOH). 1H NMR (400 MHz, DMSO-d6) δ 3.27-3.31 (m, 2H), 3.46- 3.50 (m, 
2H), 4.70 (t, J = 5.6 Hz, 1H), 7.64 (d, J = 8.5 Hz, 2H), 7.77 (d, J = 8.6 Hz, 2H), 8.49 (broad s, 
1H, disappeared on treatment with D2O) ppm. IR ν 1629, 3082, 3279 cm-1. Anal. 
(C9H10BrNO2 (244.09)) C, H, Br, N.  
4-Bromo-N-methoxy-N-methylbenzamide (5.29). Following synthetic procedure described 
for 5.28 using N,O-dimethylhydroxylamine hydrochloride (0.975 g, 10.0 mmol), the title 
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compound was obtained as a colourless oil (1.73 g, 7.10 mmol, 71% yield).22  
(4-Bromophenyl)(phenyl)methanone (5.30). Phenyllithium (0.294 g, 3.50 mmol, 1.9 M in 
butyl ether) was added to a suspension of 4-bromo-N-methoxy-N-methylbenzamide 29 (1.00 
g, 3.50 mmol) in anhydrous Et2O (20 mL) at −30 °C under Ar stream. The reaction mixture 
was stirred in the same conditions for 2.5 h, diluted with a saturated aqueous solution of 
NH4Cl and extracted with EtOAc. The organic layer was washed with brine, dried over 
Na2SO4, filtered and concentrated in vacuo. The resulting material was putified by silica gel 
column chromatography (CH2Cl2) to obtain the title compound (0.900 g, 0.345 mmol, 98% 
yield). M.p. 65−67 °C (EtOH). Lit.23 m.p. 75−76 °C.  
(4-Bromophenyl)(4-nitrophenyl)methanone (5.31). To a suspension of AlCl3 (0.720 g, 5.40 
mmol) in bromobenzene (4.24 g, 27.0 mmol) was added dropwise a solution of 4-
nitrobenzoyl chloride (1.00 g, 5.40 mmol) in bromobenzene (10 mL). The reaction mixture 
was refluxed for 1.5 h. After cooling the mixture was quenced on crushed ice containing 6 N 
HCl and extracted with EtOAc. The organic layer was washed with brine, dried over Na2SO4, 
filtered and concentrated in vacuo. Purification via silica gel column chromatography 
(hexanes/EtOAc 80:20) afforded the title compound as a solid (0.910 g, 0.297 mmol, 55% 
yield). M.p. 115−117 °C (EtOH). Lit.24 m.p. 125 °C.  
(4-Bromophenyl)(p-tolyl)methanone (5.32). Following synthetic procedure described for 
5.31 using 4-toluoyl chloride (0.835 g, 5.40 mmol), purification by silica gel column 
chromatography (hexanes/EtOAc 80:20) afforded the title compound as a solid (0.669 g, 2.43 
mmol, 45% yield). M.p. 135−138 °C (EtOH). Lit.25 m.p. 139−140 °C.  
4-(4-Bromobenzoyl)benzoic acid (5.33). Potassium permanganate (2.84 g, 180 mmol) was 
added portionwise to a mixture of (4-bromophenyl)(p-tolyl)methanone (1.00 g, 3.60 mmol) in 
tert-buyl alcohol (5 mL) and water (7.5 mL) at 50 °C. The reaction mixture was heated and 
stirred for 3 h at 80 °C, then cooled to 0 °C, made acidic with 6 N HCl and extracted with 
EtOAc. The organic layer was washed with brine, dried over Na2SO4 and filtered. Removal of 
the solvent furnished the desired product (1.00 g, 3.28 mmol, 91% yield). M.p. 270−274 °C 
(EtOH). Lit.26 m.p. 274 °C.  
Methyl 4-(4-Bromobenzoyl)benzoate (5.34). Synthesized following synthetic procedure 
described by Campagnola, P. J. et al.27 M.p. 175−177 °C (EtOH). Lit.28 m.p. 177−178 °C.  
(4-Bromophenyl)(phenyl)methanol (5.35). Following synthetic procedure D using (4-
bromophenyl)(phenyl)methanone (0.128 g, 0.490 mmol), purification by silica gel column 
chromatography (hexanes/EtOAc 50:50) afforded the title compound as an oil (0.113 g, 0.431 
mmol, 88% yield). Lit.29  
(4-Bromophenyl)(4-nitrophenyl)methanol (5.36). Following synthetic procedure D using (4-
bromophenyl)(4-nitrophenyl)methanone (0.150 g, 0.490 mmol), purification by silica gel 
column chromatography (hexanes/EtOAc 50:50) afforded the title compound as a solid (0.128 
g, 0.416 mmol, 85% yield). M.p. 159−162 °C (EtOH). Lit.30 m.p. 158−159 °C.  
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Methyl 4-((4-Bromophenyl)(hydroxy)methyl)benzoate (5.37). Following synthetic 
procedure D using methyl 4-(4-bromobenzoyl)benzoate (2.95 g, 9.24 mmol), purification by 
silica gel column chromatography (hexanes/EtOAc 50:50) afforded the title compound as a 
white solid (2.90 g, 9.03 mmol, 98% yield). M.p. 50−53 °C (EtOH). 1H NMR (400 MHz, 
CDCl3) δ 2.39 (d, J = 3.4 Hz, 1H), 3.90 (s, 3H), 5.84 (d, J = 3.1 Hz, 1H), 7.22-7.25 (m, 2H), 
7.42-7.48 (m, 4H), 7.99-8.01 (m, 2H) ppm. IR ν 1719, 3438 cm-1. Anal. (C15H13BrO3 
(321.17)) C, H, Br.  
1-Benzyl-4-bromobenzene (5.38). Following synthetic procedure F using (4-
bromophenyl)(phenyl)methanol (1.00 g, 3.80 mmol), purification by silica gel column 
chromatography (hexanes/EtOAc 67:33) furnished the title compound as an oil (0.800 g, 
0.324 mmol, 85% yield).31  
1-Bromo-4-(4-nitrobenzyl)benzene (5.39). Following synthetic procedure F using (4-
bromophenyl)(4-nitrophenyl)methanol (1.00 g, 3.24 mmol), trituration with hexanes 
furnished the title compound as a brown solid (0.850 g, 2.91 mmol, 90%yield). M.p. 118−121 
°C (EtOH). 1H NMR (400 MHz, CDCl3) δ 4.05 (s, 2H), 7.06 (d, J = 8.1 Hz, 2H), 7.33 (d, J = 
8.3 Hz, 2H), 7.46 (d, J = 8.3 Hz, 2H), 8.17 (d, J = 8.6 Hz, 2H) ppm. Anal. (C13H10BrNO2 
(292.13)) C, H, Br, N.  
Methyl 4-(4-bromobenzyl)benzoate (5.40). Following synthetic procedure F using methyl 
4-((4-Bromophenyl)(hydroxy)methyl)benzoate (1.50 g, 4.67 mmol), purification by silica gel 
column chromatography (hexanes/EtOAc 80:20) furnished the title compound as a white solid 
(1.00 g, 3.28 mmol, 70% yield). M.p. 58−60 °C (EtOH). Lit.32 m.p. 60−61 °C.  
 
5.6.2 Biological Assay 
CA Inhibition Screening Assay. An Applied Photophysics stopped-flow instrument has 
been used for assaying the CA-catalyzed CO2 hydration activity.10 Phenol red (at a 
concentration of 0.2 mM) has been used as an indicator, working at the maximum absorbance 
of 557 nm, with 20 mM Hepes (pH 7.5) as buffer, and 20 mM Na2SO4 (for maintaining 
constant the ionic strength). The initial rates of the CA-catalyzed CO2 hydration reaction were 
followed for a period of 10−100 s. The CO2 concentrations ranged from 1.7 to 17 mM for the 
determination of the kinetic parameters and inhibition constants. For each inhibitor, at least 
six traces of the initial 5−10% of the reaction have been used for determining the initial 
velocity. The uncatalyzed rates were determined in the same manner and subtracted from the 
total observed rates. Stock solutions of inhibitor (0.1 mM) were prepared in 
distilled−deionized water, and dilutions up to 0.01 nM were done thereafter with 
distilled−deionized water. Inhibitor and enzyme solutions were preincubated together for 15 
min at room temperature prior to assay to allow for the formation of the E−I complex. The 
inhibition constants were obtained by nonlinear least-squares methods using the 
Cheng−Prusoff equation and represent the mean from at least three different determinations. 
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Errors were in the range of ± 5−10% of the reported Ki values. CA isoforms were 
recombinant enzymes obtained in house as reported earlier.33−35 The enzyme concentrations in 
the assay system were: hCA I, 13.2 nM; hCA II, 8.4 nM; hCA IX, 7.9 nM; hCA XII, 15.2 
nM; hCA XIV, 10.7 nM.  
 
5.6.3 X-ray Crystallography 
Co-crystallization. hCA XIV enzyme was prepared and purified as previously described.11 
The hCA XIV/20 adduct was prepared by adding a 50-fold excess of the inhibitor to a 0.1 
mg/mL enzyme solution in 20 mM Tris-HCl pH 7.5. After incubation overnight at 4 °C, the 
complex was concentrated to 10 mg/mL. Crystals were obtained at 20 °C using the hanging 
drop vapor diffusion technique by equilibrating drops containing 1 µL of complex solution 
and an equal volume of precipitant solution consisting of 1.9 M ammonium sulfate, 0.1 M 
Tris-HCl, pH 8.5, over a reservoirs containing 1 mL of precipitant solution. Crystals appeared 
after 3 days. Crystals of the hCA II/5.20 adduct were obtained as previously described.36 
Diffraction Data and Collection. X-ray diffraction data for both hCA XIV/5.20 and hCA 
II/5.20 adducts were collected at 100 K, using a copper rotating anode generator developed by 
Rigaku and equipped with Rigaku Saturn CCD detector. Prior to cryogenic freezing, the 
crystals were transferred to the respective precipitant solution with the addition of 20% (v/v) 
glycerol. Data were integrated, merged, and scaled using HKL2000.37 Crystal parameters and 
data collection for both adducts are reported in Table 1S of Supporting Information from Lit. 
12. 
Structure Determination. Phasing of the complexes was carried out with CNS38 using as 
starting model the structures of previously solved hCA XIV (PDB ID: 4LU3)8 and hCA II 
(PDB ID: 1CA2).39 The graphic program O40 was used to view the electron density maps, and 
the structure was adjusted based on the calculated electron density. Composite simulated-
annealing omit maps were used regularly during the building process to verify and correct the 
models.38 Topology files of the inhibitor was generated using the PRODRG2 server.41 The 
geometric restraints of the final models were analyzed using PROCHECK.42 The refinement 
statistics of the final models are summarized in Table 1S, Supporting Information from Lit. 12. 
Coordinates and structure factors were deposited in the Protein Data Bank (accession code 
5CJF and 5E2R).  	
5.6.4 Molecular Modeling 
All molecular modeling studies were performed on a MacPro dual 2.66 GHz Xeon running 
Ubuntu 14.04 LTS. The CA structures were downloaded from the PDB 
(http://www.rcsb.org/). Hydrogen atoms were added to the protein, using Molecular 
Operating Environment (MOE) 2010 (Molecular Operating Environment (MOE 2010.10), 
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Chemical Computing Group, Inc., Montreal, Quebec, Canada, http://www.chemcomp. com) 
and minimized, keeping all the heavy atoms fixed until a rmsd gradient of 0.05 kcal mol−1 Å−1 
was reached. Ligand structures were built with MOE and minimized using the MM-FF94x 
force field until a rmsd gradient of 0.05 kcal mol−1 Å−1 was reached. The docking simulations 
were performed using PLANTS13,14 and Autodock 4.0.15 The images presented here were 
created with PyMOL.43  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 216 
5.7 References 
1. Supuran, C. T. Carbonic anhydrases. Bioorg. Med. Chem. 2013, 21, 1377−1378. 
2. Alterio, V.; Di Fiore, A.; D’Ambrosio, K.; Supuran, C. T.; De Simone, G. Multiple 
binding modes of inhibitors to carbonic anhydrases: how to design specific drugs 
targeting 15 different isoforms? Chem. Rev. 2012, 112, 4421−4468. 
3. De Simone, G.; Di Fiore, A.; Capasso, C.; Supuran, C. T. The zinc coordination pattern 
in the η-carbonic anhydrase from Plasmodium falciparum is different from all other 
carbonic anhydrase genetic families. Bioorg. Med. Chem. Lett. 2015, 25, 1385−1389. 
4. Neri, D.; Supuran, C. T. Interfering with pH regulation in tumours as a therapeutic 
strategy. Nat. Rev. Drug Discovery 2011, 10, 767−777. 
5. Ogilvie, J. M.; Ohlemiller, K. K.; Shah, G. N.; Ulmasov, B.; Becker, T. A.; Waheed, A.; 
Hennig, A. K.; Lukasiewicz, P. D.; Sly, W. S. Carbonic anhydrase XIV deficiency 
produces a functional defect in the retinal light response. Proc. Natl. Acad. Sci. U. S. A. 
2007, 104, 8514−8519. 
6. Supuran, C. T.; Scozzafava, A. Carbonic anhydrases as targets for medicinal chemistry. 
Bioorg. Med. Chem. 2007, 15, 4336−4350. 
7. Supuran, C. T. Carbonic anhydrases: novel therapeutic applications for inhibitors and 
activators. Nat. Rev. Drug Discovery 2008, 7, 168−181.  
8. Alterio, V.; Pan, P.; Parkkila, S.; Buonanno, M.; Supuran, C. T.; Monti, S. M.; De 
Simone, G. The structural comparison between membrane-associated human carbonic 
anhydrases provides insights into drug design of selective inhibitors. Biopolymers 2014, 
101, 769−778. 
9. Bollbuck, B.; Denholm, A.; Eder, J.; Hersperger, R.; Janser, P.; Revesz, L.; Schlapbach, 
A.; Waelchli, R. Preparation of amino-pyrimidines as IKK inhibitors for treating 
autoimmune diseases and inflammations. PCT Int. Appl. WO 2004089913 A1, October 
21, 2004. 
10. Khalifah, R. G. The carbon dioxide hydration activity of carbonic anhydrase. I. Stop-flow 
kinetic studies on the native human isoenzymes B and C. J. Biol. Chem. 1971, 246, 
2561−2573. 
11. Supuran, C. T. Carbonic anhydrases: from biomedical applications of the inhibitors and 
activators to biotechnologic use for CO2 capture. J. Enzyme Inhib. Med. Chem. 2013, 28, 
229−230. 
12. La Regina, G.; Coluccia, A.; Famiglini, V.; Pelliccia, S.; Monti, L.; Vullo, D.; Nuti, E.; 
Alterio, V.; De Simone, G.; Monti, S. M.; Pan, P.; Parkkila, S.; Supuran, C. T.; Rossello, 
A.; Silvestri, R. Discovery of 1,1′-biphenyl-4-sulfonamides as a new class of potent and 
selective carbonic anhydrase XIV inhibitors. J. Med. Chem. 2015, 58, 8564–8572. 
	 217 
13. Korb, O.; Stutzle, T.; Exner, T. E. PLANTS: Application of ant colony optimization to 
structure-based drug design. In Ant Colony Optimization and Swarm Intelligence, Lecture 
Notes in Computer Science; Springer: Berlin, Heidelberg, 2006, 4150, 247, 
24710.1007/11839088_22. 
14. Dorigo, M.; Gambardella, L. M.; Birattari, M.; Martinoli, A.; Poli, R.; Stutzle, T. Eds. 
Lecture Notes in Computer Science; Series 4150; Springer: Berlin, 2006, 247−258. 
15. Morris, G. M.; Huey, R.; Lindstrom, W.; Sanner, M. F.; Belew, R. K.; Goodsell, D. S.; 
Olson, A. J. Autodock4 and AutoDockTools4: automated docking with selective receptor 
flexiblity. J. Comput. Chem. 2009, 30, 2785−279. 
16. Rubino, M. T.; Agamennone, M.; Campestre, C.; Campiglia, P.; Cremasco, V.; Faccio, 
R.; Laghezza, A.; Loiodice, F.; Maggi, D.; Panza, E.; Rossello, A.; Tortorella, P. 
Biphenyl sulfonylamino methyl bisphosphonic acids as inhibitors of matrix 
metalloproteinases and bone resorption. Chem. Med. Chem. 2011, 6, 1258−1268. 
17. Halverstadt, I. F.; Kumler, W. D. p-(p-Aminophenyl)- benzenesulfonamide and 
derivatives. J. Am. Chem. Soc. 1941, 63, 624−625. 
18. Moskvichev, Y. A.; Timoshenko, G. N.; Mironov, G. S.; Gracheva, S. G.; Kryukova, G. 
G.; Kozlova, O. S. Synthesis of bifunctional aromatic trinuclear bridging compounds. Zh. 
Org. Khim. 1982, 18, 1006−1010. 
19. Yin, W.-P.; Shi, M. Indium triflate as a recyclable catalyst for the nitration of aromatic 
compounds without a halogenated solvent. J. Chem. Res. 2006, 9, 549−551. 
20. Taylor, E. C.; Ray, P. S. Pteridines. 53. A convenient synthetic approach to 10- 
deazaaminopterin and 10-deazafolic acid. J. Org. Chem. 1988, 53, 35−38.  
21. Zhang, L.; Wang, S.; Zhou, S.; Yang, G.; Sheng, E. Cannizzaro-type disproportionation 
of aromatic aldehydes to amides and alcohols by using either a stoichiometric amount or 
a catalytic amount of lanthanide compounds. J. Org. Chem. 2006, 71, 3149−3153. 
22. Kishore Kumar, G. D.; Chavarria, G. E.; Charlton-Sevcik, A. K.; Arispe, W. M.; 
MacDonough, M. T.; Strecker, T. E.; Chen, S.-E.; Siim, B. G.; Chaplin, D. J.; Trawick, 
M. L.; Pinney, K. G. Design, synthesis, and biological evaluation of potent 
thiosemicarbazone based cathepsin L inhibitors. Bioorg. Med. Chem. Lett. 2010, 4, 
1415−1419. 
23. Zhao, B.; Lu, X. Cationic palladium(II)-catalyzed addition of arylboronic acids to nitriles. 
One-step synthesis of benzofurans from phenoxyacetonitriles. Org. Lett. 2006, 8, 
5987−5990. 
24. Jin, T.-S.; Yang, M.-N.; Feng, G.-L.; Li, T.-S. Synthesis of diaryl ketones catalyzed by 
Al2O3-ZrO2/S2O2-8 solid superacid. Synthetic Commun. 2004, 34, 479−485. 
25. Mingzhong, C.; Guomin, Z.; Lingfang, Z.; Jian, P. Carbonylative Suzuki-Miyaura 
coupling of arylboronic acids with aryl iodides catalyzed by the MCM-41-supported 
bidentate phosphane palladium(II) complex. Eur. J. Org. Chem. 2009, 10, 1585−1591. 
	 218 
26. Shah, B. K.; Neckers, D. C. Synthesis, crystal structures, and laser flash photolysis of 
tert-butyl aroylperbenzoates. J. Org. Chem. 2003, 68, 8368−8372. 
27. Campagnola, P. J.; Howell, A. R.; Wang, J.; Goodman, S. L. Preparation of 
benzophenone derivative crosslinking photoactivators. U. S. Pat. US2004259023 A1, 
December 23, 2004. 
28. Salem, O. I. A.; Frotscher, M.; Scherer, C.; Neugebauer, A.; Biemel, K.; Streiber, M.; 
Maas, R.; Hartmann, R. W. Novel 5α-reductase inhibitors: synthesis, structure-activity 
studies, and pharmacokinetic profile of phenoxybenzoylphenyl acetic acids. J. Med. 
Chem. 2006, 49, 748−759. 
29. Barros, T. G.; Williamson, J. S.; Antunes, O. A. C.; Muri, E. M. F. Hydroxamic acids 
designed as inhibitors of urease. Lett. Drug Des. Discov. 2009, 3, 186−192.  
30. Ogawa, Y.; Saiga, A.; Mori, M.; Shibata, T.; Takagi, K. Nucleophilic additions of 
arylzinc compounds to aldehydes mediated by CrCl3: efficient and facile synthesis of 
functionalized benzhydrols, 1(3H)-isobenzofuranones, benzyl alcohols, or diaryl ketones. 
J. Org. Chem. 2000, 4, 1031−1036. 
31. Hardouin, C.; Kelso, M. J.; Romero, F. A.; Rayl, T. J.; Leung, D.; Hwang, I.; Cravatt, B. 
F.; Boger. D. L. Structure-activity relationships of α-ketooxazole inhibitors of fatty acid 
amide hydrolase. J. Med. Chem. 2007, 50, 3359−3368. 
32. Dohle, W.; Lindsay, D. M.; Knochel, P. Copper-mediated cross-coupling of 
functionalized arylmagnesium reagents with functionalized alkyl and benzylic halides. 
Org. Lett. 2001, 3, 2871−2873. 
33. Vitale, R. M.; Alterio, V.; Innocenti, A.; Winum, J. Y.; Monti, S. M.; De Simone, G.; 
Supuran, C. T. Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-
sulfamate adducts with isozymes II and IX as a platform for designing tight-binding, 
more isoform-selective inhibitors. J. Med. Chem. 2009, 52, 5990−5998. 
34. D'Ambrosio, K.; Smaine, F. Z.; Carta, F.; De Simone, G.; Winum, J.-Y.; Supuran, C. T. 
Development of potent carbonic anhydrase inhibitors incorporating both sulfonamide and 
sulfamide groups. J. Med. Chem. 2012, 55, 6776−6783. 
35. Pacchiano, F.; Carta, F.; McDonald, P. C.; Lou, Y.; Vullo, D.; Scozzafava, A.; Dedhar, 
S.; Supuran, C. T. Ureido-substituted benzenesulfonamides potently inhibit carbonic 
anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis. J. 
Med. Chem. 2011, 54, 1896−1902. 
36. De Simone, G.; Pizika, G.; Monti, S. M.; Di Fiore, A.; Ivanova, J.; Vozny, I.; 
Trapencieris, P.; Zalubovskis, R.; Supuran, C. T.; Alterio, V. Hydrophobic substituents of 
the phenylmethylsulfamide moiety can be used for the development of new selective 
carbonic anhydrase inhibitors. BioMed Res. Int. 2014, 2014, 1−11. 
37. Otwinowski, Z.; Minor, W. Processing of X-ray diffraction data collected in oscillation 
mode. Methods in Enzymology 1997, 276, 307−326. 
	 219 
38. Brünger, A. T.; Adams, P. D.; Clore, G. M.; DeLano, W. L.; Gros, P.; Grosse-Kunstleve, 
R. W.; Jiang, J.-S.; Kuszewski, J.; Nilges, M.; Pannu, N. S.; Read, R. J.; Rice, L. M.; 
Simonson, T.; Warren, G. L. Crystallography & NMR system: A new software suite for 
macromolecular structure determination. Acta Crystallogr., Sect. D: Biol. Crystallogr. 
1998, 54, 905−921. 
39. Eriksson, A. E.; Jones, T. A.; Liljas, A. Refined structure of human carbonic anhydrase II 
at 2.0 Å resolution. Proteins: Struct., Funct., Genet. 1988, 4, 274−282. 
40. Jones, T. A.; Zou, J.-Y.; Cowan, S. W.; Kjeldgaard, M. Improved methods for building 
protein models in electron density maps and the location of errors in these models. Acta 
Crystallogr., Sect. A: Found. Crystallogr. 1991, 47, 110−119. 
41. Schüttelkopf, A. W.; van Aalten, D. M. F. PRODRG: a tool for high-throughput 
crystallography of protein-ligand complexes. Acta Crystallogr., Sect. D: Biol. 
Crystallogr. 2004, 60, 1355−1363. 
42. Laskowski, R. A.; MacArthur, M. W.; Moss, D. S.; Thornton, J. M. PROCHECK: a 
program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 
1993, 26, 283−291. 
43. The PyMol Molecular Graphics System; www.pymol.org. 
 
 
 
 
 																	
	 220 
Chapter 6: Arylboronic Acids as Dual FAAH and TRPV1 Ligands 
6.1 Introduction 
Fatty acid amide hydrolase (FAAH) is an intracellular serine hydrolase that catalyses the 
hydrolysis of a broad range of endogenous signaling lipid amides, in particular of the 
endocannabinoid anandamide (AEA) (Figure 6.1).1 The inhibition of FAAH increases levels 
of AEA producing therapeutic effects in models of inflammatory2 and possibly neuropathic 
pain3−6 and a series of potent, selective and efficacious FAAH inhibitors have been disclosed 
over the last ten years.7 Furthermore, FAAH inhibition might indirectly lead to the activation 
of other, non-cannabinoid receptors involved in nociception, such as the transient receptor 
potential vanilloid 1 (TRPV1) channel.8 
TRPV1 is a non selective cation channel (Figure 6.1) gating responses to painful stimuli 
such as heat and noxious chemicals and the use of selective TRPV1 antagonists have 
indicated that this receptor is a promising target for drug development.9−20 Since AEA also 
activates the TRPV1 channel, the potential antinociceptive action of increased levels of AEA, 
which arise from FAAH inhibition, may be however offset by an increased concomitant 
TRPV1 receptor activation.8 
 
  
Figure 6.1. Schematic representation of FAAH enzyme and TRPV1 channel. 	
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6.2 Objective of the Study 
Recent works suggest that the inhibition of FAAH, combined with a concurrent blockade 
of TRPV1, may be considered as a possible new therapeutic strategy for more efficacious 
pain relief, compared to those that target only one such protein.21−25 In 2008, a series of 
commercially aryl-, heteroaryl-, alkyl-, and alkenylboronic acids was discovered to inhibit 
FAAH enzyme with IC50 values in the nanomolar or low micromolar range.26 
We hypothesized therefore that the incorporation of a boronic acid group into the 
pharmacophore model for a variety of TRPV1 antagonists16−20 (i.e., SB366791)27 could 
represent a simple multitargeted strategy for the development of dual FAAH/TRPV1 
blockers. The model can be generalized as a central hydrogen-bond acceptor/donor motif 
flanked by a lipophilic tail on one side and an aromatic group that incorporates a 
hydrogen-bond acceptor on the other side (Figure 6.2). Accordingly, we designed and 
synthesized 31 new arylboronic acid derivatives structurally related to this model that were 
evaluated for their inhibitory activities on FAAH and TRPV1. 
 
 
 
Figure 6.2. General chemical structure of arylboronic acid derivatives.28  
 
6.3 Chemistry 
The arylboronic acids 6.1−6.33 were prepared as pinacol boronate esters and subsequent 
deprotection with sodium metaperiodate, which allowed the cleavage of the boronate group.29 
The non-commercially available 4-(aminomethyl)-2-methoxyphenylboronic acid pinacol 
ester (6.37) was prepared by a palladium-catalyzed cross-coupling reaction of diboron pinacol 
ester (B2pin2) with the appropriate aryl triflate, in the presence of 1,1'-
bis(diphenylphosphino)ferrocene (DPPF) and potassium acetate in dioxane (Scheme 
6.1A).30,31 Acylation of the aminobenzyl or anilino boronate (6.38) with the appropriate 
carboxylic acid, using 1-hydroxybenzotriazole (HoBt)/N-ethyl-N'-(3-
dimethylaminopropyl)carbodiimide hydrochloride  (EDC) as carboxylate activator, followed 
by cleavage of the boronates 6.39−6.53, yielded the corresponding amides 6.1−6.9, 
6.16−6.20, and 6.31 (Scheme 6.1B). Similarly, ureas 6.28−6.30 were synthesized by 
treatment of the boronate 6.38 with the 4-tert-butyl-phenylisocyanate (t-Bu-4-PhNCO) in 
DCM/anhydrous piridine, followed by cleavage of the boronates 6.54−6.56 (Scheme 6.1B). 
Finally, the synthesis of reverse amides 6.10−6.15, 6.21−6.27, 6.32 and 6.33 was 
accomplished by reaction of the activated carboxylic acid 6.57 with the appropriate amine, 
B
HO
HO
R
X
Y lipophilic tail
R = H, OMe
n = 0,1
X = NH; Y = CO, CONH
X = CO; Y = NHn
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followed by cleavage of the boronates 6.58−6.70 (Scheme 6.1C). 
During my research activity at “Sapienza” University, I collaborated with the research 
group of Prof G. Ortar and Prof. E. Morera and I participated in the synthesis and 
characterization of compounds 6.1−6.33 (see Experimental Section, Chemistry 6.6.1). 
 
 
  
Scheme 6.1. Synthesis of arylboronic acid derivatives 6.1−6.33. 
 
OH
NHBoc
OMe
PhNTf2
Et3N, CH2Cl2
rt, 16 h
80%
OTf
NHBoc
OMe
B2pin2
PdCl2, DPPF
AcOK, dioxane
100 °C, 4 h
80%
B
NHBoc
OMe TFA/CH2Cl2 (3:1)
88%
O O
B
NH3+ X-
R1
O O
(  )n
B
N
H
R1
O O
(  )n
B
N
H
R1
O O
(  )n
O
N
H
R2
B
N
H
R1
HO OH
(  )n
O
N
H
R2
t-Bu-4-PhNCO, Et3N
CH2Cl2/anhydrous piridine (4:1)
rt, 16 h
NaIO4, 2N HCl
THF/H2O (3:1)
rt, 3–5 h
44–53%
50–85%
O
R2
B
N
H
R1
HO OH
O
R2
NaIO4, 2N HCl
THF/H2O (3:1)
2) amine
    Et3N, DMF
    rt, 16 h
     42–88%
rt, 3–5 h
43–77%
B
CO2H
R1
O O
(  )n
1) HOBt/EDC, DMF
    rt, 1 h
2) amine
           Et3N, DMF
       rt, 16 h
         47–86%
B
R1
O O
(  )n
H
N
O
R2
B
R1
HO OH
H
N R2
NaIO4, 2N HCl
THF/H2O (3:1)
rt, 3–5 h
48–93%
A)
B)
O
(  )n
(  )n
6.28–6.30
6.1–6.9, 6.16–6.20, 6.31
6.10–6.15, 6.21–6.27, 6.32, 6.33
6.34 6.35 6.36 6.37
6.54–6.56
6.39–6.53
6.57 6.58–6.70
B
NH2 . TFA
OMe
O O
6.38
X- = Cl-or CF3COO-
R = H or OMe
rt, 40 min
C)
n = 0,1
R1 = H, OMe
R2 = Ph-4-t-Bu, Ph-4-Ph, CH=CHPh-4-Cl, CH2Ph, CH2Ph-4-Ph,
       (CH2)2Ph-4-OH, (CH2)2Ph, (CH2)4Ph, (CH2)5Ph, (CH2)7Ph
1) R2COOH
    HOBt/EDC, DMF
    rt, 1 h
	 223 
6.4 Results and Discussion 
The effect of compounds 6.1−6.33 on the enzymatic hydrolysis of AEA was determined 
using rat membranes incubated in the presence of test compounds and [14C]AEA (2.4 µM), 
whereas the inhibitory activity on TRPV1 channel was assessed by measuring the 
intracellular Ca2+ elevation in HEK293 cells stably transfected with the human TRPV1 
cDNA, after addition of test compounds 5 min before stimulation of cells with the reference 
compound, the agonist capsaicin. Biological activities of arylboronic acids 6.1−6.31, the two 
most potent boronic acids reported by Minkkilä et al.26 (compounds 13 and 14) 6.32, 6.33, 
and the selective TRPV1 antagonist SB36679127 on FAAH and TRPV1 are shown in Table 
6.1. 
Inhibition of FAAH enzyme: The majority of the new derivatives (21 compounds: 6.3, 
6.5−6.9, 6.12−6.15, 6.18−6.23, 6.25−6.27, 6.28, and 6.29) showed fairly good FAAH 
inhibitory activity, regardless of the nature of substituents X and Y and the presence or 
absence of a methylene bridging group connecting the arylboronic acid moiety and the 
lipophilic tail (Figure 6.2). The presence of a boronic acid functionality appears to be 
generally an important factor that determines the ability of these compounds to produce a 
significant inhibition of the hydrolysis of AEA into ethanolamine, as demonstrated by 
comparing the active compound 6.15 with the inactive analogues 6.32 and 6.33, which do not 
bear the boronic acid group. Furthermore, a comparison between analogues 6.18 and 6.31 
suggest that the presence of the boronic functionality in para-position is required, probably 
due to the more steric tolerance near the enzyme’s catalytic site, as also previously 
demonstrated by Minkkilä and coworkers.26 Accordingly, movement of the boronic group 
away from para-position, as in 6.31, resulted in a loss of activity. With respect to the 
lipophilic tail, increasing ω-arylaliphatic chains (e.g., 6.4, 6.6, and 6.7) typically showed 
optimal FAAH inhibitiory activity, whereas aliphatic chains (6.1 and 6.2) are generally 
detrimental for activity. 
Activity on TRPV1 channel: Benzylic amides 6.1−6.9 and benzylic reverse amides 
6.10−6.15 appeared to be generally more active than the corresponding aryl counterparts 
6.16−6.20 and 6.21−6.27, and ureas 6.28 and 6.29 (e.g., compare 6.6, 6.14, 6.19 and 6.27). 
Six compounds (6.18, 6.21, 6.28−6.31) acted as ‘true antagonist’, showing that the 4-t-
butylphenyl and 4-chlorostyryl groups are generally preferred to promote a pure antagonist 
activity. Two compounds (6.12 and 6.22) were found to behave as weakly desensiting 
agonists, while for the other compounds the EC50 and IC50 values were comparable. Finally, 
with respect to the boronic functionality, comparison between 6.15, and 6.32, 6.33, and 
between 6.31 and SB-36679127, clearly suggests that, in contrast to what was observed for 
FAAH inhibition, the presence of the boronic group in para-position is not strictly required 
for TRPV1 modulating activity. 
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Thus, in light of the observed elements of SAR for the two biological targets, our data 
revealed that out of 31 tested compounds, fourtheen examples (6.3, 6.6−6.9, 6.12−6.15, 6.18, 
6.21, 6.22, 6.28, and 6.29) target both FAAH and TRPV1 channel. Among them, four 
compounds (6.18, 6.21, 6.28, and 6.29) act as dual FAAH/TRPV1 blockers with IC50 values 
between 0.56 and 8.11 µM, whereas ten other congeners 6.3, 6.6−6.9, 6.12−6.15, 6.22 inhibit 
FAAH and activate/desensitize TRPV1. 
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SB-366791 
 
<10 ND 0.19 (0.27)d >10 
 
Table 6.1. Effects of arylboronic acids 6.1–6.33 and SB-366791 on FAAH and TRPV1. aData are 
means of n = 4 separate determinations. Standard errors are not shown for the sake of clarity 
and were never higher than 10% of the means. bAs percent of ionomycin (4 µM). cDetermined 
against the effect of capsaicin (0.1 µM). dData from Ref.16 ND = not determined when 
efficacy is lower than 10%. 
 
6.5 Conclusions 
Over the past several years, inhibitors of FAAH enzyme have been extensively 
investigated as candidate treatments against pain32−34, inflammatory2 and neuropsychiatric 
disorders.3−6 However, in spite of strong preclinical data that proved that compounds of this 
type can elicit analgesic effects devoid of the CNS side effects when a cannabinoid receptors 
agonist is used,35 data from clinical trials have thus far yielded disappointing results.36 This 
raises the possibility that FAAH inhibition might indirectly activate the TRPV1 channel, a 
non-cannabinoid receptor involved in nociception.8 Thus, the development and evaluation of 
multitargeted compounds that could inhibit both FAAH and TRPV1 would be desirable. 
Accordingly, we designed and synthesized 31 arylboronic acid derivatives that were evaluated 
as dual FAAH/TRPV1 blockers. Our preliminary results showed that fourtheen compounds 
(6.3, 6.6−6.9, 6.12−6.15, 6.18, 6.21, 6.22, 6.28, and 6.29) inhibit FAAH with IC50 values in 
the low micromolar range and are able to modulate the TRPV1 activity. In particular, four 
compounds (6.18, 6.21, 6.28, and 6.29) act as dual FAAH/TRPV1 inhibitors, comparing 
favourably in terms of potency with the other chemotypes so far presented21−25 and therefore 
qualifying them as promising antinociceptive, antihyperalgesic, and antioedemic agents in 
acute and inflammatory pain preclinical studies.  
  
Figure 6.3. SAR summary of FAAH and TRPV1 inhibitory activities of arylboronic acid 
derivatives 6.1−6.33. 
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6.6 Experimental Section 
6.6.1 Chemistry 
All solvents were reagent grade. All chemical reagents were commercially available unless 
otherwise indicated and were used as received. Thin layer chromatography (TLC) was 
performed by using Merck F254 silica gel plates (Kenilworth, NJ) and TLC spots were 
detected by using UV light and an iodine chamber. Silica gel column chromatography was 
performed using Merck silica gel 60 (230–400 mesh). Preparative liquid chromatography 
(PLC) was performed with 0.5 mm Merck pre-coated silica gel plates. Melting points (m.p.) 
were acquired on a Buchi apparatus and are uncorrected. Infrared (IR) spectra were recorded 
on a Spectrum-One FT-ATR spectrometer (Perkin-Elmer, Waltham, MA). Proton (1H) and 
carbon (13C) NMR spectra were recorded on a Bruker Avance 400 MHz spectrometer 
(Pittsburgh, PA) or on a Varian Mercury 300 MHz spectrometer. Chemical shifts are 
expressed in δ units (ppm) from tetramethylsilane. The purity of tested compounds was 
>95%. 
General Procedure A for the Synthesis of Amides 6.1−6.27, and 6.31−6.33 and Ureas 
6.28−6.30. To a solution of the pinacol boronate ester (1 equiv) in THF/H2O (3:1 mL) sodium 
periodate (3 equiv) was added at room temperature and then followed by addition of 2 N HCl 
(2.5 M). The mixture was stirred at room temperature for 3-5 h, then concentrated in vacuo, 
diluted with water, and extracted with EtOAc. The organic layer was washed with water (×2), 
dried over Na2SO4, filtered, and concentrated in vacuo. The resulting material was purified by 
PLC or crystallized from THF/H2O to obtain the desired product. 
General Procedure B for the Synthesis of Pinacol Boronate Amides 6.42−6.53. To a stirred 
solution of the appropriate carboxylic acid (1 equiv) in DMF (1.0 M) at 0 °C were added 
HOBt (1 equiv) and EDC (1 equiv). The mixture was stirred for 15 min at 0 °C and for 1 h at 
room temperature. The pinacol boronate ester amine hydrochloride or trifluoroacetate (1 
equiv) and Et3N (1 equiv) were added and the mixture was stirred overnight at room 
temperature. Water was then added to the reaction mixture and the aqueous phase was 
extracted with EtOAc. The combined organic layers were washed with 2 N HCl solution, 
satd. aq. NaHCO3, and brine (×2), dried over Na2SO4, filtered, and concentrated in vacuo. The 
resulting material was purified by silica gel column chromatography to obtain the desired 
product. 
General procedure C for the Synthesis of Pinacol Boronate Ureas 6.54−6.56. To a 
solution of 4-(tert-butyl)aniline (1 equiv) and Et3N (2 equiv) in CH2Cl2 (0.2 M) bis-
(trichloromethyl) carbonate (1 equiv) was added at 0 °C under N2. The reaction mixture was 
stirred for 16 h at reflux, then cooled to room temperature and filtered. The material was 
concentrated in vacuo to obtain the intermediate 4-tert-butylphenyl isocyanate, which was 
monitored by IR analysis (ν 2260 cm-1). To a solution of the isocyanate (1 equiv) in CH2Cl2 
(0.25 M) was added a solution of the appropriate boronate ester amine (0.5 equiv) and Et3N 
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(1.5 equiv) in anhydrous piridine (0.5 M). The reaction mixture was stirred for 16 h at room 
temperature, then diluited with water and extracted with EtOAc. The organic layer was 
washed with water, dried over Na2SO4, filtered and concentrated in vacuo. The resulting 
material was purified by silica gel column chromatography or crystallized from THF/H2O to 
obtain the desired product. 
General Procedure D for the Synthesis of the Pinacol Boronate Reverse Amides 
6.58−6.70. To a stirred solution of pinacol boronate ester carboxylic acid (1 equiv) in DMF (1 
M) at 0 °C were added HOBt (1 equiv) and EDC (1 equiv). The mixture was stirred for 15 
min at 0 °C and for 1 h at room temperature. The appropriate amine (1 equiv) was added and 
the mixture was stirred overnight at room temperature. Water was then added to the reaction 
mixture and the aqueous phase was extracted with EtOAc. The combined organic layers were 
washed with 2 N HCl solution, satd. aq. NaHCO3, and brine, dried over Na2SO4, filtered, and 
concentrated in vacuo. The resulting material was purified by silica gel column 
chromatography to obtain the desired product. 
(4-(Oleamidomethyl)phenyl)boronic Acid (6.1). Following synthetic procedure A using N-
(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)oleamide (0.112 g, 0.225 mmol), 
purification by PLC (hexanes/EtOAc/MeOH 60:40:5) afforded the title compound as a white 
solid (0.042 g, 0.101 mmol, 45% yield). M.p. 132−133 °C. 1H NMR (400 MHz, CD3OD) δ 
0.88 (t, J = 6.4 Hz, 3H), 1.30 (m, 20H), 1.63 (m, 2H), 2.02 (m, 4H), 2.23 (t, J = 7.0 Hz, 2H), 
4.35 (s, 2H), 5.34 (m, 2H), 7.25 (m, 2H), 7.59 (d, J = 6.8 Hz, 1H), 7.69 (d, J = 6.8 Hz, 1H) 
ppm. 13C NMR (100 MHz, CD3OD) δ 14.47, 23.75, 27.09, 28.16, 30.27, 30.34, 30.46, 30.62, 
30.81, 30.86, 33.07, 37.10, 127.65, 127.80, 130.82, 130.90, 134.84, 135.19, 176.26 ppm. IR ν 
3382, 3296, 3002, 2918, 2850, 1634, 1611, 1551, 1465, 1405, 1345, 1327, 1227, 1111, 1022 
cm-1. 
(2-Methoxy-4-(oleamidomethyl)phenyl)boronic Acid (6.2). Following synthetic procedure 
A using N-(3-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)oleamide 
(0.104 g, 0.197 mmol), purification by PLC (hexanes/EtOAc 50:50) afforded the title 
compound as a white solid (0.029 g, 0.065 mmol, 33% yield). M.p. 97−100 °C. 1H NMR (400 
MHz, CDCl3) δ 0.88 (t, J = 6.8 Hz, 3H), 1.28 (m, 20H), 1.65 (m, 2H), 2.00 (m, 4H), 2.22 (t, J 
= 7.4 Hz, 2H), 3.89 (s, 3H), 4.44 (d, J = 6.0 Hz, 2H), 5.34 (m, 2H), 5.91 (br s, 1H), 6.28 (s, 
2H), 6.83 (s, 1H), 6.90 (d, J = 7.2 Hz, 1H), 7.79 (d, J = 7.2 Hz, 1H) ppm. 13C NMR (100 
MHz, CDCl3) δ 14.12, 22.70, 25.81, 27.19, 27.25, 29.16, 29.33, 29.54, 29.73, 29.79, 31.92, 
36.82, 43.67, 55.56, 109.57, 120.38, 129.73, 130.06, 137.27, 143.74, 164.90, 173.16 ppm. IR 
ν 3377, 3299, 3003, 2919, 2850, 1640, 1613, 1535, 1414, 1355, 1247, 1169, 1040 cm-1. 
(4-((2-([1,1'-Biphenyl]-4-yl)acetamido)methyl)phenyl)boronic Acid (6.3). Following 
synthetic procedure A using 2-([1,1'-biphenyl]-4-yl)-N-(4-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)benzyl)acetamide (0.075 g, 0.175 mmol), treatment with Et2O (5 mL) 
afforded the title compound (0.022 g, 0.064 mmol, 36% yield). M.p. 253−255 °C (Et2O). 1H 
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NMR (400 MHz, CD3OD) δ 3.61 (s, 2H), 4.40 (d, J = 4.8 Hz, 2H), 7.22−7.72 (m, 13H), 8.04 
(br s, 1H) ppm. 13C NMR (100 MHz, CD3OD) δ 43.26, 44.06, 127.20, 127.80, 129.25, 
130.06, 134.16, 134.52, 134.96, 140.63, 141.32, 173.14 ppm. IR ν 3408, 3292, 1629, 1408, 
1339, 1007, 816, 750 cm-1. 
(4-((3-Phenylpropanamido)methyl)phenyl)boronic Acid (6.4). Following synthetic 
procedure A using 3-phenyl-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)benzyl)propanamide (0.057 g, 0.156 mmol), purification by PLC (EtOAc/hexanes 70:30) 
afforded the title compound as a white solid (0.017 g, 0.06 mmol, 38% yield). M.p. >250 °C. 
1H NMR (400 MHz, CDCl3/CD3OD) δ 2.52 (t, J = 7.6 Hz, 2H), 2.95 (t, J = 7.6 Hz, 2H), 4.33 
(br s, 2H), 7.10−7.67 (m, 9H) ppm. 13C NMR (100 MHz, CDCl3/CD3OD) δ 31.95, 38.30, 
43.49, 126.41, 126.96, 128.53, 128.68, 134.14, 140.40, 140.90, 173.38 ppm. IR ν 3323, 3027, 
2928, 1626, 1610, 1408, 1338, 1018, 731, 699 cm-1. 
(E)-(4-((3-(4-Chlorophenyl)acrylamido)methyl)phenyl)boronic Acid (6.5). Following 
synthetic procedure A using (E)-3-(4-chlorophenyl)-N-(4-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)benzyl)acrylamide (0.077 g, 0.194 mmol), crystallization from THF 
afforded the title compound (0.060 g, 0.190 mmol, 98% yield). M.p. >230 °C. 1H NMR (400 
MHz, DMSO-d6) δ 4.41 (d, J = 5.6 Hz, 2H), 6.71 (d, J = 15.6 Hz, 1H), 7.26 (d, J = 7.7 Hz, 
2H), 7.45−7.49 (m, 3H), 7.60 (d, J = 8.4 Hz, 2H), 7.76 (d, J = 7.6 Hz, 2H), 8.00 (s, 2H), 8.63 
(br s, 1H) ppm. 13C NMR (100 MHz, DMSO-d6) δ 42.34, 122.83, 126.32, 128.93, 129.20, 
133.84, 134.18, 135.46, 137.57, 141.08, 164.71 ppm. IR ν 3297, 2927, 1654, 1622, 1404, 
1330, 1222, 1901, 820 cm-1. 
(4-((6-Phenylhexanamido)methyl)phenyl)boronic Acid (6.6). Following synthetic 
procedure A using 6-phenyl-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)benzyl)hexanamide (0.055 g, 0.135 mmol), crystallization from Et2O afforded the title 
compound (0.028 g, 0.086 mmol, 64% yield). M.p. 197−200 °C. 1H NMR (400 MHz, 
CD3OD) δ 1.34 (m, 2H), 1.64 (m, 4H), 2.22 (t, J = 7.6 Hz, 2H), 2.58 (t, J = 7.6 Hz, 2H), 4.34 
(s, 2H), 7.14 (m, 3H), 7.22 (m, 4H), 7.56 (d, J = 6.0 Hz, 1H), 7.71 (d, J = 6,4 Hz, 1H) ppm. 
13C NMR (100 MHz, CD3OD) δ 24.38, 27.31, 29.85, 34.25, 34.50, 41.55, 124.16, 125.27, 
126.76, 126.91, 132.33, 132.68, 141.25, 173.59 ppm. IR ν 3380, 3292, 2929, 1623, 1553, 
1404, 1339, 1231, 996, 693 cm-1. 
(4-((8-Phenyloctanamido)methyl)phenyl)boronic Acid (6.7). Following synthetic procedure 
A using 8-phenyl-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)octanamide 
(0.081 g, 0.186 mmol), purification by PLC (EtOAc) afforded the title compound as a white 
solid (0.029 g, 0.082 mmol, 43% yield). M.p. 227−230 °C. 1H NMR (400 MHz, DMSO-d6) δ 
1.28 (m, 6H), 1,53 (m, 4H), 2.14 (t, J = 7.2 Hz, 2H), 2.55 (t, J = 7.6 Hz, 2H), 4.26 (d, J = 5.6 
Hz, 2H), 7.18 (m, 7H), 7.76 (d J = 7.6 Hz, 2H), 8.05 (s, 2H), 8.30 (m, 1H) ppm. 13C NMR 
(100 MHz, DMSO-d6) δ 25.86, 26.53, 29.80, 29.85, 32.21, 36.37, 36.56, 43.23, 126.76, 
127.36, 129.40, 129.44, 135.36, 142.81, 143.51, 173.36 ppm. IR ν 3293, 2925, 1639, 1543, 
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1409, 1346, 1020 cm-1. 
(2-Methoxy-4-((6-phenylhexanamido)methyl)phenyl)boronic Acid (6.8). Following 
synthetic procedure A using N-(3-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)benzyl)-6-phenylhexanamide (0.046 g, 0.105 mmol), purification by PLC (EtOAc/hexanes 
70:30) afforded the title compound as a white solid (0.022 g, 0.062 mmol, 61% yield). M.p. 
102−105 °C. 1H NMR (400 MHz, CDCl3) δ 1.33 (m, 2H), 1,65 (m, 4H), 2.20 (t, J = 7.6 Hz, 
2H), 2.58 (t, J = 7.6 Hz, 2H), 3.82 (s, 3H), 4.39 (d, J = 6.0 Hz, 2H), 6.13 (m, 1H), 6.63 (br s, 
2H), 6.78 (s, 1H), 6.86 (d, J = 7.2 Hz, 1H), 7.15 (m, 3H), 7.25 (m, 2H), 7.77 (d J = 7.2 Hz, 
1H) ppm. 13C NMR (100 MHz, CDCl3) δ 25.57, 28.85, 31.06, 35.67, 36.54, 43.54, 55.46, 
109.44, 120.23. 125.66, 128.24, 128.33, 137.15, 142.42, 143.61, 164.78, 173.24 ppm. IR ν 
3493, 3303, 2932, 1643, 1610, 1566, 1416, 1328, 1243, 1164, 1039, 909, 729 cm-1. 
(2-Methoxy-4-((8-phenyloctanamido)methyl)phenyl)boronic Acid (6.9). Following 
synthetic procedure A using N-(3-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)benzyl)-8-phenyloctanamide (0.046 g, 0.099 mmol), purification by PLC (EtOAc/hexanes 
70:30) afforded the title compound as a white solid (0.040 g, 0.104 mmol, 74% yield). M.p. 
105−107 °C. 1H NMR (400 MHz, DMSO-d6) δ 1.27 (m, 6H), 1.52 (m, 4H), 2.14 (t, J = 7.2 
Hz, 2H), 2.55 (t, J = 7.4 Hz, 2H), 3.78 (s, 3H), 4.26 (d, J = 5.6 Hz, 2H), 6.81 (d, J = 7.4 Hz, 
1H), 6.85 (s, 1H), 7.17 (m, 3H), 7.27 (m, 2H), 7.52 (d J = 7.4 Hz, 1H), 7.62 (s, 2H), 8.3 (m, 
1H) ppm. 13C NMR (100 MHz, DMSO-d6) δ 25.25, 28.47, 28.53, 30.33, 30.89, 35.05, 35.26, 
41.98, 55.04, 108.98, 118.88, 125.47, 128.10, 128.14, 135.44, 142.20, 143.83, 163.67, 172.06 
ppm. IR ν 3410, 3296, 2931, 2851, 1640, 1610, 1546, 1411, 1353, 1243, 1045, 827 cm-1. 
(4-(2-((4-(tert-Butyl)phenyl)amino)-2-oxoethyl)phenyl)boronic Acid (6.10). Following 
synthetic procedure A using N-(4-(tert-butyl)phenyl)-2-(4-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)phenyl)acetamide (0.053 g, 0.135 mmol), crystallization from THF/H2O 
afforded the title compound (0.034 g, 0.109 mmol, 93% yield). M.p. >230 °C. 1H NMR (400 
MHz, DMSO-d6) δ 1.26 (s, 9H), 3.63 (s, 2H), 7.30 (m, 4H), 7.52 (d, J = 8.4 Hz, 2H), 7.75 (d, 
J = 7.6 Hz, 2H), 8.00 (s, 2H), 10.10 (s, 1H) ppm. 13C NMR (100 MHz, DMSO-d6) δ 31.15, 
33.93, 43.40, 118.91, 125.24, 128.08, 134.12, 136.58, 137.93, 145.52, 168.46 ppm. IR ν 3321, 
2924, 1673, 1600, 1533, 1358, 1179, 1094, 1034, 820 cm-1. 
(4-(2-(Benzylamino)-2-oxoethyl)phenyl)boronic Acid (6.11). Following synthetic 
procedure A using N-benzyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)phenyl)acetamide (0.100 g, 0.285 mmol), crystallization from THF/H2O afforded the title 
compound (0.062 g, 0.230 mmol, 80% yield). M.p. >230°C. 1H NMR (400 MHz, DMSO-d6) 
δ 3.52 (s, 2H), 4.28 (d, J = 6.0 Hz, 2H), 7.27 (m, 8H), 7.73 (d, J = 8.0 Hz, 2H), 7.99 (s, 2H) 
ppm. 13C NMR (100 MHz, DMSO-d6) δ 42.21, 42.49, 126.74, 127.19, 128.06, 128.24, 
134.08, 138.24, 139.42, 170.02 ppm. IR ν 3392, 3286, 3030, 2925, 1641, 1543, 1410, 1341, 
1182, 1022, 818, 695 cm-1. 
 (4-(2-(([1,1'-Biphenyl]-4-ylmethyl)amino)-2-oxoethyl)phenyl)boronic Acid (6.12). 
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Following synthetic procedure A using N-([1,1'-biphenyl]-4-ylmethyl)-2-(4-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetamide (0.102 g, 0.239 mmol), crystallization 
from THF/H2O afforded the title compound (0.039 g, 0.113 mmol, 47% yield). M.p. >230 °C. 
1H NMR (400 MHz, DMSO-d6) δ 3.45 (s, 2H), 4.26 (d, J = 5.8 Hz, 2H), 7.20 (d, J = 8.0 Hz, 
2H), 7.29 (m, 3H), 7.41 (m, 2H), 7.58 (m, 4H), 7.67 (d, J = 7.6 Hz, 2H), 7.94 (s, 2H), 8.54 (t, 
J = 5.8 Hz, 1H) ppm. 13C NMR (100 MHz, DMSO-d6) δ 41.82, 42.40, 126.48, 126.52, 
127.22, 127.74, 127.98, 128.80, 133.99, 138.13, 138.61, 139.82, 149.62, 169.92 ppm. IR ν 
3292, 3281, 3061, 2924, 1632, 1548, 1333, 1255, 1079, 808 cm-1. 
(4-(2-Oxo-2-((4-phenylbutyl)amino)ethyl)phenyl)boronic Acid (6.13). Following synthetic 
procedure A using N-(4-phenylbutyl)-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)phenyl)acetamide (0.072 g, 0.183 mmol), crystallization from THF/H2O afforded the title 
compound (0.039 g, 0.125 mmol, 68% yield). M.p. 219−230 °C. 1H NMR (400 MHz, 
DMSO-d6) δ 1.41 (m, 2H), 1.53 (m, 2H), 2.54 (t, J = 7.6 Hz, 2H), 3.08 (m, 2H), 3.38 (s, 2H), 
7.15 (m, 3H), 7.25 (m, 4H), 7.72 (d, J = 8.0 Hz, 2H), 7.99 (s, 2H), 8.03 (m, 1H) ppm. 13C 
NMR (100 MHz, DMSO-d6) δ 28.31, 28.72, 34.73, 38.27, 42.61, 125.58, 127.94, 128.17, 
128.22, 134.05, 138.44, 142.07, 169.81. IR ν 3268, 2965, 1652, 1604, 1535, 1359, 1142, 
1089, 962, 858 cm-1. 
(4-(2-Oxo-2-((5-phenylpentyl)amino)ethyl)phenyl)boronic Acid (6.14). Following synthetic 
procedure A using N-(5-phenylpentyl)-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)phenyl)acetamide (0.111 g, 0.272 mmol), crystallization from THF/H2O afforded the title 
compound (0.063 g, 0.194 mmol, 72% yield). M.p. >230 °C. 1H NMR (400 MHz, DMSO-d6) 
δ 1.23 (m, 2H), 1.42 (quintet, J = 7.2 Hz, 2H), 1.54 (quintet, J = 7.6 Hz, 2H), 2.50 (m, 2H), 
3.02 (q, J = 7.2 Hz, 2H), 3.37 (s, 2H), 7.16 (m, 3H), 7.20 (d, J = 8.0 Hz, 2H), 7.26 (m, 2H), 
7.70 (d, J = 8.0 Hz, 2H), 7.96 (s, 2H), 7.98 (t, J = 5.6 Hz, 1H) ppm. 13C NMR (100 MHz, 
DMSO-d6) δ 25.98, 28.84, 30.63, 35.07, 38.46, 42.57, 125.56, 127.94, 128.17, 128.21, 
134.02, 138.42, 142.17, 169.72 ppm. IR ν 3696, 3387, 3291, 2923, 1633, 1604, 1556, 1332, 
1055, 733 cm-1. 
(4-(2-Oxo-2-((7-phenylheptyl)amino)ethyl)phenyl)boronic Acid (6.15). Following synthetic 
procedure A using N-(7-phenylheptyl)-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)phenyl)acetamide (0.180 g, 0.413 mmol), crystallization from THF/H2O afforded the title 
compound (0.092 g, 0.260 mmol, 63% yield). M.p. >230 °C. 1H NMR (400 MHz, DMSO-d6) 
δ 1.20 (m, 6H), 1.37 (quintet, J = 6.8 Hz, 2H), 1.54 (quintet, J = 7.2 Hz, 2H), 2.50 (t, J = 7.6 
Hz, 2H), 3.02 (q, J = 6.8 Hz, 2H), 3.37 (s, 2H), 7.17 (m, 7H), 7.70 (d, J = 8.0 Hz, 2H), 7.93 (s, 
2H), 7.98 (m, 1H) ppm. 13C NMR (100 MHz, DMSO-d6) δ 24.57, 26.26, 28.48, 28.54, 28.98, 
30.88, 35.08, 42.55, 125.47, 127.89, 128.10, 128.16, 133.99, 138.39, 142.21, 169.72 ppm. IR 
ν 3388, 3292, 2923, 1633, 1604, 1560, 1342, 1109, 716 cm-1. 
 (4-(4-(tert-Butyl)benzamido)phenyl)boronic Acid (6.16). Following synthetic procedure A 
using 4-(tert-butyl)-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)benzamide 
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(0.110 g , 0.290 mmol), crystallization from THF/H2O afforded the title compound (0.091 g, 
0.306 mmol, 103 % yield). M.p. 172−174 °C. 1H NMR (400 MHz, DMSO-d6) δ 1.32 (s, 9H), 
7.55 (d, J = 11.0 Hz, 2H), 7.76 (m, 4H), 7.89 (d, J = 11.0 Hz, 2H), 7.93 (s, 2H), 10.19 (s, 1H) 
ppm. 13C NMR (100 MHz, DMSO-d6) δ 30.84, 34.58, 118.83, 125.04, 127.44, 132.19, 
134.59, 140.83, 154.30, 165.44 ppm. IR ν 3380, 3295, 2955, 1644, 1589, 1526, 1402, 1326, 
1154, 1039, 1013, 829 cm-1. 
(4-(2-([1,1'-Biphenyl]-4-yl)acetamido)phenyl)boronic Acid (6.17). Following synthetic 
procedure A using 2-([1,1'-biphenyl]-4-yl)-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)phenyl)acetamide (0.106 g, 0.256 mmol), crystallization from THF/H2O afforded the title 
compound (0.049 g, 0.148 mmol, 56% yield). M.p. >210 °C. 1H NMR (300 MHz, DMSO-d6) 
δ 3.70 (s, 2H), 7.43 (m, 5H), 7.64 (m, 6H), 7.74 (d, J = 8.1 Hz, 2H), 7.91 (s, 2H), 10.23 (s, 
1H) ppm. 13C NMR (75 MHz, DMSO-d6) δ 42.90, 117.76, 126.45, 126.52, 127.19, 128.79, 
129.59, 134.76, 135.10, 138.39, 139.86, 140.73, 169.02 ppm. IR ν 3440, 3296, 1657, 1591, 
1525, 1367, 1346, 1110, 1005, 801 cm-1. 
(E)-(4-(3-(4-Chlorophenyl)acrylamido)phenyl)boronic Acid (6.18). Following synthetic 
procedure A using (E)-3-(4-chlorophenyl)-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)phenyl)acrylamide (0.128 g, 0.334 mmol), crystallization from THF/H2O afforded the title 
compound (0.071 g, 0.235 mmol, 71% yield). M.p. >230 °C. 1H NMR (400 MHz, DMSO-d6) 
δ 6.86 (d, J = 16.0 Hz, 1H), 7.52 (d, J = 8.4 Hz, 2H), 7.59 (d, J = 16.0 Hz, 1H), 7.66 (m, 4H), 
7.77 (d, J = 8.4 Hz, 2H), 7.94 (s, 2H), 10.25 (s, 1H) ppm. 13C NMR (100 MHz, DMSO-d6) δ 
117.95, 123.03, 128.98, 129.33, 133.60, 134.13, 134.84, 138.77, 140.71, 163.29 ppm. IR ν 
3302, 1661, 1626, 1589, 1524, 1340, 1242, 1124, 1013, 972, 817 cm-1. 
(4-(6-Phenylhexanamido)phenyl)boronic Acid (6.19). Following synthetic procedure A 
using 6-phenyl-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)hexanamide (0.156 
g, 0.397 mmol), crystallization from THF/H2O afforded the title compound (0.096 g, 0.308 
mmol, 77% yield). M.p. 191−193 °C. 1H NMR (300 MHz, DMSO-d6) δ 1.33 (m, 3H), 1.60 
(m, 3H), 2.30 (t, J = 7.2 Hz, 2H), 2.57 (t, J = 7.5 Hz, 2H), 7.20 (m, 5H), 7.55 (t, J = 8.0 Hz, 
2H), 7.71 (t, J = 8.0 Hz, 2H), 7.89 (s, 2H), 9.87 (s, 1H) ppm. 13C NMR (75 MHz, DMSO-d6) 
δ 24.84, 28.19, 30.68, 34.92, 36.31, 117.66, 125.48, 128.09, 128.15, 134.70, 140.87, 142.11, 
171.21 ppm. IR ν 3400, 3306, 2926, 2854, 1662, 1587, 1509, 1346, 1315, 1249, 1107, 1009, 
808 cm-1. 
(4-(8-Phenyloctanamido)phenyl)boronic Acid (6.20). Following synthetic procedure A 
using 8-phenyl-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)octanamide (0.121 
g, 0.287 mmol), crystallization from THF/H2O afforded the title compound (0.068 g, 0.200 
mmol, 69% yield). M.p. 166−169 °C. 1H NMR (400 MHz, DMSO-d6) δ 1.55 (m, 6H), 1.56 
(m, 4H), 2.29 (t, J = 9.6 Hz, 2H), 2.55 (m, 2H), 7.16−7.28 (m, 5H), 7.55 (d, J = 10.8 Hz, 2H), 
7.70 (d, J = 10.8 Hz, 2H), 7.89 (s, 2H), 9.87 (s, 1H) ppm. 13C NMR (100 MHz, DMSO-d6) δ 
24.97, 25.61, 28.43, 28.50, 30.87, 30.31, 36.33, 117.64, 125.45, 128.08, 128.12, 134.69, 
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140.88, 142.18, 171.23 ppm. IR ν 3437, 3309, 2925, 2853, 1663, 1587, 1509, 1345, 1105, 
1008, 807 cm-1. 
 (4-((4-(tert-Butyl)phenyl)carbamoyl)phenyl)boronic Acid (6.21). Following syntetic 
procedure A using N-(4-(tert-butyl)phenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)benzamide (0.076 g, 0.200 mmol), crystallization from THF/H2O afforded the title 
compound (0.030 g, 0.101 mmol, 50% yield). M.p. >230 °C. 1H NMR (400 MHz, DMSO-d6) 
δ 1.28 (s, 9H), 7.36 (d, J = 8.8 Hz, 2H), 7.70 (d, J = 8.8 Hz, 2H), 7.93 (s, 4H), 8.26 (s, 2H), 
10.19 (s, 1H) ppm. 13C NMR (100 MHz, DMSO-d6) δ 31.18, 34.00, 120.15, 125.15, 126.44, 
133.95, 136.19, 136.52, 145.99, 165.43 ppm. IR ν 3349, 2959, 1656, 1638, 1517, 1407, 1320, 
1251, 1100, 1008, 835, 729 cm-1. 
(4-([1,1'-Biphenyl]-4-ylcarbamoyl)phenyl)boronic Acid (6.22). Following synthetic 
procedure A using N-([1,1'-biphenyl]-4-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)benzamide (0.078 g, 0.195 mmol), crystallization from THF/H2O afforded the title 
compound (0.030 g, 0.095 mmol, 48% yield). M.p. >230 °C. 1H NMR (400 MHz, DMSO-d6) 
δ 7.36 (t, J = 7.6 Hz, 1H), 7.46 (t, J = 7.6 Hz, 2H), 7.69 (d, J = 8.0 Hz, 4H), 7.97 (m, 6H), 
8.32 (s, 2H), 10.45 (s, 1H) ppm. 13C NMR (100 MHz, DMSO-d6) δ 120.68, 126.26, 126.58, 
126.73, 127.02, 128.87, 134.02, 135.23, 136.09, 138.71, 139.69, 165.69 ppm. IR ν 3323, 
2923, 1646, 1530, 1403, 1251, 1125, 1033, 834, 760 cm-1. 
(4-(Benzylcarbamoyl)phenyl)boronic Acid (6.23). Following synthetic procedure A using 
N-benzyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (0.105 g, 0.310 mmol), 
crystallization from THF/H2O afforded the title compound (0.053 g, 0.208 mmol, 66% yield). 
M.p. >230 °C. 1H NMR (400 MHz, DMSO-d6) δ 4.49 (br s, 2H), 7.25 (br s, 1H), 7.33 (br s, 
2H), 7.86 (br s, 4H), 8.19 (s, 2H), 8.19 (s, 2H), 9.03 (br s, 1H) ppm. 13C NMR (100 MHz, 
DMSO-d6) δ 42.60, 126.12, 126.69, 127.19, 128.24, 133.96, 135.59, 139.64, 166.38 ppm. IR 
ν 3402, 3301, 3030, 2925, 1636, 1539, 1352, 1314, 1120, 1025, 805, 695 cm-1. 
(4-((4-Hydroxyphenethyl)carbamoyl)phenyl)boronic Acid (6.24). Following synthetic 
procedure A using N-(4-hydroxyphenethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)benzamide (0.062 g, 0.170 mmol), crystallization from THF/H2O afforded the title 
compound (0.016 g, 0.056 mmol, 33% yield). M.p. 195−202 °C. 1H NMR (400 MHz, 
DMSO-d6) δ 2.73 (t, J = 7.2 Hz, 2H), 3.44 (m, 2H), 6.70 (d, J = 7.6 Hz, 2H), 7.03 (d, J = 7.6 
Hz, 2H), 7.78 (d, J = 7.6 Hz, 2H), 7.86 (d, J = 7.6 Hz, 2H), 8.20 (s, 2H), 8.52 (t, J = 5.2 Hz, 
1H), 9.19 (s, 1H) ppm. 13C NMR (100 MHz, DMSO-d6) δ 34.28, 41.20, 115.09, 125.97, 
129.47, 129.54, 133.87, 135.89, 155.58, 166.24 ppm. IR ν 3315, 1633, 1542, 1513, 1342, 
1249, 1106, 1005, 823 cm-1. 
(4-(([1,1'-Biphenyl]-4-ylmethyl)carbamoyl)phenyl)boronic Acid (6.25). Following 
synthetic procedure A using N-([1,1'-biphenyl]-4-ylmethyl)-4-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)benzamide (0.150 g, 0.363 mmol), crystallization from THF/H2O afforded 
the title compound (0.069 g, 0.208 mmol, 59% yield). M.p. >230 °C. 1H NMR (400 MHz, 
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DMSO-d6) δ 4.58 (br s, 2H), 7.35 (br s, 1H), 7.45 (br s, 4H), 7.64 (br s, 4H), 7.95 (br s, 2H), 
8.29 (s, 2H), 8.19 (br s, 2H), 9.15 (br s, 1H) ppm. 13C NMR (100 MHz, DMSO-d6) δ 42.38, 
126.18, 126.54, 126.59, 127.27, 127.87, 128.88, 134.02, 135.60, 138.69, 138.92, 139.96, 
166.42 ppm. IR ν 3294, 1636, 1539, 1352, 1315, 1121, 807 cm-1. 
(4-((4-Phenylbutyl)carbamoyl)phenyl)boronic Acid (6.26). Following synthetic procedure 
A using N-(4-phenylbutyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (0.114 
g, 0.300 mmol), crystallization from THF/H2O afforded the title compound (0.057 g, 0.192 
mmol, 63% yield). M.p. 173−180 °C. 1H NMR (400 MHz, DMSO-d6) δ 1.56 (m, 4H), 2.59 (t, 
J = 7.2 Hz, 2H), 3.29 (m, 2H), 7.19 (m, 3H), 7.26 (m, 2H), 7.78 (d, J = 8.0 Hz, 2H), 7.84 (d, J 
= 8.0 Hz, 2H), 8.19 (s, 2H), 8.44 (m, 1H) ppm. 13C NMR (100 MHz, DMSO-d6) δ 28.39, 
28.70, 34.73, 38.79, 125.52, 125.89, 128.11, 128.18, 133.77, 135.85, 142.05, 166.11 ppm. IR 
ν 3464, 3308, 3026, 2917, 1627, 1533, 1470, 1319, 1118, 804, 742, 694 cm-1. 
(4-((5-Phenylpentyl)carbamoyl)phenyl)boronic Acid (6.27). Following synthetic procedure 
A using N-(5-phenylpentyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (0.099 
g, 0.252 mmol), crystallization from THF/H2O afforded the title compound (0.068 g, 0.218 
mmol, 94% yield). M.p. 210−211 °C. 1H NMR (400 MHz, DMSO-d6) δ 1.29 (m, 2H), 1.54 
(m, 4H), 2.54 (m, 2H), 3.21 (m, 2H), 7.15 (m, 3H), 7.21 (m, 2H), 7.75 (m, 2H), 7.81 (m, 2H), 
8.17 (s, 2H), 8.41 (br s, 1H) ppm. 13C NMR (100 MHz, DMSO-d6) δ 24.56, 26.06, 28.87, 
30.69, 35.02, 125.55, 125.97, 128.17, 128.23, 133.84, 135.95, 142.19, 166.15 ppm. IR ν 3438, 
3311, 2930, 2854, 1633, 1555, 1352, 1118, 1007, 805, 743, 696 cm-1. 
(4-((3-(4-(tert-Butyl)phenyl)ureido)methyl)phenyl)boronic Acid (6.28). Following 
synthetic procedure A using 1-(4-(tert-butyl)phenyl)-3-(4-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)benzyl)urea (0.142 g, 0.348 mmol), purification by PLC (hexanes/EtOAc 
30:70) followed by treatment with a mixture of Et2O/hexanes (2:1 mL) gave a residue that 
was cristallized from THF/H2O to obtain the title compound (0.060 g, 0.183 mmol, 53% 
yield). M.p. >230 °C. 1H NMR (400 MHz, DMSO-d6) δ 1.24 (s, 9H), 4.30 (d, J = 6.0 Hz, 
2H), 6.54 (t, J = 6.0 Hz, 1H), 722−7.33 (m, 6H), 7.52 (d, J = 7.8 Hz, 2H), 8.00 (s, 2H), 8.46 
(s, 1H) ppm. 13C NMR (100 MHz, DMSO-d6) δ 31.17, 33.69, 42.66, 117.45, 125.10, 125.95, 
134.07, 137.70, 142.14, 143.24, 155.19 ppm. IR ν 3319, 2959, 1639, 1598, 1550, 1408, 1359, 
1231, 1114, 1016, 816 cm-1. 
(4-((3-(4-(tert-Butyl)phenyl)ureido)methyl)-2-methoxyphenyl)boronic Acid (6.29). 
Following synthetic procedure A using 1-(4-(tert-butyl)phenyl)-3-(3-methoxy-4-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)urea (0.092 g, 0.21 mmol), purification by silica 
gel column chromatography (EtOAc/hexanes 60:40) afforded the title compound as an oil 
(0.033 g, 0.093 mmol, 44% yield). 1H NMR (400 MHz, DMSO-d6) δ 1.24 (s, 9H), 3.81 (s, 
3H), 4.30 (d, J = 6.0 Hz, 2H), 6.55 (m, 1H), 6.90 (m, 2H), 7.23 (d, J = 8.0 Hz, 2H), 7.32 (d, J 
= 8.0 Hz, 2H), 7.55 (d, J = 7.2 Hz, 1H), 7.63 (s, 2H), 8.47 (s, 1H) ppm. 13C NMR (100 MHz, 
DMSO-d6) δ 31.18, 33.70, 39.42, 42.84, 109.00, 117.52, 118.81, 125.13, 135.51, 137.71, 
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143.30, 144.47, 155.21, 163.70 ppm. IR ν 3470, 3330, 2959, 1644, 1597, 1548, 1416, 1361, 
1316, 1243, 1165, 1043, 823, 755 cm-1. 
 (4-(3-(4-(tert-Butyl)phenyl)ureido)phenyl)boronic Acid (6.30). Following synthetic 
procedure A using 1-(4-(tert-butyl)phenyl)-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)phenyl)urea (0.098 g, 0.25 mmol), crystallization from THF/H2O afforded the title 
compound (0.082 g, 0.263 mmol, 105% yield). M.p. 213−214 °C. 1H NMR (400 MHz, 
DMSO-d6) δ 1.26 (s, 9H), 7.29 (d, J = 8.8 Hz, 2H), 7.37 (d, J = 8.4 Hz, 2H), 7.41 (d, J = 8.4 
Hz, 2H), 7.71 (d, J = 8.0 Hz, 2H), 7.84 (s, 2H), 8.59 (s, 1H), 8.64 (s, 1H) ppm. 13C NMR (100 
MHz, DMSO-d6) δ 31.21, 33.84, 116.72, 118.03, 125.34, 134.98, 136.94, 141.49, 144.14, 
152.39 ppm. IR ν 3316, 2958, 1673, 1647, 1589, 1518, 1401, 1360, 1316, 1216, 1111, 830 
cm-1. 
(E)-(3-(3-(4-Chlorophenyl)acrylamido)phenyl)boronic Acid (6.31).  Following synthetic 
procedure A using (E)-3-(4-chlorophenyl)-N-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)phenyl)acrylamide (0.152 g, 0.396 mmol), crystallization from THF/H2O afforded the title 
compound (0.095 g, 0.315 mmol, 79% yield). M.p. >230 °C. 1H NMR (400 MHz, DMSO-d6) 
δ 6.87 (d, J = 15.6 Hz, 1H), 7.31 (m, 1H), 7.52 (m, 3H), 7.58 (d, J = 15.6 Hz, 1H) 7.65 (d, J = 
8.4 Hz, 2H), 7.89 (m, 2H), 8.05 (s, 2H), 10.17 (s, 1H) ppm. 13C NMR (100 MHz, DMSO-d6) 
δ 121.143, 123.197, 125.153, 127.70, 128.97, 129.17, 129.29, 133.66, 134.04, 138.27, 138.43, 
163.14 ppm. IR ν 3303, 1659, 1627, 1547, 1489, 1350, 1091, 1003, 818 cm-1. 
2-Phenyl-N-(7-phenylheptyl)acetamide (6.32). Following synthetic procedure D using 2-
phenylacetic acid (0.082 g, 0.602 mmol) and 7-phenylheptan-1-amine (0.113 g, 0.591 mmol), 
crystallization from hexanes/CH2Cl2 afforded the title compound (0.110 g, 0.355 mmol, 60% 
yield). M.p. 79−80 °C. 1H NMR (400 MHz, CDCl3) δ 1.35 (m, 6H), 1.37 (m, 2H), 1.39 (m, 
2H), 2.57 (t, J = 7.8 Hz, 2H), 3.18 (m, 2H), 3.55 (s, 2H), 5.38 (br s, 1H), 7.15−7.35 (m, 10H) 
ppm. 13C NMR (100 MHz, CDCl3) δ 26.67, 29.04, 29.11, 29.41, 31.34, 35.90, 39.63, 43.90, 
125.59, 127.31, 128.23, 128.38, 129.01, 129.44, 135.06, 142.75, 170.87 ppm. IR ν 3293, 
2921, 2848, 1633, 1557, 1452, 1350, 1186, 1027, 708 cm-1. 
2-(4-Hydroxyphenyl)-N-(7-phenylheptyl)acetamide (6.33). Following synthetic procedure 
D using 2-(4-hydroxyphenyl)acetic acid (0.102 g, 0.670 mmol) and 7-phenylheptan-1-amine 
(0.128 g, 0.669 mmol), crystallization from hexanes/CH2Cl2 afforded the title compound 
(0.126 g, 0.387 mmol, 58% yield). M.p. 93−94 °C. 1H NMR (400 MHz, DMSO-d6) δ 1.21 
(m, 6H), 1.35 (m, 2H), 1.54 (m, 2H), 2.55 (t, J = 7.6 Hz, 2H), 3.00 (m, 2H), 3.24 (s, 2H), 6.66 
(d, J = 8.4 Hz, 2H), 7.02 (d, J = 8.4 Hz, 2H), 7.16 (m, 3H), 7.26 (m, 2H), 7.85 (m, 1H), 9.22 
(s, 1H) ppm. 13C NMR (100 MHz, DMSO-d6) δ 26.22, 28.44, 28.50, 28.98, 30.85, 35.04, 
38.41, 41.54, 114.82, 125.47, 126.61, 128.10, 128.15, 129.68, 142.21, 155.73, 170.30 ppm. 
IR ν 3420, 3290, 2922, 2849, 1633, 1558, 1513, 1451, 1251, 755 cm-1. 
N-[(1,1-Dimethylethoxy)carbonyl]-4-hydroxy-3-methoxybenzylamine (6.34). To a solution 
of 4-(aminomethyl)-2-methoxyphenol hydrochloride (1.138 g, 6.00 mmol) in a mixture of 
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THF/H20 (25:10 mL) was added Et3N (0.607 g, 6.00 mmol) at 0 °C and followed by addition 
of di-tert-butyl dicarbonate (1.309 g, 6.00 mmol). The reaction mixture was stirred at 0 °C for 
30 min, then at room temperature for 18 h. The mixture was concentrated in vacuo and the 
residue was diluited with water and EtOAc. The organic layer was washed with brine (×3), 
dried over Na2SO4, filtered and concentated in vacuo. The resulting material was purified by 
silica gel column chromatography (CH2Cl2/EtOAc 95:5) to obtain the desired product (1.26 g, 
4.99 mmol, 83% yield). 1H NMR (400 MHz, CDCl3) δ 1.46 (s, 9H), 3.87 (s, 3H), 4.22 (d, J = 
5.2 Hz, 2H), 4.80 (br s, 1H), 5.63 (s, 1H), 6.76 (d, J = 8.0 Hz, 1H), 6.81 (s, 1H), 6.66 (d, J = 
8.0 Hz, 1H) ppm. 
N-[(1,1-Dimethylethoxy)carbonyl]-4-[(trifluoromethyl)sulfonyl]oxy-3-
methoxybenzylamine (6.35). To a solution of N-[(1,1-dimethylethoxy)carbonyl]-4-hydroxy-3-
methoxybenzylamine (0.785 g, 3.10 mmol) and N-phenyl-bis(trifluoromethanesulfonimide) 
(1.107 g, 3.10 mmol) in CH2Cl2 (8 mL) was added dropwise Et3N (0.314 g, 3.10 mmol) at 0 
°C. The mixture was stirred at room temperature for 16 h and then diluited with brine. The 
aqueous phase was extracted with CH2Cl2 (×3). The organic layer was washed with brine, 
dried over Na2SO4, filtered and concentrated in vacuo. The resulting material was purified by 
silica gel column chromatography (hexanes/EtOAc 80:20) to obtain the desired product 
(0.950 g, 4.46 mmol, 80% yield). M.p. 99−101 °C (hexanes/CH2Cl2). 1H NMR (400 MHz, 
CDCl3) δ 1.47 (s, 9H), 3.90 (s, 3H), 4.31 (d, J = 5.6 Hz, 2H), 4.94 (br s, 1H), 6,87 (d, J = 8,4 
Hz, 1H), 6.97 (s, 1H), 7.16 (d, J = 8,4 Hz, 1H) ppm. 13C NMR (100 MHz, CDCl3) δ 28.37, 
44.30, 56.17, 80.00, 112.21, 119.46, 122.44, 137.84, 140.85, 151.48, 155.97, 166.80 ppm. IR 
ν 3374, 2984, 2943, 1685, 1609, 1528, 1507, 1422, 1284, 1199, 1141, 1033, 883 cm-1. 
N-[(1,1-Dimethylethoxy)carbonyl]-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-
methoxybenzylamine (6.36). A mixture of palladium(II) chloride (0.012 g, 0.07 mmol), 1,1'-
bis(diphenylphosphino)ferrocene (0.078 g, 0.140 mmol), potassium acetate (0.687 g, 7.0 
mmol), N-[(1,1-dimethylethoxy)carbonyl]-4-[(trifluoromethyl)sulfonyl]oxy-3-
methoxybenzylamine (0.902 g, 2.34 mmol), and bis(pinacolato)diboron (0.653 g, 2.57 mmol) 
was stirred min at room temperature for 10 under N2. Dioxane was added (16 mL) and the 
reaction mixture was stirred at 100 °C for 4 h. The reaction mixture was cooled to room 
temperature and diluited with water and EtOAc. The organic layer was washed with brine, 
dried over Na2SO4, filtered and concentrated in vacuo. The resulting material was purified by 
silica gel column chromatography (hexanes/EtOAc 65:35) to obtain the desired product 
(0.680 g, 1.80 mmol, 80% yield). M.p. 85−86 °C (hexanes/Et2O). 1H NMR (400 MHz, 
CDCl3) δ 1.34 (s, 12H), 1.45 (s, 9H), 3.87 (s, 3H), 4.28 (d, J = 4.8 Hz, 2H), 4.97 (br s, 1H), 
6.77 (s, 1H), 6.83 (d, J = 7.2 Hz, 1H), 7.62 (d, J = 7.2 Hz, 1H) ppm. 13C NMR (100 MHz, 
CDCl3) δ 24.81, 28.41, 44.88, 55.81, 79.48, 83.43, 109.66, 119.12, 137.09, 143.89, 155.97, 
164.61 ppm. IR ν 3371, 2977, 2934, 1709, 1612, 1567, 1525, 1463, 1418, 2358, 1252, 1166, 
1067, 862 cm-1. 
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4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-3-methoxybenzylamime trifluoroacetate 
(6.37). A solution of N-[(1,1-dimethylethoxy)carbonyl]-4-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)-3-methoxybenzylamine (0.541 g, 1.43 mmol) in a mixture of TFA/ 
CH2Cl2 (4 mL, 3:1) was stirred for 40 min at room temperature. Then, the reaction mixture 
was concentrated in vacuo, diluited with CHCl3 and concentrated in vacuo (×4). The resulting 
material was washed crystallized from hexanes/Et2O to obtain a white solid (0.474 g, 1.26 
mmol, 88% yield). M.p. 145−147 °C. 1H NMR (400 MHz, CDCl3) δ 1.30 (s, 12H), 3.74 (s, 
3H), 4.00 (br s, 2H), 6.85 (m, 2H), 7.58 (d, J = 7.2 Hz, 1H), 7.84 (br s, 3H) ppm. 13C NMR 
(100 MHz, CDCl3) δ 24.59, 44.23, 55.69, 84.32, 111.13, 115.80 (q, J = 320 Hz), 120.78, 
136.41, 137.55, 160.97 (q, J = 38.7 Hz), 164.48 ppm. IR ν 2981, 1669, 1614, 1420, 1347, 
1140, 1067, 798 cm-1. 
N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)oleamide (6.39). A solution of 
oleic acid (0.071 g, 0.251 mmol) and 1,1'-carbonyldiimidazole (0.081 g, 0.5 mmol) in CH2Cl2 
(2 mL) was stirred at room temperature for 1 h and added to a solution of 4-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)-benzylamine trifluoroacetate (0.094 g, 0.250 mmol) in 
CH2Cl2 (1 mL). Et3N (0.026 g, 0.260 mmol) was added at 0 °C. Reaction mixture was stirred 
at room temperature for 16 h, then diluited with EtOAc. The organic layer was washed with 
satd. aq. NaHCO3 and brine (×2), dried over Na2SO4, filtered and concentrated in vacuo. The 
resulting material was used in the next step without further purification (0.119 g, 0.239 mmol, 
96% yield). 1H NMR (400 MHz, CDCl3) δ 0.88 (t, J = 6.4 Hz, 3H), 1.29 (m, 32H), 1.63 (m, 
2H), 2.00 (m, 4H), 2.19 (t, J = 7.6 Hz, 2H), 4.41 (d, J = 5.6 Hz, 2H), 5.34 (m, 2H), 6.16 (m, 
1H), 7.24 (d, J = 8.0 Hz, 2H), 7.75 (d, J = 8.0 Hz, 2H) ppm. 13C NMR (100 MHz, CDCl3) δ 
14.10, 22.68, 24.86, 25.02, 25.79, 27.20, 27.23, 29.15, 29.32, 29.53, 29.72, 29.78, 31.91, 
34.38, 36.71, 43.58, 83.82, 127.02, 129.76, 129.99, 135.19, 141.58, 173.28 ppm. IR ν 3447, 
3029, 2920, 2856, 1665, 1613, 1513, 1466, 1398, 1357, 1322, 1273, 1143, 1088, 1021, 962, 
857 cm-1. 
N-[4-(4,4,5,5-Tetrametil-1,3,2-diossiborolan-2-il)-3-metossibenzil]oleamide (6.40). 
Following synthetic procedure described for 6.39 using oleic acid (0.076 g, 0.269 mmol) and 
3-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-benzylamine trifluoroacetate 
(0.100 g, 0.265 mmol), the resulting material was used in the next step without further 
purification (0.146 g, 0.277 mmol, 104% yield). 1H NMR (400 MHz, CDCl3) δ 0.88 (t, J = 
7.2 Hz, 3H), 1.29 (m, 32H), 1.64 (m, 2H), 2.00 (m, 4H), 2.21 (t, J = 7.4 Hz, 2H), 3.75 (s, 3H), 
4.39 (d, J = 5.6 Hz, 2H), 5.34 (m, 2H), 6.41 (br s, 1H), 6.73 (s, 1H), 6.82 (d, J = 7.6 Hz, 1H), 
7.62 (d, J = 7.6 Hz, 1H) ppm. 13C NMR (100 MHz, CDCl3) δ 14.10, 22.67, 24.81, 25.85, 
27.18, 27.23, 29.15, 29.32, 29.52, 29.72, 29.77, 31.90, 36.73, 43.63, 55.74, 83.48, 109.94, 
119.40, 129.73, 130.00, 137.18, 143.38, 164.56, 173.30 ppm. IR ν 3285, 2924, 2853, 1646, 
1610, 1567, 1412, 1355, 1255, 1146, 1066, 860 cm-1. 
2-([1,1'-Biphenyl]-4-yl)-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
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yl)benzyl)acetamide (6.41). Following synthetic procedure described for 6.39 using 4-
biphenylacetic acid (0.042 g, 0.198 mmol) and 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)-benzylamine trifluoroacetate (0.069 g, 0.199 mmol), the resulting material was used in the 
next step without further purification (0.075 g, 0.175 mmol, 88% yield). 1H NMR (400 MHz, 
CDCl3) δ 1.31 (m, 12H), 3.60 (s, 2H), 4.39 (d, J = 5.2 Hz, 2H), 6.15 (m, 1H), 7.18 (d, J = 7.2 
Hz, 2H), 7.31 (m, 3H), 7.41 (m, 2H), 7.54 (m, 4H), 7.74 (d, J = 7.2 Hz, 2H) ppm. 13C NMR 
(100 MHz, CDCl3) δ 24.83, 43.23, 43.65, 83.80, 126.83, 127.00, 127.36, 127.64, 128.78, 
129.81, 133.76, 135.15, 140.24, 140.51, 141.24 ppm. IR ν 3427, 3009, 2983, 1664, 1613, 
1517, 1361, 1322, 1197, 1143, 1089, 857 cm-1. 
3-Phenyl-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)propanamide (6.42). 
Following synthetic procedure described for 6.39 using 3-phenylpropanoic acid (0.030 g, 0.2 
mmol) and 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-benzylamine trifluoroacetate 
(0.069 g, 0.199 mmol) the resulting material was used in the next step without further 
purification (0.057 g, 0.156 mmol, 78% yield). 1H NMR (400 MHz, CDCl3) δ 1.33 (m, 12H), 
2.48 (t, J = 7.6 Hz, 2H), 2.95 (t, J = 7.6 Hz, 2H), 4.35 (d, J = 5.6 Hz, 2H), 5.99 (br s, 1H), 
7.11 (d, J = 7.6 Hz, 2H), 7.15−7.25 (m, 5H), 7.72 (d, J = 7.6 Hz, 2H) ppm. 13C NMR (100 
MHz, CDCl3) δ 24.85, 31.69, 38.36, 43.55, 83.81, 126.25, 126.95, 128.36, 128.54, 135.12, 
140.76, 141.33, 172.03 ppm. IR ν 3344, 3005, 2981, 1667, 1612, 1516, 1360, 1235, 1143, 
1088, 1021, 857 cm-1. 
(E)-3-(4-chlorophenyl)-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)benzyl)acrylamide (6.43). Following synthetic procedure B using (E)-3-(4-
chlorophenyl)acrylic acid (0.091 g, 0.500 mmol) and 4-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)-benzylamine trifluoroacetate (0.174 g, 0.500 mmol), purification by silica 
gel column chromatography (CH2Cl2/EtOAc 95:5) afforded the title compound (0.077 g, 
0.194 mmol, 39% yield). 1H NMR (400 MHz, CDCl3) δ 1.32 (m, 12H), 4.53 (s, 2H), 6.43 (d, 
J = 15.6 Hz, 1H), 6.52 (s, 1H), 7.27−7.34 (m, 6H), 7.55 (d, J = 15.6 Hz, 1H), 7.74−7.76 (m, 
2H) ppm. 13C NMR (100 MHz, CDCl3) δ 24.84, 43.80, 83.83, 121.12, 127.08, 128.95, 
129.01, 133.27, 135.21, 135.46, 139.91, 141.28, 165.68 ppm. IR ν 3264, 2980, 1655, 1616, 
1405, 1359, 1142, 1089, 818 cm-1. 
6-Phenyl-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)hexanamide (6.44). 
Following synthetic procedure B using 6-phenylhexanoic acid (0.076 g, 0.395 mmol) and 4-
(4,4,5,5-tetramethyl-1,3,2-dioxborolan-2-yl)-benzylamine trifluoroacetate (0.138 g, 0.415 
mmol), purification by silica gel column chromatography (hexanes/EtOAc 70:30) afforded 
the title compound as an oil (0.055 g, 0.135 mmol, 34% yield). 1H NMR (400 MHz, CDCl3) δ 
1.33 (m, 14H), 1.63 (m, 4H), 2.17 (t, J = 7.4 Hz, 2H), 2.58 (t, J = 7.6 Hz, 2H), 4.39 (d, J = 
6.0, 2H), 6.01 (br s, 1H), 7.13−7.27 (m, 7H), 7.76 (d, J = 7.6 Hz, 2H) ppm. 13C NMR (100 
MHz, CDCl3) δ 24.83, 25.55, 28.83, 31.09, 35.70, 36.53, 43.50, 83.79, 125.63, 127.02, 
128.24, 128.36, 135.15, 141.54, 142.47, 173.02 ppm. IR ν 3287, 2930, 1644, 1612, 1358, 
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1142, 1087, 858 cm-1. 
8-Phenyl-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)octanamide (6.45). 
Following synthetic procedure B using 8-phenyloctanoic acid (0.077 g, 0.349 mmol) and 4-
(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-benzylamine trifluoroacetate (0.121 g, 0.349 
mmol), purification by silica gel column chromatography (hexanes/EtOAc 70:30) afforded 
the title compound as an oil (0.081 g, 0.186 mmol, 54% yield). 1H NMR (400 MHz, CDCl3) δ 
1.32 (m, 18H), 1.61 (m, 4H), 2.16 (t, J = 7.2 Hz, 2H), 2.58 (t, J = 7.6 Hz, 2H), 4.40 (d, J = 5.6 
Hz, 2H), 6.01 (m, 1H), 7.17 (m, 3H), 7.25 (m, 4H), 7.77 (d, J = 8.0 Hz, 2H) ppm. 13C NMR 
(100 MHz, CDCl3) δ 24.83, 25.70, 29.08, 29.18, 31.39, 35.90, 36.65, 43.49, 83.79, 125.55, 
127.03, 128.20, 128.37, 135.15, 141.59, 142.76, 173.06 ppm. IR ν 3284, 2927, 1644, 1612, 
1359, 1142, 1087, 858 cm-1. 
N-(3-Methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)-6-phenylhexanamide 
(6.46). Following synthetic procedure B using 6-phenylhexanoic acid (0.048 g, 0.250 mmol) 
and 3-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-benzylamine trifluoroacetate 
(0.087 g, 0.251 mmol), purification by silica gel column chromatography (hexanes/EtOAc 
50:50) afforded the title compound as an oil (0.046 g, 0.105 mmol, 42% yield). 1H NMR (400 
MHz, CDCl3) δ 1.34 (m, 14H), 1.65 (m, 4H), 2.20 (t, J = 7.8 Hz, 2H), 2.60 (t, J = 7.8 Hz, 
2H), 3.81 (s, 3H), 4.41 (d, J = 5.6 Hz, 2H), 5.74 (m, 1H), 6.75 (s, 1H), 6.82 (d, J = 7.2 Hz, 
1H), 7.17 (m, 3H), 7.27 (m, 2H), 7.64 (d J = 7.2 Hz, 1H) ppm. 13C NMR (100 MHz, CDCl3) δ 
24.80 , 25.61, 28.88, 31.13, 35.72, 36.69, 43.74, 55.84, 83.49, 109.99, 119.44, 125.68, 128.28, 
128.38, 137.22, 142.49, 143.14, 164.60, 172.88 ppm. IR ν 3286, 2931, 1646, 1567, 1412, 
1355, 1256, 1144, 1066, 859 cm-1. 
N-(3-Methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)-8-phenyloctanamide 
(6.47). Following synthetic procedure B using 8-phenyloctanoic acid (0.081 g, 0.368 mmol) 
and (3-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-benzylamine trifluoroacetate 
(0.140 g, 0.371 mmol) purification by silica gel column chromatography (hexanes/EtOAc 
70:30) afforded the title compound as an oil (0.070 g, 0.150 mmol, 41% yield). 1H NMR (400 
MHz, CDCl3) δ 1.32 (m, 18H) 1.60 (m, 4H) 2.18 (t, J = 7.6 Hz, 2H), 2.58 (t, J = 7.6 Hz, 2H), 
3.79 (s, 3H), 4.40 (d, J = 6.0 Hz, 2H), 5.84 (m, 1H), 6.74 (s, 1H), 6.82 (d, J = 7.4 Hz, 1H), 
7.16 (m, 3H), 7.26 (m. 2H), 7.62 (d, J = 7.4 Hz, 1H) ppm. 13C NMR (100 MHz, CDCl3) δ 
24.83, 25.55, 28.83, 31.09, 35.70, 36.53, 43.50, 83.79, 125.63, 127.02, 128.24, 128.36, 
135.15, 141.54, 142.47, 173.02 ppm. IR ν 3285, 2928, 1644, 1609, 1411, 1354, 1255, 1144, 
1066, 859 cm-1. 
4-(tert-Butyl)-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)benzamide (6.48). 
Following synthetic procedure B using 4-(tert-butyl)benzoic acid (0.089 g, 0.500 mmol) and 
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (0.109 g, 0.497 mmol), purification by 
silica gel column chromatography (hexanes/EtOAc 70:30) afforded the title compound (0.161 
g, 0.424 mmol, 81% yield). M.p. 172−175 °C (hexanes/CH2Cl2). 1H NMR (400 MHz, CDCl3) 
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δ 1.35 (s, 21H), 7.48 (d, J = 11.2 Hz, 2H), 7.67 (d, J = 11.2 Hz, 2H), 7.82 (m, 4H), 7.92 (s, 
1H) ppm. 13C NMR (100 MHz, CDCl3) δ 24.87, 31.15, 34.99, 83.74, 118.83, 125.74, 126.88, 
131.99, 135.87, 140.76, 155.52, 165.57 ppm. IR ν 3335, 2970, 1652, 1606, 1586, 1397, 1356, 
1317, 1144, 1084, 831 cm-1. 
2-([1,1'-Biphenyl]-4-yl)-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)phenyl)acetamide (6.49). Following synthetic procedure B using 2-([1,1'-biphenyl]-4-
yl)acetic acid (0.106 g, 0.499 mmol) and 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)aniline (0.109 g, 0.497 mmol), purification by silica gel column chromatography 
(hexanes/EtOAc 60:40) afforded the title compound (0.133 g, 0.322 mmol, 62% yield). 1H 
NMR (400 MHz, CDCl3) δ 1.32 (s, 12H), 3.76 (s, 2H), 7.28 (br s, 1H), 7.42 (m, 7H), 7.60 (m, 
4H), 7.74 (d, J = 11.2 Hz, 2H) ppm. 13C NMR (100 MHz, CDCl3) δ 24.85, 44.55, 83.74, 
118.58, 127.05, 127.50, 127.90, 128.84, 129.97, 133.20, 135.76, 140.29, 140.43, 140.62, 
169.00 ppm. IR ν 3299, 2978, 1662, 1594, 1528, 1398, 1356, 1142, 1089, 859 cm-1. 
(E)-3-(4-chlorophenyl)-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)phenyl)acrylamide (6.50). Following synthetic procedure B using (E)-3-(4-
chlorophenyl)acrylic acid (0.183 g, 1.00 mmol) and 4-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)aniline (0.219 g, 1.00 mmol), purification by silica gel column 
chromatography (CHCl3/MeOH 97.2:2.5) afforded the title compound (0.301 g, 0.784 mmol, 
79% yield). 1H NMR (400 MHz, DMSO-d6) δ 1.30 (s, 12H), 6.87 (d, J = 16.0 Hz, 1H), 7.52 
(d, J = 8.4 Hz, 2H), 7.61 (d, J = 16.0 Hz, 1H), 7.67 (m, 4H), 7.75 (d, J = 8.4 Hz, 2H), 10.39 
(s, 1H) ppm. 13C NMR (100 MHz, DMSO-d6) δ 24.60, 83.39, 118.25, 122.85, 128.98, 129.38, 
133.53, 134.22, 135.30, 139.05, 141.92, 163.45 ppm. IR ν 3282, 2979, 2929, 1662, 1630, 
1587, 1532, 1398, 1358, 1147, 1087, 978, 819 cm-1. 
6-Phenyl-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)hexanamide (6.51). 
Following synthetic procedure B using 6-phenylhexanoic acid (0.110 g, 0.572 mmol) and 4-
(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (0.131 g, 0.598 mmol), purification by 
silica gel column chromatography (CH2Cl2/EtOAc 95:5) afforded the title compound (0.156 
g, 0.397 mmol, 66% yield). 1H NMR (300 MHz, CDCl3) δ 1.40 (s, 12H), 1.63 (m, 2H), 1.71 
(m, 4H), 2.33 (d, J = 7.5 Hz, 2H), 2.61 (d, J = 7.5 Hz, 2H), 7.17 (m, 3H), 7.26 (m, 3H), 7.51 
(d, J = 8.0 Hz, 2H), 7.76 (d, J = 8.0, 2H) ppm. 13C NMR (75 MHz, CDCl3) δ 24.86, 25.32, 
28.82, 31.16, 35.71, 37.74, 83.72, 118.49, 125.68, 128.27, 128.34, 135.80, 140.59, 142.46, 
171.27 ppm. IR ν 3301, 2930, 2857, 1663, 1592, 1527, 1397, 1356, 1319, 1142, 859 cm-1. 
8-Phenyl-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)octanamide (6.52). 
Following synthetic procedure B using 8-phenyloctanoic acid (0.110 g, 0.500 mmol) and 4-
(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (0.109 g, 0.497 mmol), purification by 
silica gel column chromatography (hexanes/EtOAc 80:20) afforded the title compound (0.142 
g, 0.337 mmol, 67% yield). 1H NMR (400 MHz, CDCl3) δ 1.33 (m, 18H), 1.62 (m, 4H), 1.69 
(m, 4H), 2.32 (t, J = 10.4 Hz, 2H), 2.58 (t, J = 10.4 Hz, 2H), 7.14−7.77 (m, 9H) ppm. 13C 
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NMR (100 MHz, CDCl3) δ 24.85, 25.49, 29.08, 29.16, 29.21, 31.40, 35.91, 37.81, 83.70, 
118.53, 125.56, 128.21, 128.38, 135.77, 140.69, 142.76, 171.52 ppm. IR ν 3291, 2976, 2922, 
1662, 1593, 1529, 1359, 1144, 1092, 838 cm-1. 
(E)-3-(4-chlorophenyl)-N-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)phenyl)acrylamide (6.53). Following synthetic procedure B using (E)-3-(4-
chlorophenyl)acrylic acid (0.183 g, 1.00 mmol) and 3-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)aniline (0.219 g, 1.00 mmol), purification by silica gel column 
chromatography (CHCl3/MeOH 97.5:2.5) afforded the title compound (0.292 g, 0.761 mmol, 
76% yield). M.p. 165−166 °C. 1H NMR (400 MHz, DMSO-d6) δ 1.31 (s, 12H), 6.83 (d, J = 
15.6 Hz, 1H), 7.37 (m, 2H), 7.52 (d, J = 8.4 Hz, 2H), 7.59 (d, J = 15.6 Hz, 1H) 7.66 (d, J = 
8.4 Hz, 2H), 7.90 (m, 1H), 8.01 (s, 1H), 10.28 (s, 1H) ppm. 13C NMR (100 MHz, DMSO-d6) 
δ 24.61, 83.63, 99.45, 122.08, 122.94, 125.12, 128.38, 128.98, 129.28, 129.34, 133.54, 
134.14, 138.72, 163.24 ppm. IR ν 3269, 2980, 1661, 1624, 1550, 1427, 1357, 1141, 1093, 
964, 817, 704 cm-1. 
1-(4-(tert-Butyl)phenyl)-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)urea 
(6.54). Following synthetic procedure C using 4-tert-butylphenyl isocyanate (0.140 g, 0.800 
mmol) and 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-benzylamine trifluoroacetate 
(0.170 g, 0.490 mmol), purification by silica gel column chromatography (hexanes/EtOAc 
60:40) afforded the title compound (0.178 g, 0.435 mmol, 88% yield). M.p. 87−89 °C. 1H 
NMR (400 MHz, CDCl3) δ 1.20 (s, 9H), 1.32 (s, 12H), 4.16 (t, J = 5.6 Hz, 2H), 6.32 (m, 1H), 
7.05 (t, J = 8.8 Hz, 2H), 7.08 (t, J = 8.8 Hz, 2H), 7.13 (t, J = 7.6 Hz, 2H), 7.69 (t, J = 7.6 Hz, 
2H), 7.82 (s, 1H) ppm. 13C NMR (100 MHz, CDCl3) δ 24.78, 31.34, 34.08, 43.66, 83.62, 
120.00, 125.67, 126.25, 135.02, 136.14, 142.46, 146.85, 156.85 ppm. IR ν 3324, 2965, 1645, 
1598, 1551, 1515, 1358, 1316, 1235, 1142, 1086, 1020, 858 cm-1. 
1-(4-(tert-Butyl)phenyl)-3-(3-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)benzyl)urea (6.55). Following synthetic procedure C using 4-tert-butylphenyl isocyanate 
(0.065 g, 0.371 mmol) and 3-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-
benzylamine trifluoroacetate (0.070 g, 0.186 mmol), purification by silica gel column 
chromatography (hexanes/EtOAc 60:40) afforded the title compound (0.062 g, 0.141 mmol, 
85% yield). 1H NMR (400 MHz, CDCl3/CD3OD) δ 1.29 (s, 9H), 1.35 (s, 12H), 3.83 (s, 3H), 
4.40 (s, 2H), 6.89 (m, 3H), 7.28 (s, 4H), 7.63 (t, J = 7,6 Hz, 2H) ppm. 13C NMR (100 MHz, 
CDCl3/CD3OD) δ 24.92, 31.66, 34.62, 44.30, 55.73, 84.28, 109.94, 119.55, 119.78, 126.19, 
137.32, 137.70, 145.56, 146.11, 157.68, 165.34 ppm. IR ν 3334, 2962, 1646, 1599, 1547, 
1409, 1315, 1239, 1142, 1062, 830 cm-1. 
1-(4-(tert-Butyl)phenyl)-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)urea 
(6.56). Following synthetic procedure C using 4-tert-butylphenyl isocyanate (0.220 g, 1.25 
mmol) and 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (0.198 g, 0.500 mmol), 
purification by column chromatography (CH2Cl2/EtOAc 95:5) afforded the title compound 
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(0.098 g, 0.248 mmol, 50% yield). M.p. >220 °C. 1H NMR (400 MHz, CDCl3) δ 1.19 (s, 9H), 
1.30 (s, 12H), 7.10 (d, J = 8.4 Hz, 2H), 7.16 (d, J = 8.8 Hz, 2H), 7.19 (d, J = 8.0 Hz, 2H), 7.63 
(d, J = 8.4 Hz, 2H), 7.75 (s, 1H), 7.82 (s, 1H), ppm. 13C NMR (100 MHz, CDCl3) δ 24.85, 
31.31, 34.20, 85.54, 118.99, 120.97, 125.87, 135.13, 135.83, 141.25, 146.82, 154.23 ppm. IR 
ν 3319, 2965, 1652, 1592, 1543, 1360, 1315, 1142, 1091, 828 cm-1. 
N-(4-(tert-butyl)phenyl)-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)phenyl)acetamide (6.58). Following synthetic procedure D using 2-(4-(4,4,5,5-tetramethyl-
1,3,2-dioxaborolan-2-yl)phenyl)acetic acid (0.100 g, 0.381 mmol) and 4-(tert-butyl)aniline 
(0.057 g, 0.381 mmol), purification by silica gel column chromatography (CH2Cl2) afforded 
the title compound as an oil (0.064 g, 0.163 mmol, 43% yield). 1H NMR (400 MHz, CDCl3) δ 
1.27 (s, 9H), 1.35 (s, 12H), 3.71 (s, 2H), 7.30 (m, 7H), 7.82 (d, J = 8.0 Hz, 2H) ppm. 13C 
NMR (100 MHz, CDCl3) δ 24.86, 31.31, 34.31, 83.89, 119.77, 125.68, 128.84, 135.00, 
135.57, 137.69, 147.41, 168.85 ppm. IR ν 3259, 2966, 1650, 1604, 1536, 1516, 1360, 1270, 
1142, 1090, 1023, 962, 859 cm-1. 
N-benzyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetamide (6.59). 
Following synthetic procedure D using 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)phenyl)acetic acid (0.131 g, 0.500 mmol) and phenylmethanamine (0.054 g, 0.500 mmol), 
purification by silica gel column chromatography (hexanes/EtOAc 70:30) afforded the title 
compound (0.132 g, 0.376 mmol, 75% yield). M.p. 132−134 °C (hexanes/CH2Cl2). 1H NMR 
(400 MHz, CDCl3) δ 1.33 (s, 12H), 3.55 (s, 2H), 4.33 (t, J = 5.6 Hz, 2H), 6.16 (br s, 1H), 7.14 
(d, J = 7.4 Hz, 2H), 7.25 (m, 5H), 7.76 (d, J = 7.4 Hz, 2H) ppm. 13C NMR (100 MHz, CDCl3) 
δ 24.83, 43.47, 43.77, 83.81, 127.30, 127.45, 128.56, 128.74, 135.37, 138.01, 138.13, 170.66 
ppm. IR ν 3260, 2983, 1644, 1552, 1359, 1140, 1089, 858 cm-1. 
N-([1,1'-biphenyl]-4-ylmethyl)-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)phenyl)acetamide (6.60). Following synthetic procedure D using 2-(4-(4,4,5,5-tetramethyl-
1,3,2-dioxaborolan-2-yl)phenyl)acetic acid (0.131 g, 0.500 mmol) and (1,1'-biphenyl)-4-
ylmethanamine (0.092 g, 0.500 mmol), purification by silica gel column chromatography 
(hexanes/EtOAc 60:40) afforded the title compound (0.181 g, 0.423 mmol, 85% yield). M.p. 
110−111 °C (hexanes/CH2Cl2). 1H NMR (400 MHz, DMSO-d6) δ 1.28 (s, 12H), 3.56 (s, 2H), 
4.34 (br s, 2H), 7.34 (m, 5H), 7.43 (m, 2H), 7.65 (m, 6H), 8.68 (br s, 1H) ppm. 13C NMR (100 
MHz, DMSO-d6) δ 24.60, 41.96, 42.56, 83.48, 126.54, 126.58, 127.27, 127.83, 128.59, 
128.86, 134.45, 138.62, 138.73, 139.87, 139.91, 169.83 ppm. IR ν 3291, 2978, 1641, 1612, 
1542, 1358, 1143, 1088, 858 cm-1. 
N-(4-phenylbutyl)-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetamide 
(6.61). Following synthetic procedure D using 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-
2-yl)phenyl)acetic acid (0.100 g, 0.381 mmol) and 4-phenylbutan-1-amine (0.057 g, 0.381 
mmol), purification by silica gel column chromatography (hexanes/EtOAc 60:40) afforded 
the title compound as an oil (0.102 g, 0.259 mmol, 68% yield). 1H NMR (400 MHz, CDCl3) δ 
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1.34 (s, 12H), 1.41 (m, 2H), 1.53 (m, 2H), 2.54 (t, J = 7.2 Hz, 2H), 3.44 (m, 2H), 3.53 (s, 2H), 
5.67 (br s, 1H), 7.09 (d, J = 7.4 Hz, 2H), 7.13 (m, 1H), 7.23 (m, 4H), 7.78 (d, J = 7.4 Hz, 2H) 
ppm. 13C NMR (100 MHz, CDCl3) δ 24.64, 28.27, 28.74, 35.13, 39.19, 43.73, 83.62, 125.52, 
128.08, 128.10, 128.54, 135.19, 137.98, 141.78, 170.48 ppm. IR ν 3288, 2977, 2933, 1643, 
1551, 1358, 1143, 1089, 858 cm-1. 
N-(5-phenylpentyl)-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetamide 
(6.62). Following synthetic procedure D using 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-
2-yl)phenyl)acetic acid (0.126 g, 0.481 mmol) and 5-phenylpentan-1-amine (0.078 g, 0.481 
mmol), purification by silica gel column chromatography (hexanes/EtOAc 70:30) afforded 
the title compound (0.142 g, 0.349 mmol, 73% yield). M.p. 101−102 °C (hexanes/Et2O). 1H 
NMR (400 MHz, DMSO-d6) δ 1.28 (m, 14H), 1.42 (m, 2H), 1.53 (m, 2H), 2.52 (m, 2H), 3.04 
(m, 2H), 3.50 (s, 2H), 5.67 (br s, 1H), 7.16 (m, 3H), 7.25 (m, 2H), 7.30 (m, 2H), 7.64 (d, J = 
6.4 Hz, 2H), 8.08 (br s, 1H) ppm. 13C NMR (100 MHz, DMSO-d6) δ 24.58, 24.90, 25.99, 
28.85, 30.70, 35.12, 42.67, 73.43, 125.53, 128.14, 128.17, 128.44, 134.38, 140.05, 142.12, 
169.58 ppm. IR ν 3263, 2982, 2920, 1643, 1549, 1357, 1140, 1087, 858 cm-1. 
N-(7-phenylheptyl)-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetamide 
(6.63). Following synthetic procedure D using 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-
2-yl)phenyl)acetic acid (0.120 g, 0.458 mmol) and 7-phenylheptan-1-amine (0.088 g, 0.458 
mmol), purification by silica gel column chromatography (hexanes/EtOAc 70:30) afforded 
the title compound as an oil (0.135 g, 0.310 mmol, 67% yield). 1H NMR (400 MHz, CDCl3) δ 
1.26 (m, 6H), 1.34 (s, 12H), 1.36 (m, 2H), 1.57 (m, 2H), 2.57 (t, J = 7.6 Hz, 2H), 3.15 (q, J = 
7.2 Hz, 2H), 3.56 (s, 2H), 5.46 (m, 1H), 7.15 (m, 3H), 7.25 (m, 4H), 7.79 (d, J = 8.0 Hz, 2H), 
8.08 (s, 1H) ppm. 13C NMR (100 MHz, CDCl3) δ 24.88, 26.70, 29.05, 29.10, 29.42, 31.36, 
35.90, 39.69, 44.06, 83.89, 125.59, 128.24, 128.39, 128.84, 135.46, 138.19, 142.75, 170.62 
ppm. IR ν 3298, 2981, 2930, 1644, 1547, 1359, 1143, 1088, 908, 858, 727 cm-1. 
N-(4-(tert-Butyl)phenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (6.64). 
Following synthetic procedure B using 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)benzoic acid (0.124 g, 0.500 mmol) and 4-(tert-butyl)aniline (0.075 g, 0.500 mmol), 
purification by silica gel column chromatography (hexanes/EtOAc 80:20) afforded the title 
compound (0.146 g, 0.385 mmol, 77% yield). M.p. 160−162 °C (hexanes/CH2Cl2). 1H NMR 
(400 MHz, CDCl3) δ 1.29 (s, 9H), 1.37 (s, 12H), 7.31 (d, J = 8.4 Hz, 2H), 7.56 (d, J = 8.4 Hz, 
2H), 7.83 (m, 4H), 8.32 (s, 1H) ppm. 13C NMR (100 MHz, CDCl3) δ 24.86, 31.36, 34.35, 
84.11, 120.35, 125.73, 126.26, 134.97, 135.35, 137.26, 147.45, 165.91 ppm. IR ν 3347, 2961, 
1640, 1532, 1354, 1324, 1142, 1102, 834 cm-1. 
N-([1,1'-biphenyl]-4-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (6.65). 
Following synthetic procedure D using 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)benzoic acid (0.248 g, 1.00 mmol) and (1,1'-biphenyl)-4-amine (0.169 g, 1.00 mmol), 
purification by silica gel column chromatography (EtOAc) afforded the title compound (0.187 
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g, 0.468 mmol, 47% yield). 1H NMR (400 MHz, CDCl3 + 10% CD3OD) δ 1.37 (s, 12H), 7.33 
(m, 1H), 7.43 (m, 2H), 7.59 (m, 4H), 7.76 (m, 2H), 7.91 (m, 4H) ppm. 13C NMR (100 MHz, 
CDCl3 + 10% CD3OD) δ 24.88, 84.43, 121.05, 121.15, 126.60, 126.90, 127.21, 127.57, 
128.88, 135.01, 137.42, 140.62, 166.78 ppm. IR ν 3394, 2979, 1643, 1523, 1354, 1322, 1140, 
1085, 832, cm-1. 
N-benzyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (6.66). Following 
synthetic procedure D using 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid 
(0.124 g, 0.500 mmol) and phenylmethanamine (0.054 g, 0.500 mmol), purification by silica 
gel column chromatography (hexanes/EtOAc 70:30) afforded the title compound as an oil 
(0.105 g, 0.311 mmol, 63% yield). 1H NMR (400 MHz, CDCl3) δ 1.34 (s, 12H), 4.60 (t, J = 
5.6 Hz, 2H), 6.72 (br s, 1H), 7.30 (m, 5H), 7.76 (t, J = 8.0 Hz, 2H), 7.84 (d J = 8.0 Hz, 2H) 
ppm. 13C NMR (100 MHz, CDCl3) δ 24.86, 44.10, 84.11, 126.13, 127.55, 127.90, 128.73, 
134.93, 136.58, 138.18, 167.35 ppm. IR ν 3312, 2978, 1638, 1537, 1353, 1140, 1088, 856, 
cm-1. 
N-(4-hydroxyphenethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (6.67). 
Following synthetic procedure D using 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)benzoic acid (0.124 g, 0.500 mmol) and 4-(2-aminoethyl)phenol (0.069 g, 0.500 mmol), 
purification by silica gel column chromatography (hexanes/EtOAc 50:50) afforded the title 
compound (0.070 g, 0.191 mmol, 38% yield). M.p. 189−193 °C (hexanes/CH2Cl2). 1H NMR 
(400 MHz, CDCl3 + 10% CD3OD) δ 1.36 (s, 12H), 2.55 (m, 2H), 3.60 (m, 2H), 6.78 (d, J = 
6.2 Hz, 2H), 7.06 (d, J = 6.2 Hz, 2H), 7.38 (br s, 1H), 7.71 (d, J = 7.2 Hz, 2H), 7.84 (d J = 7.2 
Hz, 2H) ppm. 13C NMR (100 MHz, CDCl3 + 10% CD3OD) δ 24.87, 34.77, 41.90, 84.46, 
115.58, 126.28, 129.92, 130.04, 135.00, 136.97, 155.53, 168.66 ppm. 
N-([1,1'-biphenyl]-4-ylmethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide 
(6.68). Following synthetic procedure D using 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)benzoic acid (0.124 g, 0.500 mmol) and (1,1'-biphenyl)-4-ylmethanamine (0.092 g, 0.500 
mmol), purification by silica gel column chromatography (hexanes/EtOAc 70:30) afforded 
the title compound as an oil (0.150 g, 0.363 mmol, 72% yield). 1H NMR (400 MHz, CDCl3) δ 
1.32 (s, 12H), 4.59 (d, J = 5.6 Hz, 2H), 7.13 (m, 1H), 7.32 (m, 3H), 7.39 (m, 2H), 7.50 (m, 
4H), 7.80 (d, J = 7.6 Hz, 2H), 7.84 (d J = 7.6 Hz, 2H) ppm. 13C NMR (100 MHz, CDCl3) δ 
24.82, 43.64, 84.06, 126.22, 126.98, 127.25, 127.31, 128.23, 128.72, 134.88, 136.49, 137.26, 
140.29, 140.62, 167.49 ppm. IR ν 3325, 2977, 1637, 1541, 1358, 1141, 1089, 856 cm-1. 
N-(4-phenylbutyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (6.69). 
Following synthetic procedure D using 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)benzoic acid (0.124 g, 0.500 mmol) and 4-phenylbutan-1-amine (0.089 g, 0.600 mmol), 
purification by silica gel column chromatography (hexanes/EtOAc 70:30) afforded the title 
compound (0.114 g, 0.300 mmol, 60% yield). M.p. 145−148 °C (MeOH). 1H NMR (400 
MHz, CDCl3) δ 1.35 (s, 12H), 1.66 (m, 4H), 2.65 (t, J = 7.0 Hz, 2H), 3.44 (m, 2H), 6.28 (br s, 
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1H), 7.17 (m, 3H), 7.27 (m, 2H), 7.72 (d, J = 8.0 Hz, 2H), 7.84 (d J = 8.0 Hz, 2H) ppm. 13C 
NMR (100 MHz, CDCl3) δ 24.88, 28.70, 29.21, 35.48, 39.92, 84.10, 125.83, 125.99, 128.35, 
128.41, 134.92, 136.98, 142.06, 167.44 ppm. IR ν 3310, 2979, 2935, 1633, 1543, 1356, 1137, 
1089, 853 cm-1. 
N-(5-phenylpentyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (6.70). 
Following synthetic procedure D using 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)benzoic acid (0.124 g, 0.500 mmol) and 5-phenylpentan-1-amine (0.082 g, 0.500 mmol), 
purification by silica gel column chromatography (hexanes/EtOAc 70:30) afforded the title 
compound (0.169 g, 0.430 mmol, 86% yield). M.p. 104−106 °C (MeOH). 1H NMR (400 
MHz, CDCl3) δ 1.30 (m, 14H), 1.56 (m, 4H), 2.53 (m, 2H), 3.26 (m, 2H), 7.16 (m, 3H), 7.23 
(m, 2H), 7.76 (t, J = 7.4 Hz, 2H), 7.87 (d J = 7.4 Hz, 2H) 8.26 (br s, 1H) ppm. 13C NMR (100 
MHz, CDCl3) δ 24.61, 26.09, 28.87, 30.74, 35.06, 39.14, 83.81, 125.52, 126.47, 128.13, 
128.19, 134.22, 137.13, 142.15, 165.77 ppm. IR ν 3306, 2978, 2931, 1637, 1542, 1357, 1141, 
1089, 856 cm-1. 
 
6.6.2 Biological Assay 
Fatty acid amide hydrolase (FAAH) assay. The effect of compounds on the enzymatic 
hydrolysis of anandamide was obtained using membranes prepared from rat brain, incubated 
with the test compounds and [14C]AEA (2.4 µM) in 50 mM Tris-HCl, pH 9, for 30 min at 37 
°C. [14C]Ethanolamine produced from [14C]AEA hydrolysis was measured by scintillation 
counting of the aqueous phase after extraction of the incubation mixture with 2 volumes of 
CHCl3/MeOH 2:1 (by volume). Data are expressed as the concentration exerting 50% 
inhibition of AEA hydrolysis (IC50), calculated by GraphPad. 
Transient receptor potential vanilloid 1 (TRPV1) channel assay. HEK293 (human 
embryonic kidney) cells stably over-expressing recombinant human TRPV1 were grown on 
100 mm diameter Petri dishes as mono-layers in minimum essential medium (MEM) 
supplemented with non-essential amino acids, 10% fetal bovine serum, and 2 mM glutamine, 
and maintained at 5% CO2 at 37 °C. The effect of the substances on intracellular Ca2+ 
concentration ([Ca2+]i) was determined by using the selective intracellular fluorescent probe 
Fluo-4. On the day of the experiment, cells were loaded for 1 h at room temperature with the 
methyl ester Fluo-4-AM (4 µM in dimethyl sulfoxide containing 0.02% Pluronic F-127, 
Invitrogen) in MEM without fetal bovine serum, then were washed twice in Tyrode’s buffer 
(145 mM NaCl, 2.5 mM KCl, 1.5 mM CaCl2, 1.2 mM MgCl2, 10 mM D-glucose, and 10 mM 
HEPES, pH 7.4), resuspended in the same buffer, and transferred (about 100,000 cells) to the 
quartz cuvette of the spectrofluorimeter (Perkin-Elmer LS50B equipped with PTP-1 
Fluorescence Peltier System; PerkinElmer Life and Analytical Sciences, Waltham, MA, 
USA) under continuous stirring. The changes in [Ca2+]i were determined before and after 
addition of various concentrations of test compounds by measuring cell fluorescence (λEX = 
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488 nm, λEM = 516 nm) at 25 °C. Curve fitting (sigmoidal dose–response variable slope) and 
parameter estimation were performed with GraphPad Prism® (GraphPad Software Inc., San 
Diego, CA). Potency was expressed as the concentration of test substances exerting a half-
maximal agonist effect (i.e., half-maximal increases in [Ca2+]i) (EC50). The efficacy of the 
agonists was determined by normalizing their effect to the maximum Ca2+ influx effect on 
[Ca2+]i observed with application of 4 µM ionomycin (Cayman). When significant, the values 
of the effect on [Ca2+]i in wild-type (i.e., not transfected with any construct) HEK293 cells 
were taken as baseline and subtracted from the values obtained from transfected cells. 
Antagonist/desensitizing behaviour was evaluated against capsaicin (0.1 µM), by adding the 
test compounds in the quartz cuvette 5 min before stimulation of cells with agonists. Data are 
expressed as the concentration exerting a half-maximal inhibition of agonist-induced [Ca2+]i 
elevation (IC50), which was calculated again using GraphPad Prism® software. The effect on 
[Ca2+]i exerted by agonist alone was taken as 100%. Dose response curves were fitted by a 
sigmoidal regression with variable slope. All determinations were performed at least in 
triplicate. Statistical analysis of the data was performed by analysis of variance at each point 
using ANOVA followed by the Bonferroni’s test.  
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Chapter 7: Structure-Property Relationships of Carboxylic Acid 
Isosters 
7.1 Introduction  
The (bio)-isosteric replacement of the carboxylic acid moiety of biologically active 
compounds with a surrogate structure that exhibits broadly similar biological properties is a 
common strategy employed in medicinal chemistry to improve/modify the pharmacokinetic 
and/or pharmacodynamic properties of compounds of interest.1−3 For example, the oxetane 
ring has been recently reported to be able to modulate important physicochemical properties 
of molecules, including aqueous solubility,4 lipophilicity, and metabolic stability.5 This four-
membered ring heterocycle has been described as an isostere of the gem-dimethyl and the 
carbonyl group of the carbonyl moiety (Figure 7.1A,B)5−8 Furthermore, 3-substituted 
oxetanes have been proposed as potential replacements of carboxylic esters and amides 
(Figure 7.1C,D).7,9−12 These findings indicate that the oxetan-3-ol could be a potentially 
promising replacement of the carboxylic acid. Thus far, however, an evaluation of this 
fragment as a carboxylic acid surrogate has not been reported (Figure 7.1E).  
In recent years the development of dual cyclooxygenase (COX)/5-lipoxygenase (5-LOX) 
inhibitors (e.g., licofelone) for peripheral diseases such as arthritis, has attracted considerable 
attention. Indeed, the concurrent inhibition of both these arachidonic acid metabolic pathways 
provides advantages in terms of efficacy and safety relative to standard nonsteroidal anti-
inflammatory drugs (NSAIDs). However, there are no examples in literature of such dual-
acting inhibitors for central nervous system (CNS) indications. Prior studies demonstrated 
that selected bio-isosteric replacements of the carboxylic acid moiety of NSAIDs (e.g., 
ibuprofen, indomethacin, lonazolac and several fenamates) can result in derivatives with 
balanced, multitargeted activities against COX and 5-LOX pathways.13,14  
 
 
Figure 7.1. The oxetane ring proved to be an isosteric replacement of the gem-dimethyl (A), 
and the carbonyl group in the context of ketones (B), esters (C), and amides (D); similar 
replacements may be of interest in the context of carboxylic acids (E).15 
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7.2 Objective of the Study 
To investigate the structural unit of the oxetan-3-ol, as well as the thietan-3-ol and the 
corresponding sulfoxide and sulphone derivatives, as potential carboxylic acid bioisosteres, a 
set of model compounds was designed, synthesized, and evaluated for 
physicochemical properties, including acidity (pKa), lipophilicity (logD7.4), and permeability 
in the parallel artificial membrane permeability assay (PAMPA). Hydrogen-bonding studies 
were also conducted to evaluate these fragments as hydrogen bond (HB) donors. We explored 
a focused set of derivatives of the phenylpropionic acid (7.1, Table 7.1), as this compound 
was already employed as a template structure for the evaluation of analogues comprising a 
wide selection of known carboxylic acid surrogates.16 In addition, we investigated novel 
potential isosteric replacements of the carboxylic acid moiety of the COX inhibitor, ibuprofen 
(7.2, Table 7.2). Accordingly, we constructed a small set of derivatives of ibuprofen that were 
evaluated as inhibitors of eicosanoid formation in rat basophilic leukemia (RBL-1) cells. 
 
7.3 Chemistry 
Oxetane and thietane derivatives 7.3–7.6 and 7.7–7.10 have been prepared as described in 
Scheme 7.1 and 7.2. 
Reaction of phenethyl-magnesium chloride (7.11) with the appropriate oxetan-3-one (7.12) 
or thietan-3-one (7.13) in anhydrous tetrahydrofuran furnished the alcohols 7.3 and 7.4, 
respectively (Scheme 7.1). Treatment of 7.4 with urea-hydrogen peroxide complex (UHP) in 
acetic acid led to the formation of the corresponding sulfoxide as a mixture (6:4) of cis- and 
trans-isomers, as determined by 1H NMR. When m-chloroperbenzoic acid (m-CPBA) was 
used for the oxidation step, the cis/trans ratio was >98:2. Recrystallization of this mixture 
afforded crystals of the cis-isomer 7.5 that were suitable for X-ray diffraction analysis (Figure 
7.2). Oxidation of 7.4 with oxone led to the formation of the fully oxidized sulfone derivative 
7.6 (Scheme 7.1). 
As a visiting PhD student of Prof. C. Ballatore’s research group, I accomplished the re-
synthesis of compound 7.3 in 0.2 g scale (see Experimental Section, Chemistry 7.6.1). 
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Scheme 7.1. Synthesis of compounds 7.3–7.6. 
 
 
 
  
Figure 7.2. X-ray structure determination of compound 7.5.15 
 
 
Synthesis of ibuprofen derivatives 7.7−7.10 was achieved starting from the alkyl chloride 
7.14, which was prepared in two steps from commercially available ketone 7.15, as shown in 
Scheme 7.2. Grignard addition to the oxetan-3-one (7.12) or thietan-3-one (7.13) resulted in 
derivatives 7.7 and 7.8, respectively. Finally, treatment of 7.8 with m-CPBA furnished the 
sulfoxide derivative 7.9 (cis/trans ratio >20:1), while oxidation of 7.8 with oxone yielded the 
sulfone derivative 7.10 (Scheme 7.2). 
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Scheme 7.2. Synthesis of compounds 7.7–7.10. 
 
 
7.4 Results and Discussion 
Evaluation of physicochemical properties of the phenylpropionic acid derivatives 7.3–7.6 
showed that oxetan-3-ol, thietan-3-ol and related structures are comparatively less acidic than 
the carboxylic acid functionality of compound 7.1 (cf., pKa value of 7.1, 7.6 and the other 
derivatives, Table 7.1). A previously reported colorimetric assay17 was employed to assess the 
HB acidity of compounds 7.3–7.6. Data revealed that the replacement of the carboxylic acid 
of 7.1 with a four-member ring heterocycle generally causes a far less dramatic reduction in 
the HB acidity scale. This is evident from the fact that compound 7.3 was at least eight orders 
of magnitude less acidic than 7.1, but it exhibited less than two orders of magnitude weaker 
binding via hydrogen bonding to the fluorescent HB acceptor used in the assay (Keq shown in 
Table 7.1). Interestingly, derivatives 7.3–7.6 showed significantly higher Keq values than that 
of alcohol 7.16, confirming that the replacements play an important role in determining the 
HB-donating ability of the hydroxyl moiety. Thus, the drastic reduction in acid character 
combined with the significant HB capacity exhibited by our derivatives, may be a desirable 
feature of these structural units with possible applications in drug design, especially when the 
presence of a negatively ionizable acid in a drug candidate may be responsible for an 
insufficient passive diffusion across biological membranes. Indeed, consistent with the 
O
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relatively high pKa values and with these molecules being mostly neutral at physiological pH, 
the new derivatives were found to be comparatively more lipophilic and permeable in 
PAMPA than our reference 7.1. Furthermore, a comparison of physicochemical properties of 
7.3–7.6 with 33 other phenylpropionic acid derivatives, in which the carboxylic acid moiety 
was replaced by known isosters, revealed that the new derivatives are among the most 
permeable compounds within the entire set (Figure 7.3). 
 
 
Cmpd Structure logD7.4a 
logD7.4 
calc.b 
PAMPA 
pKaf 
pKa 
calc.b 
H 
bonding 
ln(Keq)g 
Pe (cm/s)c 
% 
reten 
tiond 
logPappe 
7.1 
 
−0.49 ± 
0.19* 
−0.56* 
1.66E−06 
± 
3.48E−7* 
−6.8 ± 
11* 
−5.79 ± 
0.10* 
4.64* 4.7* 4.31* 
7.3 
 
2.07 1.7 8.27E−06 −11.9 −5.08 >12 13.5 2.53 
7.4 
 
2.99 2.28 1.32E−05 11.4 −4.88 >12 14.3 2.40 
7.5 
 
1.22 0.48 6.23E−06 10.0 −5.21 >12 14.2 3.46 
7.6 
 
1.24 0.58 1.22E−05 10.7 −4.91 9.31 13.6 3.76 
7.16 
 
ND 2.64 ND ND ND ND 15.4 1.62 
 
Table 7.1. Calculated and experimental properties of test compounds. aDistribution 
coefficient between n-octanol and aqueous buffer (pH 7.4) determined by LC/MS (experiment 
run by WuXi AppTech). bCalculated values using ChemAxon. cEffective permeability 
(PAMPA assay run by Analiza, Inc.). dMembrane retention. eLog of the apparent permeability 
coefficient. fpKa values determined by capillary electrophoresis (experiment run by Analiza, 
Inc.). gEquilibrium constants (Keq) determined from a colorimetric assay that monitors the 
blue-shift of the maximum wavelength of a fluorescent pyrazinone HB acceptor upon 
complexation with the HB donor analyte. *Data previously reported.16 ND = not determined. 
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Figure 7.3. Comparison of physicochemical properties of phenylpropionic acid derivatives 
7.3–7.6 (compounds shown in red boxes), with a set of corresponding model compounds 
bearing other known carboxylic acid bio-isosteres that had been previously tested in the same 
assays and under identical assay conditions.15,16 
 
 
Evaluation of compound inhibition of the biosynthesis of COX- and 5-LOX-derived 
eicosanoids was conducted in a modified RBL-1 cell assay18 that can be used to assess both 
COX-derived prostaglandins (PGs) and 5-LOX-derived leukotrienes (LTs) formed in the 
presence or absence of test compounds. Thus, RBL-1 cells were incubated for 2h in the 
presence of different concentrations of test compounds, including the ibuprofen derivatives 
7.7–7.10, the ibuprofen analogue bearing a tetrazole 7.17,19 and the cyclopentane-1,3-dione 
7.18. Incubation was followed by the addition of the calcium ionophore, A23187, for 15 min 
to induce arachidonic acid production, then LC−MS/MS analysis was employed to quantify 5-
LOX-derived LTB4 and COX-derived PGD2 and PGE2 production. Data from RBL-1 assay 
are shown in Table 7.2. Unlike 7.2, 7.17 and 7.18, the presence of a less acidic and more 
permeable four-membered ring heterocycle, as in 7.7–7.10, led to the inhibition of 5-LOX-
mediated synthesis of LTB4. Furthermore, analogues 7.7, 7.9, and 7.10 were found to inhibit 
the formation of both COX- and 5-LOX-derived eicosanoids with 7.9 and 7.10 exhibiting 
balanced inhibitory activity in the micromolar range (Figure 7.4). In this initial analysis LTB4 
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and combined PGD2 and PGE2 coeluted under the chromatographic conditions during 
LC−MS/MS. Thus, we performed further confirmatory studies using a refined protocol to 
individually detect and quantitate PGD2 and PGE2, as well as LTB4 and LTC4 (data shown in 
Table 7.3). Although the RBL-1 assay does not permit to unambiguously determine the 
enzymes in the arachidonic acid cascade that are inhibited by the test compounds, the 
formation of each of these eicosanoids depends on separate enzymatic steps in the COX- and 
5-LOX pathways.20 Taken together these data suggest that compounds 7.7, 7.9, and 7.10 
effectively reduce the formation of multiple PGs and LTs, thus inhibiting concurrently 
multiple enzymes in the COX- and 5-LOX biosynthetic pathways.  
 
 
Cmpd Structure 
PGE2/PGD2 
IC50 (µM)a 
LTB4 
IC50 (µM)b 
7.2 
 
0.6 (0.3−1.1)* >100 
7.7 
 
34.1 (25.9−44.9)* 8.4 (6.4−10.9)* 
7.8 
 
>100 7.6 (4.9−11.8)* 
7.9 
 
17.4 (5.7−53.5)* 11.7 (6.2−22.4)* 
7.10 
 
14.6 (12.1−17.5)* 20.2 (16.0−25.4)* 
7.17 
 
31.8 (24.6−41.0)* >100 
7.18 
 
28.1 (10.6−74.5)* >100 
 
Table 7.2. IC50 values of test compounds in the PGE2/PGD2 and LTB4 assays. aInhibition of 
COX pathway as determined by LC−MS/MS analyses of the combined production of COX-
derived PGD2 and PGE2 in RBL-1 cells upon stimulation with arachidonic acid in the 
presence or absence of test compounds. bInhibition of 5-LOX pathway as determined by 
LC−MS/MS analyses of the production of 5-LOX- derived LTB4 in RBL-1 cells upon 
stimulation with arachidonic acid in the presence or absence of test compounds. *The data 
represent the calculated IC50 values and associated 95% confidence intervals as determined 
from triplicate samples at each concentration after a sigmoidal curve fit using GraphPad 
Prism software.  
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Figure 7.4. Concentration−response analyses of inhibition of 5-LOX-derived LTB4 and 
COX-derived PGE2/PGD2 by compounds 7.2 (left) and 7.10 (right). Error bars represent 
standard error of the mean from triplicate samples. Adapted from Ref. 15. 
 
 
Cmpd 
PGE2 % 
Inhibition at 100 µM 
PGD2 % 
Inhibition at 100 µM 
LTB4 % 
Inhibition at 50 µM 
LTC4 % 
Inhibition at 50 µM 
7.7 79 ± 4 88 ± 4 96 ± 1 99 ± 1 
7.8 40 ± 10 70 ± 20 98 ± 1 96 ± 4 
7.9 70 ± 10 89 ± 5 92 ± 2 98 ± 2 
7.10 95 ± 2 99 ± 2 86 ± 1 92 ± 4 
7.17 89 ± 6 92 ± 1 18 ± 7 30 ± 20 
7.18 60 ± 20 80 ± 8 30 ± 10 60 ± 10  
Table 7.3. Inhibitory activity of ibuprofen isosteres for multiple COX- and 5-LOX pathway 
eicosanoids.  
 
7.5 Conclusions 
In recent years the oxetane ring has attracted considerable attention in medicinal 
chemistry.21 Ongoing interest in the area of carboxylic acid bioisosteres16,22−25 prompted the 
exploration of the oxetan-3-ol, thietan-3-ol and the corresponding sulfoxide and sulfone 
derivatives, as potential carboxylic acid bioisosteres. Collectively, the data from our studies 
provide a characterization of a range of physicochemical properties of oxetan-3-ol, thietan-3-
ol, and related structures and suggest that they may be considered as possible bioisosteres of 
the carboxylic acid functional group. Given the relatively low acidity and high permeability, 
these fragments may be considered especially in the context of CNS drug design, when 
isosteric replacement of the carboxylic acid is often needed to improve the brain penetration 
of a drug candidate.  
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7.6 Experimental section 
7.6.1 Chemistry 
General description of common materials and instrumentation has been previously 
discussed in section 3.6.1. 
3-Phenethyloxetan-3-ol (7.3). To a stirred solution of oxetan-3-one (100 µL, 1.56 mmol, 1 
equiv) in THF (4 mL) at –78 °C under N2 was added dropwise phenethylmagnesium chloride 
(1.88 mL of a 1 M solution in THF, 1.2 equiv). The reaction was stirred at this temperature 
for 10 min, then at room temperature for 1 h. The reaction was quenched with satd. aq. 
NH4Cl, then extracted with Et2O (×3). The combined organic extracts were washed with 
brine, dried over MgSO4, filtered, and concentrated in vacuo. Purification by silica gel 
column chromatography (hexanes/EtOAc 60:40) afforded the title compound as a colorless 
low-melting solid (0.190 g, 1.07 mmol, 68% yield). 1H NMR (500 MHz, CDCl3) δ 7.34–7.27 
(m, 2H), 7.25–7.18 (m, 3H), 4.56 (d, J = 6.8 Hz, 2H), 4.49 (d, J = 7.2 Hz, 2H), 2.89 (s, 1H), 
2.78–2.71 (m, 2H), 2.21–2.14 (m, 2H) ppm. 13C NMR (126 MHz, CDCl3) δ 141.4, 128.7, 
128.5, 126.3, 84.1, 74.6, 39.6, 29.9 ppm. IR (KBr) ν 3389, 3026, 2950, 2872, 2359, 2344, 
1603, 1495 cm–1. HRMS (Cl+) calculated for C10H12O [M–CH2O]+ 148.0888, found 
148.0892. 
7.6.2 Biological Assay 
RBL-1 Cell PG and LT Assay. Inhibition of PG and LT synthesis by test compounds was 
determined through an established RBL-1 cell assay18 previously discussed in section 3.6.2. 
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General Conclusions 
During the PhD program, my research interest aimed at the discovery of molecules of 
therapeutic relevance, through modern methods of organic synthesis, for the treatment of 
diseases that affect health.  
In this context, I have been primarily involved in the development of agents that target 
tubulin and microtubules. Thus, during the first year in the PhD program I conducted my 
research activity at the Department of Drug Chemistry and Technologies of “Sapienza” 
University in Rome, where I worked on the design and synthesis of new tubulin 
polymerization inhibitors as anticancer agents. I also had the opportunity to collaborate with 
the research group of Prof. Giorgio Ortar and Prof. Enrico Morera, gaining practical 
experience in the rational design and synthesis of multitargeted agents. 
The passion for research combined with my interest in the study of tubulin-targeting 
agents, prompted me to move abroad and work for six months at the Department of 
Chemistry of University of Pennsylvania in the laboratory of Prof. Carlo Ballatore and Prof. 
Amos B. Smith III. There, I was involved in the development of multitargeted microtubule-
stabilizing agents, as drug candidates for Alzheimer’s disease, working in collaboration with 
the Center for Neurodegenerative Disease Research (CNDR) of Philadelphia. Furthermore, I 
had the opportunity to be part of Prof. A. B. Smith’s group meetings and present my research 
goals and results. Finally, my research achievements in the Alzheimer’s disease field were 
awarded the Alzheimer’s Drug Discovery Foundation’s (ADDF) scholarship, which allowed 
me to participate to the ADDF International Conference in New Jersey with a poster 
communication. 
To continue my experience as a visiting PhD student in the research group of Prof. C. 
Ballatore, I moved to San Diego, where I spent a year at the Skaggs School of Pharmacy and 
Pharmaceutical Sciences and I continued to work on microtubule-stabilizing agents for 
neurodegenerative disease. I also had the great opportunity to be trained in the biological 
laboratory of Prof. Conor R. Caffrey, where I gained practical experience in maintaining cell 
cultures of Trypanosoma brucei and Caenorhabditis elegans, and performing in vitro 
screening of libraries of compounds. 
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As well as five poster or oral presentations: 
1. Monti, L.; Ortar, G.; Silvestri, G.; De Petrocellis, L.; Di Marzo, V.; Morera, E. “Synthesis 
and Biological Evaluation of Arylboronic Acid Derivatives as FAAH and TRPV1 Dual 
Ligands”. XXIII National Meeting on Medicinal Chemistry (NMMC) and 9th Young 
Medicinal Chemists Symposium “Nuove Prospettive in Chimica Farmaceutica” 
(NPCF9). Poster presentation. September 6–9, 2015, Fisciano (Salerno, Italy). 
2. Monti, L.; Cornec, A.-S.; Kovalevich, J.; James, M.; Vijayendran, K.; Lee, V. M.-Y.; 
Trojanowski, J. Q.; Smith, A. B. III; Brunden, K. R.; Ballatore, C. “Multitargeted 
Heterocyclic Compounds as Therapeutic Leads for Alzheimer’s Disease”. 17th 
International Conference on Alzheimer’s Drug Discovery. Poster presentation. September 
12–13, 2016, Jersey City (New Jersey, USA). 
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3. Monti, L.; Cornec, A.-S.; Kovalevich, J.; Makani, V.; James, M. J.; Vijayendran, K. G.; 
Oukoloff, K.; Yao, Y.; Lee, V. M.-Y.; Trojanowski, J. Q.; Smith, A. B. III; Brunden, K. 
R.; Ballatore C. “Multitargeted Imidazoles as Therapeutic Leads for Alzheimer’s 
Disease”. UC-Wide Drug Discovery Symposium. Poster presentation. February 21–22, 
2017, University of California, Los Angeles, Los Angeles (CA, USA). 
4. “CNS-Active Microtubule-Stabilizing Agents as Potential Leads for Neuroparasitic 
Infections”. Skaggs School of Pharmacy and Pharmaceutical Sciences Seminar Series. 
Oral presentation. June 30, 2017, University of California, San Diego, La Jolla (CA, 
USA). 
5. Monti, L.; Oukoloff, K.; Wang, S.; Brunden, K. R.; Debnath, A.; Caffrey, C. R.; 
Ballatore C. “CNS-Active Microtubule-Stabilizing Agents as Potential Leads for Human 
African Trypanosomiasis and Other Neuroparasitic Infections”. Biology and Molecular 
Medicine Symposium. Poster presentation. November 20, 2017, “Sapienza” University of 
Rome, Rome (Italy). 
 
Finally, in December 2017 I was awarded the “Premio Minerva alla ricerca scientifica”, 
recognition of merit founded by “Sapienza” University for the innovation, internationalization 
and high quality level of the research conducted in the PhD program. 
In conclusion, I believe that the PhD experience has given me the opportunity to improve 
my scientific competence and knowledge as a student of “Sapienza” University, also training 
undergraduate students, working in different research groups and participating to scientific 
meetings, seminaries and conferences. 
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